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Intellectual disability (ID) is a highly prevalent disorder that affects 1-3% of the population, 
with ~ 100 causative genes mapped to the X-chromosome. The Aristaless-related 
homeobox gene (ARX) is an important transcription factor with critical roles in 
development, particularly in the developing brain. Variants are not well tolerated within 
ARX, with missense mutations resulting in phenotypes that always involve ID with frequent 
comorbidities of epilepsy, infantile spasms, hand dystonia, autism or dysarthria. 
Historically, it was thought that only males were affected by mutations in ARX due to their 
single X-chromosome. In this thesis, we describe a family with multiple affected 
individuals, including two females with a novel insertion mutation within ARX. We 
furthermore review the reported phenotype of females with mutations in ARX and highlight 
the importance of screening ARX in both male and female patients with ID and seizures. 
 
The majority of patients with ARX mutations are affected by expansion mutations in 
polyalanine tract 1 and 2 within the protein, giving rise to ID with or without epilepsy and 
movement disorders of varying severity. Mice modelling the two most frequent 
polyalanine expansion mutations (Arx(GCG)7 referred to as PA1 and Arx432-455dup24 referred 
to as PA2) recapitulate many of the clinical features seen in humans (Kitamura et al. 2009, 
Jackson et al. Submitted 2017). To dissect the molecular basis of different polyalanine 
expansions in vivo, we used 12.5 dpc brain samples from PA1 and PA2 mice to analyse 
disruptions in gene expression in the developing forebrain to capture the primary disruption 
leading to the developmental phenotypes caused by these mutations. A greater number of 
genes deregulated in the more severe PA1 mice was shown, with the majority of genes also 
XVI 
perturbed in the milder PA2 mice, but failed to reach significance compared to WT at this 
early stage of development. We saw a significant overlap with a number of known direct 
targets of ARX (5%) and genes implicated in ID, epilepsy and autism (12%). From my 
analysis, I predict a core pathway of transcription regulators as potential drivers of the ID 
and infantile spasms in patients with ARX polyalanine expansion mutations. 
 
Next, I investigated the mechanisms driving the partial loss of function. My data indicates 
this reduced function does not occur through disruptions of binding to DNA or protein 
interactors in relation to the region of ARX spanning both polyalanine tract 1 and 2. 
However, in this thesis, I demonstrate a marked reduction in polyalanine mutant protein 
may be the contributing factor to disease manifestation. Transcription activity assays 
indicated ARX responds in a dose-depend manner, and greater reduction in protein leads 
to an increased severity of the disease. Investigations into the molecular mechanism 
contributing to this reduction in protein level show no significant change in protein stability 
(in vitro). Instead, initial studies indicate inefficiency of translation resulting in reduced 
protein abundance. From my data and other previous studies, I discuss the likelihood of a 
multiple hit model contributing to the partial loss of function and leading to the variability 
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The human brain is a highly complex structure, and its normal development and 
functioning is critically dependent on the proper and tightly regulated activity of a large 
number of genes. Consequently, there are more than 1,000 Mendelian disorders listed in 
OMIM for which intellectual disability is one or the only hallmark of the condition. 
Hundreds of causative genes have already been identified. However, it is predicted many 
more genes remain to be identified due to patients remaining undiagnosed.  
 
1.1 Intellectual disability 
Intellectual disability (ID) encompasses a range of clinically and genetically variable 
disorders defined by defects in the central nervous system and involving a reduced capacity 
for intellectual functioning and adaptive behaviour (Schalock et al. 2011). The defining 
feature of intellectual disability is characterised by an IQ (intelligence quotient) of less than 
70, impairment in at least two adaptive skills, and disease onset before 18 years of age. 
With a prevalence of 1-3% worldwide, intellectual disability has a high impact on public 
health systems and families of affected individuals alike (Larson et al. 2001, Maulik et al. 
2011). In Australia, it is conservatively estimated that intellectual disability costs $14,720 
billion annually (Doran et al. 2012).   
 
Clinical manifestations distinguish intellectual disability into a syndromic form with 
additional consistent biological, physiological or radiological abnormalities, or a 
nonsyndromic ID with cognitive impairment the only consistent clinical feature (Ropers 
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2010). The level of intellectual functioning is assessed by the status of the IQ value, and 
this value subclasses the disease condition as mild (IQ level: 50-55 to 70), moderate (IQ 
level: 35-40 to 50-55) severe (IQ level: 20-25 to 35-40), or profound (IQ level: below 20-
25) (Puzynski 1992). 
 
1.2 Genetic etiology of intellectual disability 
In developed countries, intellectual disability is caused by both genetic and environmental 
factors, with equal rates of incidence. The environmental factors may involve 
malnutrition/undernutrition, prolonged depressing conditions due to cultural deprivation, 
exposure to toxic substances, physical trauma or head injury, severe infection, pregnancy 
complications and childhood illness. Genetic forms of intellectual disability prevail in 50% 
of ID cases, and this number might be expected to be even higher in those countries where 
consanguineous marriages are commonly practised. However severe intellectual disability 
occurs in 0.5% of newborns and is thought to be largely genetic in origin (Ropers 2010, 
Mefford et al. 2012) and can arise due to chromosomal anomalies, mitochondrial disorders, 
epigenetic defects, repeat expansion diseases and single gene impairments 
(Winnepenninckx et al. 2002). 
 
Next-generation sequencing (NGS) has revolutionised gene discovery in patients with 
intellectual disability and has enabled an unprecedented expansion in the number of genes 
implicated in this disorder. Now a genetic basis for ID is well established. Cytogenetic 
alterations including aneuploidies, duplications, deletions, translocations, and inversions 
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visible on standard karyotype account for approximately 5% of cases (Stankiewicz and 
Beaudet 2007), and smaller copy number variants (>400 kb) (CNVs) detected by array 
comparative genomic hybridization (CGH) explain a further 14% of cases (Cooper et al. 
2011). Among the monogenic causes, there are more than 100 genes on the X chromosome 
(Lubs et al. 2012) and more than 600 autosomal recessive genes in which mutations of 
which cause ID (Vissers et al. 2016). With the use of high throughput technologies, the 
detection of autosomal genes has not only increased but has become instrumental in the 
detection of de novo mutations.  
 
1.3 X-linked intellectual disability 
X-linked gene defects have long been considered to be substantial causes of ID. ID is 
significantly more common in males than in females, with a reported excess of 30% to 40% 
of males versus female patients (Lehrke 1972, Lehrke 1974, Penrose 1983, Leonard and 
Wen 2002). However, only in part due to mutations in genes on the X-chromosome (10%) 
(Mandel and Chelly 2004). X-linked inheritance can be recognised in families, even cases 
with only two affected male patients and an obligate female carrier can be considered for 
X-linked genes. Additionally, the hemizygous status of males means that variant 
identification is often more straightforward to detect and validate than for autosomal 
conditions. These reasons lead the initial interest of investigators and clinicians into X-
linked intellectual disability (XLID) and consequently, more than 150 XLID syndromes 
have been characterized and have led to the discovery of more than 100 genes known to 
date which are responsible for 81 of the known XLID syndromes and over 50 families with 
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nonsyndromic XLID (Lubs et al. 2012, Tzschach et al. 2015). Additionally, 30 XLID 
syndromes and 48 families with nonsyndromic XLID have been regionally mapped, 
however, the genes have not yet been identified (Lubs et al. 2012).  
 
1.4 The Aristaless-related homeobox gene 
Of particular interest to our area of research focus, is that impact of mutations in genes 
involved in early neurodevelopment and embryogenesis. One of the main genes frequently 
mutated on the X-chromosome and resulting in ID, the Aristaless-related homeobox (ARX), 
was first identified in 2002 (Bienvenu et al. 2002, Stromme et al. 2002). Since then, over 
60 different mutations have been described and implicate ARX in a wide spectrum of 
disorders extending from phenotypes with severe neuronal migration defects such as X-
linked lissencephaly with abnormal genitalia (XLAG) to milder forms of intellectual 
disability without apparent brain abnormalities but with associated features of dystonia and 
epilepsy (Shoubridge et al. 2016).   
 
The ARX gene (Genbank: NM_139058.2) (MIM# 300382) spans a 12.25-kb region at 
Xp21.3 (Human Genome Build: GRCh38/hg38) and has a 1689 bp open reading frame 
(ORF), comprising of five coding exons, and encoding for a 562 amino acid protein (Figure 
1.1) (Ohira et al. 2002).  Designated ARX in humans and Arx in mice, with significant 
homology between human and mouse (89.3% sequence and 95% amino acid homology). 
ARX encodes a transcription factor which belongs to the family of Aristaless-related genes, 
a subset of the Paired-related homeobox genes. These genes are important regulators of 
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essential events during vertebrate embryogenesis, including the development of the central 
and peripheral nervous systems (Meijlink et al. 1999). ARX has several conserved 
domains: the octapeptide domain, three nuclear localisation sequences, four polyalanine 




Figure 1.1 Gene and protein structure of ARX/ARX homeobox transcription factor.  
Exon-intron structure of ARX gene with the five exons boxed, and the open reading frame 
in dark grey, ATG and STOP codon positions, 5’ and 3’ untranslated regions depicted with 
diagonal light grey stripes, base pair sequence span of individual exons shown below each 
exon (top panel). Predicted protein structure of ARX with known functional domain 
highlighted; Octapeptide (OP, horizontal stripes), three nuclear localisation sequences 
(NLS, black), four polyalanine tracts (PA, white), acidic domain (vertical stripes), 
homeodomain (diagonal stripes), and the Aristaless domain (OAR, crosshatched) with the 
corresponding amino acid below each domain (middle panel). 
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1.5 Mutations within ARX leads to a spectrum of phenotypes 
Mutations in the Aristaless-related homeobox gene are identified in a broad spectrum of 
neurocognitive disorders. Since its discovery, 138 cases (individuals/families) have been 
reported in ARX that lead to 10 distinct clinical phenotypes that all feature ID (Table 1) 
(Shoubridge et al. 2010a). The number of cases, however, is likely to be an underestimation 
as many are diagnosed in a diagnostic setting and not reported. The finding of a single gene 
having significant clinical and genetic heterogeneity has led to a considerable amount of 
research on this gene, both at the clinical and basic science levels. 
 
Patients with mutations in ARX present with ID alone, or in conjunction with an array of 
additional co-morbidities including lissencephaly, infantile spasms, epilepsy, autism, 
testicular malformation, dysarthria, and hand dystonia (Shoubridge et al. 2010a). Due to 
its location on the X-chromosome, hemizygous males that carry the mutation are 
symptomatic and heterozygous females transmit the mutant allele but are often 
asymptomatic (Bonneau et al. 2002). The clinical spectrum of phenotypes due to ARX 
mutations has been recently reviewed by our group and others (Kato et al. 2004, 
Wallerstein et al. 2008, Shoubridge et al. 2010a, Marques et al. 2015, Shoubridge et al. 
2016). For this introduction, I will briefly summarise ARX disorders which can generally 
be divided into malformation and non-malformation groups. 
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1.5.1 Malformation disorders 
The most severe clinical phenotypes cause brain malformation and include X-linked 
lissencephaly associated with abnormal genitalia (XLAG) (MIM# 300215) (Kitamura et 
al. 2002), hydranencephaly and abnormal genitalia (HYD-AG) (MIM# 300215) (Kato et 
al. 2004) and Proud syndrome (MIM# 300004) (Proud et al. 1992). These phenotypes are 
a result of premature termination mutations, missense mutations within the homeobox 
domain and the nuclear localisation sequences flanking this domain (Table 1 and Figure 
1.2) (Kitamura et al. 2002, Kato et al. 2004, Shoubridge et al. 2010a, Shoubridge et al. 
2010b).  
 
1.5.2 Non-malformation disorders 
In the non-malformation patients, the clinical severity ranges from ID as a sole consistent 
clinical presentation (NS-XLID) (MIM# 300419), to disorders with additional symptoms, 
including seizures and movement disorders. The seizure types include infantile spasms X-
linked (ISSX/West syndrome) (MIM# 308350), X-linked myoclonic epilepsy with 
spasticity and ID (XMESID) (MIM# 308350), and Ohtahara syndrome / early infantile 
epileptic encephalopathies (EIEE) (MIM# 308350). In addition, the movement disorder 
Partington syndrome (PRTS) (MIM# 309510) describes dystonia, particularly of the hands. 
These non-malformation phenotypes are frequently caused by expansions of the first or 
second polyalanine tracts and missense mutations outside the homeodomain (Table 1 and 
Figure 1.2) (Stromme et al. 2002).  
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1.6 Emerging heterozygous female phenotype  
As ARX is on the X-chromosome, mutations in this gene typically result in families with 
affected males across multiple generations transmitted via (usually) asymptomatic carrier 
females. With decreasing costs of new sequencing technologies, increased access and 
numbers of samples have been screened for mutations, including singleton females 
screened for X-chromosome gene mutations. Removing the ascertainment bias has 
revealed ARX, and a growing number of X-chromosome genes, including IQSEC2, USP9X 
and PHF6, that have phenotypic effects in males and females that are distinct, depending 
on the functional severity of the mutation  (Zweier et al. 2013, Reijnders et al. 2016, Zerem 
et al. 2016). Examination of heterozygous females from families with known mutations in 
ARX supports that the female carrier phenotype might be under-ascertained. A number of 
carrier females display intellectual or learning disabilities, although other carriers of the 
same mutation are phenotypically normal.  In females, the only CNS malformation 
currently described is agenesis of the corpus callosum (ACC) with or without intellectual 
disability and seizures (Kato et al. 2004, Marsh et al. 2009). Females have also been 
reported to have infantile spasms, epilepsy, and varying degrees of cognitive dysfunction 
without obvious brain malformation (Figure 1.2) (Kato et al. 2004, Wallerstein et al. 2008, 
Marsh et al. 2009, Eksioglu et al. 2011, Bettella et al. 2013, Kwong et al. 2015).  
 
Variation within ARX is not well tolerated. This is demonstrated from the single largest 
aggregation of coding variants in the world known as the ExAC database (Lek et al. 2016). 
The ExAC database consists of exome sequencing data from 60,706 individuals from more 
than 20 research studies and a resource that can be used to look at the level of selective 
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constraint against variation across genes. Highly pathogenic variants with a large effect 
should be selected against and seen with a lower frequency in the general population. For 
ARX, there are no loss of function variants reported emphasising the critical requirement 
for this gene. As many as 40 missense variants are reported at a very low frequency 
(<0.03%), but no incidence of homozygote variants, 11 (27.5%) hemizygotes (likely 
males) and the remaining (72.5%) are likely heterozygous females, hence, they cannot be 
ruled out as potentially pathogenic in males. These variants occur across ARX however, the 
very few that fall within functional domains are in heterozygous female non-symptomatic 
carriers (Figure 1.2).  The variable penetrance in females, which is further discussed in 







Figure 1.2 Identified ARX mutation in Male and Females leading to arrange of phenotypes.  
Overview of ARX with the protein domain locations highlight in black and the polyalanine tract 1 (orange) and polyalanine tract 2 
(blue). All reported mutations are shown according to their relative position at the protein level in both males and females. Different 
mutation types are indicated by a change in symbol while missense mutation is shown by a diamond and all other nonsense, insertion 
or deletion mutation by a square. Polyalanine expansion mutations are shown by green triangles. Phenotype severity is indicated on 
the y-axis. Along the bottom of the graph are the reported ExAC variants in ARX indicated by a circle symbol, with hemizygote variants 
(likely male) shown in black and the remaining variants (likely heterozygous females) in grey.  
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Table 1 Clinical phenotypes of patients with mutations in ARX. 







Families per mutation type and location 
 NS-XLID 48 37 Duplication Expanded PA 2 
5 Insertion Expanded PA 1 (4)/ PA 2(1) 
4 Missense  
 AG 1 1 Missense OAR 
Seizures PRTS 12 12 Duplication Expanded PA 2 
MR/TS/Dys 1 1 Insertion Expanded PA 1 
XMESID 1 1 Missense HD 
ISSX (WS) 22 2 Deletion Loss of OAR  
8 Duplication Expanded PA 2 
8 Insertion Expanded PA 1 
4 Missense  
IEDE 10 10 Insertion Expanded PA 1 
OS / EIEE 11 1 Nonsense Protein restart after Oct domain 
5 Insertion OAR (3)/ Expanded PA1 (2) 
4 Missense OAR (3 male/1 female) 
2 Deletion OAR (1 male/ 1 female) 
Brain 
Malformation 
Proud (ACC/AG) 1 1 Missense HD 
HYD/AG 2 2 Nonsense HD 
ISSX, PMG, PVNH 1 1 Insertion Expanded PA 1 
XLAG + other 
features 
28 14 Deletion Protein truncation 
4 Insertion Protein truncation 
7 Missense HD and OAR  
2 Nonsense Protein truncation 
2 Splice Skip exons/protein truncation 
AG: abnormal genitalia. HD: Homeodomain. HYD/AG: hydranencephaly with abnormal genitalia. IEDE: 
infantile epileptic encephalopathy. ISSX, PMG, PVHG: X-linked infantile spasms with periventricular 
nodular heterotopia and polymicrogyria. ISSX (WS): infantile spasms X-linked (West syndrome). 
MR/TS/Dys: Mental retardation with tonic seizures with dystonia. NS-XLID: nonsyndromic X-linked 
intellectual disability. OAR: Aristaless domain. Oct: Octapeptide domain. OS: Ohtahara syndrome – early 
infantile epileptic encephalopathy. PA: Polyalanine tract. Proud (ACC/AG): Proud syndrome with agenesis 
of the corpus callosum and abnormal genitalia. PRTS: Partington syndrome – intellectual disability with 
dystonic movements, ataxia and seizures. XLAG: X-linked lissencephaly with abnormal genitalia. XMESID: 




1.7 Identification of mutations within ARX  
Although fifteen years has passed since the first disease-causing mutations were identified 
in ARX, novel mutations and new clinical phenotypes are still being characterised. Genetic 
diagnose of an ARX-related neurodevelopmental (NDD) disorder can be problematic due 
to the number of phenotypes associated with ARX mutations and variable penetrance of the 
severity of the overlapping phenotypes with other neurodevelopment disorders. These 
subtleties result in initial genetic screening not always focused on ARX. This is particularly 
relevant in the case of affected females. With the improvement in technology and increased 
diagnostic services, we have seen the implementation of whole genome sequencing, whole 
exome sequencing, and ID gene panels. Despite improvements in diagnosis with these 
tools, the high GC content of ARX means that even these sophisticated sequencing 
approaches often fail to reach adequate coverage across this gene. For example, exome 
sequencing using benchtop ion proton machines result in poor coverage of the ARX gene, 
with mean coverage reported at 43% (Lacoste et al. 2016). Although disease-causing 
variants occur across all five coding exons, most are located in the largest exon, exon 2, 
resulting in expansion mutations of the first or second polyalanine tracts. As most 
mutations are in the largest exon ARX mutation analysis is routinely confined to screening 
exon 2 using Sanger sequencing or PCR size analysis. To continue characterising this 
complex genotype-phenotype relation researchers (Poirier et al. 2006, Fullston et al. 2011, 
Tan et al. 2013, Marques et al. 2015) have designed specific sequencing conditions to 
provide comprehensive screening of the whole gene. The continued characterization of 
ARX variants not only contributes to the identification of specific phenotype features but 
also assists in unravelling the pathogenicity of additional rare variants. This type of 
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information and correct diagnosis has particular implications for accurate genetic 
counselling for families and furthering our understanding of the underlying biology of 
ARX. 
 
Result Chapter 3 Summary: An emerging female phenotype with loss of function 
mutations in the Aristaless-related homeodomain transcription factor.  
In my first result chapter (chapter 3) I present the outcomes of ARX screening in a family 
presenting ARX NDD. 
 
Hypothesis: Patients with negative results using gene panels or WES/WGS and clinical 
presentation compatible with ARX NDD will have an ARX mutation when tested by an 
optimised Sanger sequencing protocol.  
  
Aim: To provide comprehensive Sanger sequencing of the entire ARX gene in patients 
presenting with key clinical features associated with ARX mutations which may have also 
been missed by high-throughput sequencing technologies and targeted sequencing of the 
polyalanine tract 1 and 2 diagnosed screening. 
 
Expected Outcomes: Collate data of ARX mutations to highlight the relationships 
between genotype and phenotype ‘severity’. This information is required to be able to 
provide evidence-based recommendations for the consideration of pathogenicity in 
affected individuals with novel variants identified in ARX.  
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1.8 ARX is highly expressed during brain development  
ARX is expressed in several structures including the brain, pancreas, developing testes, 
heart, skeletal muscle and liver. However, the most striking consequences of loss of 
function of ARX concern the function and development of the brain and testis in both 
mouse and human (Kitamura et al. 2002, Colombo et al. 2004, Poirier et al. 2004). 
Considering the association between ARX mutations and congenital disorders involving 
ID, it is not surprising that the highest levels of ARX expression is found within the human 
fetal brain. Given the difficulties in mapping ARX expression during development in the 
human setting, researchers rely on surrogate models.  In mice, Arx expression is first 
detectable at the three-somite stage. After the 10-somite stage, Arx expression is confined 
to a specific area in the anterior neural plate (Colombo et al. 2004). By embryonic day 8 
(E8) Arx is expressed in the developing hypothalamus, thalamus, basal ganglia and 
cerebral cortex (Bienvenu et al. 2002, Colombo et al. 2004). By E10.5, the expression is 
clearly observed in the ventricular zone (VZ) of the dorsal cortex and begins to be 
expressed in the mantle zone of the emerging ganglionic eminences (GE) (Colombo et al. 
2004). Ventral telencephalic Arx expression is clearly present in the mantle zone of the GE 
at E12.5 (Figure 1.3 and Figure 1.4) (Colombo et al. 2004).  At later stages, it is widespread 
throughout telencephalic structures such as the ganglionic eminences, the cerebral cortex 
and the hippocampus (Bienvenu et al. 2002, Colombo et al. 2004, Poirier et al. 2004). This 
expression pattern remains until shortly after birth when the dorsal VZ and GE is no longer 
present, and ARX expression in the forebrain is observed only in scattered cells in the 




Figure 1.3 ARX expression throughout embryo development and in the brain across 
postnatal life. 
Images are taken from the Allen Mouse Brain Atlas show Arx expression at four embryonic 
developmental time points and three postnatal time points with the log expression (red = 
high and yellow – low) shown. Image credit: Allen Institute for Brain Science 
(http://mouse.brain-map.org). 
 
1.9 Modelling ARX mutations 
The functional role of ARX in the telencephalon is an active area of research by our 
laboratory and others. To understand the role of ARX in brain development, investigators 
have performed overexpression or loss-of-expression experiments using different models 
including X. laevis, C. elegans and M. musculus. Since the first description of ARX-related 
disorders, a number of Arx mouse models have been developed and have led to various 
insights into the disorder.  
 
Kitamura et al. (2002) generated a knock-out mouse replacing Arx exon 2 with LacZ gene, 
producing an Arx allele with a premature stop codon and resulting in a truncated protein. 
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These mice died at P0-P2 but were found to have many of the features of XLAG in humans. 
These mice have been instrumental in the study of the downstream targets of Arx and the 
alterations in interneurons, basal ganglia, and cholinergic neurons during brain 
development. Similarly, Collombat and colleagues created a mouse line with target knock-
out of exon 1 and 2, producing a mutant protein with the loss of the first 360 N-terminal 
amino acids (Collombat et al. 2003). As these Arx-deficient mice died 2 days after birth 
due to developing severe hypoglycemia, attributable to the loss of glucagon-producing 
alpha cells, no phenotypic or physiological analysis could be performed. Therefore, a series 
of other Arx mice lines were developed and published in 2009.  
 
A conditional knockout model was established using the Cre-Lox system to stop expression 
of Arx in cells expressing Dlx5/6, a transcription factor that is expressed in the majority of 
developing interneurons within the GE (Marsh et al. 2009). The male mice developed 
convulsive seizures at P14 and as indicated disruption to ARX function impacts 
development of interneuron subpopulations. In contrast to the mice modelling knock-out 
of Arx, models with known human mutations associated with disease were next to be 
generated. These include two mutations disrupting the homeodomain, one associated with 
the XLAG phenotype and the other with the XLID phenotype (Kitamura et al. 2009). Two 
mice models exist for a knock-in Arx mouse with the expansion of the first polyalanine 
tract, increasing the repeat size by 7 alanines (Kitamura et al. 2009, Price et al. 2009). 
Although it is essential to consider the limitations of each model when interpreting the 
various mutation-specific results, particularly when relating back to the human setting, the 
investigation of how Arx impacts normal brain formation and contributes to gene 
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regulatory networks of telencephalon development requires the continued use of these 
various Arx mutant mouse models. It is my hope by furthering our understanding of how 
Arx dysfunction contributes to varying degrees of cognitive dysfunction with and without 
epilepsy phenotypes, will contribute to the knowledge that will be vital to be able to 
generate potential therapeutic interventions for patients with Arx mutations. I predict that 
by identifying key regulatory events in brain development may provide mechanistic 
insights into other genetic disorders with overlapping phenotypes of ID and epilepsy. 
 
1.10 Understanding the functional role of ARX in interneuron development 
The loss of interneurons in patients with ARX mutations are believed to be a major 
contributor to the epilepsy and infantile spasms phenotype (Kato and Dobyns 2005). 
Interneurons make up 25% of human cortical neurons with almost all originating from the 
ganglionic eminences (Ma et al. 2013). Their dynamic modulation of cortical activity is 
necessary for normal cognition and underlies multiple aspects of learning and memory. 
Cortical interneurons collectively function to maintain the excitatory-inhibitory balance in 
the cortex by dampening hyperexcitability and synchronising activity of projection 
neurons, primarily through the use of the inhibitory neurotransmitter gamma-aminobutyric 
acid (GABA). Disruption of the excitatory-inhibitory balance is a common 
pathophysiological feature of multiple seizure and neuropsychiatric disorders, including 
epilepsy, schizophrenia, and autism. The mice modelling mutations or knock-out of Arx 
all indicate a pivotal role in tangential and radial migration (Figure 1.4) of a broad range 
of GABAergic interneuron precursors (Kitamura et al. 2002, Friocourt et al. 2008). The 
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extensive cellular co-localization of Arx with GABA in mouse (and human) brains, as well 
as the absence of interneurons documented in the cortex of XLAG patients and Arx mice,  
have led the field to propose ‘interneuronopathy’ as the term to describe the group of 
pathologies ARX are responsible for (Kato and Dobyns 2005). This ‘interneuronopathy 
hypothesis’ proposes that a developmental deficiency of inhibitory cortical interneurons 
caused by defects in proliferation, specification, differentiation and/or migration, result in 
epilepsy (Kato and Dobyns 2005, Marsh et al. 2009). Complete loss of Arx within the 
developing subpallium is detrimental for tangential migration of GABAergic interneuron 
precursors into the developing cortex such that a significant loss of a broad range of 
GABAergic interneurons was noted in mutant mouse models, with specific subtypes 
affected including calbindin (Cb), calretinin (Cr), acetylcholine (ChAT) positive cells in 
both cortex and striatum (Kitamura et al. 2002, Collombat et al. 2003, Fulp et al. 2008, 
Marsh et al. 2009). 
 
While a number of transcription factors have been identified as critical to establishing the 
diversity of interneuron subtypes, the specific role of these transcription factors, including 
Arx, in delineating interneuron subpopulations is incompletely understood. Early Mash1 
expression is known to set ventral forebrain identity (Rallu et al. 2002), and subsequent 
expression of Dlx1/2 is vital for interneuronal fate determination (Anderson et al. 1997a, 
Anderson et al. 1997b). The Dlx transcription factors, expressed early in the interneuron 
lineage, appear to be essential in controlling interneuron fate. Multiple other transcription 
factors (Nkx2.1, Lhx6, and Sox6) have also been identified as necessary for interneuron 
subtype determination, refinement of the lateral, medial and caudal ganglionic eminence 
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populations, and migration to the olfactory bulb, striatum, and cortex (Butt et al. 2005, 
Wonders and Anderson 2006, Hebert and Fishell 2008). Though it is clear that loss of Arx 
alters interneuron development, and that Arx function is primarily, though not exclusively, 
downstream of the Dlx transcription factors, the ultimate role of Arx in this process needs 
to be further elucidated (Colasante et al. 2008).  
 
 
Figure 1.4 ARX expression profile in key neuronal proliferative zones. 
A representation of a coronal section of the brain from an embryonic day 14 mouse and the 
major subdivisions of the telencephalic zones (left panel).  Ctx, cortex; LGE, lateral 
ganglionic eminence; MGE, medial ganglionic eminence; VZ, ventricular zone; SVZ 
subventricular zone, MZ, Mantel zone. The ARX expression profile in a coronal section of 
an embryonic day 14 mouse with the major migration pathways followed by neurons from 
the proliferative zones.  Green arrows follow tangential migration and red arrows represent 
the transverse migration across the cortex and radial migration into the 6 layer of the cortex. 
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1.11 ARX as a transcription factor 
ARX transcription activity is defined by the presence of a homeodomain consisting of a 
conserved 60 amino acid DNA binding domain. The homeodomain is comprised of three 
α-helices that are preceded by a flexible N-terminal arm. Helix II and III form a helix-turn-
helix major structural motif that folds to make contact with the major groove of DNA. 
Further contact with DNA is made in the minor groove as mediated by the N-terminal arm 
(Kissinger et al. 1990, Gehring et al. 1994). Because of this feature, homeodomain proteins 
are identified as DNA-binding transcription factors that recognise specific DNA sequences 
to access their target genes in the genome and to control their expression. The molecular 
mechanisms employed by homeodomain proteins to regulate transcription, such as ARX, 
are still poorly understood. A central issue is how homeodomain transcription factors select 
their target genes in the genome using a DNA binding domain with limited sequence 
specificity, which recognises short (four to six nucleotides), AT-rich sequences. A study in 
1988 identified a conserved 5’-TAAT-3’ motif as a binding site of high-affinity for 
numerous homeodomain proteins (Desplan et al. 1988), which is now accepted as the 
canonical homeodomain binding sequence. It was later confirmed by mutational studies 
that illustrated the preferred binding motif for engrailed is 5’-TAATTA-3’ (Ades and Sauer 
1994). Microarray and Chromatin Immunoprecipitation (ChIP) approaches have added to 
our general understanding of how ARX regulates gene expression in vivo and further 
defined possible targets and binding preferences.  
 
In addition to the homeodomain, the ARX protein contains a number of conserved 
domains, providing some insight into its potential role(s). The aristaless domain, which is 
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present in more than 40 other members of the paired class homeobox family is located off 
the carboxyl-tail of ARX. The function of this domain is not well understood, although a 
number of studies have shown it is involved in transcription activation (Figure 1.5) (Norris 
et al. 2000, Norris and Kern 2001, Collombat et al. 2003, Collombat et al. 2005, McKenzie 
et al. 2007). Four hydrophobic polyalanine tracts, located throughout the ARX protein, are 
suggested to be involved in protein-protein and protein-DNA interaction and as such to 
stabilise the interaction between transcription regulators and/or DNA (Brown and Brown 
2004). A study identifying 95 amino acids within ARX that includes the fourth polyalanine 
tract, showed this region is largely responsible for the transcription repression activity of 
ARX (McKenzie et al. 2007) (Figure 1.5). Also contributing to the repressive nature of 
ARX is a highly conserved octapeptide domain located near the N-terminus. This sequence 
shares high similarity with the Engrailed homology repressor domain (eh1) known to be 
involved in transcriptional repression both in vitro and in vivo. This domain recruits 
Grouch/transducing-like enhancer of split (TLE) co-factor protein (TLE1-4), which 




Figure 1.5 Mapping of the ARX transcription regulatory domains.  
 A schematic diagram showing the distribution and relative strength of the transcription 
activator and repressor domains along the ARX protein shown belong (adapted from 
McKenzie et al. 2007). 
 
1.12 Investigation of ARX-dependent transcriptional networks. 
Given that ARX is a transcription factor, defining the transcriptional targets and gene 
regulatory networks in which ARX participates has been essential in further elucidating its 
role in normal brain development and how disruptions in ARX lead to human disease. Due 
to the fundamental role that ARX plays in the brain, multiple studies have been conducted 
with the majority using complete knock-out of ARX to determine its regulatory function 
and specific impact on brain development. Although two gene expression profiles 
comparing E14.5 wild-type and Arx mutant ventral telencephalic tissues have recently 
been published in mouse, very few targets for this transcriptional factor have been 
described, and only three have been confirmed to be direct (Fulp et al. 2008, Colasante et 
al. 2009). Evidence indicates that Arx is primarily a transcriptional repressor, which binds 
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to the 5’ promoter region of Shox2, Ebf3, and Lmo1 and represses their expression.  
However, these studies focused on the ventral telencephalon for their gene expression 
experiments, thus possibly overlooking genes involved in neuroblast proliferation and/or 
radial migration. Using chromatin immunoprecipitation in Arx-transfected neuroblastoma 
cells (N2a) or E15.5 mouse embryonic brain, followed by hybridization to mouse promoter 
arrays (ChIP-chip), Quille et al. identified new direct targets of Arx (mouse) (Quille et al. 
2011). A total of 1006 Arx-bound genes were found, with a significant proportion of these 
promoters enriched for a sequence very similar to a motif previously identified as an ARX-
binding motif (6-mer 5’-TAATTA-3’). Similarly, Quille selected only one stage of 
development in the mouse for their ChIP experiment, and it is, therefore, likely that they 
have not identified genes involved in earlier steps such as brain patterning or later steps 
such as synaptogenesis and connectivity.  A limitation with overexpression studies is that 
Arx is not normally expressed in N2a cells and thus may lack binding partners and/or co-
factors necessary to regulate the expression of certain genes. Hence, while expression 
studies using Arx-transfected cell lines may provide important insights for further research, 
these studies are likely to underappreciate the full profile of ARX function.  
 
The question of how the loss of ARX in humans (and mice) results in the catastrophic 
XLAG phenotypes is unknown but must reflect significant alterations in ARX-dependent 
transcriptional networks. Gene expression studies have shown genes regulated (directly or 
indirectly) by ARX are involved in the patterning of the central nervous system, axonal 
guidance, neurodevelopment, and neurotransmission and neurite outgrowth (Quille et al. 
2011). Interestingly, these studies also suggest new possible functions for Arx, for example 
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in osteoblast differentiation or mesenchymal cell proliferation and differentiation (Quille 
et al. 2011).  
 
1.13 Polyalanine expansion mutations leads to partial loss of function  
Strikingly, mutations leading to the expansion of the first or second polyalanine tracts 
account for over half of the mutations reported in ARX (Shoubridge et al. 2010a, Marques 
et al. 2015).  It remains challenging to assess the true prevalence of ARX mutations given 
the potential ascertainment bias and also due to routine diagnostic screening of polyalanine 
1 and 2 findings often not reported. The in-frame 24 duplication (previously reported as 
c.429_452dup, now following HGVS nomenclature reported as c.441-464dup; referred to 
as PA220A mutation in this thesis) of the second polyalanine tract, and expansion of the 
first polyalanine tract (previously reported as c.304ins(GCG)7, now following HGVS 
nomenclature reported as c.306GGC[17] ; referred to as PA123A mutation in this thesis) 
are the most common. These two mutations alone are causative of an array of clinical 
presentations (Stromme et al. 2002, Absoud et al. 2010, Mirzaa et al. 2013, Marques et al. 
2015). It was commonly thought that there was a correlation between increasing expansion 
length and an increase in phenotype severity. However, the growing number of phenotypic 
reports for these mutations, have highlighted the expansion of this genotype-phenotype 
relationship. ARX polyalanine tract expansion mutations of the same size and composition 
can cause a range of overlapping, but distinct clinical phenotype and mutations in different 
tracts can result in the same clinical phenotype. Figure 1.6 captures the unusual span of 
variation in the clinical presentation, intra and interfamilial variability, associated with the 
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frequent expansion mutations in polyalanine tract 1 and 2, in particular, that has been 
noticed, but not adequately explained, and thus research is continuing into the molecular 
mechanism driving the pathogenesis associated with these mutations (Shoubridge et al. 
2007, Price et al. 2009, Fullston et al. 2011, Nasrallah et al. 2012, Beguin et al. 2013, Lee, 
K. et al. 2014, Olivetti et al. 2014).  
 
 
Figure 1.6 Clinical variability associated with expanded in polyalanine tract 
mutations in ARX. 
The panel above the graph shows the normal length of the polyalanine tract 1 (PA1) as 16 
alanine residues and polyalanine tract 2 (PA2) as 12 alanine residues. The graph shows the 
relationship between the number of alanines and phenotype severity in published families 
with polyalanine tract 1 (orange) and polyalanine tract 2 families (blue). The size of each 
circle is proportional to the number of reported cases. With increasing length of residues 
in the polyalanine tracts, the clinical presentation becomes more severe (adapted from 
Shoubridge et al. 2016).  
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1.14 Polyalanine tract expansion mutations 
1.14.1 Role of polyalanine tracts  
Almost 500 proteins have been identified in humans that contain polyalanine segments, 
making polyalanine tracts the third-most prevalent homopeptide repeat in eukaryotes, 
behind polyglutamine and polyasparagine (Bernacki and Murphy 2011). In contrast to 
polyglutamine tracts, which can tolerate a broad number of residues with expansions in the 
hundreds often required to produce disease, polyalanine tracts never consist of  >20 
alanines (Albrecht and Mundlos 2005) (Figure 1.7). Furthermore, they do not undergo the 
dynamic expansion that leads to the significant intergenerational increase of repeat length 
encoding glutamines.  
 
Figure 1.7 Distribution of polyalanine repeat-containing proteins in the genome, and 
the frequency of nuclear localisation. 
A genome-wide search based on Swiss-Prot and Trembl revealed a total of 461 proteins 
that contain polyalanine repeats between 7 to 20 alanines. Almost 50% (218) of these are 
known to have a nuclear localisation. (Albrecht and Mundlos 2005) 
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The function of polyalanine tracts within proteins has not been unequivocally confirmed. 
However, the interdomain or terminal location of the repeat tract within genes suggests that 
they may play a role as flexible space elements between individually folded domains in 
molecules, mediating protein-protein or protein-nucleic acid interaction. These tracts may 
also serve a function in mediating the assembly of protein complexes. Repeats of seven or 
more alanines are particularly common in transcription factors (Bernacki and Murphy 
2011) and in several transcription factors, alanine-rich regions have been shown to be 
responsible for activation/repression of target genes (Han and Manley 1993, McKenzie et 
al. 2007). Therefore it has also been proposed that polymeric runs might serve to fine-tune 
the activity of these transcription factors (Karlin and Burge 1995). Although the precise 
molecular mechanism of this activity via polyalanine tracts remains to be determined.  
 
1.14.2 Expansions to polyalanine tracts cause disease 
Unlike polyglutamine, expanded alanine tracts are stably transmitted across multiple 
generations, most giving rise to a number of congenital disorders (Figure 1.8) (Albrecht 
and Mundlos 2005). The ubiquitous RNA-binding protein PABPN1 has disease causing 
expansions to polyalanine tracts and is associated with the late onset disease 
oculopharyngeal muscular dystrophy (OPMD). In contrast, all other expansions occur in 
developmentally important transcription factors including SOX3 (X-linked 
Hypopituitarism), HOXA13 (hand–foot–genital syndrome), HOXD13 (synpolydactyly 
type II), PHOX2B (congenital central hypoventilation syndrome), FOXL2 
(blepharophimosis, ptosis and epicanthus inversus), ZIC2 (holoprosencephaly) and 
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RUNX2 (cleidocranial dysplasia) and ARX (Figure 1.8). The absence of any wild-type 
protein with a polyalanine tract exceeding 20 residues indicates that there is a critical 
threshold above which polyalanine expansion are not tolerated. The number of tracts within 
these proteins ranges between 1-4 while also varying in length and with no clear preference 
in location, extending right across the protein (Figure 1.8). The normal length of 
polyalanine tracts tends to be between 9-20 alanines with a sharp threshold for expansion 
(+1-14A) resulting in a disease phenotype (Figure 1.9). Wild-type proteins with tracts as 
low as 12A are prone to expansion (HOXA13 and ARX) with an addition of even a single 
alanine to tract 1 in ARX (16A to 17A) resulting in disease. The largest reported expansion 
is an addition of 14A in tract 3 of HOXA13 (18A to 32A) however the longest tract 
resulting is disease in an addition of 13A in tract 2 of PHOX2B resulting is a total tract 
length of 33A.  Both replication slippage and non-homologous recombination have been 
proposed to explain the increase in tract length and reviewed in Shoubridge and Gecz, 2012 
(Shoubridge and Gecz 2012). Despite considerable functional analyses, the mechanism by 





Figure 1.8 Polyalanine expansion mutations linked to eight developmentally important transcription factors.  
A brief description of the disease resulting from polyalanine expansions in the transcription factors listed. The protein structure 
highlights the main functional domain/s (light grey) and the number/location of polyalanine tract within each protein (grey). Tracts 
with reported expansions are in black.  
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Figure 1.9 Polyalanine tract expansions resulting in disease. 
Polyalanine tract rarely exceeds 16 alanine within a single tract. For each transcription 
factor with reported polyalanine expansion mutations, the number of alanine in each tract 
of wild type is shown in grey and reported expansions result in disease shown in orange. 
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1.15 Mechanisms of polyalanine expansion disease 
Protein aggregation occurs in the related polyglutamine disorders, where polyglutamine 
expansion confers a toxic gain of function (Davies et al. 1997, La Spada and Taylor 2010). 
In the case of polyalanine disease, nuclear inclusions that contain mutant PABPN1 protein 
are a hallmark of OPMD (MIM# 164300) (Calado et al. 2000). Together, this type of data 
suggests that aggregate formation might have a pathogenic role in polyalanine disease 
alleles with a gain of function activity. In support of this prediction, initial studies from 
multiple groups indicate that expansion of polyalanine tracts above a certain threshold may 
induce misfolding and aberrant protein interactions, degradation, mislocalisation and/or 
aggregation (Albrecht et al. 2004, Caburet et al. 2004, Bachetti et al. 2005, Utsch et al. 
2007, Moumne et al. 2008), including studies from our laboratory in regards to ARX 
(Shoubridge et al. 2007, Fullston et al. 2011). The thresholds at which these events occur 
differs between proteins, but all polyalanine tract proteins behaved similarly in vitro such 
that over-expression in cell culture results in the generation of cytoplasmic and/or nuclear 
aggregates (Albrecht et al. 2004, Caburet et al. 2004, Nasrallah et al. 2004, Bachetti et al. 
2005, Shoubridge et al. 2007, Fullston et al. 2011). Out of a cellular context, filter 
precipitation assays have demonstrated that polyalanine expansion proteins are extremely 
prone to spontaneously from aggregates compared to wildtype proteins (Albrecht et al. 
2004). This indicates that the polyalanine expansion is necessary and sufficient for 
aggregation of the protein. All polyalanine expansion mutations that have been modelled 
in cell assays show a clear correlation between increasing expansion length and the 
propensity to aggregate and mislocalise (Albrecht and Mundlos 2005, Fullston et al. 2011), 
contributing to the prediction that the length of the tract contributes to phenotypic severity.  
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Apart from OPMD, for all diseases due to expanded polyalanine tract mutations, the human 
data on in vivo aggregation of mutant proteins is not available or not supportive of 
aggregation as a mechanism. Hence, the critical question of whether aggregates form in 
vivo and, if so, how they may be implicated in the pathogenesis of loss of function 
polyalanine diseases remains to be answered. The growing evidence, however, does 
indicate that aggregation formation is likely to be an inherent artefact due to the 
overproduction and/or inefficient degradation of the mutant proteins due to in vitro 
overexpression. As such, when mutant protein is studied at physiological levels, 
aggregation does not seem to occur. Retroviral infection systems permitting incorporation 
of a single gene copy per cells (Albrecht et al. 2004) and targeted mutagenesis of embryonic 
stem cell lines (Hughes et al. 2013) have been used to test the effect of low levels of 
polyalanine expansion mutant proteins. Both these systems expressing either HOXD13 
(Albrecht et al. 2004) or SOX3 (Hughes et al. 2013) at a physiological dose revealed a 
dramatic reduction of the mutant protein.  
 
Over the last decade, a number of polyalanine expansion mutation mouse models have 
been generated to study the phenotypic outcomes of these common mutations seen in 
humans and include Hoxd13 (15Ala+9Ala) (spdh) (Bruneau et al. 2001), Hoxa13 
(18Ala+10Ala) (Innis et al. 2004), ARX (Kitamura et al. 2002, Price et al. 2009), Phox2B 
(20Ala+7Ala)(Dubreuil et al. 2008) and Sox3 (15Ala+11A)(Hughes et al. 2013). Whilst 
limited molecular work has been completed on these models, a lack of in vivo aggregation 
and instead a reduction of protein is a consistent finding across all models (Bruneau et al. 
2001, Albrecht et al. 2004, Innis et al. 2004, Goridis et al. 2010, Hughes et al. 2013, Lee, 
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K. et al. 2014).  Immunohistochemistry and immunoblot analysis show the differing extent 
of the reduction to mutant protein levels in the heterozygous and homozygous states for 
SOX3 (Hughes et al. 2013). Hoxd13 protein in spdh/+ showed a reduction by ~50% in the 
heterozygous and by ~90% in the homozygous spdh/spdh animals. This was mirrored in 
the Hoxa13 model, and even though no reduction of protein is noted from phox2b27ala/+ 
(Dubreuil et al. 2008), protein cannot be visualised in the phox2b27ala/lazC model 
(Goridis et al. 2010).   
 
It is unclear if polyalanine expansion causes partial loss of function, a toxic gain of function 
or a dominant negative effect. Of the nine genes reported with polyalanine expansion 
mutations, seven are located on the autosomes. The predicted mechanism of protein 
dysfunction for these autosomal genes becomes complicated by the fact heterozygotes 
carry one wild-type allele and one mutant allele. Cells specifically expressing the genes in 
question will, therefore, have both wild-type and mutant protein present in the same cell 
leading to this heterozygotes states with a more severe phenotype than a heterozygous null 
mutation.  This dominant negative or toxic gain of function is thought to arise from the 
mutant protein sequestrating the wild-type protein and/or other factors. The remaining two 
genes, ARX and SOX3 are located on the X-chromosome and due to X-inactivation in 
females, do not result in expression of both mutant and wild-type protein in a single cell. 
Thus, characterisation with X-linked models of the effect of polyalanine expansion 
mutations on protein function and the molecular mechanism behind disease can be 
elucidated without the added complexity of the presence of wild-type protein. 
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1.15.1  ARX polyalanine expansion mutations modelled in mice 
Currently, two mouse models of the most common ARX polyalanine expansion mutations 
have been generated. There are two independently generated mouse models for the 
expansion in the first polyalanine tract from 16 to 23Ala (Arx(GCG)7 referred to as PA1 
throughout this thesis), (Kitamura et al. 2009, Price et al. 2009); and one mouse model for 
the expansion of the second tract from 12 to 20Ala (Arx432-455dup24 referred to as PA2 
throughout this thesis) (Kitamura et al. 2009). As mentioned previously, patients with these 
mutations display a wide spectrum of clinical presentations, ranging from mild intellectual 
disability only to intellectual disability with early onset of epileptic seizures (Ohtahara 
syndrome). Similarly, these mouse models recapitulate many of the phenotypic features 
(Kitamura et al. 2009, Price et al. 2009). Kitamura et al. (2009) reported nuclear 
localisation in 12.5dpc GE-originated migrating cells and in 18.5dpc cortical interneurons 
(18.5dpc) in the two mouse models, PA1 and PA2, that recapitulate the respective human 
mutations (Kitamura et al. 2009). In contrast, Price et al. (2009) reported an increased Arx 
cytoplasmic localisation in the cerebral neurons from adult brains of their independent 
mouse line modelling the PA1 mutation. Our subsequent investigations of both PA1 and 
PA2 mice (originally from Kitamura 2009) confirm that aggregate formation is an unlikely 
pathogenic hallmark for ARX polyalanine expansion mutations, and as such, alternative 
mechanisms require investigation.  
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1.16 Alternative mechanisms of polyalanine expansion pathogenesis 
Although a reduction of mutant polyalanine expansion proteins has been shown, no change 
in mRNA across multiple genes has been detected (SOX3 (Hughes et al. 2013), HOXA13 
(Innis et al. 2004), ARX (Lee, K. et al. 2014), HOXD13 (Bruneau et al. 2001, 
Villavicencio-Lorini et al. 2010)). Therefore, the reduction in mutant protein is 
hypothesised to result from either a disruption in translation efficiency of the RNA 
encoding the expanded protein or degradation of the mutant protein in vivo. At present, the 
evidence indicates that post-translational etiology may be involved. In support, in vitro 
transcription/translation of SOX3-26ala and HOXA13-28ala shows no difference in the 
translation efficiency of polyalanine expansion proteins compared to wild type (Innis et al. 
2004, Hughes et al. 2013). However, this has not been confirmed in vivo.  
 
1.16.1 Mutant polyalanine expansion proteins are degraded via the proteasome.  
Inhibition of the proteasome results in increased aggregation indicating the proteasome 
plays a significant role in the clearance of polyalanine expansion mutant proteins (Albrecht 
et al. 2004, Di Zanni et al. 2012, Parodi et al. 2012). On the other hand, up-regulation of 
hsp40 and hsp70 (two heat shock proteins involved in recognition and refolding denatured 
molecules and disassembly intracellular protein aggregates) drastically reduces aggregate 
formation in overexpression studies and leads to an increase in nuclear localisation of the 
transcription factor (Albrecht et al. 2004, Bachetti et al. 2005, Utsch et al. 2007).  Taken 
together, this data suggests polyalanine expansion mutations do not intrinsically disrupt 
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nucleus translocation of the protein and can sustain nuclear localisation provided 
aggregation does not occur. Furthermore, indicates that mutant protein is normally 
degraded by the proteasome. 
 
Expansion of polyalanine tracts has also been reported to increase the turnover of the 
mutant protein in comparison to wildtype (Parodi et al. 2012). Cycloheximide treatment 
showed the half-life of the polyalanine expansion protein was half that of wildtype 
indicating that the presence of an expanded polyalanine tract increases the turnover rate of 
the protein (Parodi et al. 2012). Therefore, it is hypothesised that the polyalanine expansion 
modifies the stability of mutant proteins. Degradation of expanded polyalanine tract 
proteins by the ubiquitin-proteasome system are indicated by mutant proteins having a 
higher degree of ubiquitination and proteasome inhibition resulting in increased 
accumulation of mutant protein (Parodi et al. 2012).  Thus, at low (physiological levels) of 
production, the mutant protein can be efficiently degraded via the proteasome, and we can 
speculate that in vivo the mouse has a protective mechanism against the formation of 
aggregates.  
 
1.16.2 Functional consequences of polyalanine expansion mutations. 
The regulation of transcription by these developmentally important transcription factors is 
complex, involving many interactions that are tissue and developmental stage-specific. In 
vitro assays of transcriptional activity are highly simplified and are likely to detect only 
severe alterations in transcription factor function. Some constraints of in vitro assays 
include the interpretation of result as the finding that a mutation results in near-total loss 
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of activity in such as assay implies that the protein must be altered such that very basic 
components of the transcriptional machinery do not function correctly. Transactivation 
assays using firefly luciferase reporter constructs with various proximal promoters saw a 
correlation with the length the alanine expansion and decrease in activity (Brown et al. 
2005, Woods et al. 2005, Bachetti et al. 2007). However determining the effect of 
increasing alanine tract length on activity of the protein as a transcription factor seems to 
be problematic as a reduction of similar magnitude to the reduced luciferase outputs is also 
observed with lower nuclear protein levels of the mutant protein due to aggregation which 
is an inherent defect of in vitro overexpression systems (Hughes et al. 2013). Therefore, 
this would suggest that the mutant protein that is present in the nucleus has similar activity 
to WT or is there still an inherent defect in the mutant protein transactivation activity. To 
combat this, various treatments shown to reduce aggregation have been added to cell 
culture to alleviate the impact of aggregation on the transactivation assay system (Bachetti 
et al. 2007, Di Zanni et al. 2012, Parodi et al. 2012). Successful treatments showed to 
enhance the refolding which prompts the correct localisation of the remaining protein to 
the nuclear with a decrease in aggregate formation (Bachetti et al. 2007, Di Zanni et al. 
2012). PHOX2B polyalanine expansion proteins were shown to recover their 
transactivation activity when two of the shorter expansion were tested (20Ala+5Ala & 
+9Ala) however the largest expanded alanine tract mutation (20Ala + 13Ala) could only 
regain part of the transcriptional activity.  
 
Any loss of activity does not appear to be due to the inability of the protein to bind to DNA 
(Woods et al. 2005, Takagi et al. 2014) indicating it could be due to an alteration in some 
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other function of the protein. Many of these transcription factors harbouring polyalanine 
expansion can function as both activators and repressors. In the case of ARX, recent data 
indicates, polyalanine expansion mutations have loss of function at only selective targets 
in vivo (Lee, K. et al. 2014) indicating partial loss of function is in a context-dependent 
manner. It still needs to be established whether the transcriptional impact of the polyalanine 
expansion mutations depends on the nature of the promoter. Furthermore, it is unclear 
whether different target promoters have different sensitivities to decreased amount of 
available mutant protein if selective protein-protein interactions are perturbed, or DNA 
binding is affected. 
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1.17 Summary of understanding the molecular mechanism of polyalanine expansion 
mutations in ARX causing ID and seizures 
Result Chapter 4 Summary: Embryonic forebrain transcriptome of mice with 
polyalanine expansion mutation in the Arx homeobox gene 
 
While in vitro methods have permitted a rapid growth in our understanding of Arx-driven 
molecular pathology and transcriptional defects, the use of rodent models engineered with 
Arx mutations remains necessary. It highlights the importance to investigate how 
endogenously expressed mutant Arx proteins alter specific steps in interneuron 
development leading to the neural circuit deficits and clinical features. The recent studies 
investigating how Arx mutations alter function, the identification of novel transcriptional 
targets (Fulp et al. 2008, Colasante et al. 2009, Quille et al. 2011), and the creation of 
clinically relevant models of ARX, represent a significant advance towards understanding 
the pathogenesis of human ARX-mediated disease. In my research, a major aim was to 
examine the early consequences of altered transcriptional activity of ARX due to the 
polyalanine expansion mutations during embryonic development in mice modelling the 
most frequent mutations in polyalanine tract 1 and 2 (Kitamura et al. 2009). This approach 
will enable us to examine the expanded polyalanine tract containing protein in an 
endogenous setting to determine if expanded polyalanine tract in Arx have a functional 
impact on binding to transcriptional targets and transcriptional activity in a relevant 
neuronal cell environment. Together with the genome-wide expression data, we aim to 
identify affected gene targets that contribute to the manifestation of clinical features of the 
associated disease outcomes. Gene expression patterns driven by ARX mutations can also 
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be examined to highlight genes whose precise roles in neurodevelopment have yet to be 
described. The mouse models used will be valuable tools to validate downstream gene 
changes in the context of the development brain, and an opportunity to link these with the 
human neurological phenotypes. These models are also likely to provide useful tools for 
investigating novel therapies for ARX-related diseases, for which only limited treatment 
options exist.  
 
Hypothesis: Expanded polyalanine tract mutations in Arx alter the capacity of Arx as a 
transcription factor in vivo leading to the phenotype observed in patients. 
 
Aim: By transcriptome-wide analysis determine the consequences of polyalanine tract 
expansions mutations on Arx ability to act as a transcription factor in vivo.  
 
Aim: To determine the transcription changes caused by expansion polyalanine tract 
mutations in Arx contributing to intellectual disability and seizures.  
 
Expected outcomes: To identify transcriptional targets and differences in deregulated 
targets due to the more severe PA12-3A compared to the milder PA2-20A expanded 
polyalanine tract mutations contributing to the spectrum of phenotype severity. 
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Result Chapter 5 Summary: Investigating the molecular mechanism of how polyalanine 
expansion mutations in ARX lead to a partial loss of function. 
 
Years of in vitro data indicate the poly-A tract expansions result in nuclear inclusions most 
likely caused by misfolding of the mutant protein. However, the lack of inclusions or 
aggregates in neurons in the brains of our mouse models suggests that aggregation is not 
the likely pathogenic mechanism contributing to disease. Hence, another major aim of my 
research was to consider and investigate alternative mechanisms. As the reduction in 
mutant protein levels is a consistent feature across multiple polyalanine expansion models 
determining the molecular mechanism driving this reduction may provide important 
insights for treatment across all polyalanine expansion disorders. 
 
Hypothesis: Reduction of ARX polyalanine expansion mutant protein abundance drives 
disease in a dose depend manner. 
 
Aim: To determine whether the mutation or reduced protein contributes to the partial loss 
of function and the phenotype severity between PA1-23A and PA2-20A.  
 
Aim: To establish if inefficiency of translation or increase in degradation underpins the 








Material and Methods 
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2 Material and Methods 
2.1 General solutions 
PBS: Phosphate Buffered Saline; 10X: 1.37M NaCl, 27mM KCl, 100mM Na2HPO4, 
20mM KH2PO4, adjusted to pH7.4 
TBS: Tris Buffered Saline: 50mM Tris-Cl, 150mM NaCl, adjusted to pH7.4 
TBE: Tris/Borate/EDTA: 89mM Tris, 89mM boric acid, 2mM EDTA, pH7.6 
2.2 Patient screening 
2.2.1 DNA extraction 
The extraction was set up in a 1.5 ml Eppendorf screw cap tube (containing the cell pellet) 
with 400 µl of proteinase K buffer, 50 µl of 10% SDS and 50 µl of 10 mg/ml proteinase K 
(final concentration 1 mg/ml (Proteinase K, recombinant, PCR Grade Cat#03115836001, 
Roche). The tube was sealed off with laboratory film (Parafilm, Cat# MNP52858-000, 
VWR) to prevent leakage and placed on rotating wheel overnight at 37°C. DNA was 
isolated from water insoluble cell components by extracting twice with Phenol/chloroform 
(1:1 ratio). Aqueous and organic phases were separated by centrifugation for 5 minutes at 
10,000 x g between each extraction. To remove RNA contamination, 2 µl of RNase A 
(RNase A (17,500 U) made up to 2.5 ml (100 mg/ml; 7000 units/ml, solution), Cat#19101, 
QIAGEN) was added to the DNA mixture and incubated for 1 hour at 37°C. DNA was 
precipitated by adding ice cold absolute ethanol (EtOH) and incubated at -20°C for 30 
minutes, then centrifuged at 10,000 x g for 10 minutes. All supernatant was discarded, and 
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the DNA pellet was dried under vacuum. The dried DNA pellet was resuspended in 100-
300 µl of H2O depending on the size of the original sample. DNA concentration was 
determined by measuring absorbance at 260 nm using a UV spectrophotometer (Nanodrop, 
Cat#ND-1000). 
2.2.2 Patient screening 
The screening protocol were approved by the appropriate institution review board, and 
informed consent was obtained from the parents of patients via clinical genetics colleagues. 
Genomic DNA from the proband was extracted from whole blood using standard 
techniques. Each of the five exons of ARX was amplified by PCR using primers designed 
to amplify coding and flanking non-coding sequence. The exception to this was exon 2, for 
which four overlapping amplicons were used to achieve robust amplification of GC-rich 
regions coding for three polyalanine tracts. The PCR conditions and primer sequences 
(Table 2.1) and are described in detail previously (Tan et al. 2013). All primer sequences 
are based on the human sequence of the ARX gene [NG_008281.1]. Sequencing reactions 
were performed using ABI Big Dye terminator chemistry version 3.1 and purified products 
subjected to an automated capillary sequencing on ABI 3100 sequencer (Applied 
Biosystems, Foster City, CA, USA) and sequence was compared to the ARX reference 
sequence (NM_139058) using SeqMan module of the Lasergene DNA and protein analysis 
















1  ARXe1-F Forward GTCCACTACACTTGTTACCGC 21 60 520 
1  ARXe1-R Reverse AATTGACAATTCCAGGCCACTG 22 
  
2.1 CH-ARX2F Forward CTGATAGCTCTCCCTTGCCC 20 60 262 
2.1 CH-ARX2JR Reverse GCGGCCCCTGCGCCGTCCGGCCGTTC 26 
  
2.2 CH-ARX2J-F2 Forward CCCCTCCGCCGCCACCGCCAAC 22 60 313 
2.2 CH-ARX2J-R2 Reverse TCCTCCTCGTCGTCCTCGGTGCCGGT 26 
  
2.3 ARX02-2F Forward GCAAGTCGTACCGCGAGAACG 21 60 371 
2.3 ARXE2-R7 Reverse CAGCTCCTCCTTGGGTCACA 20 
  
2.4 ARXE2P2-F5 Forward AACTGCTGGAGGACGACGAGG 21 60 392 
2.4 ARX02-R2 Reverse TGCGCTCTCTGCCGCTGCGA 20 
  
3 ARXe3-F Forward GAAATAGCTGAGAGGGCATTGC 22 60 231 
3 ARXe3-R Reverse TCTCTTGGTTTTGTGAAGGGGAT 23 
  
4 ARXe4-F Forward GACGCGTCCGAAAACAACCTGAG 23 60 551 
4 ARXe4-R Reverse CCCCAGCCTCTGTGTGTATG 20 
  
5 ARXe5-F Forward ACAGCTCCCGAGGCCATGAC 20 60 347 




2.2.3 PCR product purification 
The QIAquick PCR purification kit (Cat#28106, QIAGEN) was used to remove 
components of the PCR reaction (unused primers) that may interfere with subsequent 
sequencing reactions. Whole PCR reaction volume mixed with five-time volume of buffer 
PB. Up to 600 µl of the PCR and buffer PB was transferred into the QIAquick spin column, 
and centrifuged in a conventional tabletop microcentrifuge at room temperature (15–25°C) 
at 10,000 x g to bind PCR products onto the membrane. The membrane was washed once 
with 700 µl of buffer PE. All flow through was discarded, and the column was centrifuged 
again at 15, 000 x g for 5 minutes to evaporate all leftover alcohol. PCR bands were eluted 
in 30 µl of H2O.  Purified PCR product concentration was determined using the UV 
spectrophotometer (Nanodrop, Cat#ND-1000) and stored at 4°C until further use. 
2.2.4 Sanger sequencing reaction  
Purified DNA was sequenced using BigDye™ Terminator sequencing kit (Applied 
Biosystem™ BigDye® Terminator v3.1 Cycle Sequencing Kit, Cat#4337455, 
ThermoFisher). The reaction was set up in 20 µl volume containing DNA (~100 ng of 
genomic DNA or 400 ng of plasmid DNA), 1 µl of primer at 10µM, 1 µl of BigDye™ 
V3.1, 3 µl of BigDye™ Buffer v3.1 and distilled H2O. Sequencing conditions were: 15 
cycles of denaturation at 96°C for 30 seconds, annealing at 50°C for 15 seconds and 
extension at 60°C for 4 minutes. Precipitation of sequencing products was achieved by the 
addition of 20 µl of distilled H2O and 60 µl of 100% isopropanol, incubated at room 
temperature for 15 minutes and centrifuged for 20 minutes at 15,000 x g. A second wash 
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with 250 µl of 70% isopropanol and centrifuged for 10 minutes at 15, 000 x g, prior to the 
precipitated DNA being air dried for 10 minutes to remove any residual solvents. Dried 
sequencing products were size fractionated by capillary electrophoresis using an ABI 
automated DNA sequences by a service provided by the Molecular Genetics Laboratory, 
Genetic Medicine, SA Pathology (Women’s and Children’s Hospital, Adelaide, Australia).  
2.2.5 X-inactivation testing 
Genomic DNA (2 µl total with a final DNA concentration of 100ng/µl) was digested with 
1.5 µl (15 Units) of HpaII enzyme (Cat#R0171S, NEB), 2 µl of 10x CutSmart Buffer 
(Cat#B7204S, NEB) and diluted in H2O to a final volume of 20 µl and incubated overnight 
at 37°C (minimum incubation period is 3 hours). An enzyme minus sample was also 
conducted for comparison of an uncut DNA sample. The enzyme was heat inactivated at 
80°C for 20 minutes. Routinely we undertake PCRs targeting the highly polymorphic CAG 
repeat region in exon 1 of the Androgen Receptor (AR) gene and the CGG repeat region 
in the 5’ UTR of the fragile X gene (FRAXA), amplified with fluorescently labelled 
primers.  PCR reaction set-up and cycle conditions listed in Table 2.2 for AR and  
Table 2.3 for FRAXA and primer details in Table 2.4. 
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Table 2.2 Androgen Receptor PCR reaction and cycle conditions. 
PCR Reaction  PCR Cycle Conditions 
H2O 1.6 µl 94°C – 3 mins  
2x Homemade PCR mix 5 µl 94°C – 30 secs 
X10 
cycles 
15mM MgCl2 1 µl 60°C – 30 secs 
AR mix (150ng ea. Oligo) 1 µl 72°C – 30 secs 
1M BME 0.2 µl 94°C – 30 secs 
X 12 
cycles 
Roche Taq 0.2 µl 55°C – 30 secs 
DNA (100ng/ µl) 1 µl 72°C – 30 secs 
Total 10 µl 72°C – 10 mins  
  14°C – Hold  
 
Table 2.3 FRAXA PCR reaction and cycle conditions. 
PCR Reaction  PCR Cycle Conditions 
H2O 3.4 µl 94°C – 3 mins  
10x PCR Buffer(+15mM MgCl)* 1 µl 94°C – 30 secs 
X10 
cycles 
5x Q solution* 2 µl 60°C – 35 secs 
FRAXA mix (75ng ea. Oligo) 1 µl 72°C – 60 secs 
7deaza G dNTP mix 1.2 µl 94°C – 30 secs 
X 12 
cycles 
Hot Star Taq (1/10 diln in pure H2O)* 0.2 µl 55°C – 35 secs 
Roche Taq (neat) 0.2 µl 72°C – 60 secs 
DNA (100ng/ µl) 1 µl 72°C – 10 mins  
Total 10 µl 14°C – Hold  
*Items from HotStarTaq DNA Polymerase Kit (Cat#203203, QIAGEN) 
 
Table 2.4 X-inactivation Primers. 





FRAXA-Forward Hex GCTCAGCTCCGTTTCGGTTTCACTTCCGGT 30 309 
FRAXA-Reverse Hex AGCCCCGCACTTCCACCACCAGCTCCTCCA 30  
Androgen Receptor-
Forward 
Fam TCCAGAATCTGTTCCAGAGCGTGC 24 279 
Androgen Receptor-
Reverse 




2.3 Animal model – in vivo analysis 
2.3.1 Animals and tissue collection 
Heterozygous female ArxGCG7/+ (PA1) and Arx432-455dup/+ (PA2) mice were obtained as 
described in (Lee, K. et al. 2014) and were maintained in the C57BL background. We will 
refer to these mice as PA1 and PA2 throughout this thesis. All animal procedures were 
approved by the relevant Animal Ethics committees of the University of Adelaide, SA 
Pathology and the Women’s and Children’s Hospital, Adelaide.  Mice were housed in the 
Women’s and Children’s Hospital Animal House (North Adelaide, Australia) from 2011-
2014 and in the Laboratory Animal Services (LAS), the University of Adelaide (Adelaide, 
Australia) from 2014, onwards. Mice were kept in a 12 hour day: night light cycle with ad 
libitum water and food. When mice were re-located to the LAS facility, the mice were 
housed behind the barrier under a specific pathogen free environment. For tissue collection, 
the animals were sacrificed by cervical dislocation (2 weeks or older) or decapitation 
(neonates and embryos) to achieve rapid death and to minimise distress to animals. 
2.3.2 Embryo collection and tissue extraction 
Pregnant dams were euthanised by cervical dislocation and embryos were harvested from 
the uterus. As embryos of the same gestational age may differ in their stage of development, 
each embryo was staged to allow for correct age matching of samples. For younger 
embryos (12.5 dpc) somites were counted, and for older embryos (14.5 dpc) the 
development of the eye, limb and tail formation details were taken into account to classify 
the theiler stage of an embryo. For detailed descriptions of staging criteria and theiler 
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classifications see (Theiler 1989). Skin and ectodermal layers were removed to isolate the 
telencephalic vesicles. Samples were snap frozen in liquid nitrogen and stored at −80°C 
until analysed.  
2.3.3 Tissue lyse/genotyping 
Genomic DNA was extracted as per Maxwell® 16 Tissue DNA purification Kit manual 
(Promega™ Maxwell™ 16 Purification Kits, Cat#PRAS1030, Fisher Scientific) or as per 
High Pure PCR Template Preparation Kit manual for tissue samples (Cat#11796828001, 
Roche). PCR was performed using FailSafe™ PCR 2X PreMix J (Epicentre, 
Cat#FSP995J_INCL, Gene Target Solutions) for 35 cycles of 30 seconds of 94°C for 
denaturation, 30 seconds of 60°C for annealing and 40 seconds of 72°C for elongation. 
Primers to amplify the Arx knock-in region were described (Kitamura et al. 2009) and are 
listed in Table 2.5. We also included a Sry sexing PCR as part of our genotyping pipeline 
as described in (Lee, K. et al. 2014) and listed in Table 2.5. 
Table 2.5 Mouse Genotyping PCR Primers. 











Sry-F Forward CACTGGCCTTTTCTCCTACC 20 60 349 





TGTTCAATGGCCGATCCCAT 20 60  
mArx jjr Reverse CTTTAGCTCCCCTTCCTGGCACAC 24 60  
mArx kkf 
Forward 
AAAGGCGAAAAGGACGAGGAAAGG 24   
PA1 
mutation 




ACCTCTCCACGGGGACCT 18   
PA2 
mutation 
mARX-Dp24 Forward AGGGGAGCGTCAGGACAG 19 60 282 
mARX-Dp24 Reverse AACAGCTCCTCCTCGTCGT 19   
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2.4 Transcriptome analysis 
2.4.1 RNA extraction 
RNA was extracted from the isolated telencephalon of hemizygous male mice of each 
strain (PA1 and PA2) and stage matched male wild-type littermates (WT) using Trizol 
(TRIzol® Reagent, Cat#1559026, ThermoFisher) and RNeasy Mini Kit (Cat#74104, 
QIAGEN) and RNase-Free DNase set (Cat#79254, QIAGEN).  Frozen tissue samples were 
thoroughly homogenised in 500 µl of TRIzol® Reagent, and the sample progressively 
passed through a 1 ml pipette tip, 200 µl pipette tip and a 25G needle until completely 
homogenised and left at RT for no longer than 5 minutes. 200 µl of chloroform was added 
to the tube. The tube was shaken vigorously for 1 minute and left for 2-3 minutes at RT for 
the layers to separate, then centrifuged at 10,000 x g for 15 minutes at 4°C. The upper 
aqueous phase containing RNA was transferred to a fresh tube (usually about 350 to 600 
µl). A similar amount of 70% EtOH was added to the tube and mixed well by pipetting. 
Up to 700 µl of the supernatant was transferred to an RNeasy mini column and centrifuged 
at 10,000 x g for 1 minute to bind RNA to the membrane. The flow-through was discarded, 
and the process was repeated until all aqueous phase and EtOH mixture has been used up. 
The column was washed once with 350 µl of buffer RW1. DNA was removed by adding 
80 µl of DNase I from RNase-Free DNase Set (Cat#79254, QIAGEN) incubation mix (70 
µ of buffer RDD and 10 µl of DNase I Stock) right onto the membrane. The DNase reaction 
was left at RT for 15 minutes. The membrane was washed again with 350 µl of buffer 
RW1, then twice with 500 µl of buffer RPE. RNA was eluted in 30 µl of RNase-Free H2O. 
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RNA concentration was determined us the UV spectrophotometer (Nanodrop, Cat#ND-
1000). 
2.4.2 RNASeq 
Library preparation using the TruSeq RNA Sample Preparation Kit v2 was performed on 
4.5 µg of RNA at the ACRF South Australia Cancer Genomics Facility (Adelaide, 
Australia). Samples (n=4 each from WT, PA1, PA2) were sequenced on the Illumina (San 
Diego, CA, USA) HISeq 2000 platform. 100 bp paired-end reads were obtained and were 
mapped to the mouse genome reference sequence (UCSC mm10).  The number of reads 
mapped to each gene was obtained using htseq-count (Anders et al. 2015). In order to 
correct for variation between lanes/samples, the count data was normalised to library size. 
Genes with low count data were excluded, the minimum required at least 2 sample having 
> 60-177 reads.  Differential gene expression was calculated using the R package, edge R 
(Robinson et al. 2010). Transcripts significantly altered compared to WT were selected by 
applying a log2 fold change-cutoff of 1.1 and p-value cutoff of ≤0.05. 
2.4.3 RNASeq validation – RT-PCR 
RNA-Seq results were validated using TaqMan RT-qPCR on two pools of RNA, a 
technical validation pool using RNA from the same samples used the RNASeq and a 
separate biological validation pool of RNA from 4 different samples of each genotype. 
RNA was extracted as per 2.4.1. cDNA was prepared as described in SuperScript III 
reverse transcriptase (Invitrogen™ SuperScript® III Reverse Transcriptase, 
Cat#18080093, ThermoFisher) manual with 1µg of RNA primed by random 
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hexanucleotides. Along with samples, template negative and reverse transcriptase negative 
controls were included to determine product specificity. Genes selected for validation 
studies were assayed as described in TaqMan® PreAmp Master Mix Kit user guide 
(Applied Biosystem). For each validation gene quantified with a Taqman® probe labelled 
with FAM, the expression values were normalised to the reference gene Gapdh assayed in 
the same well using the Taqman probe labelled with VIC. RNA was also extracted from 
12.5, 14.5 and 18.5 dpc telencephalon and pooled before cDNA was prepared (as described 
previously). Expression of genes was determined using TaqMan® PreAmp Master Mix 
with gene specific Taqman probes labelled with FAM. The expression values were 
normalised to the reference gene Tbp which we confirmed was stably expressed across the 









Gene ID Taqman assay ID Label 
Alx1 Mm00553295_m1 FAM 
Arx Mm00545903_m1 FAM 
Asphd1 Mm01278674_m1 FAM 
Aspm Mm00486659_m1 FAM 
Barx1 Mm01353100_m1 FAM 
Cdkl5 Mm01156815_m1 FAM 
Cxcr5 Mm00432086_m1 FAM 
Ebf1 Mm00432948_m1 FAM 
Egr3 Mm00516979_m1 FAM 
Erbb4 Mm01256793_m1 FAM 
Esrp1 Mm00839264_m1 FAM 
Gabbr2 Mm01352554_m1 FAM 
Gpr26 Mm01165717_m1 FAM 
Kcna3 Mm00434599_s1 FAM 
Lmo1 Mm00475438_m1 FAM 
Myt1l Mm00485408_m1 FAM 
Nrp Mm02391703_s1 FAM 
Pitx2 Mm01316994_m1 FAM 
Plcxd3 Mm01307828_m1 FAM 
Sacs Mm0131311_mH FAM 
Six2 Mm03003557_s1 FAM 
Six6 Mm00488257_m1 FAM 
Sorl1 Mm01169526_m1 FAM 
Tenm1 Mm00600053_m1 FAM 
Tnr Mm00659075_m1 FAM 
Twist1 Mm04208233_g1 FAM 
Zfp536 Mm00552423_m1 FAM 
Hprt Mm03024075_m1 VIC 
Gapdh Mm99999915_g1 VIC 
Tbp Mm01277042_m1 VIC 
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2.4.4 Functional annotations 
Statistical analysis of the enrichment of Gene Ontology (GO) categories was performed 
using EnrichR, a bioinformatics tool that retrieves molecular information from 
transcription factor databases and defines transcription factors statistically enriched from 
gene lists (Chen et al. 2013). To rank the enrichment results we used the score calculated 
by EnrichR using the P-value and Z-score. The top 10 results are reported with an adjusted 
p-value of p<0.05.   
2.4.5 Pathway analysis 
Ingenuity Pathway Analysis (Ingenuity Systems) was used to assess connectivity of 
deregulated proteins. The requirements for assessing protein-protein interconnectivity 
included direct interactions observed experimentally. The permitted interaction types were: 
protein-protein, protein-DNA, activation, inhibition, phosphorylation, and ubiquitination. 
ARX/Arx (Fulp et al. 2008, Quille et al. 2011) and TWIST1/Twist1 (Lee, M.P. et al. 2014) 
ChIP interaction data was manually superimposed onto this pathway. 
2.4.6 Statistics 
Statistical significance of the overlap between two groups of genes was calculated using 
exact hypergeometric probability (nemates.org/MA/progs/overlap_stats.html). Total 
genes, in this case, equalled 13821 genes with detected reads. 
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2.5 In-Situ hybridization analysis 
2.5.1 Tissue embedding 
Upon collection, embryos were fixed in RNase-free 4% paraformaldehyde in PBS 
overnight at 4°C, washed 3×10 min in PBS, cryoprotected in 30% sucrose in PBS until 
tissues sink to the bottom of the tube. Samples were embedded in OCT (TissueTEK OCT 
Compound, cryostat specimen matrix, Cat#IA018, ProSciTech) and stored at −80°C until 
sectioned. Tissue sections (10 µm) were prepared using a Leica CM1900 cryostat.   
2.5.2 Riboprobe production  
MGC fully Sequenced Mouse cDNA clones were obtained from Millennium Science for 
Hdac4 (Clone ID: 6827645, Cat#MMM1013-202859554), Cdkl5 (Clone ID: 4013904, 
Cat#MMM1013-202704375) and Twist1 (Clone ID: 4935230, Cat#MMM4769-
202766995).  To linearize the cDNA 3 µg of the plasmid template was digested with 
specific restriction enzymes (Table 2.7) for 2 hours at the required incubation temperature 
and checked on a 1% agarose gel before continuing. In order to purify linearized plasmids, 
each digested sample was mixed with 1 volume of phenol/chloroform and centrifuged at 
18,000 x g for 2 minutes. The top aqueous layer was removed and precipitated with 1/10 
volume of 3M NaAc (pH 5.2) and 2 volumes of 100% EtOH at -20°C overnight. The 
sample was then centrifuged at 18,000 x g for 30 minutes and washed with 70% v/v EtOH 
before resuspension in ultrapure H2O. DIG labelling RNA antisense probes were 
transcribed in vitro from digested plasmid templates using a DIG RNA labelling Kit 
(Cat#11175025910, Roche) and T7, Sp6 or T3 RNA polymerase (Table 2.7)  (T7 and Sp6 
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provided in Kit, T3 RNA polymerase, Cat#110311630014, Sigma-Aldrich). Template was 
eliminated with the addition of 2 µl of RNase-free DNase I to the reaction and incubated 
for 30 minutes at 37°C. Removal of unincorporated DIG label and reaction components 
and concentration of DIG-labelled probes was achieved by passing the dilute reaction 
volume through a Quick Spin Columns (CHROMA SPIN-100+DEPC-H2O Columns, 
Cat#636089, Scientifix).  Columns were pre-centrifuged to remove all contents 
immediately prior to loading probes onto the columns to prevent drying of the matrix. 
Riboprobes were eluted off the column into a fresh Eppendorf tube at 700 x g for 5 minutes, 
and integrity and size of labelled probes were confirmed on a 2% agarose gel before use. 
 
Table 2.7 Antisense Riboprobe Production. 
cDNA Plasmid 
Backbone 
Restriction Enzyme  RNA pol 
 Hdac4 pXY-Asc NaeІ T3 
Cdkl5  pCMV-SPORT6 SmaІ T7 
Twist1 pCMV-SPORT6 SapІ T7 




2.5.3 In Situ hybridization  
All details of solutions used in 0 are listed in Table 2.8. Slides were defrosted and dried at 
room temperature for at least 1 hour. Probes were diluted in RNase-free H2O to a total 
volume of 7.5 µl for each slide and denatured at 80°C for 2 minutes. Hybridization mix 
was added to each slide consisting of 7.5 µl of diluted probe and 69 µl of hybridization 
buffer (Table 2.8) covered with a coverslip and placed in a hybridization chamber filled 
with 1:1 formamide: ultrapure H2O and incubated overnight at 65°C. Slides were washed 
for 15 minutes in preheated coplin jars filled with wash solution (Table 2.8) and placed in 
a waterbath at 65°C to allow coverslips to fall off. Washing with wash solution was 
repeated two additional times for 30 minutes each at 65°C. Subsequent washes with Maleic 
Acid Buffer + Tween-20 (MABT, Table 2.8) at room temperature for 30 minutes each was 
repeated two times. After blocking with 700 µl of blocking solution (Table 2.8) for 2 hours 
in a humidified chamber to limit fluid evaporation, 75 µl anti-DIG antibody mix was added 
to each slide (0.25 µl anti-DIG antibody (Cat#11093274910, Sigma) to 1ml of Blocking 
Solution) and left overnight at room temperature in a humified chamber. Slides were 
washed in MABT four times for 20 minutes each at room temperature.  Followed by two 
washes in alkaline phosphatase staining buffer (APB, Table 2.8) for 10 minutes each. To 
complete the staining reaction 4.5 µl (450 µg) of NBT (Roche Nitrotetrazolium Blue 
Chloride solution (100mg/ml), Cat#11383213001, Sigma-Aldrich) and 3.2 µl (160 µg) of 
BCIP (Roche 5-Bromo-4-chloro-3-indolyl phosphate disodium salt (50 mg/ml), 
Cat#11383221001, Sigma-Aldrich) to 1ml of fresh APB and 95 µl of the staining mix 
added to each slide to be incubated in a clean humified chamber, sealed and in the dark for 
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> 4 hours. Slides were washed three times for 5 minutes each in PBS in the dark and fixed 
with 4% PFA to inactivate the alkaline phosphatase enzyme. 
Table 2.8 In Situ Hyribisation Solutions. 
10x Salt Buffer 
2M NaCl, 100 mM Tris-HCL pH 7.5, 50 mM sodium phosphate monobasic 
dehydrate, 50mM sodium phosphate dibasic, 50 mM EDTA 
Hybridization 
Buffer 
50% formamide, 1% dextran sulphate, 1x Salt Buffer,  2x Denharts and 1 
mg/ml tRNA 
20x SSC 3M NaCl, 300mM Sodium Citrate, pH 7.0 
Wash Solution 50% Formamide, 1x SSC diluted in ultrapure H2O 
Maleic Acid Buffer  100mM Maleic acid, 100mM NaCl, pH to 7.5 with NaOH 
MABT Maleic Acid Buffer, 0.1% Tween-20 
Blocking Solution 
20% Heat inactivated sheep serum, 2% Blocking reagent (Roche Blocking 
Reagent, Cat#11096176001, Sigma) diluted in MABT 




2.6 In Vitro analysis 
2.6.1 Plasmid generation 
All plasmids readily available within the Shoubridge Laboratory (Table 2.9). Plasmids 
were initially prepared on a small scale (Wizard Plus SV Minipreps DNA Purification 
System, Cat#A1330, Promega) and sequenced confirmed (as per section 2.2.4), using 
primers listed in Table 2.10. High volume purity stocks were generated from the original 
single colony using Qiagen Plasmid Midi Kit (Cat#12143).  
Table 2.9 Plasmid Information. 
Construct Vector Tag Ref 
empty pCMV-Myc N-terminal Myc tag (Shoubridge et al. 2012) 
ARX WT pCMV-Myc N-terminal Myc tag (Shoubridge et al. 2007) 
ARX PA1 21A pCMV-Myc N-terminal Myc tag  
ARX PA1 23A pCMV-Myc N-terminal Myc tag (Shoubridge et al. 2007) 
ARX PA1 27A pCMV-Myc N-terminal Myc tag (Fullston et al. 2011) 
ARX PA2 20A pCMV-Myc N-terminal Myc tag (Shoubridge et al. 2007) 
ARX PA2 21A pCMV-Myc N-terminal Myc tag (Fullston et al. 2011) 
ARX PA2 23A pCMV-Myc N-terminal Myc tag (Fullston et al. 2011) 
empty pcDNA3.1/nV5-DEST N-terminal V5 tag  
UBQLN4 WT pcDNA3.1/nV5-DEST N-terminal V5 tag  
3xLMO1 TFBS pGL4.13[luc2/SV40] Luciferase reporter (Shoubridge et al. 2012) 






Table 2.10 Plasmid Sequencing Primers. 
Use  Name Direction Species Primer Sequence (5'-3') Length 
Vector Primer pCMV-myc-F Forward Vector GATCCGGTACTAGAGGAACTGAAAAAC 27 
Vector Primer pCMV-myc R Reverse Vector GTTGTGGTTTGTCCAAACTCATCAATG 27 
Vector Primer pDEST-F Forward Vector TAATACGACTCACTATAGGG 20 
Vector Primer pDEST-R Reverse Vector GGAAAGGACAGTGGGAGTGG 20 
ARX ORF Plasmid 
Sequencing 
ARXc ex1/2 F Forward homo sapiens TGCAAGGCTCCCCTAAGAGCA 21 
ARXc ex2/3 F Forward homo sapiens CGTCTTCACCAGGGAGGAACT 21 
ARXc ex3/4 F Forward homo sapiens CCCAGTCCAGGTCTGGTTCCA 21 
ARXcR6 (Exon 2) Reverse homo sapiens CGCTGCTGCTCTTAGGGGAGC 21 
ARXc ex2-R (Exon 2) Reverse homo sapiens GTACGACTTGCTGCGGCTGAT 21 
ARXE2P2F5 Forward homo sapiens AACTGCTGGAGGACGACGAGG 21 
ARXE2R7 Reverse homo sapiens CAGCTCCTCCTTGGGTGACA 20 
ARXcF2 (Exon 4) Forward homo sapiens CGCTCGACTCCGCTTGGACTG 21 
ARXc-R1 Reverse homo sapiens CAGTCCAAGCGGAGTCGAGCG 21 
A1UP ORF Plasmid 
Sequencing 
A1UpE2F1 Forward homo sapiens CCGGAGGTTTAAGGCTCAG 19 
A1UpE2R1 Reverse homo sapiens CTGAGCCTTAAACCTCCGG 19 
A1UpE5F2 Forward homo sapiens GAGATGATGCGGAACCAGG 19 
A1UpE5R2 Reverse homo sapiens CCTGGTTCCGCATCATCTC 19 
A1UpE6F4 Forward homo sapiens GATCAATGCGGCTAGCCTG 19 
A1UpE6R4 Reverse homo sapiens CAGGCTAGCCGCATTGATC 19 
A1UpE9F3 Forward homo sapiens GGCATTGCTGCAGATCCAG 19 
A1UpE9R3 Reverse homo sapiens CTGGATGTGCAGCAATGCC 19 
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2.6.2 Maintaining human embryonic kidney 293T cell line 
Human Embryonic Kidney 293T cell line (HEK293T) was cultured in Dulbecco’s 
Modified Eagle’s Medium (Gibco™ DMEM, high glucose, pyruvate, no glutamine, Cat 
#10313021 , ThermoFisher), supplemented with 10% Fetal Calf Serum, 100U/ml sodium 
penicillin, 100ug/ml strestreptomycin sulfate (Gibco™ Penicillin-Streptomycin 
(10,000U/ml), Cat#15140122, ThermoFisher) and 2mM L-glutamine (Gibco™ L-
Glutamine (200mM), Cat#25030081, ThermoFisher). Cells were incubated in 5% CO2 at 
37°C. Cells were passaged or collected at 90% confluency. Cell were treated with 1 ml of 
Trypsin (Gibco™ Trypsin-EDTA (0.05%), phenol red, Cat#25300054, ThermoFisher) for 
5 minutes to allow attached cells to detach from the flask surface, and then resuspended in 
9 ml of DMEM. Cell are counted by staining with Trypan Blue (Gibco™ Trypan Blue 
Solution, 0.4%, Cat#15250061, ThermoFisher) using a haemocytometer to determine cell 
number prior to plating. 
2.6.3 Transient transfection 
One day before transfection, appropriate number of cells (see Table 2.11) were counted 
and plated in a 6 or 12 well plate (Corning® Costar® cell culture 6/12 well, flat bottom 
plates, Cat#CLS3516-50EA/CLS3513-50EA, Sigma-Aldrich) in Dulbecco’s Modified 
Eagle’s Medium (Gibco™ DMEM, high glucose, pyruvate, no glutamine, Cat #10313021 
, ThermoFisher) supplemented with 10% Fetal Cal Serum (FCS), and 2mM L-glutamine 
(Gibco™ L-Glutamine (200mM), Cat#25030081, ThermoFisher). On the day of 
transfection, two separate solutions were prepared: (1) Plasmid DNA (variable amount) 
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was diluted in 200 µl of DMEM with 2mM L-glutamine; and (2) 4 µl of Lipofectamine™ 
(Invitrogen™ Lipofectamine® 2000 Transfection Reagent, Cat#11668019, ThermoFisher) 
was diluted in 200 µl of DNA with 2mM L-glutamine. The two solutions were mixed 
together and incubated for 20 minutes at room temperature to allow for DNA-lipid 
complexes to form. Media was removed from cells and replaced with 600 µl of DMEM 
with 2mM L-glutamine, prior to 400 µl of the plasmid: Lipofectamine mixture aliquoted 
into appropriate wells. The plates were kept in 5% CO2 in 37°C incubator for 3 hours. Each 
well was then supplemented up with 1 ml 20% FCS and 2mM L-glutamine DMEM. Cells 
were collected at time points indicated in each study. 
Table 2.11 Seeding Density for Transient Transfection. 
Flask/Plate Area Cell Density Vol. of Medium (ml) 
6 well plate 9cm2 8 x 105 2 ml 
12 well plate 4cm2 4 x 105 2 ml 
 
2.6.4 Immunofluorescence 
Cells were fixed using 4% formaldehyde for 1 hour at room temperature. Cells were 
permeabilized with a solution of PBS containing 0.2% Triton (Triton™ X-100, Cat#X100, 
Sigma-Aldrich) for 5 minutes and washed with 3 x PBS to remove detergent. Cells were 
blocked with 5% skim milk. Primary and fluorescently tagged secondary antibodies were 
diluted in PBST containing 3% normal horse serum (NHS). Primary antibodies were 
incubated overnight at 4°C. Secondary antibodies were incubated for 1 hour at room 
temperature in the dark. All antibody dilutions are listed in Table 2.12 and Table 2.13. 
Prolong Diamond Antifade Mountant with DAPI (Molecular Probes™ ProLong® 
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Diamond Antifade Mountant with DAPI, Cat#P36962, ThermoFisher Scientific) as per 
manufacturer protocols was used to stain the cell Nuclei and to mount coverslips. 
 
Table 2.12 Primary Antibody List. 
 
Protein Species Affinity Cat # Company Dilution 
ARX (N-15) Goat Polyclonal SC-48845 Santa Cruz 1:1000 
ARX Mouse Monoclonal - Neurogenetics 1-2 µg/ml final 
ARX Sheep Polyclonal - Neurogenetics 1-2 µg/ml final 
ARX Rabbit Polyclonal - Gifted by 
Kitamura 
1:500 
Myc-HRP Mouse Monoclonal 46-0709 Invitrogen 1:5000 
Myc (9E10) Mouse Monoclonal SC-40 Santa Cruz 1:1000 
V5 Rabbit Polyclonal A190-120A Bethyl 1:5000 
V5 Mouse Monoclonal 46-0705 Invitrogen 1:5000 
V5-HRP Mouse Monoclonal 46-0708 Invitrogen 1:5000 
 
Table 2.13 Secondary Antibody List. 
 
Host Target Conjugate Clonality Concn Cat # Company 
Donkey α Mouse  Alexa 488 Polyclonal 2mg/mL A21202 Invitrogen 
Goat α Mouse  FITC Monoclonal  - F0479 Dako 
Goat α Rabbit Cy3 Polyclonal 
 
111-165-144 Jackson Lab 
Goat α Mouse  HRP Polyclonal 1 g/L P0447 Dako 
Goat α Rabbit HRP Polyclonal 0.25 g/L P0448 Dako 
Rabbit α Goat HRP Polyclonal 0.65 g/L P0160 Dako 







All immunofluorescence images were captured using Zeiss Axio Imager.M2 microscope 
equipped with Axio Vision 5.1 Software. Immunofluorescence images were acquired by 
Zeiss AxioCam mRM black and white camera. All captured images were processed by the 
Axio Vision 5.1 Software and Image J for analysis.   
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2.7 Gene expression analysis 
2.7.1 RNA extraction 
Total RNA from cell pellets were extracted using a combined method with TRIzol® 
Reagent (Cat#1559026, ThermoFisher), RNeasy Mini Kit (Cat#74104, QIAGEN) and 
RNase-Free DNase set (Cat#79254, QIAGEN) following the protocol described in 2.4.1.  
Depending on the size of the cell pellets collected RNA was eluted in 30 µl - 50 µl of 
RNase-Free H2O. 
2.7.2 Reverse transcription cDNA synthesis 
cDNA was prepared as described in section 2.4.3 with 2 µg of RNA per sample. For 
negative controls, SuperScript™ III RT was replaced with 1 µl of H2O. The newly 
synthesised cDNA was diluted by adding 20 µl of H2O and stored at -20°C for further use. 
The efficiency of the RT-PCR was determined by PCR using primers specific to 
ubiquitously expressed housekeeping genes Esterase D (human samples) or Beta Actin 
(mouse samples) (Primers listed in Table 2.14) (results not shown). 
Table 2.14 House Keeper Primer Sets. 









homo sapiens GGAGCTTCCCCAACTCATAAATGCC 25 60 453 
Esterase D-
Reverse 
homo sapiens GCATGATGTCTGATGTGGTCAGTAA 25   
Beta Actin–
Forward 
mus musculus GATATCGCTGCGCTGGTCGTC 21 60 177 
Beta Actin–
Reverse 
mus musculus TCTCTTGCTCTGGGCCTCGTCAC 23   
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2.7.3 Polymerase chain reaction (PCR) 
cDNA was amplified with 1 µl (5 U) of Taq DNA Polymerase (Cat# 11146173001, Roche), 
1x PCR buffer with MgCl2 (stock at 10x, Cat# 11699121001, Roche), specific single-
stranded DNA primers and H2O to 50 µl volume. The PCR cycle condition was as follows: 
initial denaturation at 94°C for 5 minutes, then 35 cycles of denaturation at 94°C for 30 
seconds, annealing for 30 seconds at 60°C (or specific annealing Tm of each primer pair), 
extension at 72°C for 30 seconds, followed by final extension at 72°C for 10 minutes.  
2.7.4 Gel electrophoresis 
PCR products were visualised on a 1-2% (w/v) agarose gel in TBE buffer (45mM Tris-
borate, 1mM EDTA, pH 8.5) with the addition of Ethidium Bromide (0.2 µg/ml)  for 40 
minutes at 100V alongside pUC19/HpaII or 1kb+ molecular weight markers. Samples were 
premixed with loading buffer (20% (v/v) Ficoll 400, 0.1M Na2EDTA, 0.25% (w/v) 
bromophenol blue, 1.0% (w.v) SDS) before being loaded onto the gel. Gels were then 
visualised under UV (Sygene INGENIUS LHR: Gel Documentation System, LabGear 
Australia)  
2.7.5 Quantitative real-time PCR (RT-PCR) 
Pre-designed TaqMan® Gene Expression Assays were selected from ThermoFisher.  
Reactions were set up on 96-well plate. Each well contains 2 µl of cDNA template (of a 
1ng/ µl to 50ng/ µl stock), 1 µl of the 20x TaqMan® Gene Expression Assay (FAM™ dye-
labelled MGB probe) and 1 µl of 20xTaqMan® Endogenous Control Assay (VIC® dye-
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labelled MGB probe), 10 µl of the 2x TaqMan® Gene Expression Master Mix (Applied 
Biosystems™, Cat#4369016, ThermoFisher Scientific) and RNase-free H2O. Reactions 
were run on the Applied Biosystems StepOnePlus™ Real-Time PCR System using a 
standard run with the following conditions: activation at 50°C for 2 minutes followed by 
95°C incubation for 10 minutes, 40 cycles of denaturation at 95°C for 15 seconds and 
extension at 60°C for 1 minute. Signal emitted from the dye reporter was recorded at the 
end of each cycle. All sample were analysis in triplicate and efficiency of the assay was 
determine by the amplication of the standard curve of diluted control cDNA. Expression 
values were calculated using comparative ∆Ct method (Bookout and Mangelsdorf 2003). 
Refer to Table 2.6 all probes used in thesis.  
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2.8 Protein analysis 
2.8.1 Protein extraction 
RIPA activated buffer (65.3 mM Tris, 150 mM NaCl, 1% (v/v) Nonidet P-40) was made 
up by adding 80 µl of 25 x protein inhibitor cocktail (Protease Inhibitor Cocktail, 
Cat#P8340, Sigma), 10 µl of 200mM Na2VO4, 200mM NaF and 200mM 
phenylmethylsulfonyl fluoride (PMSF) to 2 ml of RIPA buffer. Cell pellets were kept 
frozen on dry ice until they were homogenised with 100-200 µl of RIPA activated buffer 
to minimise protein degradation. The tube containing the homogenised cell lysate was 
placed horizontally in normal ice with shaking for 15 minutes. To shear DNA, the lysates 
were passed through an 18G needle and 1 ml syringe 10 times. Lysates were clarified by 
centrifugation (15 minutes, 13,000 x g at 4°C). The supernatant containing the soluble 
proteins was transferred to a clean 1.5 ml screw cap tube and stored at -80°C until further 
use.  
2.8.2 Protein quantification  
Diluted sample (1/10 and 1/20 with H2O) of each protein aliquot were made from the 
original stock. In a 98 well plate (Corning® 96 well plates PVC flat bottom, Cat#CLS2595-
100EA, Sigma-Aldrich), the diluted samples were aliquoted in triplicates of 10 µl per well. 
Pre-made Bovine Serum Albumin (BSA) standards were used to construct a standard curve 
at 0, 0.2, 0.4, 0.6, 0.8 and 1.0 mg/ml. 200 µl of a 1 in 4 dilution of Bradford reagent in H2O 
was added to each well. The OD of each well was read immediately at 570nm using 
automated plate reader (Cat#MR5000, Dynateach). Relative starting protein was 
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established for each protein dilution utilising the pre-determined BSA standard curve. The 
final protein concentration was determined by averaging the values of the two dilutions. 
2.8.3 Running SDS-PAGE 
Protein samples (usually 10 – 20 µg) were prepared in 1 x DTT reducing agent (10x 1M 
stock), 1 x loading buffer (Novex™ NuPAGE® LDS Sample Buffer (4x), Cat#NP0008, 
Thermofisher) and H2O to 16 µl volume. The protein was heat denatured at 95°C for 5 
minutes. To detect protein smaller than 100 kDa, samples were loaded onto 4-12% Bis-
Tris Protein Gel  1.0 mm  (Invitrogen™ NuPAGE™ Novex™ 4-12% Bis-Tris Protein 
Gels, 1.0 mm, Cat#NP0321BOX, Thermofisher) as part of the Xcell Surelock® Mini-Cell 
(Novex™ Cat#E10002, Thermofisher). The inner chamber was filled with cold 1x MOPS 
running buffer (Novex™ NuPAGE® MOPS SDS Running Buffer (20X), Cat#NP0001, 
Thermofisher) and 500 µl of NuPAGE® Antioxidant (Novex™ NuPAGE Antioxidant, 
Cat#NP0005, Thermofisher). The outer chamber was filled with only the cold 1x MOPS 
running buffer. 
2.8.4 Membrane transfer 
The separated proteins in the gel were transferred onto Pure Nitrocellulose Blotting 
Membrane (Pall Laboratory BioTrace™ NT Nitrocellulose Transfer Membrane, Cat#732-
3031, VWR) using the XCell II™ Blot Module (Novex™, Cat#EL9051, Thermofisher 
Scientific). The inner chamber was filled with freshly made cold transfer buffer (1xTowbin 
Buffer (0.025M Tris, 0.192M Glycine) and 20% Methanol diluted in deionized H2O); the 
72 
outer chamber was filled with ice cold H2O. Proteins were transferred at 30 volts powered 
by PowerPac HV High-Voltage Power Supply (Cat#1645056, Bio-Rad) for 1 hour. 
2.8.5 Immunoblot 
Membranes were rinsed with ultrapure H2O to remove residual methanol prior to blocking 
with a solution of Tris-buffered saline with Tween-20 (TBST) and 5% skim milk powder 
and incubated with shaking for 1 and a half hours at room temperature. Primary antibody 
(Ab) was diluted in a solution of TBST, and 1% skim milk. The membrane was incubated 
with primary Ab for 4 hours at room temperature or at 4°C overnight in the fridge on the 
shaker. The membrane was washed 3 x 10 minutes with shaking using TBST before 
incubated with Horse Radish Peroxidase (HRP)-conjugated secondary antibody diluted in 
a solution of TBST and 1% skim milk. The membrane was washed 3 x 5 minutes with 
shaking using TBST to remove all unbound secondary antibody.  
Table 2.12 and Table 2.13 describes all primary and secondary antibodies used in this 
thesis. Signal was detected via chemiluminescence (Amersham ECL Western Blotting 
Detection Reagent, Cat#RPN2106, GE Healthcare Life Science) and exposure of the 
membrane to X-ray sensitive film (CURIX ORTHO HT-G AGFA Medical X-Ray Film 
(18x24cm), Cat#E7FYQ, Total Medical Imaging Solutions or Amersham Hyperfilm ECL, 
Cat#28906839, GE Healthcare Life Science). 
2.8.6 Co-immunoprecipitation (Co-IP) 
Cells transfected with Myc-ARX, both with and without V5-UBQLN4  were harvested at 
24 hours post-transfection and cell lysates prepared using lysis buffer (120mM NaCl, 
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50mM Tris-HCl (pH 8.0), 0.5% NP-40 (v/v), 1× protease inhibitor cocktail (Cat#P8340, 
Sigma-Aldrich), 1mM Na3VO4, 1mM NaF, 1mM PMSF). Lysates were clarified by 
centrifugation (15 minutes, 13,000 x g at 4°C). Aliquots of extracts were 
immunoprecipitated (IP) overnight at 4°C. Protein-A sepharose (Cat#17-0780-01, VWR) 
was pre-treated with non-transfected HEK293T cell lysate to reduce non-specific binding 
of cell proteins. The IP reactions were incubated with the pre-treated protein-A sepharose 
for 1 h at 4°C before removal of non-specifically bound proteins with four changes of high 
stringency wash buffer (250 mM NaCl, 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5% 
NP-40 (v/v)) to ensure adequate removal of non-specific binding of alanine tract containing 
ARX protein. Proteins bound to the protein-A sepharose were eluted in SDS loading buffer 
(62.5 mM Tris-HCl (pH 6.8), 2% SDS (v/v), 10% glycerol (v/v), 5% β-Mercaptoethanol 
(v/v), 0.001% bromophenol blue (w/v), heated to 65°C before addition and incubated for 
3 min). IP proteins were subjected to SDS-PAGE and transferred to nitrocellulose 
membrane. Lysates from HEK293T cells producing either Myc-ARX alone or V5-IPO13 
alone were used as controls. In co-transfected cells; V5-UBQLN4 was IP with 0.5 µg of 
rabbit anti-V5 antibody (Cat#A190-120A, Bethyl Laboratories). IP proteins were analysed 
for the presence of V5-UBQLN4 and Myc-ARX by immunoblotting using mouse anti-V5 
HRP conjugated antibody, and mouse anti-Myc HRP conjugated antibody respectively 
(listed in Table 2.13). 
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2.8.7 In silico protein modelling 
The software package I-TASSER suite was used (http://zhanglab.ccmb.med.umich.edu/I-
TASSER/) to model protein structures. The predicted secondary structures are calculated 
from the target amino acid sequence in which the prediction contain three states: alpha 
helix, beta strand, and coil. The secondary structure with the highest confidence score is 
provided with the B-factor profile. B-factor is associated with the inherent thermal mobility 
of local atoms and residues, which is essential for proteins to fold and function in the 
physiological environment.  The predicted secondary structure can be used for estimating 





2.9 Biochemical assays 
2.9.1 Pulse-chase 
For pulse-chase experiments, cells were transfected with 0.5 µg of cMyc-ARX WT or 
cMyc-ARX PA123A plasmid. The day following transfection, cells were rinsed once with 
phosphate-buffered saline (PBS) and incubated for 15 minutes in Met/Cys-free DMEM 
(Cat#21013024, Thermofisher Scientific) and then radiolabeled in the same medium 
containing 50 μCi/ml of EasyTag™ EPRESS35S Protein Labeling Mix 
(Cat#NEG772014MC, PerkinElmer) for 1 hour. Cells were rinsed with PBS and incubated 
for chase intervals of 0, 1 and 3 hours in non-radioactive complete DMEM (Cat#11960051, 
Thermofisher Scientific) supplemented with 10% fetal bovine serum. At the end of each 
time point the cells were rinsed in cold PBS and cell lysates prepared using lysis buffer 
(120 mM NaCl, 50 mM Tris-HCl (pH 8.0), 0.5% NP-40 (v/v), 1× protease inhibitor 
cocktail (Cat#P8340, Sigma-Aldrich), 1 mM Na3VO4, 1 mM NaF, 1 mM PMSF). Lysates 
were passed through a 25G needle and clarified by centrifugation (15 minutes, 13,000 x g 
at 4°C). Aliquots of extracts were immunoprecipitated (IP) overnight at 4°C with anti-
cMyc (c-Myc Antibody (9E10), Cat#sc-40, Santa Cruz Biotechnology). Protein-A 
sepharose (Cat#P3391, Sigma-Aldrich) was pre-treated with untransfected HEK293T cell 
lysate to reduce non-specific binding of cell proteins (Mattiske et al. 2013). The IP 
reactions were incubated with the pre-treated protein-A sepharose for 1 hour at 4°C. 
Samples were then loaded on a MultiScreenHTS-DV Plate (Cat#MSDVN6B50, Millipore) 
and washed under suction  for removal of non-specifically bound proteins with 10 changes 
of high stringency wash buffer (250 mM NaCl, 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, 
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0.5% NP-40 (v/v)) to ensure adequate removal of non-specific binding of alanine tract 
containing ARX protein. The plastic webbing on the MultiScreenHTS-DV Plate was 
removed and placed in a heated drying rack until samples/filter paper was dry.  50µl of 
optiphase supermix was added to each well containing a sample, and 35S level was 
measured using beta scintillation plate counter. 
2.9.2 Luciferase assay 
We used the orthologous sequence upstream of the human LMO1 gene to generate 
luciferase reporter constructs containing specific TFBSs for ARX. As previously described 
in (Shoubridge et al. 2012) an oligo containing three TFBS sequences in tandem 5′-
(gaattgattTAATTAacaggggaa) ×3-3′ and BamH1 and BglII sites flanking the end of the 
oligo was directionally cloned upstream of either the SV40  promoter driving the luciferase 
reporter gene (luc2) in the pGL4.13[luc2/SV40] vector (Cat#E668A/#E5061, Promega). 
HEK293T cells (4 × 105 per well) were plated into 12-well plates, and 24 h later were 
transfected with 500 ng of luciferase reporter plasmid DNA, 10 ng of pGL4.74[hRluc/TK] 
plasmid DNA (Cat#E692A, Promega) and 500 ng of Myc-expression plasmid DNA 
containing full-length ARX-WT or homeodomain mutation sequence using Lipofectamine 
2000 (Cat#11668019, Thermofisher Scientific). Cells were lysed 24 h posttransfection and 
the measurement of both Firefly and renilla luciferase was achieved using Dual-Glo 
Luciferase Assay System (Cat#E2920, Promega) on a Veritus Microplate Luminometer 
(Turner BioSystems, Sunnyvale, CA, USA). In four independent transfections, each 
sample was carried out in replicate, with triplicates of each replicate measured in the 
reporter assay. The Firefly luciferase activity was normalised according to the 
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corresponding renilla luciferase activity, and the ratio of luciferase activity was reported 








An emerging female phenotype with loss of 
function mutations in the Aristaless- related 









3 An emerging female phenotype with loss of function mutations in the Aristaless- 
related homeodomain transcription factor. 
 
Publications, Presentations and Published Abstracts from this work: 
Accepted first author publication 
 Mattiske, T., C. Moey, L. E. Vissers, N. Thorne, P. Georgeson, M. Bakshi and C. 
Shoubridge (2017). "An Emerging Female Phenotype with Loss-of-Function 
Mutations in the Aristaless-Related Homeodomain Transcription Factor ARX." Hum 
Mutat. (DOI: 10.1002/humu.23190) 
 
In addition to the patient screening featured in this chapter, a number of other 
individuals/families were screened for ARX mutations. This data was combined with a 
larger study and resulted in the following publication, with my inclusion as a co-author for 
this work.  
 Marques, I., M. J. Sa, G. Soares, C. Mota Mdo, C. Pinheiro, L. Aguiar, M. Amado, C. 
Soares, A. Calado, P. Dias, A. B. Sousa, A. M. Fortuna, R. Santos, K. B. Howell, M. 
M. Ryan, R. J. Leventer, R. Sachdev, R. Catford, K. Friend, T. R. Mattiske, C. 
Shoubridge and P. Jorge (2015). "Unraveling the pathogenesis of ARX polyalanine 
tract variants using a clinical and molecular interfacing approach." Mol Genet 
Genomic Med 3(3): 203-214. (DOI: 10.1002/mgg3.133)  
81 
3.1 Abstract 
The devastating clinical presentation of X-linked lissencephaly with abnormal genitalia 
(XLAG) is invariably caused by loss of function mutations in the Aristaless- related 
homeobox (ARX) gene. Mutations in this X-chromosome gene contribute to intellectual 
disability (ID) with co-morbidities including seizures and movement disorders such as 
dystonia in affected males. The detection of affected females with mutations in ARX is 
increasing. We present a family with multiple affected individuals, including two females. 
Two male siblings presenting with XLAG were deceased prior to full term gestation or 
within the first few weeks of life. Of the two female siblings, one presented with 
behavioural disturbances, mild ID, a seizure disorder and complete agenesis of the corpus 
callosum, similar to the mother’s phenotype. A novel insertion mutation in Exon 2 of ARX 
was identified, c.982delCinsTTT predicted to cause a frameshift at p.(Q328Ffs*37). Our 
finding is consistent with loss-of-function mutations in ARX causing XLAG in hemizygous 
males and extends the findings of ID and seizures in heterozygous females. We review the 
reported phenotypes of females with mutations in ARX and highlight the importance of 
screening ARX in male and female patients with ID, seizures and in particular with 




The Aristaless-related homeobox gene (ARX) (NM_139058.2) (MIM# 300382) 
(Shoubridge et al. 2010a), is critical for early development and formation of a normal brain 
(Kitamura et al. 2002, Ohira et al. 2002, Scheffer et al. 2002). This paired-type 
homeodomain transcription factor plays a vital role in telencephalic development 
specifically in tangential migration and differentiation of GABAergic and cholinergic 
neurons (Kitamura et al. 2002, Colombo et al. 2007, Friocourt et al. 2008, Colasante et al. 
2009, Lee, K. et al. 2014). Mutations in ARX result in a range of phenotypes with 
intellectual disability (ID) as a consistent feature. Mutations leading to loss of function of 
the ARX protein typically lead to brain malformation phenotypes, including X-linked 
lissencephaly with abnormal genitalia (XLAG, also known as LISX2) (MIM# 300215) 
(Kitamura et al. 2002, Shoubridge et al. 2010a). XLAG is a developmental disorder 
characterised by structural brain anomalies leading to agyria (absent cerebral grooves 
brain) or pachygyria (reduced folds or grooves) and agenesis of the corpus callosum. In 
addition, patients commonly have early-onset intractable seizures, severe psychomotor 
retardation, and ambiguous genitalia (Dobyns et al. 1999, Kitamura et al. 2002). Males are 
severely affected and often die within the first days or months of life.  
 
As the ARX gene is on the X-chromosome, mutations in this gene typically result in families 
with affected males across multiple generations transmitted via (usually) asymptomatic 
carrier females. However, there is an increasing prevalence of reported mutations in ARX 
that result in the severe phenotypic outcomes of XLAG in male patients that, with variable 
penetrance, affect females within the families resulting in a generally milder phenotype 
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than affected males (Kitamura et al. 2002, Scheffer et al. 2002, Stromme et al. 2002, Kato 
et al. 2004, Marsh et al. 2009, Eksioglu et al. 2011). Here we report a novel mutation in 
ARX in a family ascertained by a female proband displaying a phenotype of mild learning 
disabilities, seizure disorder and agenesis of the corpus callosum. As part of this work, we 
have reviewed reported phenotype of females with mutations in ARX and recommend 
screening of the ARX gene in female patients with suitable intellectual disability, seizure 
phenotypes and corpus callosum agenesis, particularly if there is evidence of X-linkage 
and no surviving males. ARX adds to a growing list of genes on the X chromosome 
including genes such as USP9X, PHF6 and IQSEC2 that have phenotypic effects in males 
and females that are distinct depending on the functional severity of the mutation (Zweier 
et al. 2013, Reijnders et al. 2016, Zerem et al. 2016). 
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3.3 Materials and Methods 
3.3.1 Clinical description of patient and family 
The proband presented to a Genetics Clinic at 10 years of age with learning difficulties, 
mild ID and seizures. The proband was born at term weighing 3.2kg, with no admission 
into the neonatal intensive care unit nor special-care nursery required. She was reported as 
sitting with support at 9 months of age with single words spoken at 9-10 months of age and 
walking at 22 months of age. Seizure onset was around 5 years of age with the first seizure 
classified as a prolonged generalised tonic-clonic which required intubation. At this time 
she was assessed and was able to draw a triangle with help, able to hop, dress herself and 
talk in simple sentences, knowing a few colours and numbers. No unusual grasping is 
reported. She was evaluated using the WISC-IV Australian at age 8 years and 10 months. 
She scored in the “Extremely Low” range for verbal comprehension, perceptual reasoning 
index, working memory index, processing speed index with a resulting full-scale IQ in the 
“Extremely Low” range. She was assessed as operating in the mild range of intellectual 
disability. She subsequently had a number of complex partial seizures, which were 
reasonably well controlled on Tegretol. Brain MRI revealed complete agenesis of the 
corpus callosum with mild dilated ventricles and colpocephaly. No lissencephaly, 
dysmorphic features or behaviour problems were reported.  
 
The mother of the proband was aged 46 years old at the time of this report and presented 
with mild ID, seizures and mental health challenges. After admission to the public health 
hospital she was diagnosed with borderline personality disorder and major depressive 
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disorder however, no neuropsychiatric assessment is currently available.  She was non-
dysmorphic. History revealed that her first seizure was around 7-8 years of age and 
classified as complex partial seizures. Brain MRI scan done at the age of 38 showed 
complete agenesis of the corpus callosum, with no grey matter heterotopia. Small white 
matter lesions were noted which comprised of tiny FLAIR (fluid attenuated inversion 
recovery) hyperintensities involving the left centrum semiovale bilaterally and in the 
frontal region. The treating neurologist at the time felt these were specific white matter 
hyperintensities however the actual films are no longer available for review. In addition, 
EEG showed intermittent spike, and wave discharge maximal over left hemispheres, which 
were at a frequency of 2.5-3.5 Hz.  
 
Two male offspring of II-4 were affected and died in early infancy, or were terminated 
during pregnancy. A maternal half-brother (III-1) of the proband was born at 36 weeks of 
gestation with an onset of seizures 20 minutes after birth. III-1 died at 26 days of age. 
Investigation of brain morphology identified agenesis of the corpus callosum, 
lissencephaly, grey matter heterotopias and bilateral optic nerve hypoplasia. Genitalia were 
ambiguous with labioscrotal folds, bilateral gonads and microphallus. Pelvis 
ultrasonography revealed the presence of a bicornuate uterus, while a male urethra was 
confirmed with a genitogram. Karyotype analysis showed a normal male chromosomal 
constitution (46,XY). Facial dysmorphic features included a large head, large anterior 
fontanels, low set ears, and abnormal nails. III-3 eventuated with a medical termination of 
pregnancy due to identification at 18 weeks gestation via ultrasonography of 
ventriculomegaly and abnormal genitalia. Brain malformations were confirmed at post 
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mortem showing lissencephaly, absent corpus callosum, wide-open sylvian fissure and 
dilated ventricles. Facial dysmorphic features included flattened facies, mild macrocephaly 
and wide open sutures. Abnormal genitalia consisted of rudimentary genitalia with a small 
phallus. Karyotype analysis established the presence of male chromosomes.  
 
Another pregnancy, III-5 was terminated when chorionic villus sampling revealed 45XO 
after an ultrasound showed fetal hydrops. The remaining sibling (III-2) is a healthy female 
with normal intelligence.  A maternal uncle’s (II-1) death at one month of age was 
attributed to sudden infant death syndrome. The maternal grandmother (I-2) is reported to 
be healthy with no seizures.  
 
3.3.2 Molecular analysis of ARX gene 
The screening protocols were approved by the appropriate institution review boards, and 
informed consent was obtained from the parents of patients. Genomic DNA from the 
proband was extracted from whole blood using standard techniques. Each of the five exons 
of ARX was amplified by PCR using primers designed to amplify coding and flanking non-
coding sequence. The exception to this was exon 2, for which four overlapping amplicons 
were used to achieve robust amplification of GC-rich regions coding for three polyalanine 
tracts. The PCR conditions and primer sequences are described in detail previously (Tan et 
al. 2013). Sequencing reactions were performed using ABI Big Dye terminator chemistry 
version 3.1 and purified products subjected to an automated capillary sequencing on ABI 
3100 sequencer (Applied Biosystems, Foster City, CA, USA) and sequence was compared 
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to the ARX reference sequence (NM_139058.2) using SeqMan module of the Lasergene 




3.4.1 Molecular Analysis of the ARX variant 
The diagnoses of intellectual disability and seizures in the female proband in conjunction 
with XLAG in her male siblings, from two different fathers, prompted evaluation of the 
ARX gene.  Sequence analysis demonstrated a novel indel mutation, c.982delCinsTTT in 
exon 2 of the ARX gene, that is predicted to result in the creation of a premature stop codon, 
p.(Q328Ffs*37) (LOVD ID 0000128956) (http://www.lovd.nl/ARX). The child’s mother 
presented with a similar phenotype and was confirmed to also be a symptomatic carrier of 
this novel ARX mutation. The father (II-5) and unaffected sister (III-2) do not carry the 
mutation (Figure 3.1). The ARX mutation was confirmed in III-4 in genomic DNA 
extracted from amniocytes. The amino acid affected by the mutation p.328Q is located at 
the start of the region containing the second nuclear localisation signal (NLS2) preceding 
the conserved paired-type homeodomain. The predicted stop codon arising from this 
variant occurs within 29 nucleotides of the exon 3-4 junction and is likely to escape 
nonsense-mediated decay (NMD). Due to restricted levels of ARX expression in the patient-
derived materials we are unable to confirm if this truncated protein is produced. Despite 
this, even if the predicted C-terminal truncated protein was produced and subsisted at 
appreciable levels, the severe XLAG phenotype in affected male patients is expected with 
this variant resulting in a nonsense peptide being transcribed after residue p.328 and 











Figure 3.1 Identification of a c.982delCinsTTT mutation resulting in (p.(Q328Ffs*37) 
in ARX 
a) Pedigree of immediate family members tested. Open symbols represent normal 
individuals, filled black circles represent females with moderate intellectual disability and 
seizures, filled squares represent males with Lissencephaly, hydrocephalus, profound 
developmental delay and ambiguous genitalia. Individual generations are numbered with 
Roman numerals on the left-hand side of the pedigree. Individuals who were sequence 
confirmed to carry either the normal (N) or mutant (M) are shown b): DNA sequence 
electropherograms for the chrX: 25,031,130 (GRCh37/hg19 assembly) deletion of a C and 
insertion of TTT mutation in exon 2 of 5 of ARX reported in this study. A normal sequence 
was confirmed in unaffected father (II-5) and sister (III-2) with the normal sequence 
shown. The mutation in the heterozygous state is shown in both the affected proband (III-
4) and mother (II-4). The dotted line highlights the disrupted heterozygous trace present in 
females caused by the insertion (solid black underline). Additional mutation sequence 
change was seen in the hemizygous state of an affected brother (III-3). c) The predicted 
functional consequence of a novel nonsense mutation in ARX. Schematic of the human 
ARX protein (top panel). Human ARX domains and regions are indicated above the 
schematic. Known functional domain are highlighted, octapeptide (OP) as horizontally 
hatched rectangle, nuclear localisation sequences (NLS) as three black rectangles, 
polyalanine tracts (PA) as four white rectangles, acidic domain as vertically hatched 
rectangle, homeodomain as crosshatched, and aristaless domain (OAR) as hatched. A 
schematic of the homeodomain and the flaking NLS domains (middle panel) with the 
amino acid sequence below (homeodomain sequence underlined). The amino acid change 
indicated by the first black arrow resulting in a nonsense peptide and a stop codon indicated 
by the second red arrow. 
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A methylation-specific PCR at the human FraxA and Androgen Receptor genes was 
performed on genomic DNA from blood as previously described (Plenge et al. 1997). X-
inactivation studies for both the proband (III-3) and the healthy sister (III-2) detected no 
significant deviation.  
 
As part of initial investigations, both II-4 and III-3 were identified to carry a duplication 
on chromosome 5 at 5p15.5 (Chr5:10,907,608-11,363,857). This duplication contains only 
part of one gene, Catenin Delta 2 (CTNND2). This duplication was classified as a variant 
of unknown significance. This duplication was later also identified in the female sibling 
III-2, who is healthy and has no learning issues, indicating this copy number variant is 






Here we report a family with a novel truncating mutation 
(c.982delCinsTTT/p.(Q328Ffs*37)) in ARX. The mutation is predicted to yield a non-
functional protein product after p.328 due to the nonsense peptide prior to truncation of the 
protein at amino acid 364. This variant was not found in either the ExAC 
(http://exac.broadinstitute.org/) or 1000 genome project databases 
(http://www.internationalgenome.org/). Although this mutation may escape nonsense-
mediated decay, the resulting protein will have functional loss of the homeodomain and 
Aristaless domains. The catastrophic phenotype of XLAG reported in 2 males in this family 
is consistent with the predicted disruption of the ARX homeodomain function.  The female 
proband and mother have a milder phenotype consisting of ID, seizures and agenesis of the 
corpus callosum. The investigation of ARX as a cause of the phenotype in the female 
proband was due largely to the distinctive phenotypic presentation and early deaths of the 
affected male siblings.  
 
Our report underscores that a carrier female phenotype is likely to be under-ascertained for 
ARX. This is supported by a recent examination of heterozygous females from families 
identified with ARX mutations (Marsh et al. 2009) and examples of gender bias (92% male: 
8% female) in a recent cohort of patients referred for molecular analysis of ARX (Marques 
et al. 2015). Under-ascertainment may be occurring due to several contributing factors. 
Patients with phenotypes such as intellectual disability and infantile spasms have been 
typically screened for mutations in known genes such as 
STXBP1, CDKL5, KCNQ2, GRIN2A, MAGI2 and ARX. However, in the case of ARX, 
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screening is commonly only considered in affected males. Moreover, as the majority of all 
mutations reported to date in ARX lead to an expansion of the first or second polyalanine 
tracts, both located in exon 2, ARX mutation analysis is routinely limited to screening exon 
2 and often using size variant analysis approaches (Marques et al. 2015). The expanding 
use of next generation sequencing approaches on cohorts of individuals with intellectual 
disability and or seizure phenotypes are likely to provide a platform to potentially 
overcome some of these biases. However, even these types of approaches have constraints 
that need to be considered, particularly for genes with high GC content or near regions of 
low gene density, such as ARX. For example, sequence coverage across the ARX gene in 
50 representative whole exome sequencing (WES) experiments undertaken at the Radboud 
University Medical Centre showed the median coverage for ARX was 40-fold less than the 
coverage of all ID genes; with the median percentages of ARX bases covered at 20x only 
being 73% compared to 97% for all ID genes (Figure 3.2). However, experience at this, 
and other centres indicates that the coverage differences although lower for ARX generally, 
may also depend on the region of the gene being considered (Figure 3.3). Exome 
sequencing using benchtop ion proton machines also result in poor coverage of the ARX 
gene, with mean coverage reported at 43% (Lacoste et al. 2016). It remains to be 
determined how the increasing use of whole genome sequencing approaches as well as 
improvements to WES technologies and analysis pipelines address some of these coverage 
issues.   
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a)                                      b)                                
 
Figure 3.2 Radboud University Medical Center coverage analysis of 50 representative 
WES experiments of an ID gene panel consisting of 749 genes.  
Boxplots representing a) the median coverage of all ID genes in 101-fold, whereas for ARX 
this is 60-fold. b) The median percentage of bases covered at 10x for all ID gene is 100%, 
whereas this is 80% of bases for ARX. Similarly, the average percentage of bases covered 









Figure 3.3 Melbourne Genomics Health Alliance cohort of 250 WES samples analysed 
with valid coverage 
a) The coverage for each sample across the 5 ARX exons, as well as the mean coverage for 
males, females and the overall means. b) The median coverage of ARX compared to the 




To date there have been both familial and de novo cases of affected females due to ARX 
mutations (Scheffer et al. 2002, Kato et al. 2004, Wallerstein et al. 2008, Marsh et al. 2009, 
Eksioglu et al. 2011, Bettella et al. 2013, Kwong et al. 2015) (Table 3.1). Penetrance is 
variable both within and across families, with 55% of carrier females in these families 
presenting with a phenotype of intellectual disability to some degree with and without 
seizures (Table 3.1). Intellectual disability and/or developmental delay are prominent 
features in affected females across all families.  A seizure phenotype was reported in 64% 
of the females with ID which equates to ~ 35% of all females in these families (Table 3.1).   
 
Table 3.1 Clinical Summary of Females with ARX mutations 
 
 
Familial This report De novo Total  
Females  25 2 4 31 
Females with ID, with and 
without Seizures  
11 2 4 17 
ID or DD 
11 2 4 17 
Seizures 
5 2 4 11 
Other clinical features number (symptomatic : non-symptomatic) 
MRI reported  10   (5:5) 2   (2:0) 3 15        . 
Brain malformation 9    (4:5) 2   (2:0) 3 14 (9:5) 
ACC 8    (4:4) 2   (2:0) 1 11 (7:4) 
Other 1    (0:1) 0         . 2 3   (3:0) 
Movement disorder 4    (3:1) 0         . 4 8   (7:1) 
Psychiatric features 4    (3:1) 1   (1:0) 0 5   (4:1) 




Similar to the novel case we report here, affected females have been reported in families 
in which the male proband presents with severe XLAG or seizure phenotypes (Scheffer et 
al. 2002, Kato et al. 2004, Marsh et al. 2009, Eksioglu et al. 2011). In these familial cases 
ascertained by the male proband, the mutations are either missense mutations of residues 
in the homeodomain or nonsense/ deletion mutations resulting in a loss of function of the 
ARX homeodomain and/or aristaless domain activity (Table 3.2). Similarly, a smaller 
number of de novo cases also result in truncation and loss of ARX function (Wallerstein et 
al. 2008, Marsh et al. 2009, Bettella et al. 2013, Kwong et al. 2015). Across these cases, 
there is a consistent phenotype of intellectual disability and/or developmental delay, 
infantile seizures and hypotonia/ dystonia/ ataxia (Table 3.3). The type and location of 
mutations in affected females are restricted compared to those contributing to affected 
males (Figure 3.4). Brain MRI imaging is reported in approximately 35% of all females in 
these cases/ families, including the two females from this current report. Interestingly, of 
those individuals screened, 73% had features consistent with agenesis of the corpus 
callosum (ACC), but only 64% of these patients were those classed as symptomatic based 
on intellectual disability and/or developmental delay and seizure phenotypes. Hence, there 
are a number of asymptomatic carrier females that do not display these key clinical features 
but still have the brain abnormality of ACC. There is also variable penetrance of both 
psychiatric and behavioural phenotypes across the symptomatic and asymptomatic females 
within these families. Movement disorders including ataxia and hypotonia are noted, 
particularly prevalent in the cases of de novo mutations (Table 3.3).  
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Table 3.2 Clinical features of females in familial cases of ARX mutations 
Mutation 











Additional Features References 
Truncation mutations 
Exon1_2del 1, 2 XLAG Mother N onset 12y (GTCS)   
(Kitamura, et al., 2002), 




HD + OAR 
XLAG 
Mother N    (Kato, et al., 2004) 




HD + OAR 
XLAG 
Mother N  ACC  (Kato, et al., 2004) 
Sister N  ACC Duane anomaly 
Mother N  ACC-p  (Kato, et al., 2004) 




HD + OAR 
XLAG-
HYD 
Mother N    (Kato, et al., 2004) 




HD + OAR 
XLAG 
Proband Mild ID onset 5y ACC  this report 





OS, AG, ID 
Mother ID   Anxiety, depression & personality disorder (Eksioglu, et al., 2011) 
Mat aunt 1 N   Depression, Bicornuate uterus 
Mat aunt 2 ID   
Schizophrenia. Small Genitals & small bladder 
with pockets 
Mat half aunt 1 ID +DD Generalized  Enlarged Clitoris 
Mat half aunt 2 N    
Mat grandmother MD   Anxiety & depression 







Mother N  ACC-p  (Kato, et al., 2004) 
Cousin Mod ID    
Aunt N    






Mat grandmother N  
small vessel 
ischemic changes 
Progressive spastic ataxia 
(Stromme, et al., 2002) , 
(Scheffer, et al., 2002) 
Mat Aunt ID   subtle hyperreflexia 






Mother N    (Marsh, et al., 2009) 
Aunt N    
Cousin ID onset 5y (absence) N PDD 
ACC = agenesis of the corpus callosum; ACC-p = partial ACC; / = not reported; ADD = attention deficit disorder; AG= ambiguous genitalia; CVH = cerebellar 
vermis hypoplasia; DD = developmental delay; HD = Homeodomain;  ID = Intellectual Disability; ISSX = X-linked infantile spasm syndrome;  Mat = Maternal;  
MD= Mild Delay;  mo = months;  Mod ID = Moderate ID;  N=Normal;  OAR = Aristaless; OS = Ohtahara Syndrome; PDD = Pervasive developmental disorder; 
Sev ID = Severe ID;  y=years;  XMESID = X-linked myoclonic epilepsy with generalized spasticity and ID. Nucleotide numbering reflects cDNA numbering 







Table 3.3 Clinical features of females with de novo mutations in ARX 
Mutation 















HD + OAR 





Del GPD ID EIEE N 
significantly 
ataxic 
Divergent Strabismus. Congenital 
hip dislocation 





Del DD ID ISSX (WS) Cysts 
hypotonia + 
torticollis 
Poor visual tracking. 
Hydronephrosis. Plagiocephaly + 
small bilateral epicanthal fold with 
mildly low-set ear with slightly 
overfolded helices. 
(Wallerstein, et al., 2008) 
Inversion 
interruption of the 
whole gene 
Inversion DD ID ISS onset in utero ACC + HYD 
Mild truncal 
hypotonia 
Prominent forehead with mild frontal 
bossing, wide nasal bridge, slightly 
up slant palpebral fissures, wildly 
downturned corners of the mouth, 
slightly low-set ears with normal ear 
shape, and high palate 
(Marsh, et al., 2009) 
ACC-t = total agenesis of the corpus callosum; CVI = cortical visual impairment; DD = developmental delay; Del = deletion; EIEE – Early infantile epileptic 
encephalopathy; GPD = global psychomotor delay; HD = homeodomain; HYD = hydranencephaly; ID = Intellectual Disability; ISS = infantile spasm syndrome; 
ISSX = X-linked infantile spasm syndrome; N=Normal; NS = nonsense; OAR = aristaless domain; Sev Delay = Severe DD; UMN = upper motor neuron 
syndrome; WS = West Syndrome. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in 








Figure 3.4 Identified ARX mutations in Females and Males leading to a range of phenotypes 
a) ARX exon structure in relation to the ARX protein. b) Overview of ARX including the homeodomain (crosshatched) and aristaless 
domain (hatched) and the location of reported mutations according to their relative position at the protein level in both males and 
females. Differences in mutation type are indicated by a change in colour while missense mutation is shown in grey and all other 
nonsense, insertion or deletion mutation in black. Phenotype severity is indicated on the y-axis with unaffected carrier females (below 
clinical threshold) shown below the dotted line.  
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Given that the ARX gene is located on the X chromosome and is subject to X chromosome 
inactivation (XCI), the contribution of skewed X-inactivation (80:20) to the phenotype in 
heterozygous females is always a consideration. However, in the female proband of this 
current report we detected no skewing of X-inactivation in samples collected from blood. 
X-inactivation in previous studies has been inconclusive with little correlation of the 
affected status in heterozygous females to preferential inactivation of the normal ARX allele 
(measured in blood) (Marsh et al. 2009). Indeed, skewing of X-inactivation that is not 
consistent with disease severity has been reported for other X-linked genes that were 
originally thought to affect males but have had affected female cases described, including 
mutations in genes such as USP9X, MTM1, SLC9A6 and MED12 (Prontera et al. 2016) 
(Reijnders et al. 2016, Savarese et al. 2016, Sinajon et al. 2016). This highlights the 
complexity of X-linked inheritance. Recently, the variability and complexity of X-
inactivation status within the brain has been demonstrated in an Arx knockout mouse model 
(Marsh et al. 2016). Heterozygous female mice only have one functional copy of Arx and 
consistent with human data, female mice showed great variation of phenotype 
manifestations. These mice display striations of radially oriented streams of Arx positive 
neurons within and emerging from the ganglionic eminence (GE) ventricular zone, which 
was noted to vary dramatically between embryos. This is consistent with the site of random 
X-inactivation suggested to occur in the ventral forebrain, followed by clonal proliferation 
of Arx positive or negative cells migrate radially away during early stages of development. 
Even this incomplete loss of Arx in female mice was detrimental and resulted in a change 
in the profile of interneurons in the adult female mice, consistent with a loss to a greater 
extent in hemizygous male mice.   
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We have identified a novel truncating mutation (c.982delCinsTTT/p.(Q328Ffs*37)) in 
ARX in a family ascertained by a female proband displaying a phenotype of mild 
intellectual disability, seizure disorder and agenesis of the corpus callosum, in conjunction 
with a phenotype of XLAG in her deceased male siblings. Review of the phenotypes of 
affected females with published mutations in ARX indicates that screening of the ARX gene 
in female patients with intellectual disability, seizure phenotypes and corpus callosum 
agenesis, particularly if there is evidence of X-linkage and no surviving males is warranted. 
Moreover, recent de novo mutations reported in females recommends scrutiny of ARX in 
all cases with suitable phenotypic presentation with and without other indications of X-
linked inheritance. The emerging appreciation of phenotypic consequences in females with 
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4 Embryonic forebrain transcriptome of mice with polyalanine expansion 
mutations in the Arx homeobox gene 
 
Publications, Presentations and Published Abstracts from this work: 
Accepted first author publication 
 Mattiske, T., K. Lee, J. Gecz, G. Friocourt and C. Shoubridge (2016). "Embryonic 
forebrain transcriptome of mice with polyalanine expansion mutations in the ARX 
homeobox gene." Hum Mol Genet. (DOI: 10.1093/hmg/ddw360) 
 
Accepted publication 
 Lee, K., T. Mattiske, K. Kitamura, J. Gecz and C. Shoubridge (2014). "Reduced 
polyalanine-expanded Arx mutant protein in developing mouse subpallium alters 





 Mattiske, T.R, Lee, K., Gécz J and Shoubridge, C (Nov 2016). Investigating the 
molecular and cellular disruptions in the developing brain resulting in intellectual 
disability and seizures caused by polyalanine expansion mutations in ARX. 
Proceedings of the 6th Adelaide ANZSCDB Meeting 2016, Adelaide, Australia.  
107 
 Mattiske, T.R, Lee, K., Gécz J and Shoubridge, C (April 2016). Global gene disruption 
resulting in ISSX caused by polyalanine expansion mutations in ARX. Proceedings of 
the International Congress Meeting of Human Genetics (ICHG) 2016 Kyoto, Japan. 
 Mattiske, T.R, Lee, K., Gécz J and Shoubridge, C (July 2015). Investigating the 
transcriptome-wide impact of expanded polyalanine tract mutations in ARX 
contributing to intellectual disability and seizures. Proceedings of the Genetics Society 
of Australasia 2015, Adelaide, Australia. 
 
Posters presented 
 Mattiske, T.R, Lee, K., Gécz J and Shoubridge, C (Feb 2015). Investigating the 
transcriptome-wide impact of expanded polyalanine tract mutations in ARX 
contributing to intellectual disability and seizures. Proceedings of the 2015 Lorne 
Genome Conference, Lorne, VIC. 
 Mattiske, T.R, Lee, K., Gécz J and Shoubridge, C (Aug 2014). Casting the net 
transcriptome-wide: How do expanded polyalanine tract mutations in ARX contribute 
to intellectual disability and seizures? Proceedings of the 38th Human Genetics Society 




The Aristaless related homeobox (ARX) gene encodes a paired-type homeodomain 
transcription factor with critical roles in embryonic development. Mutations in ARX give 
rise to intellectual disability (ID), epilepsy and brain malformation syndromes. To capture 
the genetic and molecular disruptions that underpin the ARX-associated clinical 
phenotypes, we undertook a transcriptome-wide RNASeq approach to analyse developing 
(12.5 dpc) telencephalon of mice modelling two recurrent polyalanine expansion mutations 
with different phenotypic severities in the ARX gene. Here we report 238 genes 
significantly deregulated (Log2FC >+/-1.1, P-value <0.05) when both mutations are 
compared to wild-type (WT) animals. When each mutation is considered separately, a 
greater number of genes were deregulated in the severe PA1 mice (825) than in the PA2 
animals (78). Analysing genes deregulated in either or both mutant strains, we identified 
12% as implicated in ID, epilepsy and autism (99/858), with ~5% as putative or known 
direct targets of ARX transcriptional regulation. We propose a core pathway of 
transcription regulators, including Hdac4, involved in chromatin condensation and 
transcriptional repression, and one of its targets, the transcription factor Twist1, as potential 
drivers of the ID and infantile spasms in patients with ARX polyalanine expansion 
mutations. We predict that the subsequent disturbance to this pathway is a consequence of 
ARX protein reduction with a broader and more significant level of disruption in the PA1 
in comparison to the PA2 mice. Identifying early triggers of ARX-associated phenotypes 
contributes to our understanding of particular clusters/pathways underpinning comorbid 
phenotypes that are shared by many neurodevelopmental disorders. 
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4.2 Introduction 
Neurodevelopmental disorders (NDDs), which include intellectual disability, seizure 
disorders and autism spectrum disorders are prevalent in the population. Large-scale 
sequencing efforts have highlighted the genetic heterogeneity contributing to each of these 
disorders (Epi et al. 2013, Chen et al. 2014, Euro et al. 2014, Krumm et al. 2014, Pinto et 
al. 2014). Understanding how such divergent etiologies produce similar clinical features 
remains a major challenge. Despite this, recent studies indicate that many of the 
pathophysiological mechanisms might be shared, opening the possibility that more than 
one condition may be amenable to a treatment or disease modification that exploits a 
common mechanism (Chen et al. 2014, Krumm et al. 2014, Pinto et al. 2014). Here we 
investigate the molecular mechanisms and functional impact of mutations in the disease-
causing gene contributing to intellectual disability and infantile spasms, the Aristaless 
related homeobox gene (ARX) [NM_139058.2] (MIM# 300382).  
 
ARX is a member of the paired-type homeodomain transcription factor family with critical 
roles in development, particularly in the developing brain (Kitamura et al. 2002, Ohira et 
al. 2002) Depositario-Cabacar, 2010 #78}. ARX is indispensable for telencephalic 
morphogenesis particularly involved in radial and tangential migration of GABAergic 
interneuron progenitors, early commitment of cholinergic neurons and is emerging as a 
selector gene important in preserving identity of specific brain regions (Kitamura et al. 
2002, Colombo et al. 2007, Friocourt et al. 2008, Colasante et al. 2009, Lee, K. et al. 2014). 
In accordance with the essential function of ARX during early brain development, Arx 
expression is detected in mice at embryonic day 8 in a restricted area of the neuroepithelium 
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corresponding to the prospective forebrain (Bienvenu et al. 2002). During peak neural 
proliferation and neurogenesis expression of Arx within the subpallium peaks between 12.5 
to 14.5 days post coitum (dpc), persisting during embryogenesis and is down regulated 
during postnatal life (Miura et al. 1997, Kitamura et al. 2002).  
 
ARX is an X-chromosome gene. As such, patients are generally affected males with carrier 
females being asymptomatic. Over 60% of all mutations in ARX expand the first or second 
polyalanine tract, and affected males with these mutations invariably present with 
intellectual disability with and without infantile spasms and epilepsy (Shoubridge et al. 
2010a, Marques et al. 2015). In particular, patients with expansions to the first polyalanine 
tract (previously reported as c.304ins(GCG)7, now following HGVS nomenclature 
reported as c.306GGC[17] ; referred to as PA1 mutation in this study) invariably display 
seizures, with infantile spasms in 85% of these PA1 patients (Marques et al. 2015). The 
key phenotypic features seen in these patients are recapitulated in well characterised mutant 
mouse models, including infantile spasm-like movements, electrodecremetal discharges, 
and multifocal EEG spikes, with seizures in juvenile and older mice (Kitamura et al. 2009, 
Price et al. 2009, Beguin et al. 2013). The most frequent mutation in ARX in patients results 
in an expansion to the second polyalanine tract (previously reported as c.429_452dup, now 
following HGVS nomenclature reported as c.441-464dup; referred to as PA2 mutation in 
this study) with at least 10-15% of these PA2 patients presenting with infantile spasms in 
addition to intellectual disability (Marques et al. 2015). Although there is a mouse model 
of the most common PA2 mutation (Kitamura et al. 2009), phenotypic data for this strain, 
including the prevalence of seizures is limited.  
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Our recent investigations in these mice modelling to two most frequent polyalanine 
expansion mutations in human patients demonstrated aggregation of mutant Arx protein 
does not occur in the embryonic brain. Instead, we identified a marked reduction in mutant 
Arx protein expression in the developing forebrain (Kitamura et al. 2009, Lee, K. et al. 
2014). Interestingly, this data indicates that both PA1 and PA2 mutations give rise to 
similar molecular outcomes. Despite recent studies identifying genes regulated by ARX 
(Fulp et al. 2008, Colasante et al. 2009, Friocourt and Parnavelas 2011) there is limited 
understanding of what impact the expanded polyalanine tract mutations in Arx may have 
on the transcriptional activity (Nasrallah et al. 2012, Lee, K. et al. 2014) and how this may 
contribute to phenotypic outcomes. In this study, we use RNASeq on brain tissue at 12.5 
dpc during embryonic development to capture early disruptions of Arx function. We show 
that the gene expression consequences of the polyalanine expansion mutations of Arx do 
overlap but the PA1 mutation leads to a greater and broader disturbance than the PA2 
mutation. From our analysis of the deregulated genes, we propose a pathway involving 
Histone Deacetylase 4 (Hdac4) and Twist Family BHLH Transcription Factor 1 (Twist1) 
that when deregulated by either Arx mutation contributes to the comorbid phenotypes of 




4.3 Results  
4.3.1 PA1 and PA2 mice deregulated transcriptomes overlap.  
Arx is indispensable for brain development with expression detected as early as 8 dpc 
(Miura et al. 1997, Bienvenu et al. 2002). To capture early changes to the transcriptome 
due to mutations in Arx we collected and investigated the 12.5 dpc telencephalon of mice 
modelling two mutations in Arx, PA1 and PA2 (Figure 4.1). We compared four males from 
each strain with stage-matched WT male littermates.  Sequences were aligned using 
TopHat and count data generated from HTSeq was used as the input for EdgeR to identify 
genes with differential expression between samples.  
 
 
Figure 4.1 Arx expression during embryonic development. 
In the top panel in situ hybridization images taken from the Allen Mouse Brain Atlas show 
Arx expression at four embryonic developmental time points with the log expression (red 
= high and yellow = low) shown in the bottom panel. The telencephalon structure is 
indicated on the 3D reference image (orange shading). Image credit: Allen Institute for 




Analysis of the PA1 mice revealed 825 genes deregulated by Log2 fold change greater than 
+/- 1.1 with a P-value of less than 0.05, with 54% found at higher levels of expression than 
WT (Figure 4.2a).  In contrast, the PA2 mutation resulted in 78 genes deregulated using 
the same fold cutoff, with 72% of these found at higher levels of expression than the WT 
animals (Figure 4.2a). Despite the large difference in the number of genes significantly 
deregulated between the two PolyA strains, we noted that expression of many of the genes 
deregulated in the PA1 mice shared the same trend of deregulation in the PA2 mice 
although the lower log2FC values did not reach the required significance (Figure 4.2b -
within dotted lines). Given the similarities of the transcriptome changes between PA1 and 
PA2, we speculate that the disrupted pathway may be shared between PA1 and PA2. This 
is supported by previous studies suggesting both PA mutations result in a reduction of the 
ARX protein together with the overlap of clinical phenotypes in human patients with either 
PA1 or PA2 mutations. With this in mind, we analysed the genome-wide expression data 
of both the PA1 and PA2 mice as a single mutation group (referred to as PolyApool) 
compared to the WT samples to capture genes deregulated in both mutant strains. Lists of 
deregulated genes for each analysis are provided in Appendix Table 1-Appendix Table 3. 
From this analysis, a total of 238 genes were identified (Log2 fold change greater than +/- 
1.1 with a P-value < 0.05) (Figure 4.2c). The majority of genes deregulated in the PolyApool 
(89%) were at higher levels of expression in mutant mice (Figure 4.2a). Not surprisingly, 
all genes identified as deregulated by this analysis had already been identified as 
deregulated in either PA1 or PA2 mice. When we consider the 238 genes identified as 
deregulated in the PolyApool analysis, the mean log2FC value of the more severe PA1 group 
on its own is at 1.3, above the 1.1 cutoff value. In contrast, the milder PA2 group when 
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considered on its own is below the 1.1 cutoff at 0.7.  This means that of the total 238 
significantly deregulated genes in the PolyApool data, 94% (224/238) of genes in PA1 and 
24% (56/238) of genes in PA2 met the cutoff values, respectively (Figure 4.2d). Of the 238 
genes that were significantly deregulated in the PolyApool analysis, 42 genes (18%) were 
significantly deregulated in both PA1 and PA2 animals when each mutant strain was 
considered independently compared to WT (P>3.753e-31). When considered 
independently, 182 genes (76%) were significantly deregulated in PA1 animals only, and 
14 genes (6%) were deregulated specifically in the PA2 animals. Of the 42 significantly 
deregulated genes compared to WT in both PA1 and PA2, 79% (33/42) of the genes had 
increased expression (Figure 1E). The overall disruption to the transcriptome observed 
supports the notion that PA1 and PA2 disrupt overlapping pathways, with PA2 mice being 




PA1 PA2 PolyApool 
# genes deregulated 825 78 238 
Increased expression 446 (54%) 56 (72%) 212 (89%) 













Figure 4.2 Transcriptome analysis of embryonic brains of PolyA Arx mutant mice. 
Differential expression of genes from 12.5 dpc mice was determined using EdgeR and 
selected based on a Log2 fold change greater than +/- 1.1 with a P-value < 0.05. (a) Total 
number of deregulated genes and the proportion of either increased or decreased expression 
from our analysis from both mutant mice strains independently, PA1 and PA2, and analysis 
of pooled PA1 and PA2 strains, PolyApool when compared to WT animals. (b) Log2FC was 
plotted for all deregulated genes for both PA1 (orange) and PA2 (blue) (total = 858). Genes 
within the darker red shaded area are deregulated in different directions compared to WT 
with expression of genes significantly different between PA1 and PA2 (58/858, 6.75%). 
Genes within the lighter red area are deregulated in the same direction in both PA mutation 
groups compared to WT, but are still significantly different between PA1 and PA2 
(498/858, 58.05%). The remaining genes are deregulated in the same direction compared 
to WT, but are not significantly different between PA1 and PA2 (35.2%). The dotted line 
indicates the log2FC +/- 1.1 cut off. (c) Gene lists from PA1 (orange), PA2 (blue) and 
PolyApool analysis (dotted outline) was used to determine the overlap of genes deregulated 
in each group and visualised as a Venn diagram. Overlapping genes in PA1 and PA2 
samples with log2FC>+/-1.1 in both lists and a P-value <0.05 are highlighted in grey (solid 
outline) with logFC values for individual genes shown in (e). *significantly different 
between groups with a log2FC<1.1 and P-values <0.05, **significantly different between 
groups with a log2FC>+1.1 and P-values <0.05.  
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4.3.2 PA1 and PA2 mutations disturb overlapping biological processes in the 
developing brain. 
Functional enrichment analysis is a common tool to understand global changes in 
phenotypes in cells and tissues. EnrichR (Chen et al. 2013) analysis was used to investigate 
the enrichment of groups of genes with overlapping gene ontology (GO) terms representing 
gene properties with the focus on biological process. To interrogate the types of genes 
disturbed due to polyalanine tract expansion mutations in Arx we focused on the 
deregulated genes identified in our analysis with higher levels of expression compared to 
WT (+1.1 log2FC). This focus was due mainly to the very small numbers of deregulated 
genes at lower levels of expression in PolyA mutant groups compared to WT in the core 
and PolyApool subgroups. GO Terms were ranked using the EnrichR method of combining 
the p-value computed using the Fisher exact test with the z-score of the deviation from the 
expected rank by multiplying these two numbers as follows: c = log(p) * z (Chen et al. 
2013). Enrichment of GO biological process identified 12 biological processes (adjusted P-
value <0.05) enriched in the differentially expressed genes (with higher levels of 
expression compared to WT) relative to all expressed genes (Figure 4.3). These biological 
processes fall into three main categories; those implicated in cell-cell adhesion 
(GO:0007156, GO:0098609, GO:0098742); regulation of neuron differentiation/nervous 
system development (GO:0045664, GO:0010975, GO:0007399); and neuron membrane 
properties such as synaptic transmission (GO:0007268), regulation of membrane potential 
(GO:0042391) and potassium ion transmembrane transport (GO:0071805) (Figure 4.3). 
The levels to which each GO biological process is enriched in each group is displayed as a 
heat map on the right of Figure 4.3. This analysis indicates that the same categories of GO 
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processes were enriched whether the deregulated genes considered were from the core 
overlap group, the PolyApool group or the broadest PA1 group of deregulated genes, 
particularly for the cell-cell adhesion process (Figure 4.3).  Overlap was also seen in the 
terms identified by Panther pathway analysis when comparing the top 10 enriched 
pathways in genes deregulated in PA1 mice and genes deregulated in PA2 mice (Table 4.1-
Table 4.2).  
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Figure 4.3 Gene ontology classification of deregulated genes. 
Functional enrichment analysis of gene ontology (GO) terms for biological processes 
shows the differentially expressed genes within subgroups, PolyApool, PA1 only and all 
deregulated genes from both PA1 and PA2 (All deregulated (DE) genes) with a log2 fold 
change with +>1.1 cutoff value used as the input into EnrichR. The GO terms were ranked 







Table 4.1 Top 10 enriched Panther pathways for deregulated genes in PA1. 
























GABA-B receptor II 
signaling_P05731 
5/35 0.026 0.55 -1.6 0.96 GABBR2;ADCY9;CACNA1B;GNG8;KCNJ3 
Metabotropic glutamate 
receptor group II 
pathway_P00040 
4/30 0.054 0.87 -1.3 0.19 VAMP8;STX1B;CACNA1B;CACNA1E 
p53 pathway_P00059 6/71 0.107 0.98 -0.92 0.019 CREBBP;PERP;BAX;MDM4;SFN;GADD45G 
Synaptic vesicle 
trafficking_P05734 
3/23 0.096 0.98 -0.35 0.007 UNC13C;RIMS1;STX1B 
Cortocotropin releasing 
factor receptor signalling 
pathway_P04380 
3/30 0.164 0.99 -0.65 0.004 POMC;VAMP8;GNG8 
Metabotropic glutamate 
receptor group III 
pathway_P00039 




3/41 0.289 0.99 -0.36 0.002 VAMP8;CACNA1B;CACNA1E 
Muscarinic acetylcholine 
receptor 2 and 4 signalling 
pathway_P00043 






Table 4.2 Top 10 enriched Panther pathways for deregulated genes in PA2 mice. 
 
 









6/150 5.9E-05 0.00059 -1.6 11.9 CDH3;ERBB4;PCDHGA1;PCDHGB1;PCDHA2;PCDHA12 
Wnt signalling 
pathway_P00057 
5/278 0.011 0.055 -1.68 4.89 CDH3;PCDHGA1;PCDHGB1;PCDHA2;PCDHA12 
Alzheimer disease-presenilin 
pathway_P00004 
2/99 0.099 0.33 -1.39 1.54 CDH3;ERBB4 
GABA-B receptor II 
signaling_P05731 
1/35 0.177 0.44 -1.45 1.178 GABBR2 
Alzheimer disease-amyloid 
secretase pathway_P00003 




1/68 0.314 0.47 -1.04 0.8 CHRNA7 
p53 pathway_P00059 1/71 0.326 0.47 -0.92 0.7 PERP 
EGF receptor signalling 
pathway_P00018 
1/109 0.455 0.57 -1.08 0.6 ERBB4 
Integrin signalling 
pathway_P00034 
1/156 0.58 0.6 -1.02 0.51 COL8A1 
CCKR signalling map 
ST_P06959 
1/165 0.6 0.61 -0.94 0.47 NOS1 
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4.3.3 Identifying early triggers of ARX associated phenotypes  
To ascertain which of the deregulated genes were likely to be direct transcriptional targets 
of Arx, the data from Arx knockout expression analysis (Fulp et al. 2008, Colasante et al. 
2009) and ChIP studies (Quille et al. 2011) were used to identify that 46 genes deregulated 
in this studies data set are either known or putative direct targets of Arx. These targets 
accounted for 5% of all 858 deregulated genes and were detected across all groups 
considered, with a small level of enrichment in the PolyApool group (Figure 4.4). Consistent 
with the fact that ARX is a transcriptional repressor, the majority of these targets were 
detected at higher levels of expression in the PolyA mutant animals compared to WT. We 
have previously demonstrated a marked reduction of mutant Arx protein abundance within 
the developing forebrain of both PA1 and PA2 (Lee, K. et al. 2014), indicating that the 
expanded polyalanine tract mutations in our mouse models represent a partial loss of Arx 
function.  In Figure 4.4c we captured the response of these target genes to PolyA mutation 
in Arx in our study compared to the response in the previously reported studies modelling 
knocked-out or ablated Arx expression in mouse brain (Fulp et al. 2008, Colasante et al. 
2009) or in response to exogenous Arx overexpression in N2a cells (Quille et al. 2011). 
This analysis indicates that less than half (43%) of the direct gene targets of Arx identified 
as deregulated in the brains of 12.5 dpc mice with Arx PolyA mutations were also 
deregulated in Arx deficient mice. In general, the direction of deregulation of the target 
genes was in agreement between the loss of function studies and the partial loss of function 
in our PolyA mice. Not unexpectedly, there was more variation in the direction of 
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deregulation between our partial loss of function in the PolyA mice when compared to the 
overexpression of exogenous Arx in Na2 cells (Figure 4.4c).  
 









Genes per Group 42 182 598 858 
Direct Targets 3 (7%) 13 (7%) 28 (4.7%) 46 (5%) 
Increased 
expression 
3 (100%) 11 (85%) 13 (46%) 27 (59%) 
Decreased 
expression 







Figure 4.4 Disruption to putative and known ARX target genes. 
a) The number of putative and known direct targets of ARX and the direction of 
deregulation in the PolyA mutant mice is shown for each subgroup of the RNASeq 
analysis. b) The putative and known direct gene targets of ARX are spread across all 
subgroups of the RNASeq analysis as illustrated on the Venn diagram.  c) For each of these 
putative or direct gene targets of Arx identified in the PolyA mutant mice the change in 
expression compared to WT from this study (PA1 and PA2) with comparison of the 
changes to expression in studies of Arx loss of function (ARX KO) (Fulp et al. 2008, 
Colasante et al. 2009), Arx overexpression in N2a cells (ARX OE) (Quille et al. 2011) and 
ChIP studies (Quille et al. 2011). Red indicates an increase in expression with Green a 
decrease in expression compared to WT.  
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4.3.4 De-regulation of early triggers of ARX associated phenotypes persists across 
embryonic development 
Considering the spatial expression of Arx in the subpallium is restricted to the in both lateral 
and medial ganglionic eminence, we were interested if there was any obvious relationship 
of spatial localisation in regard to the genes deregulated in our PA mice. We compared 
expression of a number of deregulated genes that had available expression data from the 
Allen Developing Mouse Brain Atlas and EURExpress at suitable embryonic stages. Genes 
with a similar spatial expression profiles as determined by in situ hybridization images to 
that of Arx include Ebf1, Rapgef5, Myt1l, Erbb4, Al606473, Zfp536 and Gpr26. In contrast, 
several genes had an opposite spatial expression profiles compared to Arx including 
Zbtb20, Ptch1 and Hdac4, which are expressed in the proliferating cells in the ventricular 
zone (Figure 4.5). This analysis highlights that the early triggers of Arx associated 
phenotypes identified in this study includes both directly regulated and indirectly regulated 




Figure 4.5 Spatial expression profiles of selected genes deregulated in expanded polyA 
mutant mice 
Arx expression is present in the subpallium (in both lateral and medial ganglionic 
eminence) with similar spatial expression profiles seen for in situ hybridization images of 
Ebf1, Rapgef5, Myt1l, Erbb4, Al606473, Zfp536 and Gpr26. In contrast, Zbtb20, Ptch1 and 
Hdac4 are expressed within the proliferating cells in the ventricular zone.  The in situ 
hybridization images for Arx, Erbb4, Ebf1, Rapgef5, Myt1l, Zbtb20, and Ptch1 are from 
the Allen Mouse Brain Atlas at developmental time point E13.5 dpc. The in situ 
hybridization images of Zfp536, Gpr26, Al606473 and Hdac4 are from EURExpress at 
developmental time point 14.5 dpc. Image credit: Allen Institute for Brain Science 




To determine whether disruption to the transcriptome was constrained to very early 
development in the time point tested by RNASeq or continued throughout embryonic life 
we chose to test fifteen genes by quantitative PCR in the WT compared to PA1 mice across 
three developmental time points, 12.5, 14.5 and 18.5 dpc. The genes selected included a 
number a putative targets of Arx previously reported, Plcxd3, Gpr26, Ebf1, Myt1l, Aspm, 
Hdac4 and Ptch1.  Of interest also were deregulated genes that were known 
neurodevelopment genes (Cdkl5, Erbb4, Sor1l, Twist1, Myt1l, Aspm, Hdac4 and Ptch1) or 
displayed spatial expression patterns indicated above (Erbb4, Zfp536, Zbtb20, Gpr26, 
Ebf1, Myt1l, Hdac4 and Ptch1), or were deregulated in both PA1 and PA2 (Kcna3 and 
Six2).  Our analysis indicates that 11/15 genes validated with deregulated gene expression 
at 12.5 dpc by quantitative PCR, but also had deregulated expression in PA1 mutant mice 
across more advanced stages of embryonic development, with Myt1l, Plcxd3, and Six2 
consistently significantly deregulated across all time points examined (Figure 4.6). For 
several genes with validated deregulation by quantitative PCR in PA1 mice we confirmed 
that the deregulation was also validated in PA2 samples at 12.5 dpc by this analysis, and 
moreover identified that deregulation in these genes persisted in later embryonic 
developmental time points (Figure 4.6).  Considering that the expression of Arx during 
development significantly diminishes at 18.5 dpc it was not surprising that we noted less 
consistent deregulation of genes persisting in the 18.5 dpc time point compared to earlier 
14.5 dpc. This variability at 18.5 dpc could be due to a number of factors, but is likely 
influenced by the increased complexity and size of the brain (tissue sample collected) at 
this time point and underscores the strategy for targeting the early developmental stages 













  % relative to WT  % relative to WT 
 12.5 dpc 14.5 dpc 18.5 dpc 12.5 dpc 14.5 dpc 18.5 dpc 
Erbb4   11.70 * 13.03 * 1.37   NT NT NT 
Plcxd3   33.25 ** 30.18 ** 13.04 * NT NT NT 
Zfp536   51.00 ** 31.13 ** -26.26 * 59.22 ** 30.21 * -17.81 * 
Kcna3   42.60 ** 27.22 ** -23.36 * 43.50 ** 16.35 * -19.24 * 
Sorl1   81.88 ** 33.73 ** -30.33 * 72.44 ** 24.85 ** -22.02 * 
Zbtb20   -7.69   23.87 * 24.29 ** NT NT NT 
Gpr26   20.79 * 1.51  4.62 * NT NT NT 
Ebf1   19.04 ** -12.62   39.93 ** NT NT NT 
Cdkl5   7.38   15.89 * 24.61   NT NT NT 
Aspm   26.27   -38.37   -50.65 * NT NT NT 
Myt1l   27.98 ** 34.18 ** 50.31 * NT NT NT 
Hdac4   -4.97 * 1.47  -2.56  NT NT NT 
Ptch1   13.09 * -13.58 * -29.57 ** NT NT NT 
Twist1   -30.78 * -44.28 * -9.01   -6.75  -45.90 * 5.38   
Six2   -35.05 ** -31.96 ** -4.63 * -21.14 * -35.49 ** 10.69 * 
               
  Up-regulated    * p<0.05 **p<0.001    
  Down-regulated     Opposite level of deregulation 










Figure 4.6 Real-time Analysis of deregulated genes across embryonic development 
due to polyalanine tract mutations in Arx 
Sample tested were pooled RNA samples isolated from the telencephalon of embryos for 
each genotype across the three time points and compared to pooled WT samples with the 
same number of individual samples (12.5 and 14.5 dpc n=8, 18.5 dpc n=4). Expression 
values were normalised to the reference gene Tbp. A) Summary of the genes analysed for 
PA1 and selected genes analysed for PA2. B) Individual graphs of relative quantity for 
each gene across three embryonic time points for WT (white bars), PA1 (dark grey bars) 
and PA2 expression (pale grey bars). *P < 0.05, **P< 0.01 (one-tailed t-test of PA1 or PA2 
compared to WT at each time point). 
 
4.3.5 Deregulation of neurodevelopment disorder genes contribute to the 
polyalanine expansion mutation phenotype  
Deregulated genes that overlap with lists of genes implicated in epilepsy, ID and autism 
(Pinto et al. 2014) showed in the total group of 858 deregulated genes, 99 genes (12%) are 
known disease-causing genes for Epilepsy (55 genes), ID (29 genes) and Autism (51 genes) 
(Figure 4.7a). This overlap is significant when considering the total group of deregulated 
genes (P<0.014), the PolyApool group (29/182 = 16%, P<0.003) and the core overlap group 
(9/42 = 21%, P<0.014) but not in the PA1 only group (P<0.292) (Figure 4.7a and b). Given 
the incidence of comorbidity of phenotypic features of these particular neurodevelopmental 
disorders (NDD), we were not surprised to see that many of the ID genes (22/29 = 76%) 
identified in our data also contribute to epilepsy and autism, with 8 genes contributing to 
all three comorbidities of epilepsy, ID and autism (Figure 4.7c). The distribution of these 
NDD genes that were deregulated in our PolyA mice are shown in Figure 4.7d. Of these 
99 NDD genes, only 7 are currently identified as direct targets of ARX (bold entries on 
Figure 4.7d) (Quille et al. 2011). Movement disorders including dystonia and dyskinesia 
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are a frequent co-morbidity in patients with expanded polyA mutations in ARX. Known 
genes for these disorders are highlighted in the 99 NDD genes (underlined entries on  























42 182 598 858 
ID Genes 3 (7%) 6 (3%) 20 (3%) 29 (3%) 
Epilepsy Genes 4 (10%) 15 (8%) 35 (6%) 55 (6%) 
Autism 6 (14%) 16 (9%) 29 (5%) 51 (6%) 
Total NDD genes 9 (21%) 29 (16%) 60 (10%) 99 (12%) 
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Core 
Overlap 










Cbl, Csmd1, Csmd3, Fos, 
Gatad2b, Kcnh5, Lyst, 
Mib1, Mrs2, Syt14 
Chrm3, Gabrq, Gan, Grid2, 
Pcdha6, Pcdha7, Pcdha9, 
Pcdhac1, Pcdhac2, 























Alg10b, Aqp4, Casc5, 
Ccdc88c, Cit, Dtnbp1, Epg5, 
Nalcn, Nanos3, Ndufa2, 
Ndufa8, Npy, Pet100, Pomc, 
Rest, Scarb2, Sepsecs, 
Vps13a, Xpnpep3 
Aff4, Cacna1b, Cib2, Cntn5, 
Cntnap3, Fat1, Grcc10, 
Myo16, Nbea, Ndufa5, 
Nos1ap, Pcdh9, Pcdha3, 
Pcdha5, Rims3, Tbl1x, Wnk3 
PA2 Only       Msx2 
Total 8 9 6 5 7 32 32 
 
Figure 4.7 Genes deregulated in expanded polyA mice include known ID, epilepsy and autism genes.  
a) Total number of genes associated with overlapping phenotypes of ID, epilepsy and autism and the proportion (%) per mutation 
subgroup. P-value indicates the significance of overlap between each PolyA mutant subgroup and the known neurodevelopment 
disorder genes. b) A combined graph showing the total number of genes per subgroup (grey bars) on the right-hand y-axis compared 
to the proportion of overlap with known neurodevelopmental disorder genes across RNASeq analysis subgroups shown on the left-
hand y-axis (legend for line graph shown below the graph). b) Venn diagram showing the overlap of genes associated with ID, Epilepsy 
and Autism comorbid phenotypes. d) List of known neurodevelopmental disorder genes within each PolyA mutant subgroup, grouped 
by the associated disease phenotypes. Known movement disorder genes are underlined. The putative and known direct targets of ARX 
/ Arx are highlighted in bold. 
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Table 4.3 Muscle disorder genes found in polyalanine expansion mutant mice. 
The following gene panels were interrogated: Blueprint Genetics & The University of 
Chicago Ataxia panels, CGC genetics Dystonia Panel, Radboud University Medical Centre 
muscle disorder gene panel (DGD20062014).  
 Ataxia Dystonia Muscle Disorder 
Core Group Sacs   
PolyAPool 




Atp8a2, Ccdc88c, Cep290, 
Dmxl2, Herc1, Kcna1, 








4.3.6 Early triggers of ARX associated Overlap Arx-Hdac4-Twist1 pathway  
The top 10 enriched terms by KEGG and Reactome pathway analysis for genes deregulated 
in the PolyA pool group highlight the breadth of neurological processes impacted by the 
genes deregulated in these mutant mice (Table 4.4 and Table 4.5). Interestingly, from our 
analyses, we propose one particular pathway of transcriptional regulators implicated in 
NDD and deregulated in the PolyA mutant mice that may act as potential drivers of the 
phenotypes, particularly ID and epilepsy (Figure 4.8). The pathway highlights direct 
interactions based on Ingenuity Pathway analysis and includes manually curated data from 
the literature based on ChIP studies to identify additional direct interactions across the 
pathway. We propose that the reduced protein expression in the developing brains of the 
PolyA mice (Lee, K. et al. 2014) leads to inadequate regulation of Hdac4, involved in 
chromatin condensation and transcriptional repression (Fischer et al. 2010), which in turn 
has a flow on effects directly on targets such as Mef2c and Twist1. Twist1 is a basic-helix-
loop-helix transcription factor involved in cell lineage determination & differentiation 
(Nieto 2013). The expression of Twist1 was significantly decreased in both the PA1 and 
PA2 mutant mice when analysed independently and confirmed by qRT-PCR (Figure 4.6b).  
 
A recent study using a ChIP approach to identify targets of TWIST1 (Lee, M.P. et al. 2014) 
indicates that 302 genes deregulated in the current study overlap with TWIST1 targets, 
23/302 of which were deregulated in both PA1 and PA2 mutant mice, 17/302 being known 
ID genes and 32/302 being known epilepsy genes. We recently demonstrated that there 
was a consistently greater level of reduction of mutant Arx protein in the developing brains 
of the PA1 mice with a more variable reduction of mutant protein in the embryonic brains 
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of PA2 mice (Lee, K. et al. 2014). Hence, we propose that adequate levels of Arx protein 
are required to regulate direct targets such as Hdac4 for normal brain development. When 
this regulation is not achieved the subsequent disturbance is relative to the reduction in Arx 
mutant protein expression, with a broader and more significant level of disruption observed 
in the PA1 mice as compared to the PA2 mice.  
 
We performed in situ hybridization of Arx, Cdkl5, Hdac4 and Twist1 in 14.5 dpc brain 
sections from WT and PA1 embryos to test whether there is a change in the ectopic 
expression of these genes in cells that would not normally express Cdkl5, Hdac4 and 
Twist1. In situ hybridization confirmed no overall loss of Arx transcript (Lee, K. et al. 2014) 
and showed normal Arx spatial expression pattern within the 14.5 dpc forebrain in PA1 
(Figure 4.10 b, c, k and l).     Riboprobes for Cdkl5, Hdac4 and Twist1 were tested over 
multiple in situ series to determine the riboprobe efficiency and specificity with the optimal 
chosen dilutions shown in Adult WT samples in Figure 4.9. The efficiency of probes was 
low compared to Arx, used at a 1/50 dilution, with used at Cdkl5 at 1/10, Hdac4 at 1/5 and 
Twist1 was used neat. In an effort to improve probes, they were remade however no 
increases in strength was seen.  Cdkl5 shows robust expression in the adult tissue in the 
cortex and hippocampus with specificity confirmed with previously published work 
(Rusconi et al. 2008). Twist1 and Hdac4 also showed expression in the cortex and 
hippocampus however staining was not robust. Specificity of Twist1 and Hdac4 was in 
agreement with Allen Brain Atlas for Adult Mice (http://mouse.brain-map.org/).  No   
change in ectopic expression was present in PA1 when compared to WT embryos at 14.5 
dpc for Cdkl5, Hdac4 and Twist1 (Figure 4.10 d-I and m-r). Due to poor efficiency of in 
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situ hybridization of these probes in both WT and PA1 embryos, it would need to be 
confirmed in a repeat experiment with probes possible directed towards alternative mRNA 






Table 4.4 Top 10 enriched KEGG pathways for PolyAPool genes (238). 
 








Cholinergic synapse 04725 7/111 5.E-05 0.007138 -2.06 10.19 CHRM3;ADCY9;CHRNA7;KCNQ3;FOS;CREB5;KCNJ3 
Estrogen signalling 
pathway 04915 
6/99 0.0002 0.016 -1.896 7.87 GABBR2;ADCY9;SHC3;FOS;CREB5;KCNJ3 
Calcium signalling 
pathway 04020 
7/180 0.0009 0.04 -1.91 6.098 CHRM3;ADCY9;ERBB4;CHRNA7;ATP2B3;NOS1;CACNA1E 
cAMP signalling pathway 
04024 
6/199 0.007 0.14 -1.84 3.606 GABBR2;ADCY9;PTCH1;ATP2B3;FOS;CREB5 
Insulin secretion 04911 4/85 0.006 0.141 -1.81 3.549 CHRM3;ADCY9;KCNN3;CREB5 
Viral carcinogenesis 05203 6/205 0.008 0.141 -1.80 3.534 HDAC4;EGR3;CDK6;HIST1H4K;HIST1H4F;CREB5 
Salivary secretion 04970 4/89 0.007 0.141 -1.71 3.34 CHRM3;ADCY9;ATP2B3;NOS1 
Circadian entrainment 
04713 
4/95 0.009 0.144 -1.71 3.317 ADCY9;FOS;NOS1;KCNJ3 










Table 4.5 Top 10 enriched Reactome pathways for PolyAPool genes (238). 
 


















5/43 4.4E-05 0.006091 -1.99 10.13 KCNH5;KCNH7;KCNB2;KCNQ3;KCNA3 
GABA receptor 
activation-977443 




7/211 0.0021 0.174529 -2.17 3.79 GABRQ;GABBR2;RIMS1;ADCY9;CHRNA7;CACNA1E;KCNJ3 
GABA B receptor 
activation-977444 
3/39 0.00498 0.293 -1.99 2.45 GABBR2;ADCY9;KCNJ3 
Activation of GABAB 
receptors-991365 
3/39 0.00498 0.293 -1.98 2.43 GABBR2;ADCY9;KCNJ3 
Neurotransmitter 
Receptor Binding And 
Downstream 
Transmission In The  
Postsynaptic Cell-
112314 
5/142 0.0073 0.378 -2.047 1.99 GABRQ;GABBR2;ADCY9;CHRNA7;KCNJ3 
Signaling by FGFR1-
5654736 
7/336 0.023 0.513 -2.52 1.68 ADCY9;SHC3;ERBB4;FLRT1;KSR2;FOXO3;CBL 
Signaling by FGFR-
190236 











Figure 4.8 Arx-Hdac4-Twist1 PolyA-deregulated pathway 
Pathway analysis was used to assess connectivity of deregulated genes of PolyA-Arx loss-of-function embryonic brains.  The geometric 
shapes reflect differing types of proteins as defined by ingenuity analysis (Ingenuity Systems) (see legend) with direct connections 
shown as solid lines.  Published ChIP data highlighting relationships between genes and proteins are shown as dotted lines. The 
direction of deregulation in PolyApool is indicated with arrows (↑ = increased expression, ↓ = decreased expression). Known NDD 












Figure 4.9 Confirmation of in situ riboprobes directed towards Cdkl5, Hdac4 and Twist1 validity in Adult Brain Tissue. 
Coronal adult brain sections (16 µm) probed with in situ hybridization confirms the performance of riboprobes. In situ hybridization 
of Cdkl5 (probe dilution 1/10), Hdac4 (probe dilution 1/5) and Twist1 (neat probe) with all three showing expression in the cortex and 











Figure 4.10 In situ analysis of deregulated targets Cdkl5, Hdac4 and Twist1 in E14.5 Tissue 
Coronal embryonic (E14.5) brain sections (10 µm) probed with in situ hybridization in both WT (a-i) and PA1 (j-r) samples across 
two section series (S1 and S2). In situ hybridization of Cdkl5 (d, e, m, n) (probe dilution 1/10), Hdac4 (f, g, o, p) (probe dilution 1/5) 
and Twist1 (h, o, q, r) (neat probe). Arx probe (b, c, k, l) was used as a positive control, and Arx Sense probe (a, j) was used as a 




Expanded polyalanine tracts are the most frequent mutations reported in the ARX gene 
(Shoubridge et al. 2010a) with the patients’ phenotypic features invariably including ID 
with early onset seizures as a frequent comorbidity. To gauge the early events of 
compromised ARX function, we assessed transcriptome-wide outcomes of the two most 
frequent ARX polyalanine tract expansion mutations within the telencephalon of their 
respective mouse models. RNASeq analysis of the forebrain of 12.5 dpc telencephalon 
highlights early alterations that are common to both PolyA mutants, with a greater impact 
in mice modelling the more severe PA1 mutation. Our validation analysis indicates that 
this deregulation identified at 12.5 dpc persists across embryonic development. Many of 
the genes deregulated are known ID, epilepsy or autism disease genes.  The enrichment of 
genes with synaptic function supports the convergence of common pathways contributing 
to these disorders. Interrogating the profile of deregulated genes from the developing brains 
of Arx PolyA mutant mice we have identified a number of pathways impacted by genes 
deregulated in the mutant mice including a ‘core’ pathway of transcriptional regulators that 
we suggest may represent early triggers of ARX-associated phenotypes.  
 
The molecular pathogenesis of expanded polyalanine tracts is not well understood.  In the 
case of Arx/ARX, we have demonstrated a marked reduction of the Arx protein expression 
in the developing forebrain of mutant PA1 and PA2 mice, occurring as early as embryonic 
stage 12.5 dpc (Lee, K. et al. 2014). Reduced protein expression of the mutant protein in 
vivo may be a common molecular mechanism contributing to the disease associated with 
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expanded polyalanine tracts (Innis et al. 2004, Kuss et al. 2009, Krumm et al. 2014, Lee, 
K. et al. 2014). At this early embryonic stage, Arx/ARX is highly expressed in the 
telencephalon during peak cellular proliferation/neurogenesis and the first wave of 
tangential migration of neurons from the ganglionic eminence to the developing cortex. 
There is evidence that polyalanine expansion mutations in Arx retain transcription 
regulation capacity for some gene targets, but fail to repress a subset of predicted or known 
targets (Quille et al. 2011, Nasrallah et al. 2012, Lee, K. et al. 2014). Our RNASeq 
approach offers an unbiased and comprehensive interrogation of deregulation of gene 
expression due to these mutations. We show a substantial number of deregulated genes as 
a consequence of PolyA expansion mutations in Arx during early embryonic brain 
development. Interestingly, most of the significantly deregulated genes in the PA1 mutant 
mice were also perturbed in PA2 mice, but failed to reach significance by our analysis. We 
cannot rule out the possibility that the structure and location of the PA2 mutation within 
Arx contributes to the milder phenotypic outcomes in both our mice and affected patients. 
However, a combination of data from this study and our previous work leads us to suggest 
an alternative hypothesis. We have shown that the reduction in Arx mutant protein in the 
embryonic brain appears more variable in the PA2 mice compared to the PA1 mice (Lee, 
K. et al. 2014). Hence, the variability in Arx protein abundance in the PA2 mouse brains 
may diminish the power with which to detect significant deregulation of gene expression 
in some genes significantly altered in the PA1 mice. Our previous report identified 
expression of a direct transcriptional target of Arx, Lmo1 in the PA1 mutant mice was 
deregulated significantly across all stages of embryonic development tested. In contrast, 
the deregulated expression of this gene did not reach significance in the PA2 mutant mice 
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compared to wild-type until much later in embryonic development (Lee, K. et al. 2014). 
Hence, in the subsequent analysis undertaken in this study, we included not only genes 
significantly deregulated in both mutant animals but also those genes deregulated in either 
PA1 and PA2 animals. 
 
The deregulated expression of several genes tested was maintained across increasing 
developmental time points.  It is attractive to speculate that perhaps the cells with altered 
gene expression at E12.5 dpc maintain this altered state as they migrate and develop, 
despite the reduction in Arx expression with embryonic development. From our current 
data, we cannot speculate on alterations to the migration of particular neurons impacted by 
expanded polyA mutant Arx. However, we have conducted our analysis on a very spatially 
discrete region of the brain, namely the telencephalon at E12.5. We know from a recent 
elegant study (Marsh et al. 2016) that only a small subset of cells is affected even when 
there is a complete loss of Arx function. Hence, to address if there is migration deficit in 
these mutant animals extensive and painstaking cellular analysis of interneuron migration 
will be required. In addition, other approaches such as single cell expression analysis on 
the different interneuron subtypes would be very powerful and with the increasing 
technologies available, perhaps increasingly possible. 
 
To date, there are only a handful of known or putative direct targets of ARX. In our study, 
approximately 5% of the overall deregulated genes in the PA1 and PA2 mice identified as 
direct ARX targets (known or putative). Knock-out studies (Fulp et al. 2008, Colasante et 
al. 2009) include phosphatidylinositol-specific phospholipase C, X domain containing 3 
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gene (PLCXD3) which is primarily expressed in the brain and associated with lipid 
catabolism and signal transduction, along with AF4/FMR2 Family, Member 2 (Aff2), 
Cellular Retinoic Acid Binding Protein 1 (Crabp1) and 5'-3' Exoribonuclease 1 (Xrn1). 
Other direct targets of Arx regulation identified using ChIP based approaches (Quille et al. 
2011) that were deregulated in the PolyA Pool group included Histone Deacetylase 4 
(Hdac4). However, we hypothesise that ARX drives key transcriptional events not only 
through the impact on specific gene targets but in combination with the regulation of key 
transcription factors and transcriptional regulators. Hence, we predict that deregulation of 
other transcription factors and regulators are likely to be contributing to the global changes 
observed in the PolyA mutant mice.  
 
A number of transcription factors are present in the list of significantly deregulated genes 
in PA1 and PA2 mice, including Twist1, ALX Homeobox 1 (Alx1), SIX Homeobox 2 
(Six2), Early B-Cell Factor 1 (Ebf1), Early Growth Response 3 (Egr3), Zinc Finger And 
BTB Domain Containing 20 (Zbtb20) and Zinc Finger Protein 536 (Zfp536) which are 
likely contributing to the downstream deregulation of the transcriptome captured in this 
study. From our analysis, we propose a ‘core’ Arx-Hdac4-Twist1 pathway is likely 
contributing to the downstream phenotypic outcomes.  The pathway indicates that Arx 
directly represses Hdac4, which in turn is involved in chromatin condensation and 
transcriptional repression (Fischer et al. 2010). Overexpression of HDAC4 has been shown 
to impair long-term memory in a drosophila model (Fitzsimons et al. 2013), and 
overexpression has also been found in patients with autism (Nardone et al. 2014). Salt-
inducible kinase 2 (SIK2) an AMP-activated protein kinase, shown to regulate HDAC4 via 
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phosphorylation, is significantly up-regulated in PA1 and PA2 (although the change in 
transcript level is subtle). This modification of HDAC4 disrupts the MEF2C-HDAC4 
complexes and mediates the activation of MEF2-dependent transcription. MEF2C is highly 
expressed during embryo development and involved in neurogenesis and synaptic function. 
In mice, it has been indicated to have an essential role in hippocampal-dependent learning 
and memory by suppressing the number of excitatory synapses and thus regulating basal 
and evoked synaptic transmission (Barbosa et al. 2008). The hyperexcitability of 
hippocampal and neocortical networks found in Arx PA1 mice is thought to be most likely 
due to an increase in excitatory drive rather than an inhibitory failure (Beguin et al. 2013). 
Pathway analysis indicates Arx has a direct interaction with Mef2c, although we did not 
detect significant disturbances in transcript expression in our PolyA mutant mice at 12.5 
dpc. 
 
As we travel down the Arx-Hdac4-Twist1 pathway, likely outside of direct regulation by 
Arx, we encounter Twist1, a basic-helix-loop-helix transcription factor involved in cell 
lineage determination & differentiation (Nieto 2013). A wide range of mutations have been 
reported in TWIST1 resulting in a variable phenotype from mild to severe intellectual 
disability as a consequence of large gene deletions however, the majority of missense and 
nonsense mutations have been associated with the craniosynostosis disorder Saethre-
Chotzen syndrome (el Ghouzzi et al. 1997). A recent study using a ChIP approach has 
identified targets of TWIST1, and comparison with our deregulated gene lists indicates that 
over one-third of all deregulated genes in PolyA mutant mice identified in our current study 
are direct or likely targets of TWIST1 regulation, including genes known to cause ID and 
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epilepsy (Lee, M.P. et al. 2014). The influence of TWIST1 is further demonstrated with 
the down-regulation of a known target Dnm30s (mir199a/214 cluster) normally 
upregulated via TWIST1 during development (Lee et al. 2009).  Research has focused on 
determining the role of Twist1 in cancer development with little emphasis to date of the 
contribution of Twist1 in brain development.  
 
The Arx-Hdac4-Twist1 pathway we propose is one that may reflect very early 
consequences of ARX loss (or partial loss) of function. For multiple genes deregulated at 
12.5 dpc, we have confirmed that the deregulation persists across later stages of embryonic 
development. Interestingly, genes that are enriched in the proposed pathway contain 
estrogen response elements (EREs) in their promoter regions. More broadly, when we 
examine our list of deregulated genes, we find 30% contain EREs (Bourdeau et al. 2004, 
Tang et al. 2004, Kamalakaran et al. 2005). This is of significant interest given the recent 
findings that early postnatal treatment with 17 β-estradiol (E2) prevents spasms, restored 
depleted interneuron populations without increasing GABAergic synaptic density and 
altered mRNA levels of three downstream targets of ARX (Ebf3, Shox2, Lgi1) in an 
independent PA1 mutant mouse model (Olivetti et al. 2014). It remains to be established if 
administration of E2 during early stages of postnatal life, leading to seizure ablation, is 
impacting upon the transcriptome specifically at the ERE-containing genes we have 
identified as deregulated in the PolyA mice at early stages of embryonic development.  
 
In summary, we have interrogated the transcriptome of mice modelling the most frequent 
expansion mutations of PolyA tracts of ARX. Based on our analysis we propose the Arx-
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Hdac4-Twist1 as the ‘core’ pathway, which is contributing significantly to the ARX 
mutation-associated phenotypes, namely ID and epilepsy. While other gene targets and 
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Disease-causing polyalanine expansion mutations have been identified in nine genes, eight 
of which encode transcription factors with important roles in development. In vitro studies 
have shown that expanded polyalanine tracts result in protein misfolding and aggregation. 
In recent years, significant advances have been made through the analysis of a number of 
engineered (knock-in) and spontaneous polyalanine expansion mouse models, indicating 
reduced levels of mutant protein as a contributing factor of disease. As loss of function 
mutations in ARX are associated with a more severe disorder (XLAG), the phenotype in 
patients with polyalanine expansion mutations suggests a partial loss of function. Further 
evidence of partial loss of function is provided in chapter 4 with only selective target genes 
deregulated in our polyalanine expansion mutant mouse models. However it is still not 
clear what causes this defect.  My data indicates this reduced function does not occur 
through disruptions of binding to DNA or protein interactors in relation to the region of 
ARX spanning both polyalanine tract 1 and 2. However, I demonstrate a marked reduction 
in polyalanine mutant protein may be the contributing factor to disease manifestation, 
reported in both strains at 12.5 dpc (Lee, K. et al. 2014) and confirmed here in adult testes 
samples. Transcription activity assays indicate ARX may respond in a dose-depend manner 
and suggests a greater reduction in protein leads to an increase in the severity of the disease. 
Investigations into the molecular mechanism contributing to this reduction in protein level 
show no significant change in protein stability (in vitro), instead, initial studies indicate 
inefficiency of translation resulting in reduced protein abundance. This has relevance to 
other polyalanine tract disorders. 
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5.2 Introduction  
Polyalanine tract disorders are the result of an expansion of trinucleotide sequence and give 
rise to a number of congenital disorders. Expansion of polyalanine tracts results in at least 
9 inherited human diseases with eight of these nine diseases due to expansions in 
transcription factors. In the human proteome, approximately 500 proteins contain 
polyalanine tracts of greater than 4 residues, with a quarter of these containing a tract of 
seven or more uninterrupted alanines but not exceeding 20 residues (Lavoie et al. 2003, 
Albrecht and Mundlos 2005). Thus, it appears that strong structural or physicochemical 
constraints are imposed on the length of the polyalanine tract. It has been proposed that 
polyalanine tracts act as flexible spacer elements between functional domains, and 
lengthening such a spacer could readily perturb the interaction between these domains and 
their targets either by affecting their orientation or by steric hindrance. 
 
Expansion of polyglutamine tracts also forms the basis of several human diseases, 
including Huntington’s disease and six spinocerebellar ataxias (SCA) types 1, 2, 6, 7, and 
17. These diseases are characterised by the expansion of unstable trinucleotide repeats and 
generally result in neuronal dysfunction from mid-life progressing to severe 
neurodegeneration. In contrast, neither the penetrance nor severity of the phenotype of the 
congenital disorders due to expanded polyalanine tracts increases in successive 
generations, consistent with the observed stability of the expansion leading to alanines. The 
often large expansions of polyglutamine tracts are thought to contribute to the generation 
of misfolded protein intermediates that eventually lead to aggregates in susceptible 
neuronal sub-types, a hallmark of the associated disease states. Therefore, for many years 
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aggregation of expanded polyalanine tract mutant proteins was predicted to be the 
mechanism leading to disease. Despite this prediction, the human data for in vivo 
aggregation is not supported. The exception is the non-transcription factor with expanded 
polyalanine tracts, PABPN1. This is a protein involved in mRNA polyadenylation, in 
which expanded polyalanine tract mutations cause later onset oculopharyngeal myotonic 
dystrophy (OPMD) (Brais 2003).  
 
ARX is one of eight transcription factors in which expansions of the polyalanine tracts 
cause hereditary disease. Over half of all mutations in ARX lead to an expansion of the 
first and second polyalanine tracts (Marques et al. 2015). The evidence to date leads us to 
predict that polyalanine expansion mutations in ARX are likely to result in a partial loss of 
function. In support of this prediction, in chapter 4 of this thesis, analysis of direct and 
candidate Arx target genes in Arx-WT and polyalanine expansion mutant animals during 
embryonic brain development demonstrated that there was no blanket loss of 
transcriptional activity due to the expansion of either PA1 and PA2. Instead, there was a 
selective loss of transcriptional activity that we propose contributes to the manifestation of 
disease features.  However, the mechanism underpinning this outcome remains unknown. 
Interestingly, although there was significant overlap between the genes deregulated in the 
PA1 and PA2 mutant mice the level of deregulation mirrored the phenotypic severity 
generally noted due to these mutations, as highlighted by the greater magnitude of 
deregulation in the severe PA1 mice. The increased level of deregulation was correlated 
with the amount of residual Arx protein observed in embryonic brain samples (16-17% in 
PA1 compared to 8-50% in PA2 12.5 dpc brains) (Lee, K. et al. 2014). 
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The correlation between phenotypic severity and expansion size in polyalanine expansion 
disease suggests that the length of the expansion in the polyalanine tract confers a 
proportional loss (or gain in the case of autosomal genes) of function on the proteins 
affected. In the case of ARX, differences in the length of the expansion size are likely to 
account for variation in severity of the phenotypes. However, what remains less clear is the 
occurrence of intrafamilial variation seen particularly with the most common PA2 
expansion mutation (Turner et al. 2002).  As the expansion to polyalanine tracts is stable 
once expanded, the striking phenotypic variation of affected individuals between families 
and even within families is difficult to reconcile. To elucidate the pathophysiologic 
mechanism underpinning the disease phenotype, let alone the variation among affected 
individuals, a number of fundamental cellular processes need to be explored. ARX has 
expansions of differing lengths in both polyalanine tract 1 and tract 2 of the protein, and 
this provides us with the opportunity to investigate aspects of the phenotype severity being 
impacted by i) the length of the expansion and ii) the position within the protein of the tract 
in which the expansion occurs. In addition to mice modelling the common ARX 
polyalanine expansions (PA1 and PA2), we have a range of naturally occurring disease 
mutations leading to different length tracts in both PA1 and PA2 cloned into a mammalian 
expression vector with an N-terminal Myc-tag including; 16A tract of PA1 is expanded to 
PA1-19A, PA1-23A, and PA1-27A; 12A tract of PA2 is expanded to PA2-20A, PA2-21A 
and PA2-23A (but with a glycine at position 11 of 23) (Figure 5.1 and Table 5.1). 
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Some of the key questions to be examined include how polyalanine expansion mutations 
affect the structure of the protein and if these expansions themselves influence the normal 
transcriptional regulation of target genes. The partial loss of ARX function due to 
polyalanine expansion mutations may rely upon changes in the protein conformation that 
could lead to modified interactions of a functional protein domain. In studies of other 
proteins mutated with expanded polyalanine tracts, the presence of the Hsp90 inhibitor 
geldanamycin during in vitro transcriptional activation assays lead to the recovery of 
mutant protein activity comparable to the levels measured with the WT protein (Bachetti 
et al. 2007). Given that Hsp90 inhibitor geldanamycin is known to up-regulate heat shock 
proteins HSP40 and HSP70, involved in disassembly of intracellular protein aggregates, 
this finding indicates that aggregation of the mutant protein in the in vitro setting was the 
likely major cause for loss of transcriptional activity. This indicates that the expanded 
polyalanine tract themselves do not negatively impact the transcriptional regulation. 
Further support of this retained functionality comes from EMSA studies confirming that 
binding of the multiple polyalanine mutant proteins to DNA does not seem to be affected 
(Woods et al. 2005, Nasrallah et al. 2012). Interestingly, in these cases, the functionality of 
polyalanine expansion mutant protein seems to be suboptimal. We cannot rule out that this 
could be a consequence of the mutation structurally affecting the interaction with other 
interactors. However, from our previous data (Lee, K. et al. 2014), we predict there may 
be a dose-dependent consideration as a consistent feature due to a reduced abundance of 
mutant protein in vivo.  
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We hypothesise that a reduction in mutant protein abundance may be a common disease 
mechanism of polyalanine expansion disease. Evidence indicates that the reduction in 
mutant protein is not a consequence of cell death (Bruneau et al. 2001, Lee, K. et al. 2014), 
nor is this due to reductions in mRNA levels detected (Innis et al. 2004, Cocquempot et al. 
2009, Hughes et al. 2013, Lee, K. et al. 2014). Hence, we propose that two molecular 
processes may underpin the reduction of the mutant protein level compared to WT; namely 
lower translation efficiency and/or increased degradation of the expanded polyalanine tract 
mutant protein.  
 
A consideration when undertaking investigations to address these questions is that studies 
into the molecular pathogenesis of ARX disorders have been restricted due to the limited 
capacity to robustly detect endogenous ARX protein, due to the lack of suitable antibodies, 
coupled with a tightly regulated expression profile in vivo. So, although multiple antibodies 
have been generated against ARX, including several from our laboratory, that are robustly 
successful in the detection of overexpressed ARX in vitro, the detection and manipulation 
of endogenous ARX protein remains difficult. Hence, we (and others) have chosen to 
utilise an in vitro (overexpression) conditions to undertake selected investigations, mindful 




It remains unclear if the pathogenesis of expanded polyalanine tracts is due to the mutation 
disrupting protein function directly, or if the mutation itself leads to a reduction of the 
protein driving the disease. It is also unclear if the contribution to the severity of phenotype 
is due to the polyalanine tract length and/or its location within the protein. Our 
investigations address if the transcriptional activity of ARX is altered due to the mutations 
themselves, or is a product of the marked reduction in the mutant protein expression.  
 
Hypothesis: Reduction of ARX polyalanine expansion mutant protein abundance drives 
disease in a dose depend manner. 
 
Aim: To determine whether the mutation or reduced protein contributes to the partial loss 
of function and the phenotype severity between PA1-23A and PA2-20A.  
 
Aim: To establish if inefficiency of translation or increase in degradation underpins the 




Figure 5.1 Common mutations reported in ARX in polyalanine tract 1 and 2.  
Expanded view of the polyalanine tract 1 (orange) and tract 2 (blue) and the addition of 
alanines (A) due to expansion mutations.  
 
Table 5.1 Summary of the Nomenclature for the Polyalanine Tract Mutation tested 




Referred to in thesis 





+3A 16>19 c.306GGC[13] p.(Ala113_Ala115dup) PA1-19A 
+ 4A 16>20 c.306GGC[14] p.(Ala112_Ala115dup) PA1-23A 





+8A 12>20 c.441_464dup p.(Ala148_Ala155dup) PA2-20A 
+9A 12>21 c.435_461dup p.(Ala147_Ala155dup) PA2-21A 




5.3  Results 
5.3.1 Structural impact of polyalanine expansion mutations on the ARX protein 
To determine if polyalanine expansion mutations have a possible effect on protein 
structure, and in particular result in disruption of a functional domain a software package 
I-TASSER suite was used (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) comparing 
ARX-WT to the two most frequent polyalanine expansions PA1-23A and PA2-20A. The 
predicted secondary structure of ARX-WT contains 7 alpha helix structures spread across 
the protein with 6 corresponding to the location of the known major domains of ARX, the 
octapeptide domain, acidic domain, homeodomain and the aristaless domain (Table 5.2). 
Across the homeobox, the main functional domain, the predicted secondary structure is 
unchanged in the PA2-20A model and a slight deviation seen in the PA1-23A models with 
the longest alpha helix broken into two shorter ones with a break of 2 coil residues in-
between. However, as the location is markedly similar to the WT model, it is not clear if 
this would have any detrimental effect on the function of the homeodomain. The most 
noticeable difference between WT and the polyalanine mutations is the second predicted 
alpha helix (40-43aa) prior to the polyalanine tract 1 and 2 where PA1-23A has a loss of 
an alpha helix and is replaced with a beta strand. However, for PA2-20A, there is a shift in 
location from 40-43aa to 83-86aa. As the location of this change does not correspond to 
any known domain, it is difficult to predict the effect on the protein. Hence, this analysis 
indicates there is no consistent change in both PA mutants that may account for a similar 




Figure 5.2 I-TASSER predicted secondary structure for ARX–WT and polyalanine 
tract mutants. 
The predicted secondary structure is indicated along the bottom of each graph for ARX 
WT, PA1-23A and PA2-20A. A black line represents a coil structure with a helix structure 
shown in red and strand in green. The accuracy of the prediction is demonstrated by the 
normalised b-factor in blue. 
 
Table 5.2 Summary of the I-TASSER predicted secondary structure for ARX-WT 
and polyalanine tract mutants and the corresponding protein domains within ARX.  
Cells highlight in red=alpha helix, green = beta strand. Numbers italicised indicate the 




WT PA1-23A PA2-20A 
aa Length (aa) aa Length (aa) aa Length (aa) 
OP domain: 27-34 26-32 7 23-33 11 23-33 11 
 40-43 4 41-43 3  
NLS1: 82-89   83-86 4 
PA1 100-115 16 100-122 23 100-115 16 
PA2 144-155 12 151-162 12 144-163 20 
Acidic Domain: 224-255 240-243 4 239-243 5 239-243 5 
Homeodomain: 
329-387 
337-350 14 337-350 14 337-350 14 
355-365 11 355-365 11 355-365 11 
369-389 21 369-376 8 369-389 21 
 379-388 10  
Aristaless domain: 
527-542 




For each target, I-TASSER simulations generate a large ensemble of structural 
conformations, called decoys. In this analysis, a C-score is typically in the range of [-5, 2], 
where C-score of a higher value signifies a model with higher confidence. TM-score and 
RMSD are estimated based on C-score, and protein length following the correlation 
observed between these qualities. Similar to the secondary structure predictions, ARX-WT 
(-0.53) and PA2-20A (-0.52) resulted in similar model predictions and C-score. In contrast, 
as a consequence of the changes seen in the PA1-23A predicted secondary structure a 
divergent 3D model to ARX-WT and ARX-PA2-20A is evident (Figure 5.3). In particular, 
we were interested if any structural impact occurred within the main functional 
homeodomain critical for DNA binding. Conformational stability of the recognition helix 
as well as the stability of the entire homeodomain is required for optimal DNA binding. 
Nucleotide binding sites were reported using S-site (Yang et al. 2013) 
(http://zhanglab.ccmb.med.umich.edu/COACH/) and listed within the homeodomain WT. 
With the addition of the polyalanine expansion mutations (+7 for PA1 and +8 for PA2), 
these sites were not disrupted in either mutant protein (Figure 5.3 and Table 5.3). Taken 
together, this analysis predicts that the differences in the predicted secondary and tertiary 
structures of PA1 and PA2 would not affect the binding capacity of the ARX homeodomain 
in these mutants, but may disrupt the conformational tertiary structure of parts of the 




Figure 5.3 3D Model Predictions by I-TASSER. 
Images of the best-ranked model prediction by I-TASSER for ARX-WT, PA123A, and 
PA2-20A. The confidence score for estimating the model quality is reported as C-score.  
 
Table 5.3 S-Site Predicted Nucleotide Binding Sites for ARX-WT and Polyalanine 
Expansion Mutants. 
S-Site Results Predicted Nucleotide Binding Site (aa) 
Wildtype 
562aa 












5.3.2 Functional impact of polyalanine expansion mutations on ARX 
transcriptional activity. 
To correlate the changes to polyalanine tract length and the functional impact on the 
transcriptional activity of polyalanine expansion mutations in polyalanine tract 1 and 2 of 
the ARX protein, a cell-based transcriptional assay using luciferase reporter constructs 
were conducted. This reporter assay models an ARX-binding site in the enhancer region of 
Lmo1 (Fulp et al. 2008) by cloning three copies of this orthologous region upstream, of the 
SV40-luciferase promoter (Shoubridge et al. 2012) (Figure 5.4a). Co-transfection of a 
renilla expression vector was used to normalise the expression of luciferase. Reporter 
constructs were transiently transfected into HEK293T cells along with a Myc-expression 
vector (Myc-empty) or fused to full-length ARX vector. The ratio of luciferase to renilla 
expression for the empty Myc-vector is set to 100% (Figure 5.4b). Compared with this 
value, the ARX-WT repressed the expression of luciferase to 71% (SEM±9.9), a 30% 
reduction. A similar level of repression was measured across all PA1 and PA2 mutations. 
The most common PA1-23A and PA2-20A mutations reflecting the expansions modelled 
in the mice, both gave very similar levels of repression as ARX-WT, with 75% (SEM±7.9) 
and 73% (SEM±7.7), respectively. Hence, expansion of either tract did not result in loss of 
transcriptional capacity of the ARX protein. Using this approach, we were able to assess 
not only PA1-23A and PA2-20A but a full range of naturally occurring expansions to both 
tracts to ascertain if length and position of the expansion impacts on the transcriptional 
activity of the ARX protein. PA1-27A showed the largest loss of repression capacity 
reducing the expression of luciferase to by only 7% (SEM±11.5) which was not significant 
compared to Myc-vector. This reflects a 21% difference between PA1-27A and WT. The 
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remaining mutations showed minor changes in repression compared to WT, ranging from 
a 1-10% difference and were not significantly different to WT. This result suggests that 
ARX polyalanine expansion mutant proteins are able to bind to DNA with a similar 
capacity to ARX-WT and retain the ability to function at similar levels in the context of 
this assay. This is in agreement with the outcomes of the I-TASSER modelling. Moreover, 
our analysis indicates that there are no significant differences in transcriptional activity due 
to which tract harboured the expansion and no significant differences due to the length of 










Figure 5.4 Polyalanine expansions mutations in the ARX polyalanine tract 1 & 2 do 
not affect the repression activity of ARX. 
Repression of luciferase expression by ARX is not affected by expansion mutations in 
polyalanine tract 1 and tract 2. a) The Luciferase reporter assay utilised three copies of the 
ARX-binding site identified in the enhancer region of LMO1, cloned upstream of SV40-
luciferase. Polyalanine expansion mutations in the ARX polyalanine tract 1 & 2 have 
similar levels of repression of LMO1, a direct target of ARX transcription repression. b) 
Luciferase data were normalised to renilla expression and expressed as a percentage 
relative to empty Myc-vector-transfected cells. Full-length Myc-tagged constructs are 
listed along the bottom of the graph: ARX WT (PA1-16A, PA2-12A) (white), Polyalanine 
expansion mutations in Tract1 PA1-19A, PA1-23A, and PA1-27A (dark grey) and in Tract 
2, PA2-20A, PA2-21A and PA2-23A (light grey). 
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To determine if protein function in the context of the reduction in protein amount seen in 
our in vivo studies is causing a decreased level of transcription activity of the ARX protein 
we repeated the luciferase reporter assay with diluted amounts of plasmid concentration 
from 500 ng to 125 ng and 30 ng (Figure 5.5a). When the plasmid concentration was 
decreased to 125ng, ARX-WT repression capacity also decreased from 77% with 500 ng 
of plasmid to 88%. All repressive capacity was lost (110%) at the lowest concentration of 
plasmid tested of 30 ng. PA1-23A and PA2-20A exhibited an equivalent loss of repression 
capacity in a dose-dependent manner to 91% and 84% respectively at 125 ng and with 
all/most repression lost at 30 ng of plasmid to 121% and 95% respectively.  Protein analysis 
(Figure 5.5b) indicates there was a consistent level of protein for ARX-WT and polyalanine 
mutants at all concentrations tested. This result supports the idea that polyalanine 
expansion mutant proteins are still functionally competent with no difference between 
which tract is mutated. This data also supports that the functional capacity ARX as a 
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Figure 5.5 Loss of repression is dose dependent in both ARX-WT and polyalanine 
tract mutant proteins 
a) Luciferase data were normalised to renilla expression and expressed as a percentage 
relative to empty Myc-vector-transfected cells (white). Full-length ARX Myc-tagged WT 
(Black/grey) and polyalanine expansion mutations in tract 1 PA1-23A (PA1: orange) and 
in tract 2, PA2-20A (PA2: blue) transfected at 500 ng, 125 ng, and 30 ng. n=4 for all 
constructs across all concentrations b) Representative image of the level of ARX protein 
expression between WT and polyalanine expansion mutants across decreased plasmid 
concentration that were used as inputs for the luciferase assay. c) Loss of repression 




5.3.3 Identifying possible protein interactions disrupted by polyalanine tract 
expansions  
As ARX with polyalanine tract expansion mutations retains DNA binding capacity and 
functions at a comparable level to WT when tested in an in vitro context, we next wanted 
to test if the mutation might structurally interfere the interaction with protein partners. To 
identify proteins interacting with the polyalanine tract regions that are expanded in disease, 
we used a GAL4-based yeast-2 hybrid screen. The bait protein contained amino acids 60 
to 174 of the mature ARX protein, to specifically focus upon the first two polyalanine tracts 
(PA1: 100-115 aa) and PA2: 144-155 aa) (Figure 5.6a). This protein did not autoactivate 
the HIS3, LacZ or URA3 reporter genes upon transformation of MaV203 yeast (data not 
shown).  We identified ubiquilin 4 (Figure 5.6b) (UBQLN4: NM_02121.3, NP_064516.2) 
interacting with this region of ARX.  UBQLN4 is also known as A1U; A1Up; UBIN; 
CIP75; C1orf6 and plays a role in the regulation of protein degradation via the ubiquitin-
proteasome system. UBQLN4 has been reported to mediate the proteasomal targeting of 
misfolded or accumulated proteins for degradation by binding (via UBA domain) to their 
polyubiquitin chains and by interacting (via ubiquitin-like domain) with the subunits of the 
proteasome. As the interaction of ARX with UBQLN4 may potentially link the production 
of ARX to efficient degradation of the proteasome to ensure tight control of the 
transcription factor, we wanted to investigate the novel interaction between ARX and 
UBQLN4 further. The yeast 2 hybrid work was undertaken by a previous member of the 








Figure 5.6 UBQLN4 interacts with a region spanning polyalanine tract 1 and 2 of 
ARX 
a) Schematic of human ARX protein. Known functional domains are highlighted in open-
reading frame (ORF): octapeptide (OP) horizontally hatched; NLS black rectangles; 
polyalanine tract 1 (PA1) orange rectangle, polyalanine tract 2 (PA2) blue rectangle, 
polyalanine tracts 3 & 4 (PA) as shades of grey; acid domain vertically hatched; 
homeodomain crosshatched and Aristaless domain (OAR) hatched. The dashed box 
highlights the bait construct spanning the first two PA tracts of ARX (60-174 aa) used in 
the GAL-4 based yeast-2 hybrid assay. b) Schematic of human UBQLN4 protein with 
known functional domains highlighted in the ORF: Ubiquilin-like domain (UbL), four 
stress-inducible, heat shock chaperoning-binding motifs (STI1), and a UBA domain at the 
C-terminus of the protein.  
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5.3.4 Confirmation of the novel interaction between ARX-UBQLN4  
The interaction between ARX-UBQLN4 was confirmed in mammalian cells by Co-IP. To 
obtain usable amounts of UBQLN4 for Co-IP, V5-tagged UBQLN4 was transiently 
transfected into HEK 293T cells along with Myc-tagged ARX-WT or ARX polyalanine 
expansion mutations. A monoclonal anti-V5 antibody was used to immunoprecipitate V5-
UBQLN4 from whole-cell extracts. Myc-tagged ARX co-immunoprecipitating with V5-
UBQLN4 was detected using an anti-Myc antibody directly conjugated to horseradish 
peroxidase (HRP).  Polyalanine tracts in the ARX protein were particularly ‘sticky’ and 
can cause the protein to bind to the protein-A sepharose in the absence of an 
immunoprecipitating antibody. Hence, several controls were run in parallel with the test 
samples to ensure interaction of the proteins was specific. One control to confirm that the 
binding and stringency of the washing buffers are optimised to detect protein binding 
specifically to the precipitated UBQLN4 and not binding to protein-A sepharose directly, 
we include a ‘no antibody’ control using a cell lysate know to contain ARX protein. Pre-
incubation of the protein-A sepharose with non-transfected cell lysate blocks binding of 
polyalanine tract containing proteins to the protein-A sepharose. When pre-blocked 
protein-A sepharose is added to the protein-antibody immune complex sample, we get 
consistent and robust enrichment of our target protein with negligible pull down in our ‘No 
Antibody’ control (Figure 5.7a). Cells transfected with Myc-ARX or V5-UBQLN4 alone 
act as negative controls. V5-UBQLN4 was detected in the V5-UBQLN4 alone control and 
no pull down was detected in Myc-ARX alone confirming specific co-immunoprecipitation 
of Myc-ARX only occurs in the presence of UBQLN4 (Figure 5.7a). 
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As this investigation was carried out in vitro we are able to examine a wide range of ARX 
polyalanine expansion mutations to include 3 polyalanine tract 1 mutations with the 
addition of +3A (PA1-19A), +7A (PA1-23A) and +11A (PA1-27A), and 3 polyalanine 
tract 2 mutations with the addition of +8A (PA2-20A), +9A (PA2-21A) and +11A (PA2-
23A) (Figure 5.1 and Table 5.1). This allows us to determine if ARX protein with expanded 
tracts in general binds or does not bind to UBQLN4 and assess if there are any differences 
due to the tract or length of the expansion in either tract 1 or tract 2.  When we tested the 
interaction of ARX with expanded polyalanine tracts we observed Co-IP with UBQLN4 
for all mutations tested, but not in parallel samples in which no IP antibody was added 
(Figure 5.7a). Our data indicates that UBQLN4 interacts with the region containing the 
first two polyalanine tracts in ARX and that this interaction is not abolished by any of the 
polyalanine expansion mutations. However, relative to ARX-WT, we measured lower 
levels of all mutant proteins interacting with UBQLN4, suggesting expanded polyalanine 
mutations may reduce the interaction with the novel partner, UBLNQ4 (Figure 5.7b).   
 
We investigated the subcellular localisation of these interacting proteins in mammalian 
cells. Myc-ARX WT demonstrates a discreet localisation to the nucleus (Figure 5.8), as 
expected for a transcription factor and in agreement with our previous data (Fullston et al. 
2011). Transfected V5-UBQLN4 was detected as diffuse signals across the cell cytoplasm 
and nucleus in non-transfected cells (data not shown) and was not altered when co-
expressed with ARX-WT. This likely reflects the dynamic and transient nature of this 
interaction. A similar outcome is seen for all polyalanine tract expansion mutations when 
localised correctly to the nucleus as seen for WT (data not shown). However, considering 
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UBQLN4 seems to localise to aggregates containing mutant ARX protein in vitro (Figure 
5.8), the amount of soluble, correctly localised ARX protein will be reduced compared to 
wild-type ARX protein. In this context, the reduced amount of mutant protein (by Co-IP) 
being pulled down by UBQLN4 may actually reflect an increased interaction with the 








Figure 5.7 Confirmation of interaction between ARX and UBQLN4 which is not loss 
due to polyalanine expansion mutations 
a) HEK293T cells transfected with Myc-ARX-WT or PA mutant constructs and V5-
UBQLN4 were lysed and protein immunoprecipitated (IP) with antibodies against the V5. 
Samples were loaded onto 4%-12% SDS-PAGE gels and analysed for the presence of co-
IP proteins. Detection of Myc-ARX proteins bound to V5-UBQLN4 by immunoblotting 
with mouse anti-Myc HRP conjugated antibody. All samples transfected with V5-
UBQLN4 showed a protein band of the predicted size upon blotting with anti-V5 HRP 
conjugated antibody. Specific IP of each over-expressed protein was achieved with no band 
present in samples from cells transfected with both Myc-ARX and V5-UBQLN4, but no 
IP antibody added (*). Cells transfected with Myc-ARX alone or V5-UBQLN4 alone was 
used as negative controls. V5-UBQLN4 (~64 kDa) and Myc-ARX (~ 62 kDa) are both 
present in protein lysates (bottom panel). b) Densitometry of Myc-ARX bands using NIH 
ImageJ program. The density of the target protein was normalised to the density of ARX 






Figure 5.8 Subcellular location and co-localisation of ARX and UBQLN4. 
a) Representative images of cells transfected with Myc-ARX-WT with normal ARX 
nuclear staining and Myc-tagged polyalanine expansion constructs, PA1-19A, PA1-23A, 
PA1-27A, PA2-20A, PA2-21A and PA2-23A show aggregates of mutant ARX form both 
inside the nucleus and outside in the cytoplasm. The nuclear material is indicated by the 
blue DAPI signal. Nuclear localisation of ARX protein overexpressed in HEK293T cells 
was detected using a mouse monoclonal anti-ARX and DonkeyαMouse IgG Alexa 488 
(green), and UBQLN4 localised to the cytoplasm was stained using a rabbit anti-V5 and 
GoatαRabbit Cy3 (Red).  ARX mutant protein formed aggregates and mislocalised to the 
cytoplasm. UBQLN4 was detected to co-localised with the outside of the ARX aggregates 
in the cytoplasm. 
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5.3.5 Alanine expansion mutations result in a reduction of mutant protein in vivo. 
Polyalanine expansion mutations in tract 1 and 2 modelled in mice have been shown to 
result in a reduction in mutant protein in the embryonic brain (Lee, K. et al. 2014).  
However, it has not been established if this reduction in mutant protein is a consistent 
feature across other tissues nor if this persists into adult life. Arx is highly expressed in the 
brain during embryonic development and then markedly downregulated in post-natal life, 
and persists in a small number of neurons spread throughout the cortex during postnatal 
and adult life (Poirier et al. 2004). Arx is also expressed in skeletal muscle, pancreas and 
testis (Kitamura et al. 2002, Ohira et al. 2002, Collombat et al. 2003). To assess if the 
mutant protein is reduced compared to WT as seen in the brain in an alternative tissue, 
testis samples were used as Arx expression is known to continue into adult life (Yu et al. 
2014).  Moreover, this analysis would allow us to better examine the relationship in the 
reduction of protein expression between the two PA tract mutations.  
 
We wanted to initially establish the level of Arx-WT protein in the testes of our mice during 
adulthood, and ensure there was no change in the protein levels across developmental ages 
of interest. We tested samples at postnatal day 40 as this was a significant time that we see 
the onset of seizures and day 70 representative of young adult life, at which time we have 
undertaken behavioural testing (Jackson et al. Submitted 2017). Samples were analysed by 
immunoblot (Figure 5.9a) and subsequent densitometry of resulting Arx and B-actin bands 
were determined using LICOR western blot analysis software (Image Studio Lite) (Figure 
5.9b). The density of Arx protein was normalised to the loading control B-actin and is 
expressed in arbitrary units.  To compare across a number of immunoblots, all analysis was 
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normalised to sample #1322 (Table 5.4). Our data indicates that ARX is robustly expressed 
in adult testes samples and the abundance of Arx protein was not significantly different 
between the testes of Arx-WT mice collected at day 40 (n=3) compared to samples 
collected at day 70 (n=10), namely 94.2% (SD±7.8) and 114.6% (SD±27.2), respectively 







Figure 5.9 Robust protein abundance in Arx-WT testes samples during adult life. 
a) Western immunoblots showing robust Arx protein abundance across Arx-WT testes 
samples from adult mice ranging in age from day 40 and day 70. Samples were loaded onto 
4-12% SDS-PAGE gels, and Arx was detected by immunoblotting with rabbit anti-Arx. B-
actin was used as a loading control. CB: P10 cerebellum was used as a negative control as 
this region lacks any Arx protein. b) Densitometry of Arx and B-actin bands were 
determined using LICOR western blot analysis software, Image Studio Lite. The density 
of Arx protein was normalised to the density of the loading control B-actin and is expressed 
in arbitrary units and all normalised to sample #1322.  
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Table 5.4 Densitometry and normalisation results for the level of Arx protein in Arx-

























Figure 5.10 Arx protein abundance across day 40 and day 70 age groups. 
Normalised densitometry of Arx protein levels detected via western immunoblot analysis 


















P10 10  236000 143.0    
#1251 40 94.5 211000 127.9 1.46 73.9 94.5 
#1230 42 93.0 213000 129.1 1.42 72.0 92.9 
#1335 42 108.6 284000 172.1 1.25 63.1 108.6 
#1237 69 67.8 235000 142.4 0.94 47.6 67.8 
#1233 69 90.8 213000 129.1 1.39 70.3 90.8 
#1135 70 84.1 188000 113.9 1.46 73.8 84.1 
#1195 70 90.2 175000 106.1 1.68 85.0 90.2 
#1340 70 104.3 234000 141.8 1.45 73.5 104.3 
#1351 70 98.5 195000 118.2 1.65 83.3 98.5 
#1361 70 112.9 166000 100.6 2.22 112.2 112.9 
#1322 71 100.0 165000 100.0 1.98 100.0 100.0 
#1309 73 113.2 165000 100.0 2.24 113.2 113.2 
#1314 73 98.5 184000 111.5 1.74 88.3 98.5 
 
No. Samples Ave SD 
D40 3 94.3 7.8 
D70 10 114.7 27.2 
All 13 110.0 25.4 
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Much of the research into ARX function, and the impact of the PA mutations, has been 
focused on embryonic stages of development with only limited studies and knowledge of 
phenotype during postnatal life. Indeed, the phenotype of the PA2 mouse model (Kitamura 
2009) that we are using has not been reported yet. Our laboratory has undertaken extensive 
phenotyping studies comparing PA1 and PA2 mice across postnatal development. 
Although this work is outside the scope of my thesis, in brief, we find that the PA2 mice 
have extensive seizure phenotypic and behavioural deficits similar, albeit less severe than 
the PA1 mouse (Jackson et al. Submitted 2017). The morbidity and mortality of the mice 
mean that collecting large cohorts at extended postnatal ages in challenging. However, as 
part of this larger study, I was able to collect testes material from animals from the time we 
see the onset of seizures (~ day 40) through to the time points of early adult life at which 
behavioural testing and end points were collected ~ day 70. Testes protein was extracted 
from Arx-WT (n=13), Arx-PA1 (n=11) and Arx-PA2 (n=10) mice and the level of protein 
abundance were measured by immunoblot analysis. Testes from PA1 mice showed a 
marked reduction in Arx protein levels across all samples tested (Figure 5.11). When the 
level of protein was normalised and compared to Arx-WT levels, a reduction of between 
30-60% was determined (Table 5.6). The reduction in Arx protein abundance wasn’t as 
marked in PA2 testes samples (Figure 5.12) with a reduction of between 3-40% measured 
(Table 5.7). The average of all the Arx-WT samples was 96.63% (SEM±3.44).  Both 
mutant groups show a clear reduction in the level of Arx protein abundance with the 
average level in PA1 testes at 59.99% (SEM±3.97) and PA2 at 79.78% (SEM±3.17), 
respectively compared to Arx-WT protein levels. (Table 5.8 and Figure 5.13a). The 40% 
reduction between Arx-WT and PA1 at P<0.0001 was highly significant, with the 20% 
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reduction between Arx-WT and PA2 also significant at P=0.0062. The 20% difference in 
Arx protein abundance was also significant between PA1 and PA2 at P=0.002. To ensure 
that we did not have a difference in the total protein abundance between genotypes due to 
different proportions of animals at varying ages of postnatal life, we also examined the 
protein levels for each animal relative to postnatal age. By this analysis, the level of 
reduction was consistent across all genotypes at differing ages ranging from day 40 to day 
70 (Figure 5.13b). This result confirms the reduction in protein in a different tissue and 
suggests it would persist across the lifetime of the animal. In accordance with our previous 
study (Lee, K. et al. 2014), protein reduction corresponds to the phenotype severity and 
deregulation of targets seen in chapter four of this thesis. As no functional difference 
between the two polyalanine tract mutations has been found, it highlights reduced levels of 







Figure 5.11 Reduced Arx protein abundance in PA1 testes samples during adult life 
compared to Arx-WT mice 
a) Western immunoblots showing reduced Arx protein abundance across PA1 testes 
samples (highlight in orange) from adult mice ranging in age from day 40-70 compared to 
the Arx-WT sample #1322 (highlight in green). Samples were loaded onto 4-12% SDS-
PAGE gels, and Arx was detected by immunoblotting with rabbit anti-Arx. B-actin was 
used as a loading control. CB: P10 cerebellum was used as a negative control as this region 
lacks any Arx protein. b) Densitometry of Arx and B-actin bands were determined using 
LICOR western blot analysis software, Image Studio Lite. The density of Arx protein was 
normalised to the density of the loading control B-actin and is expressed in arbitrary units 
and all normalised to sample #1322 (black).  
  
186 
Table 5.6 Densitometry and normalisation results for the protein abundance of Arx 




















WT #1322 71 630000 100.0 698000 100 0.90 100.0 
PA1 #1130 43 363000 57.6 677000 97.0 0.54 59.4 
PA1 #1218 49 376000 59.7 678000 97.1 0.55 61.4 
PA1 #1301 59 454000 72.1 656000 94.0 0.69 76.7 
PA1 #1302 59 463000 73.5 702000 100.6 0.66 73.1 
PA1 #1265 61 337000 53.5 712000 102.0 0.47 52.4 
PA1 #1271 61 298000 47.3 734000 105.2 0.41 45.0 
PA1 #1133 63 320000 50.8 768000 110.0 0.42 46.2 
PA1 #1200 70 363000 57.6 793000 113.6 0.46 50.7 
PA1 #1321 71 514000 81.6 807000 115.6 0.64 70.6 
PA1 #1312 73 573000 91.0 798000 114.3 0.72 79.6 






Figure 5.12 Reduced Arx protein levels in PA2 testes samples during adult life 
compared to Arx-WT mice. 
a) Western immunoblots showing reduced Arx protein abundance across PA2 testes 
samples (highlight in orange) from adult mice ranging in age from day 40-70 compared to 
the Arx-WT sample #1322 (highlight in green). Samples were loaded onto 4-12% SDS-
PAGE gels, and Arx was detected by immunoblotting with rabbit anti-Arx. B-actin was 
used as a loading control. CB: P10 cerebellum was used as a negative control as this region 
lacks any Arx protein. b) Densitometry of Arx and B-actin bands were determined using 
LICOR western blot analysis software, Image Studio Lite. The density of Arx protein was 
normalised to the density of the loading control B-actin and is expressed in arbitrary units 
and all normalised to sample #1322 (black).  
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Table 5.7 Densitometry and normalisation results for protein abundance of Arx in 
PA2 mice testes samples. 
 
Table 5.8 Summary of normalised protein abundance of Arx protein levels in testes 
samples from WT and polyalanine expansion mice 
  
WT PA1 PA2  
94.5 59.4 62.6  
93.0 61.4 83.2  
108.6 76.7 98.0  
67.8 73.1 72.8  
90.8 52.4 87.9  
84.1 45.0 81.7  
90.2 46.2 82.3  
104.3 50.7 70.8  
98.4 70.6 84.8  
112.9 79.6 73.7  
100.0 44.9   
113.2    
98.5   
Mean 96.6 60.0 79.8 
Std. Error of Mean 3.44 3.97 3.2 
Adj P Value (WTvPA1/PA2)  <0.0001 0.0062 
Adj P Value (PA1vPA2)   0.002 



















WT #1322 71 653000 100.0 548000 100 1.19 100.0 
PA2 #1160 40 423000 64.8 567000 103.5 0.75 62.6 
PA2 #1332 42 462000 70.8 466000 85.0 0.99 83.2 
PA2 #1289 44 593000 90.8 508000 92.7 1.17 98.0 
PA2 #1327 49 412000 63.1 475000 86.7 0.87 72.8 
PA2 #1373 49 486000 74.4 464000 84.7 1.05 87.9 
PA2 #1158 53 481000 73.7 494000 90.1 0.97 81.7 
PA2 #1260 67 568000 87.0 579000 105.7 0.98 82.3 
PA2 #1141 70 486000 74.4 576000 105.1 0.84 70.8 
PA2 #1349 70 609000 93.3 603000 110.0 1.01 84.8 
PA2 #1362 70 540000 82.7 615000 112.2 0.88 73.7 






Figure 5.13 Reduction of Arx polyalanine expansions mutant protein in adult testes 
samples across adult life 
a) Summary of normalised protein abundance of Arx protein levels in testes samples from 
WT (black circles) and polyalanine expansion mice, PA1 (orange triangle) and PA2 (blue 
square). *** = P <0.0001, ** = P<0.005 (Tukey’s multiple comparison test). b) The level 
of relative Arx protein abundance across different ages ranging from day 40 to day 70 in 
Arx-WT, Arx-PA1, and Arx-PA2 samples. 
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5.3.6 Polyalanine expansion mutation effect on degradation of the mutant protein. 
Reduction of mutant protein has now been established as a consistent feature across a 
number of other polyalanine tract mutations whilst the mRNA levels remain unaffected 
(Hughes et al. 2013, Lee, K. et al. 2014). Possible mechanisms to account for the reduction 
of mutant protein could be due to decrease stability or increased degradation of the mutant 
protein compared to the wild-type protein. Hence, we have investigated this possibility 
using a pulse-chase assay (Li et al. 2008). This experimental procedure allows newly made 
protein over a short period of time to be labelled within the cell, then sequentially exposed 
to the same compound, this time unlabeled, allowing the protein of interest to be followed 
from synthesis to degradation in its cellular environment. HEK293T cells were transfected 
with 500 ng of either Myc-tagged ARX-WT, PA1-23A or PA2-20A and labelled with 35S 
methionine/cysteine for 1 hour, followed by a chase of 1 or 3 hours without the radiolabel 
before harvesting the cells.  The two most common mutations were chosen to represent 
mutations in tract 1 and 2 as we see reasonably consistent data between the differing lengths 
in luciferase transcription studies. After 1 hour, ARX-WT had 72% of protein remaining 
when compared to the respective 0 hours sample which is set to 100%. The half-life of 
ARX-WT protein was reached at 3 hours with 49.5% measured (Figure 5.14a). At 1 and 3 
hours, PA2-20A showed a similar trend with 85% and 53% of protein remaining. Over the 
first hour, PA1-23A showed an increased rate of degradation compared to ARX-WT with 
57% of protein remaining. However, by 3 hours the rate of degradation plateaued with a 
similar level of measured protein at 55% remaining (Figure 5.14a). When the rate of 
degradation of PA1-23A and PA2-20A is directly compared to ARX-WT as the change in 
proportion of remaining protein when ARX-WT is set to 100% at each time point there is 
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no significant change of the rate of clearance for PA2-20A however at 1 hour PA1-23A is 
significantly different with ~30% less protein then ARX-WT indicating increase clearance 
(Figure 5.14b). However, by 3 hours ARX-WT and mutant proteins have plateaued and 
showed similar levels. This could be due to the inherent difficulties using an 
overexpression in vitro system where overexpression of ARX polyalanine expansion 
mutants increased the propensity to form aggregates (Figure 5.8) which can also be seen in 
ARX-WT to a lesser extent. It is likely the formation of aggregates renders the proteins 
resistant to proteasomal degradation as no further degradation was detected past 3 hours 







Figure 5.14 Protein stability of ARX polyalanine expansion mutant proteins. 
HEK293T cells were transiently transfected with ARX-WT, PA1-23A, and PA2-20A, 
incubated for 24 h, labelled with [35S]methionine/cysteine for 1 h, followed by a chase of 
1 or 3 h. Cell lysates were immunoprecipitated with anti-Myc, and 35S levels were 
measured using a beta scintillation plate counter. a) The rate of degradation of ARX-WT, 
PA1-23A, and PA2-20A when each sample is compared to their respective 0hr sample 
which is set to 100%. B) The change in the proportion of mutant protein when compared 
to ARX-WT at the same time point. The data represent the means of at least two 
independent experiments ± S.E. The y-axis represents the percentage of the radiolabelled 
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5.3.7 Decreased rate of translation efficiency may be contributing to the reduction 
of polyalanine expansion mutant protein. 
Considering that there was no significant change in the stability of polyalanine mutant 
protein as determined in the pulse-chase assay (Figure 5.14), we predict that stretches of 
GC-rich regions due to expanded polyalanine tract mutations in ARX may impede 
translation of the mRNA to protein. This may be the mechanism to account for the reduced 
levels of mutant protein seen in vivo (Lee, K. et al. 2014). Stretches of GCG sequences are 
known to be difficult to be transcribed and have an increased propensity to form highly 
stable mRNA hairpin loops. We predict that these factors may lead to decreased translation 
efficiency via ribosomal stalling. As an initial investigation, we conducted an in vitro time 
course experiment monitoring the rate of protein production in transfected HEK293T cells 
with PA1-23A compared to ARX-WT. We demonstrate that when cells were transfected 
with 0.5 µg of plasmid, protein production was first detected via immunoblot after 8-hours 
post-transfection with Myc-tagged ARX-WT plasmid (data not shown). Therefore, in 
subsequent tests, ARX-WT and polyalanine mutant samples were collected at 8, 10, 12, 16 
and 22-hours post transfection. HEK293T cells were transfected with 0.5ug of plasmid and 
confirmed to have a similar transfection efficiency of around 50% (data not shown). Protein 
was analysed by immunoblot, and subsequent densitometry (Image Studio Lite) was used 
to calculate the rate of protein production across time. Samples were compared to the initial 
time point of 8-hours which was given the arbitrary unit of 1. Using this approach, by 12-
hours post-transfection, ARX-WT protein had increased 4-fold. ARX-WT continued to 
increase from 12-hours across to 16 and 22-hours by 1.5 and 1-fold respectively. This was 
compared to a much lower increase in protein production for the PA1-23A which showed 
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little or no increase in the rate of production across 8-12 hours (Figure 5.15). By 16-hours 
post-transfection PA1-23A started to increase with a 2.5-fold increase, with a similar level 
also detected at 22-hours. Therefore, if ARX-WT is considered as 100% maximal 
production rate at each time point, the PA1-23A mutant displayed a 67% lower production 
levels with an efficiency of only 37.8%, which may be consistent with a disturbance 
leading to decreased efficiency of translation. Hence, this analysis reveals another possible 









Figure 5.15 Decrease rate of protein production in polyalanine tract mutant sample. 
Western immunoblots showing the rate of transfected ARX protein production across time 
in ARX-WT and PA1-23A. Samples were loaded onto 4-12% SDS-PAGE gels, and ARX 
was detected by immunoblotting with Myc-HRP (Invitrogen). B-actin was used as a 
loading control. b) Densitometry of ARX bands was determined using LICOR western blot 
analysis software, Image Studio Lite. The density of ARX protein was normalised to the 





Hours ARX-WT PA1-23A 
8 1 1 
10 1.35 1.01 
12 4.15 0.95 
16 6.87 2.52 
22 7.10 2.69 
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5.4 Discussion 
We have previously demonstrated a marked reduction of mutant Arx protein abundance 
within the developing forebrain of both PA1 and PA2 (Lee, K. et al. 2014). Assessment of 
the transcriptional consequence indicates a selective effect of these mutations impacting 
on some but not all Arx downstream targets. Therefore expanded polyalanine tract 
mutations represent a partial loss of Arx function. However, the molecular mechanism 
driving disease is still unknown. In this study, in silico tools predict that expansions to 
polyalanine tracts do not cause any major structural impact on the ARX protein. Nor do 
these mutations disrupt the functional capacity or the novel interaction with UBQLN4 
when tested in vitro. Reduction in protein due to the mutation is emerging as a major 
contributor to disease in vivo.  We show this reduction in protein levels due to the mutation 
persists into adult life and is also present in another tissue, the testes. The mechanism 
resulting in the reduction in protein is still under investigation. Our studies to date have 
shown there is no change in the ARX protein stability between the WT and polyalanine 
mutant proteins. However, our data suggests there may be a decreased efficiency of protein 
production evident in an in vitro context. Taken together, our data supports a mechanism 
of inefficient translation of the ARX mRNA with expanded GCG sequences.  
 
Polyalanine tracts are present in several transcription factors, and expansions in these 
sequences are responsible for several human genetics diseases. Structural studies have 
revealed that while short polyalanine peptides form alpha-helices (Giri et al. 2003), the 
secondary structure of longer polyalanine tracts is predicted to predominantly form beta-
strand structures (Giri et al. 2003). This suggests that longer alanine-tracts found in 
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transcription factors like ARX possess an enhanced tendency to form beta-sheet rich 
fibrillary structures.  This prediction is in agreement with in silico structure prediction of 
ARX-WT and two of the most common polyalanine expansion PA1-23A and PA2-20A. 
The I-TASSER predicted secondary structure showed several alpha helix structures 
spanning the ARX-WT protein corresponding to known functional domains with the 
exception of one located toward the C-terminal side (40-43aa) of the polyalanine tracts. In 
particular, this alpha helix appears prone to changes in secondary structure due to 
polyalanine tract mutation. We predict a shift in location (83-86aa) as a result of the 
addition of 8 alanines in polyalanine tract 2 (PA2-20A) and a more substantial disruption 
with a change in structure from an alpha helix to a beta strand (41-43aa) as a result of the 
addition of 7 alanines in polyalanine tract 1 (PA1-23A). This change in the model of the 
secondary structure is predicted to have an effect on the 3D structure, namely PA1-23A 
showing some change in protein folding. However, this is unlikely to affect the main 
nucleotide binding sites in either mutant protein. Even though the expansion itself in 
polyalanine tract 2 is longer at 8 alanines, the overall size of the tract at 20 alanines remains 
smaller than the expanded polyalanine tract 1 at 23 alanines in total. Therefore, the greater 
disturbances seen in the PA1-23A structure indicate that the resulting total size of the tract 
may play a greater role in disease than the size of the expansion itself. This may be the 
reason expansion mutations in polyalanine tract 3 and 4 of the ARX protein have not been 
reported as the smaller start size of 7 and 9 alanine, respectively may be able to tolerate 
expansions without causing disease. 
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By way of in silco predictions, the DNA binding of polyalanine mutant proteins is not 
impacted. It is well documented that mutations leading to the loss of ARX function cause 
catastrophic brain malformation disorders in addition to ID and seizures, including XLAG 
(Kitamura et al. 2002, Kato et al. 2004). Given the absence of these brain malformation 
phenotypes with polyalanine expansion mutations, it is likely these mutations cause a 
partial loss of function and retain some functional capacity (Lee, K. et al. 2014). When we 
interrogated the impact of expanded polyalanine tracts on the capacity of ARX 
transcriptional capacity using a cell-based assay, we show no loss of repressive activity 
with either mutation tested. This luciferase assay is useful in detecting changes in 
transcriptional activity when mutation impact on homeodomain binding (Shoubridge et al. 
2012). Therefore, this suggests there is no major alteration in DNA binding and 
functionality of the mutant protein in this context.  However, when we test activity in terms 
of the difference in protein levels seen in vivo, we see a concomitant loss of repression 
activity. This loss of repression due to lower levels of protein even with ARX-WT indicates 
that some targets of ARX repression are likely to be dosage sensitive. Similar results have 
been shown for SOX3, another X-linked polyalanine tract containing protein with reported 
polyalanine tract expansion mutations (Hughes et al. 2013). The effect of an expansion of 
a polyalanine tract by 11 alanines from 15 to 26 alanines in SOX3 resulted in reduced 
activity compared to SOX3-WT however a reduction of similar magnitude to the reduced 
luciferase output was observed suggesting that the mutant protein that is present in the 
nucleus has similar activity to WT (Hughes et al. 2013). Additionally, different effects of 
polyalanine mutant protein have been reported using different reporters and different cell 
types suggesting pathogenesis might be promoter and cell type specific (Di Lascio et al. 
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2013). This agrees with in vivo ARX polyalanine mutant data of selective deregulation of 
known targets (Lee, K. et al. 2014).  
  
It has been previously proposed that polymeric runs might serve to fine-tune the activity 
of the transcription factor (Karlin and Burge 1995). Hence, one of the possible mechanisms 
by which polyalanine repeats could regulate the functions of proteins that contain them is 
by mediating the interaction with other proteins. The region spanning polyalanine tract 1 
and 2 of the ARX protein was screened for novel protein binding partners, and UBQLN4 
was identified as a novel interactor of this region (Figure 5.6). Interestingly, UBQLN4 is 
not a known co-factor of transcription factors. Despite this, ubiquilins, a family of 
ubiquitin-binding proteins, are involved in several protein degradation pathways and have 
been implicated in various neurodegenerative diseases. UBQLN4 belongs to the UBL-
UBA family of proteins which play a role in the regulation of protein degradation via the 
ubiquitin-proteasome system (UPS). They mediate the proteasomal targeting of misfolded 
or accumulated proteins for degradation by binding (via the UBA domain) to their 
polyubiquitin chains and by interacting (via ubiquitin-like domain) with the subunit of the 
proteasome (Riley et al. 2004). Studies involving polyglutamine expansions have shown a 
role for Ubiquilin in the regulation of aggregate formations and suppressed polyglutamine-
induced cell death.  
 
At the time when the interaction between ARX and UBQLN4 was first identified, 
aggregation of the mutant protein was still considered to be a possible mechanism for 
disease. Therefore, we expected there might be a loss of interaction between ARX and 
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UBQLN4 resulting in the accumulation of mutant protein. However, in more recent years 
this was disproven as a likely artefact of in vitro systems and a reduction in mutant protein 
is a more likely factor contributing to disease (Innis et al. 2004, Kuss et al. 2009, Lee, K. 
et al. 2014). As the interaction between ARX and UBQLN4 is maintained with ARX 
polyalanine expansion mutant proteins, this interaction might contribute to the tight 
regulation of the ARX protein and may be implicated in the increased turnover of the 
mutant ARX protein.  As the original portion of the ARX protein used to identify the 
interaction with UBQLN4 was only focused on the region containing polyalanine tract 1 
and 2 only, this interaction could represent a common relationship across other polyalanine 
expansion containing proteins leading to tight regulation of transcription factor protein 
levels in vivo. Therefore, this may have broader implications in addressing the pathogenic 
mechanism behind expanded polyalanine tract disorders in general. Studies of several 
polyalanine expanded proteins have shown that nuclear inclusion or aggregates are often 
ubiquitinated, and the degree of ubiquitination of expanded polyalanine tracts mutant 
protein was higher than that of WT proteins (Parodi et al. 2012). This interaction with 
UBQLN4 may suggest alanine runs might serve a general function, such as regulation of 
the intracellular/intranuclear concentrations of the polyalanine tract containing 
transcription factors by establishing a chaperone-dependent equilibrium and resulting in an 
increased affinity for expanded polyalanine tracts. 
 
Transcription factors affected by polyalanine expansion mutations are important for 
embryonic development and in vivo studies have demonstrated a reduction of the mutant 
protein with a focus on embryonic time points (Bruneau et al. 2001, Innis et al. 2004, 
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Hughes et al. 2013, Lee, K. et al. 2014). Even though reduction of mutant protein has been 
shown not to be stage dependent during embryonic life (Hughes et al. 2013), it has not been 
established whether the reduction of mutant protein persists or if it is tissue specific. ARX 
is most notably expressed in the brain during development (Kitamura et al. 2002, Ohira et 
al. 2002).  Despite this, ARX-WT protein expression persists at a robust level in the adult 
testis and we demonstrate a significantly lower level of mutant ARX protein in this tissue 
in both PA1 and PA2 animals. Indicating the reduction in mutant protein continued across 
adult life and multiple sites.  
 
Similar to Hoxa13, Hoxd13 and Sox3, polyalanine expansion in Arx does not have a 
detectable impact on steady-state mRNA levels (Innis et al. 2004, Cocquempot et al. 2009, 
Hughes et al. 2013, Lee, K. et al. 2014). Therefore, reduced protein abundance could be 
secondary to a reduction in efficiency of translation or to degradation or combined effects.  
Moreover, this could be a common mechanism contributing to the disease of expanded 
polyalanine tracts more broadly. Given the interaction between ARX and UBQLN4, other 
polyalanine proteins co-localising with chaperones in vitro and that aggregation is 
promoted by pharmacological inhibition of the proteasome, it seems likely that mutant 
polyalanine proteins are cleared from the cell at an increased rate. Investigating the 
mechanisms that potentially contribute to this marked reduction in the expression of the 
mutant protein, our data indicates the stability of the mutant protein is not significantly 
compromised and exhibits the same rate of clearance as the WT protein. A primary analysis 
of translation efficiency showed slower protein production of polyalanine expansion 
mutant protein in vitro and suggested the structure of RNA carrying the expanded triplet 
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repeats impedes translation. Further investigations identifying the extent of ribosomal 
stalling is an active area of research and may prove to be the mechanism that drives the 
reduction in protein expression seen in other genes with disease-causing expansion in 
polyalanine tracts. However, these studies fall outside the capacity of my thesis to 
complete.  
 
Hence, from my studies in conjunction with existing data, we contend that polyalanine 
expansion mutations in ARX result in a partial loss of function with the regulation of the 
steady-state levels of mutant protein representing a crucial component in the pathogenesis 
of these human disorders. Interestingly this reduction is detected in other tissues including 
the testes which have no reported gross morphological deficit in patients with polyalanine 
expansion mutations. It is of interest to note that there are no reports of paternal 
transmission of polyalanine tract disorders in ARX. We cannot rule out that this may be 
due, at least in part, to reduced functionality of the testes. This could be addressed using 
our knock-in mouse models. However, the evidence to date highlights that brain 
development is sensitive to the level of ARX protein present.  Additional studies into 
understanding the molecular details of this sensitivity to gene dosage and identify the 
process causing the reduction in mutant protein will be essential in further understand the 
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6 Final Discussion: Contributing factors leading to polyalanine expansion 
disorders, particularly in ARX 
 
Missense mutations in ARX result in phenotypes that involve ID with frequent 
comorbidities of epilepsy, infantile spasms, hand dystonia, autism or dysarthria. 
Historically, it was thought that only males were affected by mutations in ARX due to their 
single X-chromosome. We identified a novel mutation in an affected female. Our 
subsequent review of female phenotypes due to mutations in ARX in the literature 
highlights that ARX could be considered a syndromic form of X-chromosome-linked ID 
with associated co-morbidities with complete penetrance but variable expressivity in 
males, with incomplete penetrance and variable expressivity in females. The disparities in 
clinical phenotypes in females compared to males may be attributed in part to differences 
in genomic background and X-inactivation patterns in the brain (Marsh et al. 2016). The 
distinct phenotypes in males and females depending on the functional severity of the 
variant with ARX-related disorders is also noted in several other X-linked conditions, such 
as PHF6, IQSEC2 and USP9X (Zweier et al. 2013, Reijnders et al. 2016, Zerem et al. 
2016). Further investigation into the mechanism(s) underlying the female phenotypes in 
X-linked conditions is required, however, is likely due to a combination of both cellular 
mosaicism and reduced functional protein expression. Our study illustrates the importance 
of screening ARX in both male and female patients with ID and seizures. 
 
The increasing awareness of female X-linked conditions in the past few years has been 
aided by unbiased approaches of next generation sequencing (NGS), allowing an 
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unprecedented increase in the ability to sequence large numbers of genes. The increased 
availability and affordability of NGS technology have been particularly important in the 
diagnosis of neurodevelopmental disorders given the broad spectrum of overlapping 
phenotypes resulting from a large number of potential genetic causes. Molecular diagnosis 
achieved by a genome-first approach using high-throughput NGS will not only resolve 
many undiagnosed ID cases, but this unbiased approach will provide accurate estimates of 
the prevalence of genetic mutations. A significant obstacle that remains to be overcome is 
the interpretation of pathogenicity of novel variants. Bioinformatics pipelines use stringent 
criteria to classify sequence variants as pathogenic, and functional data are often required 
to support the accuracy of these predictions. However, the false negative rate is not known 
making the continued development of functional studies for validation critical, especially 
for novel de novo cases. As we continue to unravel the full spectrum of genotype-
phenotype relationships associated with mutations in ARX, this knowledge will enhance 
our ability to interpret and predict more accurately the phenotypic consequence of variants 
of unknown significance.  
 
Diseases caused by ARX mutations can be considered under the umbrella of 
neurodevelopment disorders (NDDs), classified as any disorder caused by an alteration in 
how the brain develops. These include autism spectrum disorders, intellectual disability, 
seizure disorders, schizophrenia and attention deficit disorder. NDDs are a complex array 
of conditions arising due to high genetic heterogeneity (Chen et al. 2014). It is estimated 
approximately 20-45% of all NDDs are associated with variation in specific genes (Krumm 
et al. 2014).  However, the small numbers of individual cases for the majority of causative 
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genes coupled with widespread clinical outcomes has limited the research into identifying 
the pathogenic mechanisms and restricted the development and implementation of 
therapeutic strategies for each genetic case and mutation type. ARX is a good example of 
the challenges faced by researchers and clinicians in the NDDs field. ARX has over 60 
mutations reported to date, in over 138 cases with as many as 10 clinically distinct 
phenotypes (Shoubridge et al. 2016). Despite this daunting outlook, overlapping comorbid 
outcomes between NDDs arising from different genetic causes suggests the possibility that 
diseases giving rise to similar phenotypes, even due to vast genetic heterogeneity, may 
converge on similar molecular pathways (Chen et al. 2014). Hence, we have approached 
identifying molecular pathways involved in these disease outcomes using the expanded 
polyalanine tract mutations in ARX as a model. Assessment of the transcriptome-wide 
outcomes in mice modelling PA1 and PA2 mutations showed many of the genes 
deregulated were known ID, epilepsy or autism disease genes (Mattiske et al. 2016). The 
enrichment of genes with synaptic function supports the convergence of common pathways 
contributing to these disorders.  Clinically children with severe infantile spasms (seen with 
expansion to both tracts, but more frequently in PA1) respond poorly to anticonvulsants. 
Short-term reduction in spasms is achieved with the treatment of ACTH (Hrachovy and 
Frost 2013). However, ACTH can have significant side effects (Shields 2006), and better 
therapeutic alternatives are required. Our investigations into the pathways disturbed due to 
ARX mutations aim to provide insights that may underpin the development of effective 
treatment options for seizure disorders due to ARX dysfunction and in turn perhaps other 
genetic causes of epilepsy. Arising from the work in which we interrogated the profile of 
deregulated genes from the developing brain of PA1 and PA2 mice, I have identified a 
207 
number of pathways enriched by genes deregulated in the mutant mice. One ‘core’ pathway 
of transcriptional regulators we suggest may represent early drivers of ARX-associated 
phenotypes, namely ID and epilepsy. We are building on this within our laboratory treating 
ARX polyalanine expansion mice with 17B-estradiol in early postnatal life. ACTH 
stimulates the synthesis of adrenocortical steroid hormones, including androgens. This has 
focused investigations on the role that oestrogen receptor expression and 17B-estradiol 
(E2) during the development of interneurons. Treatment of a different genetic strain of PA1 
mutant mice with E2 during postnatal life resulted in sustained ablation of seizures in 
young adult mice (Olivetti et al. 2014). The treatment restored some depleted interneuron 
populations and altered mRNA levels of three downstream targets of Arx (Ebf3, Shox2, 
Lgi1) (Olivetti et al. 2014). However, the underlying molecular drivers of these responses 
have not been established. Of the 858 deregulated genes from our E12.5 dpc mutant mice, 
there were 299 genes harbouring an estrogen response element. It remains to be determined 
which genes are deregulated in early postnatal life when estrogen treatment has a beneficial 
impact on reducing seizures (Olivetti et al. 2014). The data that I have generated as part of 
my PhD studies can now be used as a baseline of early drivers contributing the ARX disease 
phenotype. We can build upon this knowledge to investigate the transcriptional changes 
that underpin long-term ablation of seizures after treatment E2 in both PA1 and PA2 mutant 
mice. Furthermore, it is unclear if this treatment has any beneficial impact on the cognitive 
impairments in this model. It is my hope that this data will enhance our knowledge of the 
pathways and clusters of deregulated genes that may be amenable to therapeutic 
manipulation to improve clinical outcomes not only disease caused by ARX mutations but 
by other ID and epilepsy disorders.  
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My research has focused on understanding the mechanism(s) by which mutations in ARX 
contribute to disease outcomes, with a particular focus on understanding the pleiotropy 
present in the patients and mouse models. When I examined Arx protein abundance in WT 
mouse testes, I found a variable expressivity occurs against the uniform genetic and 
environmental background. We predict that the protein level within individuals will lead 
to the variability of the disease outcome. Larger numbers of mice with corresponding 
phenotyping will be needed to provide statistical support for this prediction. What still 
needs to be determined is if the reduced level of the mutant protein is due to variable levels 
of ARX produced or if individuals have different efficiencies of degradation of the mutant 
protein. Although much remains to be understood about how cells degrade aberrant 
proteins, it has become clear that other components besides the mutant protein get 
sequestered and thus at least temporarily inactivated during the degradation process, 
resulting in compromised cellular function (Selkoe 2003). The extent to which other 
proteins are compromised by mutant ARX and the influence on general cellular functions 
is another potential avenue that may contribute to the variability in phenotype severity 
across affected individuals. The impact of epigenetic effects contributing to the variability 
in clinical severity observed in families with ARX expansion mutations has not been 
studied to date, and remains an area of interest for further investigation in our laboratory.  
 
Understanding the general function of ARX during brain development has been of great 
interest in my examination of the transcriptome data I have generated. From the RNA-Seq 
analysis, we can conclude that partial loss of function of Arx is selective, and does not 
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seem to be due to gross defects in DNA binding. This is supported by the majority of known 
direct targets being unaffected in the mutant mice, with only a subset of targets deregulated 
in the developing brain. Why this specificity occurs is perplexing, and may indicate that 
the effect of alanine-tract length on DNA binding and presumably on transcriptional 
activity depends on, to some extent, of the DNA sequence being queried. Assessing 
whether the transcriptional impact of polyalanine expansions depends on the nature of the 
promoter may lead to additional insights. Indeed, we predict that different target promoters 
will have different sensitivities to decreased amount of available/‘soluble’ ARX. A 
computational analysis of promoters displaying high vs. low-sensitivity to ARX 
concentration might shed light on the molecular basis of these differences (i.e. the 
difference in the number of ARX binding sites or sites for potential partners?). Further 
transcriptome-wide expression and ChIP experiments in relevant tissue samples will allow 
for the identification of true or direct gene targets in the relevant cellular context. The genes 
that are expected to display altered expression patterns will be (i) direct and indirect ARX 
targets and (ii) possibly genes whose products are involved in the adequate removal of the 
mutant protein (i.e. proteasome subunits, ubiquitination pathways members, chaperones, 
etc.). These latter genes, even though not directly regulated by ARX, are likely to be 
modifiers of an individual’s phenotype.  
 
The frequent occurrence of reduced levels of mutant protein in transcription factors with 
disease causing polyalanine expansion mutations (Bruneau et al. 2001, Innis et al. 2004, 
Goridis et al. 2010, Hughes et al. 2013, Lee, K. et al. 2014) indicates there may be a shared 
mechanism leading to the development of disease. Throughout my studies, I have 
210 
considered two fundamental cellular processes, which when perturbed could lead to a 
reduction in protein; namely decreased translation and / or increased degradation of the 
mutant protein. Determining the cause of this reduced protein abundance will help to focus 
further research on rescuing the deficit produced by polyalanine expansion mutations. It 
has long been speculated that expansion mutations result in secondary hairpin structures, 
stalling ribosome progression, leading to inefficient translation. mRNA hairpin structures 
are prevalent in human transcripts and are suggested to play a role in gene expression 
regulation.  The increased GC content due to expansion mutations is predicted to result in 
decreased translation (Jasinska et al. 2003). Recently, it was established that repetitive 
RNA motifs can support translation initiation in the absence of an AUG start codon across 
a wide variety of sequence contexts (Zu et al. 2011, Zu et al. 2013), and the products of 
these atypical translation initiation events contribute to neuronal toxicity (Sellier et al. 
2017). Studies have demonstrated that polyglutamine repeats in FMR1 elicit production of 
a toxic polyglycine protein FMRpolyG, which is now known as repeat-associated non-
AUG (RAN)-initiated translation (Todd et al. 2013). After cap-dependent initiation of 
translation and subsequent scanning through the 5’ UTR ribosome stalling at secondary 
structures formed at repeats lead to aberrant translation initiation at non-AUG codons, 
resulting in toxic repeat peptides. RNA secondary and tertiary structures contribute 
significantly to the dynamics and regulation of translation. The efficiency of RAN 
translation is dependent on repeat length and the imperfect RNA hairpin structures formed 
by the expanded repeats. Studies suggest that the ribosome engages with the mRNA as 
established but the presence of the structured repeats promotes reduced specificity of 
translation initiation which is a consequence of an activated 40S subunit stalled by a hairpin 
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structure (Kearse et al. 2016). RAN translation represents a new and provocative 
mechanism by which protein translation can occur in the setting of nucleotide repeat 
expansion to produce a novel set of toxic proteins which due to out of frame products may 
not have been detected due to antibody specificity. Establishing if the triplet repeat 
mutation leading to expansion polyalanine tract in Arx alters the translation of mRNA and 
leads to a reduced protein expression is an area of active research in our laboratory. A 
ribosome profiling approach will be undertaken. In this approach, a translating ribosome 
protects a footprint approximately 30 nucleotides of the mRNA temples. Deep-sequencing 
ribosome-protected mRNA fragments will yield subcodon resolution of translation (Ingolia 
et al. 2009). If a ribosome stalls at a particular location, an excess of a particular footprint 
will occur.  
 
A posttranscriptional reduction in protein levels is suggested, partly due to the ability of 
cells to recognise and degrade misfolded mutant protein, thus circumventing the formation 
of overt aggregates. Even though it is now accepted that polyalanine expansion protein 
does not form amyloids under normal cellular conditions, instead we and our collaborators 
have shown these expansions form α-helical clusters, thus providing another level for how 
polyalanine mutations may disrupt normal function (Polling et al. 2015). Under 
physiological expression condition using tissue slices from PA1 and PA2 mice, focusing 
on the ventrolateral mantle zone of the telencephalon of embryonic mice at 12.5 dpc, where 
Arx expression in most pronounced, Arx mutants displayed elevated granularity of nuclear-
localised protein compared to Arx WT (Polling et al. 2015). This result suggests that the 
abnormal clustering patterns caused by polyalanine expansion underlie a general 
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mechanism for the displacement of normal protein functionality and may lead to the 
disruption of normal ligand interactions. Such forms may be expected to be targeted for 
clearance by the quality control machinery, and indeed polyalanine expanded proteins have 
been shown to colocalise with cellular makers of degradation (Nasrallah et al. 2004, 
Trochet et al. 2005, Utsch et al. 2007, Parodi et al. 2012). In a polyglutamine model, these 
soluble oligomers are more pathogenic than insoluble aggregates but engage in more 
aberrant interactions with the potential to disrupt basic cellular function involving low-
complex-repeat containing proteins, such as RNA processing and ribosome biogenesis 
(Kim et al. 2016). Neuronal dysfunctional may result from a culmination of multiple 
defects that are also caused by the presumably dynamic interaction of soluble aggregates. 
 
Many of the drug treatments being investigated for polyalanine expansion disorders are 
effective at reducing aggregate formation in vitro. The prevailing model for drug action is 
that increased chaperone activity leads to a reduction in aggregate formation. The 
alternative hypothesis for drug action is that increased chaperone activity increases the 
efficiency of primary protein folding to increase the amount of functional protein. For the 
future it would be interesting to assess the effect of these drugs in a polyalanine expansion 
mouse model where protein aggregates are not seen in vivo, thus testing the toxicity of 
aggregates/oligomers in the correct cellular and physiological context. Finally, another 
avenue of investigation that has not yet been explored is the use of patient-derived induced 
pluripotent stem (iPS) cells. This approach is likely to yield further insights into the cellular 
pathology of polyalanine expansion disorders and provide a useful vehicle for 
pharmacological screening including the role of the genetic background contributing to 
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severity. However, as Arx is particularly important in interneuron development, this neuron 
population remains difficult to achieve by differentiation of iPS cells. Possible treatments 
could also be considered to target mRNA secondary structures such as TMPyP4, shown to 
reduce translation delay due to disease causing CGG repeats in FMR1 (Weisman-Shomer 
et al. 2003, Ofer et al. 2009).  
 
The molecular mechanism(s) underpinning polyalanine expansion mutations are complex. 
We predict it is likely that many factors contribute to disease manifestation and variability 
of phenotypes. From the investigations during my PhD studies, my current working 
hypothesis is that multiple defects occur to the resulting mutant protein leading to a partial 
loss of function. Polyalanine expansion mutation proteins are functional but are likely to 
be sub-optimal, due to an altered capacity to bind to interacting proteins, oligomers 
engaging in aberrant interactions, and from the reduction in the mutant protein itself 
leading to dose-dependent changes to transcriptional capacity. The process leading to the 
reduction in mutant protein is an exciting area of research as insights may lead to viable 
treatment options not only for the disorders caused by polyalanine expansion in ARX but 
the additional seven other transcription factors affected by polyalanine expansion 
mutations. In addition, modelling the molecular disruptions caused by expansion in 
polyalanine tract 1 and tract 2 of ARX has enabled us to begin to assess the degree of 
molecular convergence between these two mutations and establish the drivers of disease 
outcomes contributing to the shared phenotype that may also apply to other genetic causes 









7 Appendix  
7.1 Result Tables from Chapter 4 
Appendix Table 1: PA1 deregulated gene list 
Gene ID logFC logCPM LR PValue FDR 
0610010B08Rik -1.27201 0.376094 6.617006 0.010101 0.042781 
0610012G03Rik -1.18657 4.7496 10.86284 0.000981 0.011248 
0610040B10Rik -1.38869 1.006032 12.29983 0.000453 0.007748 
1110001J03Rik -1.11495 4.630258 14.51541 0.000139 0.004625 
1190005I06Rik -1.71375 -0.33152 12.19626 0.000479 0.007835 
1500016L03Rik -1.31547 1.72895 8.127712 0.004359 0.025371 
1500032L24Rik -1.12949 6.673542 15.71578 7.36E-05 0.003888 
1600002K03Rik -1.76795 2.050941 14.5542 0.000136 0.00459 
1700007J10Rik 1.339379 0.655445 7.738763 0.005405 0.028974 
1700008O03Rik -2.38033 0.510312 13.60667 0.000225 0.005773 
1700011J10Rik -1.25951 2.070304 13.00246 0.000311 0.006716 
1700016K19Rik -1.40064 -0.40003 6.368842 0.011614 0.047028 
1700020I14Rik 1.185394 4.864457 19.2199 1.16E-05 0.002311 
1700029I15Rik -1.5964 -0.82634 8.252613 0.004069 0.024272 
1700048O20Rik -1.19607 3.471648 10.83008 0.000999 0.011322 
1700067K01Rik -1.14392 0.039629 7.041731 0.007963 0.036771 
1700113A16Rik -1.29603 3.752218 12.43809 0.000421 0.00757 
2010320M18Rik -1.15201 2.83816 11.50988 0.000692 0.009316 
2310002D06Rik 1.675014 -0.23603 9.319089 0.002268 0.017522 
2410066E13Rik 1.522695 4.163534 18.60847 1.61E-05 0.00238 
2410137F16Rik 2.784826 1.125381 21.95337 2.79E-06 0.00099 
2610005L07Rik 1.296677 5.943825 12.07005 0.000512 0.008049 
2610017I09Rik -1.18238 6.544142 12.15462 0.00049 0.00786 
2610019E17Rik -1.12904 3.221525 11.40037 0.000734 0.009683 
2810405F15Rik -1.48493 0.820805 11.00392 0.000909 0.010795 
2810428I15Rik -1.31538 4.008788 14.40609 0.000147 0.004746 
3110021A11Rik 1.377668 -0.36248 9.948215 0.00161 0.014515 
3110021N24Rik 1.722986 1.306118 10.4136 0.001251 0.012665 
3110047P20Rik 1.249986 1.236017 10.74658 0.001045 0.011545 
3300002I08Rik 1.388177 0.294927 12.61777 0.000382 0.007294 
4632427E13Rik 1.24632 0.542107 13.50952 0.000237 0.005953 
4921525B02Rik 1.761232 0.023865 10.3895 0.001267 0.012701 
4930404N11Rik -1.14609 1.630962 8.345079 0.003867 0.023722 
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4930444P10Rik -1.94316 0.312289 16.523 4.81E-05 0.003301 
4930455C13Rik 2.07035 -0.73006 14.01351 0.000182 0.005226 
4930506C21Rik 1.297217 0.138302 7.481899 0.006232 0.031546 
4930565N06Rik 2.300628 -0.47566 8.532889 0.003488 0.022357 
4930578M01Rik 1.155101 0.358787 11.10447 0.000861 0.01044 
4931417G12Rik -1.25245 0.337899 9.4277 0.002137 0.017034 
4932411E22Rik 1.15665 0.644623 4.106265 0.042725 0.112467 
4932418E24Rik 1.707146 0.720514 11.04525 0.000889 0.010639 
4932438A13Rik 1.385145 5.781775 14.75029 0.000123 0.004535 
4933436C20Rik -1.37594 0.81167 11.10946 0.000859 0.01043 
5031434O11Rik -1.80118 -0.95457 7.755146 0.005356 0.028824 
5330426P16Rik 1.242911 2.053445 12.97902 0.000315 0.00676 
5730408K05Rik -1.31294 1.139762 15.56091 7.99E-05 0.003957 
5830454E08Rik -1.50039 -0.35417 10.09787 0.001484 0.013857 
6330403M23Rik -1.11854 1.649876 9.94876 0.00161 0.014515 
6330415B21Rik -3.86228 -0.91273 11.36401 0.000749 0.0098 
6330418K02Rik -1.26533 -0.05641 9.799575 0.001746 0.015153 
6330549D23Rik -1.2752 1.676895 4.405447 0.035824 0.099741 
8030462N17Rik 1.156862 3.99937 7.714813 0.005477 0.029225 
9530082P21Rik -1.2943 4.809901 11.11751 0.000855 0.010417 
9930013L23Rik 1.381232 2.013537 6.968165 0.008297 0.03779 
A330023F24Rik -1.42171 1.604096 12.74817 0.000356 0.007147 
A630001G21Rik -1.225 -0.24736 11.81838 0.000586 0.008528 
A630007B06Rik 1.704247 4.012707 11.15399 0.000839 0.010304 
A630089N07Rik 1.175358 2.741932 7.179838 0.007373 0.035232 
A730008H23Rik 1.672879 0.698125 8.771926 0.003059 0.020711 
Abca8b 1.132348 1.718968 8.507562 0.003537 0.022493 
Abhd14a -1.11569 4.410861 11.49221 0.000699 0.009368 
Abhd2 1.62879 4.480231 11.56001 0.000674 0.009191 
Acvr2b 1.156761 4.829312 14.70336 0.000126 0.004552 
Adamts12 1.402052 2.094112 4.833304 0.027915 0.084251 
Adamts6 1.347386 3.243249 7.464686 0.006292 0.031749 
Adamtsl3 1.458963 -0.64298 11.24414 0.000799 0.010072 
Adarb2 1.413084 2.594551 23.19265 1.47E-06 0.000693 
Adcy9 1.541791 2.108944 15.16114 9.87E-05 0.004289 
Aff2 1.991401 4.248189 12.89637 0.000329 0.006894 
Aff4 1.13488 7.632438 15.99581 6.35E-05 0.003671 
Ager -1.14503 2.669702 7.416238 0.006464 0.032284 
AI413582 -1.19663 2.891611 10.45587 0.001223 0.012484 
AI462493 -1.1917 3.261246 12.70084 0.000365 0.007212 
AI506816 1.213334 1.817627 10.37741 0.001276 0.012719 
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AI606473 -1.48263 2.387366 16.70756 4.36E-05 0.003172 
Akap6 1.111425 6.334586 24.66974 6.8E-07 0.000522 
Alg10b 1.448524 5.881762 7.920775 0.004887 0.027157 
Alkbh2 -1.33662 2.343902 15.29217 9.21E-05 0.004146 
Alkbh8 1.297815 4.206992 10.29657 0.001333 0.013037 
Alx1 -3.19149 0.446978 12.26699 0.000461 0.007788 
Amh -1.22756 -0.11543 9.116098 0.002534 0.018596 
Anapc13 -1.31005 6.058474 18.79981 1.45E-05 0.00238 
Ankfn1 1.845155 0.634943 6.728277 0.00949 0.041147 
Ankrd26 1.133347 4.84469 7.370827 0.006629 0.032801 
Ap1s3 -1.27234 2.419265 5.403281 0.020099 0.066948 
Apom -2.17905 0.162485 11.90452 0.00056 0.008259 
Aqp4 1.148759 -0.41002 6.735173 0.009453 0.041017 
Arhgap32 1.165808 5.658843 15.7437 7.25E-05 0.003886 
Arhgap5 1.241946 6.039809 7.578624 0.005906 0.030597 
Arhgdig -1.21335 -0.17272 7.956896 0.00479 0.026814 
Arid5b 1.576979 3.064004 10.54304 0.001166 0.012178 
Arl5b 1.354838 4.970345 9.291975 0.002302 0.017705 
Ascc1 -1.15884 4.016392 12.75923 0.000354 0.007147 
Ash1l 1.107099 6.602328 14.5791 0.000134 0.004552 
Asphd1 -2.05662 0.98562 11.94868 0.000547 0.008204 
Aspm 1.191281 6.90871 14.63206 0.000131 0.004552 
Asprv1 -1.22835 -0.52238 6.401175 0.011404 0.046378 
Atf7 1.606527 2.891744 13.46606 0.000243 0.006016 
Atf7ip 1.251472 6.215053 18.84171 1.42E-05 0.00238 
Atp2b3 1.436523 1.238266 12.34304 0.000443 0.007704 
Atp5e -1.51157 5.737868 16.50519 4.85E-05 0.003301 
Atp5g1 -1.15614 6.780373 14.89333 0.000114 0.00441 
Atp5g2 -1.1906 7.687985 19.20017 1.18E-05 0.002311 
Atp5h -1.18433 6.501443 15.713 7.37E-05 0.003888 
Atp5k -1.12528 5.996161 12.39453 0.000431 0.007639 
Atp7b 1.127652 2.259245 7.289666 0.006935 0.033802 
Atp8a2 1.427292 2.899832 25.02705 5.65E-07 0.000499 
B230119M05Rik 1.1055 0.569271 9.940591 0.001617 0.014534 
Barx1 -3.71234 -1.68519 7.263453 0.007037 0.034136 
Bax -1.1018 5.490625 12.17445 0.000484 0.007835 
BC002163 -1.18351 1.653945 5.981706 0.014455 0.053802 
BC005561 1.836793 3.930392 13.54843 0.000232 0.005895 
BC017612 -1.25054 2.761067 16.42664 5.06E-05 0.003339 
Beta-s -1.18488 5.485102 14.90694 0.000113 0.00441 
Bex2 -1.13413 6.11868 15.39141 8.74E-05 0.004101 
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Bfsp2 -1.27277 -0.21646 7.32199 0.006812 0.03337 
Bicd1 1.380977 3.516111 15.21719 9.58E-05 0.004191 
Birc6 1.483883 7.161296 23.7506 1.1E-06 0.00062 
Bmpr2 1.78605 4.514409 13.47674 0.000242 0.005994 
Bola2 -1.55065 5.230313 18.57273 1.64E-05 0.00238 
Brwd3 1.716507 4.337986 22.85745 1.74E-06 0.000707 
Btbd7 1.589851 5.44782 12.42903 0.000423 0.007587 
Btbd8 1.900242 -0.22009 17.35943 3.09E-05 0.00284 
C130071C03Rik 1.358523 2.38598 19.85818 8.34E-06 0.001984 
C1galt1 1.155016 2.439774 6.516916 0.010685 0.044359 
C5ar2 -1.45341 -0.55005 4.383712 0.036284 0.100645 
C77370 1.184783 3.822507 23.70593 1.12E-06 0.00062 
C78339 1.293569 4.230786 7.492418 0.006196 0.031439 
Cabp1 -1.19931 1.855533 7.412505 0.006477 0.032328 
Cacfd1 -1.13806 5.707027 11.03697 0.000893 0.010668 
Cacna1b 1.111241 4.402469 19.42999 1.04E-05 0.002289 
Cacna1e 1.454316 3.722204 9.613919 0.001931 0.016029 
Carf 1.198872 1.690007 7.235797 0.007146 0.03446 
Cartpt -1.75389 1.311517 5.666944 0.017288 0.060408 
Casc5 1.309591 5.328364 8.20905 0.004168 0.024586 
Cbl 2.159575 5.222165 12.68322 0.000369 0.007212 
Ccdc107 -1.13487 3.125673 10.64234 0.001105 0.011872 
Ccdc12 -1.48329 5.162624 16.18382 5.75E-05 0.00347 
Ccdc124 -1.32578 5.077542 13.65023 0.00022 0.005743 
Ccdc171 1.145685 2.510222 10.4567 0.001222 0.012484 
Ccdc23 -1.34044 5.309399 17.65208 2.65E-05 0.002831 
Ccdc24 -1.16876 4.150018 10.13796 0.001452 0.013692 
Ccdc38 -1.24509 0.510328 10.69736 0.001073 0.01166 
Ccdc88c 1.105373 6.872172 11.60048 0.000659 0.00904 
Ccnt1 1.66108 4.03689 10.53944 0.001169 0.012178 
Cdh13 1.19145 2.921916 15.05466 0.000104 0.004361 
Cdh3 -1.30886 0.357543 5.578471 0.018183 0.062287 
Cdh6 1.838818 3.535725 11.31515 0.000769 0.009906 
Cdk2ap2 -1.18606 4.514507 12.38186 0.000434 0.007652 
Cdk5rap2 1.281559 5.620158 24.86792 6.14E-07 0.000499 
Cdk6 1.938026 1.628986 25.52619 4.36E-07 0.000496 
Cdkl5 2.074945 2.76514 23.13058 1.51E-06 0.000693 
Cdon 1.164197 7.367636 11.72897 0.000615 0.008758 
Cep290 1.118912 3.694128 13.28278 0.000268 0.006285 
Cep350 1.252393 6.069266 18.02059 2.19E-05 0.002643 
Cep85l 1.777539 1.765974 7.455213 0.006325 0.031845 
219 
Cers6 1.521702 4.327928 11.08373 0.000871 0.010521 
Chchd1 -1.26702 5.039863 19.0912 1.25E-05 0.002311 
Chd9 1.100631 6.24118 16.99857 3.74E-05 0.003133 
Chkb -1.69613 2.229955 11.92687 0.000553 0.008233 
Chmp2a -1.22972 5.368229 16.65939 4.47E-05 0.003186 
Chrm3 1.612218 -0.24518 8.395219 0.003762 0.023388 
Chrna7 1.591034 1.546752 10.46006 0.00122 0.012484 
Cib2 -1.16433 2.480952 12.00956 0.000529 0.008127 
Cisd3 -1.22773 2.026566 8.729338 0.003131 0.021028 
Cit 1.112135 4.514056 10.07484 0.001503 0.013932 
Clcn5 1.798172 4.278019 11.25253 0.000795 0.010052 
Cldn3 -1.3225 0.209263 9.986951 0.001577 0.014325 
Cldn6 -1.60797 0.06983 6.275664 0.012241 0.048486 
Clock 1.2197 4.939799 14.10575 0.000173 0.005127 
Cnksr2 1.126403 3.268661 12.43041 0.000422 0.007587 
Cnot6 1.13126 6.302926 6.897375 0.008632 0.038796 
Cntn5 1.235768 1.297549 12.66709 0.000372 0.007217 
Cntnap3 1.222721 0.461133 5.822004 0.015827 0.057079 
Cntnap5a 2.661611 -0.86058 22.80869 1.79E-06 0.000707 
Cntnap5b 2.90496 0.237802 20.0605 7.5E-06 0.001863 
Coa3 -1.11717 4.764819 12.87013 0.000334 0.006926 
Cox17 -1.31313 4.501685 17.31555 3.17E-05 0.002841 
Cox4i1 -1.11823 7.376168 16.76486 4.23E-05 0.003172 
Cox6b2 -1.18812 2.658062 11.29844 0.000776 0.009957 
Cox7a1 -1.29641 -0.69029 5.734541 0.016634 0.058976 
Cpa2 -1.15581 0.630104 12.30583 0.000452 0.007742 
Cpeb4 1.898035 3.513677 10.39174 0.001266 0.012701 
Crabp1 -1.55693 2.168367 16.21224 5.66E-05 0.00347 
Crabp2 -1.18677 5.8457 14.48493 0.000141 0.004649 
Creb5 1.549474 2.474859 10.11387 0.001472 0.013788 
Crebbp 1.124841 5.3643 13.79009 0.000204 0.005601 
Crip1 -1.10637 0.975628 7.679131 0.005586 0.02958 
Crip3 -1.44234 -0.3104 8.353353 0.00385 0.023702 
Cript -1.10848 5.219816 14.67162 0.000128 0.004552 
Csmd1 1.752413 1.917879 18.59261 1.62E-05 0.00238 
Csmd3 1.74923 1.819934 17.33898 3.13E-05 0.00284 
Csrnp3 1.175899 5.953111 30.4826 3.37E-08 0.000266 
Cuedc2 -1.15617 6.666162 10.18597 0.001415 0.013494 
Cxcl14 -1.38701 1.865674 13.47635 0.000242 0.005994 
Cxcr5 -2.38523 -0.40142 10.61695 0.001121 0.011931 
Cxx1a -1.10696 4.296978 10.58776 0.001138 0.012028 
220 
Cxx1b -1.44784 4.776053 12.73898 0.000358 0.007147 
Cyp4x1 1.438721 -0.36712 6.342831 0.011786 0.047348 
D030047H15Rik 1.144295 2.08087 8.986846 0.002719 0.019308 
D10Bwg1379e 1.648543 2.468903 21.0052 4.58E-06 0.001456 
D130040H23Rik 1.679909 1.626747 24.39814 7.83E-07 0.00057 
D330041H03Rik 1.2467 0.925094 10.05105 0.001523 0.014028 
D430020J02Rik 1.144343 3.461164 8.028441 0.004605 0.026265 
D630041G03Rik 1.301865 -0.90309 7.781315 0.005279 0.028542 
D830031N03Rik 2.162125 4.479222 17.39447 3.04E-05 0.00284 
D8Ertd738e -1.39783 5.375905 15.40168 8.69E-05 0.004099 
D930028M14Rik -1.16723 3.000448 7.897393 0.004951 0.027404 
Dand5 -1.11053 2.510285 7.519289 0.006104 0.031129 
Darc -1.29929 3.813836 14.16624 0.000167 0.005061 
Dbpht2 -1.38791 0.079628 8.462988 0.003624 0.022841 
Dcdc2b -1.46372 4.290363 8.619996 0.003325 0.021777 
Ddi2 1.368096 4.021388 15.34271 8.97E-05 0.004106 
Ddt -1.17155 4.890628 13.67627 0.000217 0.005695 
Dennd1c -1.29311 3.535207 12.33139 0.000445 0.007704 
Dgkh 1.951137 1.244332 21.82597 2.99E-06 0.001031 
Dgki 1.459666 2.345633 17.39905 3.03E-05 0.00284 
Dhrs3 -1.16167 -0.07412 9.110471 0.002542 0.018637 
Disc1 1.194491 0.18588 5.639336 0.017562 0.06095 
Dkkl1 -1.87888 -0.61914 10.31232 0.001321 0.01298 
Dleu2 -1.26751 2.600216 13.88671 0.000194 0.005441 
Dlgap2 1.320066 1.602044 13.74388 0.00021 0.005661 
Dlk2 -1.36854 1.939745 8.95075 0.002774 0.019536 
Dmxl2 1.306287 5.854497 23.62977 1.17E-06 0.000621 
Dnahc5 1.178599 0.115558 8.35959 0.003837 0.02367 
Dnajb14 1.692645 1.905508 17.5718 2.77E-05 0.002832 
Dnm3os -1.82239 0.309098 6.433796 0.011197 0.045863 
Doc2g -1.28157 3.296994 8.51812 0.003516 0.022426 
Dock4 1.352059 4.834045 18.56236 1.64E-05 0.00238 
Dok3 -1.41428 2.806783 13.35186 0.000258 0.006218 
Dok6 2.016688 -0.1702 12.68318 0.000369 0.007212 
Dopey1 1.166896 5.116068 17.95801 2.26E-05 0.002668 
Dpm3 -1.28697 4.680548 16.76423 4.23E-05 0.003172 
Dpy19l4 1.819367 3.728988 12.2791 0.000458 0.007768 
Dpysl2 -1.88363 7.340254 18.73005 1.51E-05 0.00238 
Dpysl3 1.647775 7.90096 17.4544 2.94E-05 0.00284 
Drap1 -1.26395 6.545533 13.53404 0.000234 0.005919 
Dtnbp1 -1.13287 4.872933 13.33585 0.00026 0.006226 
221 
Dusp4 1.136163 6.405928 8.414931 0.003722 0.02323 
Dync2h1 1.211622 5.651332 22.41176 2.2E-06 0.000822 
Dynlrb2 -1.35015 0.496206 8.096235 0.004436 0.025692 
Dynlt1f -1.44417 3.446717 16.74762 4.27E-05 0.003172 
Dyrk2 1.31672 3.959067 10.99479 0.000914 0.010829 
E330009J07Rik 1.921575 3.17155 15.86023 6.82E-05 0.003785 
Ebf1 1.221055 3.546801 25.10638 5.43E-07 0.000499 
Egfl8 -1.12351 1.139903 9.760403 0.001783 0.015335 
Egr3 1.279613 0.059908 6.916402 0.008541 0.038599 
Eif1 -1.21454 8.020039 12.55505 0.000395 0.007408 
Eif2c2 1.841938 6.112434 15.04328 0.000105 0.004361 
Eif2c3 1.805612 3.342115 24.21347 8.62E-07 0.000588 
Eif3f -1.17132 6.577129 11.11682 0.000855 0.010417 
Eif4ebp3 -1.2868 3.321373 12.26502 0.000462 0.007788 
Elfn2 1.263931 1.944207 10.59271 0.001135 0.012023 
Elk4 1.613643 2.421925 14.43186 0.000145 0.004708 
Ell3 -1.27029 0.621425 9.978791 0.001584 0.014369 
Eml6 1.205643 1.981921 10.32219 0.001314 0.012938 
Endog -1.23812 -0.02571 9.094785 0.002563 0.018734 
Eno3 -1.18568 3.169377 8.804551 0.003005 0.02052 
Epg5 1.102587 4.678974 16.7109 4.35E-05 0.003172 
Epha3 1.182253 6.493735 6.011059 0.014216 0.053386 
Eppk1 -1.10637 0.440119 4.024695 0.044839 0.116501 
Erbb4 2.705876 2.252102 26.40038 2.77E-07 0.000496 
Ern1 1.661821 3.475774 9.913466 0.001641 0.014633 
Esrp1 -4.3481 -0.94951 7.773064 0.005303 0.02864 
Exoc4 1.180107 6.3829 13.50081 0.000238 0.005968 
F730043M19Rik 1.51018 1.562642 12.35083 0.000441 0.007701 
Fabp3 -1.16962 1.966222 8.72442 0.00314 0.021074 
Fam135b 2.489531 -0.61144 19.92473 8.06E-06 0.001953 
Fam159a -1.62957 0.024012 11.76483 0.000604 0.00868 
Fam171b 1.4813 5.867235 7.879969 0.004999 0.027577 
Fam183b -1.20212 -0.21987 4.99846 0.02537 0.078828 
Fam217b 1.58671 0.661525 14.66283 0.000129 0.004552 
Fam57b -1.2082 5.753549 11.85277 0.000576 0.008438 
Fam92b -1.21151 -0.47659 5.143639 0.023332 0.074347 
Fat1 1.150387 7.75576 10.67784 0.001084 0.011734 
Fat3 1.358352 6.461513 17.40787 3.02E-05 0.00284 
Fau -1.17683 7.603006 12.17408 0.000485 0.007835 
Fbxl18 1.2412 3.735558 16.19535 5.71E-05 0.00347 
Fbxo48 1.589908 2.350058 8.23336 0.004113 0.0244 
222 
Fgd4 1.121176 4.09403 12.78222 0.00035 0.007112 
Fis1 -1.13259 5.323704 10.97909 0.000921 0.010884 
Fkbp11 -1.20783 0.170898 9.315606 0.002272 0.017522 
Fkbp2 -1.52625 3.93137 13.00386 0.000311 0.006716 
Fktn 1.652059 4.198069 11.64549 0.000644 0.008962 
Flrt1 1.423708 3.240581 15.23127 9.51E-05 0.004191 
Flywch2 -1.2646 2.845391 9.027757 0.002659 0.019113 
Fos 1.663942 -0.18269 11.63908 0.000646 0.008962 
Foxo3 1.576477 3.214509 10.6712 0.001088 0.011758 
Frmd7 -1.87996 0.164286 19.09159 1.25E-05 0.002311 
Frrs1l 1.358951 3.410007 17.39304 3.04E-05 0.00284 
Fry 1.129039 4.67241 25.39851 4.66E-07 0.000496 
Ftl1 -1.16516 9.687198 11.826 0.000584 0.008516 
Fxyd7 -1.48877 1.676048 8.254028 0.004066 0.024265 
G0s2 -1.29387 1.174337 10.27512 0.001348 0.013104 
Gabarap -1.10753 7.393981 10.28635 0.00134 0.01308 
Gabbr2 1.122174 1.606292 10.19619 0.001407 0.013469 
Gabrq 1.695123 0.729874 7.510021 0.006136 0.031221 
Gadd45g -1.15004 6.019118 17.6955 2.59E-05 0.002831 
Gan 2.081829 2.495791 18.32957 1.86E-05 0.00238 
Gar1 -1.15496 5.161983 13.76108 0.000208 0.005659 
Garem 1.392916 3.744325 12.28228 0.000457 0.007768 
Gatad2b 1.718537 4.535137 12.83202 0.000341 0.006995 
Gatsl2 1.186366 5.17935 18.57336 1.63E-05 0.00238 
Gdap10 1.869155 0.625074 6.026622 0.014092 0.053122 
Gfod1 1.216736 3.13254 16.07025 6.1E-05 0.003574 
Ggnbp1 -1.22645 1.939697 9.831265 0.001716 0.014997 
Ghrh -1.31996 -0.19504 5.915035 0.015012 0.055075 
Gk5 1.387933 0.727131 7.883772 0.004988 0.02753 
Glg1 1.811977 6.615133 13.63102 0.000222 0.005773 
Glis3 1.316205 1.510247 4.25271 0.039188 0.10617 
Glrx3 -1.27071 4.823459 12.0409 0.00052 0.008063 
Gm10406 -1.16878 3.75967 14.38754 0.000149 0.004782 
Gm11974 -1.14292 2.390353 14.86915 0.000115 0.004436 
Gm12060 -2.37978 -0.7179 7.098266 0.007716 0.036184 
Gm12070 -1.13468 3.858969 8.451994 0.003646 0.022927 
Gm12709 -1.20181 -0.58965 7.133074 0.007567 0.035743 
Gm13826 -1.58267 -0.48614 7.674701 0.0056 0.029607 
Gm14827 -1.24191 2.822259 10.59849 0.001132 0.012023 
Gm15421 -1.66808 1.439452 6.607449 0.010155 0.04288 
Gm16119 1.294645 0.381587 7.415498 0.006466 0.032285 
223 
Gm16386 1.763171 1.820124 14.92643 0.000112 0.00441 
Gm16576 1.267653 1.492862 9.761958 0.001782 0.015331 
Gm16617 1.236076 -0.42242 4.820024 0.028131 0.084771 
Gm16982 1.364941 -0.37423 7.139162 0.007542 0.035646 
Gm19557 1.429528 -0.59605 9.348784 0.002231 0.017412 
Gm19757 1.207851 0.235278 10.85736 0.000984 0.011248 
Gm2694 -1.23277 3.066031 8.071482 0.004497 0.025904 
Gm3414 1.285991 3.104024 15.74208 7.26E-05 0.003886 
Gm3500 -2.39987 0.662582 18.31771 1.87E-05 0.00238 
Gm5176 -1.51736 -0.20076 13.52917 0.000235 0.005924 
Gm5415 -3.72281 1.526026 19.8059 8.57E-06 0.001984 
Gm5506 -1.46309 3.04718 10.7559 0.001039 0.01152 
Gm5617 -1.38393 1.80405 10.9628 0.00093 0.010934 
Gm5796 -1.1111 2.172572 6.5872 0.010271 0.043225 
Gm6402 -1.6636 -0.19558 4.972315 0.025756 0.079542 
Gm9839 -3.23116 -0.2531 15.54144 8.07E-05 0.003984 
Gng8 -1.48347 0.681217 14.05705 0.000177 0.005128 
Gnmt -1.11027 -0.42261 5.227069 0.022238 0.072008 
Gp1bb -1.17673 2.496783 10.78249 0.001025 0.011448 
Gpam 1.425383 4.417006 10.79574 0.001017 0.011421 
Gpr161 1.872469 4.680483 12.03669 0.000522 0.008064 
Gpr165 1.254482 0.970513 4.448607 0.03493 0.097897 
Gpr26 1.593178 2.198451 19.12836 1.22E-05 0.002311 
Gpr63 1.240192 1.004311 6.773167 0.009254 0.040506 
Gprin2 1.972105 0.482702 16.15881 5.82E-05 0.00347 
Gps2 -1.12255 5.721627 17.08677 3.57E-05 0.003084 
Gramd1b 1.326243 2.85005 12.16464 0.000487 0.007835 
Grcc10 -1.17061 6.368554 16.89721 3.95E-05 0.003172 
Grid2 1.43718 -0.51294 9.433115 0.002131 0.016994 
H2-DMa -1.21982 1.349857 11.20067 0.000818 0.01018 
H2-Ke2 -1.12513 5.852906 13.40553 0.000251 0.0061 
H2-T24 1.483173 1.681903 6.757224 0.009337 0.040748 
Hcfc1 1.146818 8.578247 14.29874 0.000156 0.004874 
Hdac4 1.480865 3.730581 13.29332 0.000266 0.006279 
Hdx 1.813528 1.604231 11.6166 0.000654 0.008999 
Hectd2 1.325376 3.47498 8.292421 0.003981 0.023984 
Hecw1 1.109564 5.202361 26.27891 2.95E-07 0.000496 
Heg1 1.410635 5.168437 9.66639 0.001877 0.015734 
Helz 1.381706 4.602012 24.14401 8.94E-07 0.000588 
Herc1 1.210039 7.60909 22.47284 2.13E-06 0.000818 
Herc2 1.249837 7.148423 20.12297 7.26E-06 0.001863 
224 
Hes6 -1.13073 6.184411 13.40357 0.000251 0.0061 
Hhipl1 1.367953 1.866488 7.997865 0.004683 0.026469 
Hipk2 1.897061 5.428741 19.38681 1.07E-05 0.002305 
Hist1h2ag -1.11255 -0.52362 4.958179 0.025968 0.080016 
Hist1h2bj -1.15257 0.406593 6.758923 0.009328 0.040744 
Hist1h4b -1.54904 0.80467 14.15036 0.000169 0.005092 
Hist1h4h -1.30464 -0.6033 5.772031 0.016283 0.058182 
Hist2h2bb -1.69987 -0.79728 7.032898 0.008003 0.036902 
Hivep3 1.40581 1.237817 10.56199 0.001154 0.01211 
Hmbox1 1.791085 4.705443 15.47347 8.37E-05 0.004074 
Hspb1 -1.77301 -0.46615 12.03886 0.000521 0.008063 
Huwe1 1.113472 9.146273 14.67867 0.000127 0.004552 
Hyi -1.14709 1.913277 6.229442 0.012564 0.04939 
Igflr1 -1.12571 3.526278 9.553425 0.001996 0.016301 
Igsf6 1.405341 0.343773 11.91737 0.000556 0.008238 
Igsf9b 2.149806 2.203568 20.93637 4.75E-06 0.001458 
Il3ra -1.18774 0.459467 7.362416 0.00666 0.032919 
Imp3 -1.20643 4.447446 14.67705 0.000128 0.004552 
Ipw 1.379733 3.891881 18.30978 1.88E-05 0.00238 
Isg15 -1.2765 -0.22718 10.8049 0.001012 0.011402 
Itga6 1.236612 5.418824 6.586521 0.010275 0.043229 
Itgb8 1.906099 3.687262 8.126188 0.004363 0.025378 
Josd2 -1.19263 4.076653 16.19985 5.7E-05 0.00347 
Kat6a 1.172227 7.409175 17.6155 2.7E-05 0.002831 
Kcna1 1.161347 0.591073 7.574711 0.005919 0.030615 
Kcna3 2.458217 2.516219 10.69615 0.001074 0.01166 
Kcnb2 1.424241 1.116385 13.79405 0.000204 0.005601 
Kcnh5 1.479921 -0.03215 10.86082 0.000982 0.011248 
Kcnh7 1.436404 2.703022 12.05275 0.000517 0.008049 
Kcnj3 1.71057 0.00667 8.549311 0.003457 0.022239 
Kcnma1 1.273384 1.499007 15.89211 6.71E-05 0.003773 
Kcnn3 1.408146 2.389437 18.57564 1.63E-05 0.00238 
Kcnq3 1.999707 1.674859 28.87847 7.71E-08 0.000266 
Kidins220 1.207609 7.751495 23.07979 1.55E-06 0.000693 
Kif13b 1.637094 3.920098 13.74697 0.000209 0.005661 
Kif26b 1.30313 3.715713 13.64982 0.00022 0.005743 
Klf12 1.733765 5.306331 14.61418 0.000132 0.004552 
Klf7 1.832694 3.116543 17.63327 2.68E-05 0.002831 
Klhdc9 -1.39084 3.419942 12.51098 0.000405 0.007471 
Klhl11 2.068372 2.931601 13.62902 0.000223 0.005773 
Klhl28 1.482887 3.098623 6.712809 0.009572 0.041359 
225 
Klhl3 1.272765 1.009257 8.907264 0.00284 0.019887 
Krt1 -1.17372 0.738685 7.106629 0.00768 0.036064 
Krt8 -1.28466 0.132339 8.914609 0.002829 0.019848 
Ksr2 1.550044 1.548651 15.49602 8.27E-05 0.004052 
Lancl3 1.405629 0.864257 11.61883 0.000653 0.008999 
Lcat -1.24639 -0.11221 11.39449 0.000737 0.009705 
Lcor 2.510665 3.013175 16.82127 4.11E-05 0.003172 
Lgals4 -1.71009 -0.64516 8.388654 0.003776 0.023452 
Lgals7 -1.24983 -0.31403 6.48079 0.010905 0.044959 
Lmbrd2 2.120035 3.42089 12.52697 0.000401 0.007449 
Lmln 1.37385 3.580508 9.20623 0.002412 0.018138 
Lnpep 2.029171 3.823017 15.04471 0.000105 0.004361 
Lphn3 1.111953 4.87382 14.66399 0.000128 0.004552 
Lrch3 1.110127 5.712017 8.80024 0.003012 0.020538 
Lrp1b 1.643148 0.781819 10.56271 0.001154 0.01211 
Lrp2 1.119804 4.054476 12.76235 0.000354 0.007147 
Lrp6 1.125296 6.185103 13.73825 0.00021 0.005661 
Lrrc23 -1.33042 1.929652 10.96992 0.000926 0.010912 
Lrrc46 -1.29193 0.909635 11.25874 0.000792 0.01003 
Lrrc7 1.425171 3.099876 22.04919 2.66E-06 0.000966 
Lrrc8b 1.597778 3.813988 8.383021 0.003787 0.023503 
Lrrc9 1.380559 1.963974 17.3869 3.05E-05 0.00284 
Lsm3 -1.45032 5.237332 18.45975 1.74E-05 0.00238 
Lsm7 -1.28446 5.574476 18.3894 1.8E-05 0.00238 
Ly6g5b -1.17136 0.058314 7.685904 0.005565 0.02952 
Ly75 1.200611 0.316598 3.878385 0.048912 0.123872 
Lyst 1.733182 4.560856 14.55562 0.000136 0.00459 
Lzts1 1.338874 3.351188 12.48363 0.000411 0.007535 
Map1lc3a -1.14365 4.164551 9.476904 0.002081 0.016715 
Map3k13 1.357633 3.906818 16.724 4.32E-05 0.003172 
MARCH11 -1.21399 0.235336 6.217533 0.012649 0.04955 
Masp1 1.267381 5.061064 10.80526 0.001012 0.011402 
Mdk -1.26986 7.958931 17.43973 2.97E-05 0.00284 
Mdm4 1.457911 6.282018 10.46495 0.001217 0.012482 
Mdn1 1.269315 6.517645 18.32571 1.86E-05 0.00238 
Med12l 1.429714 4.481823 12.8912 0.00033 0.006902 
Med13l 1.104999 6.188017 14.60045 0.000133 0.004552 
Mef2a 1.377023 4.115216 9.414019 0.002153 0.017113 
Megf9 1.677178 4.943735 9.915367 0.001639 0.014633 
Meig1 -1.30773 -0.89289 5.759572 0.016399 0.058407 
Mgat5 2.054247 3.691716 18.02829 2.18E-05 0.002643 
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Mia -1.32962 -0.29919 9.314613 0.002273 0.017522 
Mib1 1.777975 5.186639 12.14978 0.000491 0.007871 
Minos1 -1.12376 6.16726 16.91842 3.9E-05 0.003172 
Mir1191 1.160674 0.401392 6.707094 0.009603 0.041395 
Mir124a-2 1.810541 0.653584 16.22673 5.62E-05 0.00347 
Mir16-1 1.589412 -0.50152 7.544 0.006021 0.03091 
Mir186 1.501772 0.275197 5.052274 0.024594 0.077055 
Mir25 -1.16552 0.341529 10.77183 0.001031 0.011489 
Mir703 -1.29146 3.982785 5.119814 0.023654 0.074891 
Mirg -1.27367 4.598748 11.77483 0.0006 0.008643 
Mnf1 -1.15677 5.648107 9.370417 0.002205 0.017316 
Mob1a 1.143443 4.440417 5.436584 0.019719 0.066126 
Mob1b 1.234803 4.089354 9.651758 0.001892 0.015787 
Mospd2 1.204634 3.370512 5.672952 0.017228 0.060339 
Moxd1 -1.15541 0.10669 5.93748 0.014822 0.054727 
Mpv17l2 -1.17976 3.004434 10.43847 0.001234 0.012569 
Mrpl14 -1.12729 4.283761 14.43806 0.000145 0.004708 
Mrpl23 -1.30622 4.960087 17.01869 3.7E-05 0.003133 
Mrpl33 -1.23066 5.237939 17.33078 3.14E-05 0.00284 
Mrpl52 -1.12458 5.180932 14.85022 0.000116 0.004444 
Mrpl54 -1.16661 4.276868 11.15581 0.000838 0.010304 
Mrps16 -1.27127 3.831537 13.16157 0.000286 0.006483 
Mrs2 1.602955 4.029131 14.74355 0.000123 0.004535 
Mt1 -1.10082 3.118867 13.12349 0.000292 0.006564 
Mt2 -1.20842 3.235242 11.79038 0.000595 0.008625 
Mt3 -1.30652 6.070244 12.65641 0.000374 0.007217 
Myeov2 -1.32004 5.220457 15.57294 7.94E-05 0.003946 
Myl6 -1.1173 6.575545 14.76288 0.000122 0.004535 
Mylpf -1.2575 0.588535 9.379017 0.002195 0.017284 
Myo16 1.149898 3.305477 14.66174 0.000129 0.004552 
Myt1l 1.188984 5.511371 18.38108 1.81E-05 0.00238 
N4bp2 1.935574 5.923515 11.60554 0.000658 0.009024 
Naa25 1.298703 5.367776 13.37736 0.000255 0.006165 
Nalcn 1.150572 3.716196 18.62974 1.59E-05 0.00238 
Nanos3 -1.14956 1.028507 5.228279 0.022223 0.071991 
Nat9 -1.1698 2.664176 8.964674 0.002752 0.019418 
Nav3 1.818862 3.822291 15.50997 8.21E-05 0.004036 
Nbea 1.264953 6.989596 24.89171 6.06E-07 0.000499 
Nbeal1 1.681763 3.488032 11.13636 0.000847 0.010352 
Ncam2 1.535911 2.349431 25.58544 4.23E-07 0.000496 
Ndst1 1.28626 6.756393 10.8862 0.000969 0.011176 
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Ndufa13 -1.39598 5.850663 20.07195 7.46E-06 0.001863 
Ndufa2 -1.22491 5.099771 14.5267 0.000138 0.004614 
Ndufa5 -1.22103 4.632714 16.33208 5.32E-05 0.003449 
Ndufa8 -1.18995 5.782637 17.9921 2.22E-05 0.002643 
Nedd8 -1.38103 6.400413 20.9828 4.63E-06 0.001456 
Nenf -1.17021 2.698738 9.030647 0.002655 0.01911 
Nfix 1.41006 4.437181 13.33916 0.00026 0.006225 
Nhlrc2 1.192563 4.618805 14.53468 0.000138 0.004614 
Nhlrc3 1.296349 3.060894 6.144446 0.013183 0.050937 
Nhs 1.529382 2.876867 9.433699 0.00213 0.016994 
Nkain3 1.314596 0.916492 12.3246 0.000447 0.007713 
Nlrp1a -2.33663 1.89007 14.58102 0.000134 0.004552 
Nmb -1.2349 1.659926 10.16327 0.001433 0.013603 
Nos1 2.545938 -0.30619 18.8559 1.41E-05 0.00238 
Nos1ap 1.115253 2.80339 9.404801 0.002164 0.017157 
Npff -2.05923 1.465159 12.47687 0.000412 0.007552 
Npm2 -1.27953 0.666283 7.384298 0.00658 0.032638 
Npnt 1.191027 2.772113 6.400848 0.011407 0.046378 
Npy -1.64504 1.640132 15.10359 0.000102 0.004341 
Nr2c2 1.84137 5.721044 15.36262 8.87E-05 0.004106 
Nr2c2ap -1.55044 1.645056 12.91802 0.000325 0.006866 
Nr3c2 1.223806 -0.6245 4.839496 0.027815 0.084041 
Nrip1 1.77807 3.327623 9.276231 0.002321 0.017745 
Nrp -1.72905 2.624318 4.31719 0.037729 0.103559 
Nrsn2 -1.15711 3.220179 8.674816 0.003226 0.021344 
Nup98 1.439777 5.364788 14.91118 0.000113 0.00441 
Nwd1 1.823648 2.044129 17.71194 2.57E-05 0.002831 
Nyap2 1.888723 0.234556 11.19436 0.00082 0.010186 
Olfr856-ps1 -1.16534 4.309481 5.184375 0.022791 0.073232 
Onecut1 1.836227 -0.14937 6.041871 0.01397 0.052795 
Pcbd2 -1.3497 1.553811 12.86509 0.000335 0.006926 
Pcdh11x 1.836253 2.051288 29.19523 6.54E-08 0.000266 
Pcdh9 1.296309 4.233492 12.44493 0.000419 0.00757 
Pcdha12 1.603198 0.064415 8.399088 0.003754 0.02336 
Pcdha2 1.670318 -0.43926 16.67523 4.44E-05 0.003186 
Pcdha3 1.196008 0.129927 8.898984 0.002853 0.019935 
Pcdha5 1.294614 -0.53924 10.24143 0.001373 0.013259 
Pcdha6 1.752185 -0.49797 8.593534 0.003374 0.021951 
Pcdha7 1.560573 -0.00012 6.983533 0.008226 0.037521 
Pcdha9 1.647339 -0.07637 10.99622 0.000913 0.010829 
Pcdhac1 1.272348 0.500408 5.956007 0.014667 0.054285 
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Pcdhac2 1.861691 2.591087 10.08942 0.001491 0.013878 
Pcdhb2 1.721621 -0.41813 7.923551 0.00488 0.027142 
Pcdhga1 1.681244 1.09205 12.07633 0.000511 0.008049 
Pcdhga10 1.130685 2.428365 7.284323 0.006956 0.033825 
Pcdhga11 1.399907 3.897024 11.54665 0.000679 0.009205 
Pcdhga12 1.19932 3.137803 13.16846 0.000285 0.006482 
Pcdhga2 1.423584 2.010739 9.772981 0.001771 0.015287 
Pcdhga3 1.301439 2.760975 10.29638 0.001333 0.013037 
Pcdhga4 1.353822 3.115732 12.96187 0.000318 0.00679 
Pcdhga5 1.111251 2.214229 7.868254 0.005031 0.027668 
Pcdhga6 1.276124 1.936222 8.004593 0.004666 0.026461 
Pcdhga7 1.361761 2.591387 9.941427 0.001616 0.014534 
Pcdhga8 1.444029 1.808635 11.33444 0.000761 0.009864 
Pcdhga9 1.326916 2.032254 8.460653 0.003629 0.02286 
Pcdhgb1 1.683327 1.569055 12.11114 0.000501 0.007971 
Pcdhgb2 1.145134 2.258245 14.23057 0.000162 0.004951 
Pcdhgb4 1.314889 1.677036 9.000419 0.002699 0.019266 
Pcdhgb5 1.291509 2.075513 8.259044 0.004055 0.024228 
Pcdhgb6 1.371498 3.687627 8.909803 0.002836 0.019878 
Pcdhgc3 1.319643 6.21387 11.98807 0.000535 0.008188 
Pcdhgc4 1.19926 2.712505 9.907059 0.001646 0.014671 
Pcsk1n -1.26798 3.44369 10.88802 0.000968 0.011175 
Pdap1 -1.29663 7.352556 15.4722 8.37E-05 0.004074 
Pdcd5 -1.10796 5.554279 16.66555 4.46E-05 0.003186 
Pde3a 1.183225 0.767918 5.066656 0.02439 0.076591 
Pdpr 2.01147 3.833233 9.365477 0.002211 0.017333 
Pds5a 1.199183 6.565692 8.685871 0.003207 0.021269 
Peg3 1.3963 7.10989 8.695665 0.00319 0.021248 
Perp -1.60746 0.034744 13.7537 0.000208 0.005661 
Pet100 -1.30681 3.179673 11.37838 0.000743 0.00975 
Phf16 1.170001 3.510929 6.610355 0.010139 0.042836 
Plag1 1.310721 3.443369 5.655541 0.0174 0.060618 
Plcxd3 2.481108 1.543862 19.18477 1.19E-05 0.002311 
Plxna2 1.232451 7.909549 15.15176 9.92E-05 0.004289 
Plxna4 1.275236 6.116857 19.79704 8.61E-06 0.001984 
Polr2l -1.21193 4.744317 14.62774 0.000131 0.004552 
Pomc -1.56513 2.407797 10.52445 0.001178 0.012223 
Pop5 -1.49903 3.865034 17.2227 3.32E-05 0.002942 
Pou3f4 1.304893 3.923369 9.024847 0.002663 0.019113 
Ppm1l 1.634264 4.839566 20.59684 5.67E-06 0.001599 
Ppp1r12a 1.169785 5.318492 10.1872 0.001414 0.013494 
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Ppp1r12b 1.833575 3.832999 19.75625 8.8E-06 0.001993 
Prdm10 1.496236 4.294735 9.317701 0.00227 0.017522 
Prdm11 1.236128 1.511784 11.02056 0.000901 0.010707 
Prdx5 -1.41131 5.199049 19.28169 1.13E-05 0.002311 
Prg4 -1.33647 -0.24477 11.32707 0.000764 0.009866 
Prox1 1.230552 4.088017 22.86384 1.74E-06 0.000707 
Prr19 -1.15801 -0.4213 7.349738 0.006707 0.032987 
Prr22 -1.52885 0.438722 11.02892 0.000897 0.010696 
Prrc2c 1.238801 7.974996 14.74945 0.000123 0.004535 
Psmb3 -1.13011 7.147476 15.13756 1E-04 0.00429 
Psmg3 -1.28337 3.367266 14.06657 0.000176 0.005127 
Psmg4 -1.17771 5.038896 11.92411 0.000554 0.008234 
Ptar1 2.236005 2.783682 23.09303 1.54E-06 0.000693 
Ptch1 1.398424 5.458806 8.582893 0.003393 0.021989 
Ptp4a1 -1.47924 4.008398 20.6714 5.45E-06 0.00157 
Ptpn4 1.940394 3.850047 12.30597 0.000452 0.007742 
Ptprt 1.946253 1.625616 17.61719 2.7E-05 0.002831 
Pygo1 1.343313 4.079279 16.87181 4E-05 0.003172 
Rab11fip4 1.333375 5.007179 14.14346 0.000169 0.0051 
Rab24 -1.12156 5.247995 15.57564 7.93E-05 0.003946 
Ralgps1 1.779761 4.691633 18.10476 2.09E-05 0.00258 
Ramp3 -1.16876 -0.36197 7.615208 0.005788 0.030264 
Rangrf -1.21548 3.899681 17.37882 3.06E-05 0.00284 
Rapgef5 1.233415 3.958123 12.45843 0.000416 0.007567 
Rassf8 1.249635 1.660934 6.094884 0.013557 0.051815 
Rcor1 1.353459 4.634013 8.827985 0.002966 0.02038 
Reln 1.472696 6.718251 26.09471 3.25E-07 0.000496 
Rest 1.302787 4.149753 6.279117 0.012217 0.048475 
Rims1 1.369012 2.168199 13.87568 0.000195 0.005442 
Rims3 1.259465 2.343427 12.88444 0.000331 0.006907 
Rnaseh2c -1.11268 4.856157 16.82026 4.11E-05 0.003172 
Rnf223 -1.13358 1.865779 10.75678 0.001039 0.01152 
Romo1 -1.24031 5.585554 13.68349 0.000216 0.005688 
Rpl12 -1.16425 8.960003 15.65513 7.6E-05 0.00394 
Rpl13 -1.22318 8.425992 10.69211 0.001076 0.011671 
Rpl13a -1.10852 9.489128 11.73664 0.000613 0.00874 
Rpl18 -1.11307 8.808979 14.32809 0.000154 0.004838 
Rpl18a -1.40194 8.489068 12.03981 0.000521 0.008063 
Rpl21 -1.3758 9.012828 17.78312 2.48E-05 0.002804 
Rpl23 -1.14278 9.300492 16.26594 5.5E-05 0.00347 
Rpl28 -1.27541 8.947792 10.45932 0.00122 0.012484 
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Rpl29 -1.19517 8.863916 14.34367 0.000152 0.004838 
Rpl31 -1.14649 10.41732 12.90201 0.000328 0.006894 
Rpl31-ps12 -1.65946 1.324112 7.892775 0.004963 0.027459 
Rpl35 -1.17815 8.012264 7.613779 0.005792 0.030276 
Rpl35a -1.12775 8.411085 14.61547 0.000132 0.004552 
Rpl36 -1.4548 7.984897 15.23834 9.48E-05 0.004191 
Rpl36al -1.41427 6.314296 18.57054 1.64E-05 0.00238 
Rpl37 -1.22312 8.883172 15.81665 6.98E-05 0.003812 
Rpl37a -1.47984 8.327329 16.015 6.28E-05 0.003649 
Rpl38 -1.25676 8.029534 15.4348 8.54E-05 0.004084 
Rpl39 -1.11548 8.329423 12.17192 0.000485 0.007835 
Rpl41 -1.52298 8.705834 13.06982 0.0003 0.006573 
Rpl8 -1.10724 8.343902 12.05333 0.000517 0.008049 
Rplp1 -1.20102 8.963204 14.60781 0.000132 0.004552 
Rplp2 -1.72984 7.901284 20.04857 7.55E-06 0.001863 
Rpp21 -1.14411 3.920895 9.705886 0.001837 0.015573 
Rpph1 -1.46847 0.701161 6.207379 0.012722 0.049711 
Rps12 -1.48421 8.658737 16.49169 4.89E-05 0.003301 
Rps14 -1.49352 9.759923 20.88558 4.88E-06 0.001465 
Rps15 -1.53287 8.341066 12.10286 0.000503 0.007994 
Rps15a-ps6 -1.13712 1.56967 5.403884 0.020092 0.066941 
Rps16 -1.10038 8.644803 13.24092 0.000274 0.006351 
Rps18 -1.11812 9.522147 13.44025 0.000246 0.006078 
Rps19 -1.44562 9.129901 14.23121 0.000162 0.004951 
Rps19-ps3 -1.70455 1.290623 9.844551 0.001703 0.014946 
Rps20 -1.15051 8.633077 13.10565 0.000294 0.006567 
Rps21 -1.30495 8.116402 17.40582 3.02E-05 0.00284 
Rps24 -1.17232 8.729518 13.92305 0.00019 0.005382 
Rps28 -1.50523 8.96497 15.14991 9.93E-05 0.004289 
Rps4y2 -1.19564 5.206366 16.84993 4.05E-05 0.003172 
Rps5 -1.27681 8.665955 14.85836 0.000116 0.004444 
Rps8 -1.16038 9.242084 14.53974 0.000137 0.004614 
Rps9 -1.12392 9.209017 12.59489 0.000387 0.007343 
Rsbn1 1.298926 4.757458 8.499733 0.003552 0.022569 
Rsg1 1.3923 1.144316 8.618606 0.003327 0.021783 
Rsph1 -1.13585 0.341127 5.644446 0.017511 0.060848 
S100a1 -1.11718 0.174764 8.177599 0.004241 0.024909 
S100a10 -1.30315 4.126349 13.72466 0.000212 0.005665 
S100a16 -1.15039 2.472981 14.07409 0.000176 0.005127 
S100a6 -1.29306 0.578899 9.998013 0.001567 0.014267 
S100pbp 1.155094 3.933805 6.353302 0.011716 0.047226 
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Sacs 3.013629 1.850426 27.43793 1.62E-07 0.000448 
Samd5 1.418856 1.950325 9.269057 0.002331 0.017756 
Scarb2 1.139259 5.31506 9.913503 0.001641 0.014633 
Sctr -1.2676 -0.33816 5.663828 0.017318 0.0605 
Scube2 1.177667 0.038291 7.155522 0.007473 0.035443 
Sdk2 1.554259 3.110314 12.04629 0.000519 0.008058 
Selm -1.23989 2.969057 11.29611 0.000777 0.009957 
Sema3e 1.133561 1.498317 14.95044 0.00011 0.00441 
Sepsecs 1.166678 2.627471 8.979469 0.00273 0.01933 
Sept1 -1.32343 2.463707 11.41453 0.000729 0.009655 
Sepw1 -1.28939 7.735396 11.79924 0.000593 0.008593 
Serf2 -1.20293 7.788494 16.74968 4.26E-05 0.003172 
Serp2 -1.28989 3.758316 13.85014 0.000198 0.005483 
Sertad1 -1.11955 1.546584 12.57746 0.00039 0.007384 
Sesn3 1.397673 4.337472 18.46782 1.73E-05 0.00238 
Sfn -1.87924 -0.08908 14.20537 0.000164 0.004978 
Sh2d7 -1.30147 0.079088 7.575296 0.005917 0.030615 
Sh3bgrl3 -1.22236 5.512054 12.03033 0.000523 0.008081 
Shank2 1.14513 4.520646 12.83038 0.000341 0.006995 
Shc3 1.451855 2.647133 12.33736 0.000444 0.007704 
Shfm1 -1.24813 7.093693 18.76589 1.48E-05 0.00238 
Shroom4 1.506759 2.459186 5.15301 0.023206 0.074118 
Siah3 1.581912 3.368374 12.96256 0.000318 0.00679 
Sik2 1.766665 3.840019 13.7323 0.000211 0.005661 
Six2 -2.17558 1.722135 8.024594 0.004615 0.026273 
Slc16a14 1.657316 2.718963 17.58744 2.74E-05 0.002832 
Slc26a2 1.558917 2.15725 8.652935 0.003265 0.02154 
Slc30a3 -1.40172 -0.03052 9.218894 0.002395 0.018079 
Slc36a4 1.642954 3.91521 10.26309 0.001357 0.01316 
Slc39a5 -2.76336 0.690177 17.54822 2.8E-05 0.00284 
Slc44a1 1.141832 3.380938 6.117588 0.013384 0.051467 
Slc7a10 -1.39212 1.836285 8.233632 0.004112 0.0244 
Slc9a7 1.842957 0.356801 12.8451 0.000338 0.006969 
Slfn9 1.201542 3.917959 8.08294 0.004468 0.025799 
Slit1 1.152341 5.572597 18.58417 1.63E-05 0.00238 
Smim11 -1.21889 5.312722 14.40717 0.000147 0.004746 
Smim4 -1.14779 3.500216 12.56267 0.000394 0.007389 
Snapc5 -1.347 4.484627 15.89233 6.7E-05 0.003773 
Snhg8 -1.17717 4.448497 13.5245 0.000235 0.005927 
Snora28 1.144035 0.535526 7.856469 0.005064 0.027804 
Snora31 -1.17035 0.131996 10.45508 0.001223 0.012484 
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Snora68 -1.46519 -0.77671 6.256943 0.012371 0.048917 
Snord104 -1.47156 3.18886 14.93607 0.000111 0.00441 
Snord2 1.191475 0.308479 4.154328 0.041528 0.110413 
Snord64 1.966932 0.685151 6.969355 0.008292 0.037782 
Snord99 -1.5133 0.037224 12.30708 0.000451 0.007742 
Snrpd2 -1.19237 6.736997 16.19071 5.73E-05 0.00347 
Snrpg -1.22597 6.767004 17.58327 2.75E-05 0.002832 
Sntb2 1.221416 2.867029 10.35598 0.001291 0.012799 
Snx22 -1.6808 3.690697 11.17324 0.00083 0.01024 
Snx29 1.38522 3.106858 15.70425 7.41E-05 0.003892 
Socs4 1.19008 3.584108 6.572915 0.010354 0.043463 
Sod1 -1.13495 6.685787 15.26107 9.36E-05 0.004174 
Sorl1 2.061359 5.063529 17.09926 3.55E-05 0.003084 
Spa17 -1.36817 2.477321 8.02539 0.004613 0.026273 
Sphkap 1.417268 2.710074 8.518618 0.003515 0.022426 
Spred2 1.253892 5.286657 7.582688 0.005893 0.030572 
Sprtn 1.215571 3.559658 6.221961 0.012618 0.049478 
Ssh1 1.293482 3.602075 14.06134 0.000177 0.005127 
St6gal2 1.966639 2.561494 10.20259 0.001402 0.01345 
Stac3 -1.1648 1.63911 12.0558 0.000516 0.008049 
Stard10 -1.27453 2.487239 10.71086 0.001065 0.011647 
Stmn1 -1.17549 9.338249 12.46181 0.000415 0.007564 
Stra13 -1.14783 4.902291 16.85987 4.02E-05 0.003172 
Strn 1.45796 3.829379 9.404024 0.002165 0.017157 
Stx1b 1.162585 3.208823 9.686431 0.001856 0.015632 
Supt4a -1.1595 5.640387 12.40202 0.000429 0.007628 
Syne2 1.180858 8.085965 18.69783 1.53E-05 0.00238 
Syt14 1.94391 2.670329 11.69779 0.000626 0.008824 
Sytl5 1.854586 0.711377 14.62691 0.000131 0.004552 
Taf10 -1.14029 5.157479 9.448082 0.002114 0.016905 
Tbck 1.394137 3.094197 10.71301 0.001064 0.011647 
Tbl1x 1.164124 5.694238 8.606471 0.00335 0.021867 
Tceal3 -1.13768 3.715123 12.26833 0.000461 0.007788 
Tceb2 -1.3187 7.410333 16.87432 3.99E-05 0.003172 
Tekt4 -1.30354 -0.9023 7.153693 0.007481 0.035467 
Tenm1 2.487991 1.818748 15.97473 6.42E-05 0.003696 
Tenm3 1.1427 6.823606 13.84647 0.000198 0.005483 
Tenm4 2.044544 6.938024 15.80475 7.02E-05 0.003821 
Tfap2a -1.24103 0.794686 8.343258 0.003871 0.023729 
Thpo -1.36866 -0.44443 7.202757 0.007279 0.034918 
Timm13 -1.37156 5.714693 14.89606 0.000114 0.00441 
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Timm8b -1.11772 6.188553 14.28689 0.000157 0.004874 
Tle6 -1.13262 0.048383 8.352983 0.003851 0.023702 
Tmem132d 1.321475 -0.12146 7.595236 0.005852 0.03044 
Tmem178b 2.322611 3.252894 9.622811 0.001922 0.01597 
Tmem179b -1.10867 3.815001 17.32871 3.14E-05 0.00284 
Tmem191c -1.17152 2.701899 10.9359 0.000943 0.011 
Tmem196 1.101025 -0.62559 5.003095 0.025302 0.07872 
Tmem245 1.588336 3.993604 15.91148 6.64E-05 0.003773 
Tmem256 -1.19997 5.208917 12.81675 0.000344 0.007033 
Tmem42 -1.13249 2.301867 8.497191 0.003557 0.022589 
Tmem53 -1.11112 1.183673 11.74817 0.000609 0.008729 
Tmem74 1.356384 1.247409 9.160885 0.002472 0.018333 
Tmem88 -1.23922 2.019339 12.07467 0.000511 0.008049 
Tnfrsf18 1.414745 0.948684 9.76505 0.001779 0.015324 
Tnfrsf4 -1.19469 0.473686 7.97639 0.004739 0.02662 
Tnks 1.836309 6.414188 12.23063 0.00047 0.007835 
Tnni3 -1.6977 0.375094 8.12236 0.004372 0.02541 
Tnpo1 1.412169 7.389997 13.34428 0.000259 0.006219 
Tnr 2.748304 1.265542 26.33612 2.87E-07 0.000496 
Tomm6 -1.23804 5.663237 16.04381 6.19E-05 0.003609 
Tomm7 -1.1919 6.913723 12.41898 0.000425 0.007608 
Tppp3 -1.19855 2.945247 9.557881 0.001991 0.01629 
Trappc6a -1.26225 3.021136 12.98892 0.000313 0.006745 
Trim43c 1.38657 -0.73269 9.736001 0.001807 0.015453 
Trim56 1.520683 2.201869 9.814558 0.001731 0.015064 
Trip11 1.693491 4.056964 13.99529 0.000183 0.005255 
Tssc4 -1.13219 5.038514 19.11746 1.23E-05 0.002311 
Tstd1 -1.47665 1.037365 10.84209 0.000992 0.011276 
Ttbk2 1.124858 6.34403 22.95537 1.66E-06 0.000707 
Ttc28 1.263798 6.940998 18.44953 1.74E-05 0.00238 
Ttc37 1.296672 4.435353 10.71405 0.001063 0.011647 
Ttc9b -1.14466 3.21161 6.798684 0.009123 0.0402 
Ttll4 1.378866 5.786668 11.20735 0.000815 0.010153 
Twist1 -1.74519 1.893949 7.960734 0.00478 0.02679 
Uba52 -1.1065 9.980958 11.51187 0.000692 0.009316 
Ubald2 -2.24485 1.190599 11.97488 0.000539 0.008204 
Ubr4 1.146124 7.635513 20.15271 7.15E-06 0.001863 
Ubxn1 -1.10044 5.763993 14.80264 0.000119 0.004475 
Uhmk1 1.698495 3.152363 9.769525 0.001774 0.015306 
Unc13c 1.24532 1.009152 13.46151 0.000244 0.00602 
Upf3a -1.14064 4.551259 15.28056 9.27E-05 0.004158 
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Upk1a -1.11722 -0.10755 5.916471 0.015 0.055045 
Uprt 1.750611 1.533759 6.494647 0.01082 0.044719 
Use1 -1.1527 5.232062 9.723279 0.001819 0.015491 
Usp34 1.325834 6.677439 12.7098 0.000364 0.007212 
Usp53 1.310515 2.403172 9.351775 0.002228 0.017394 
Utp14b 1.259525 2.328579 9.702893 0.00184 0.015589 
Vamp5 -1.12459 0.118988 7.030339 0.008014 0.036936 
Vamp8 -1.29423 2.049835 14.69151 0.000127 0.004552 
Vgll2 -1.43573 -0.14709 4.260491 0.039009 0.105893 
Vkorc1 -1.38034 3.427133 18.45419 1.74E-05 0.00238 
Vps13a 1.164539 4.479069 18.60366 1.61E-05 0.00238 
Vps13b 1.141857 5.362688 17.61829 2.7E-05 0.002831 
Vps13c 1.801612 4.657138 15.64318 7.65E-05 0.00394 
Vps13d 1.267797 5.645336 23.48283 1.26E-06 0.000645 
Wasf3 1.101944 3.481533 6.475384 0.010938 0.045056 
Wdfy2 1.796163 3.62964 12.45252 0.000417 0.00757 
Wdfy3 1.148897 7.611394 18.90747 1.37E-05 0.00238 
Wdr52 1.111759 2.630508 7.923222 0.00488 0.027142 
Wnk3 1.111342 5.53259 15.83964 6.89E-05 0.003803 
Xkr4 2.2932 1.707996 18.30979 1.88E-05 0.00238 
Xkr7 1.790512 2.869899 11.71202 0.000621 0.008802 
Xpnpep3 1.269781 3.115469 7.898549 0.004947 0.027404 
Xpo4 1.815103 4.196897 16.16405 5.81E-05 0.00347 
Xrn1 2.034946 4.756355 14.8396 0.000117 0.004444 
Xylt1 1.85225 3.456239 12.5195 0.000403 0.007451 
Yod1 1.196445 2.540133 7.382707 0.006585 0.032644 
Zbed6 2.111239 5.57454 8.70167 0.003179 0.021236 
Zbtb20 1.632369 2.069767 20.78255 5.14E-06 0.001513 
Zbtb37 1.859659 2.921653 25.90464 3.59E-07 0.000496 
Zbtb38 1.663504 2.227117 17.03431 3.67E-05 0.003132 
Zc3h12b 1.629038 1.162345 11.19391 0.000821 0.010186 
Zc3h12c 1.172969 4.963085 11.90486 0.00056 0.008259 
Zfand2b -1.14756 4.102624 11.04846 0.000888 0.010634 
Zfp109 1.330035 2.228677 6.676152 0.009771 0.041887 
Zfp169 1.340342 2.981307 13.42686 0.000248 0.006089 
Zfp296 -1.41611 -0.29979 9.777212 0.001767 0.015261 
Zfp369 2.256045 3.049385 17.79116 2.47E-05 0.002804 
Zfp382 1.370267 2.750015 13.20407 0.000279 0.006423 
Zfp398 1.176324 3.297424 14.88692 0.000114 0.00441 
Zfp428 -1.23791 5.036374 14.07116 0.000176 0.005127 
Zfp442 1.576232 1.675122 7.987409 0.00471 0.026569 
235 
Zfp458 1.108168 1.212729 10.28811 0.001339 0.013077 
Zfp536 2.070484 4.284665 28.89152 7.65E-08 0.000266 
Zfp551 1.389092 1.711071 8.129135 0.004356 0.025371 
Zfp579 -1.27126 5.437566 14.08308 0.000175 0.005127 
Zfp580 -1.12729 3.95784 8.658926 0.003255 0.02149 
Zfp618 1.82913 4.676228 14.07745 0.000175 0.005127 
Zfp619 1.103324 3.17769 13.36059 0.000257 0.006209 
Zfp81 1.218513 3.929203 10.07896 0.0015 0.013913 
Zfpm2 1.133419 3.120055 12.55284 0.000396 0.007408 
Zglp1 -1.21891 1.13933 8.280878 0.004006 0.024095 
Zkscan16 1.319344 1.175036 4.523565 0.033431 0.095301 
Zkscan2 1.231335 4.460519 14.68828 0.000127 0.004552 




Appendix Table 2: PA2 deregulated genes 
Gene ID logFC logCPM LR PValue FDR 
2410137F16Rik 1.375975 1.125381 5.839117 0.015674 0.92136 
3110021A11Rik 1.472895 -0.36248 11.36839 0.000747 0.397084 
4930455C13Rik 1.289068 -0.73006 5.586199 0.018103 0.92136 
AI606473 -1.48794 2.387366 16.79578 4.16E-05 0.063919 
Alx1 -2.80159 0.446978 9.800454 0.001745 0.560735 
C130021I20Rik -1.51719 0.788954 8.720906 0.003146 0.663921 
Cdh3 -1.11624 0.357543 4.100674 0.042866 0.92136 
Chrna7 1.176552 1.546752 5.831131 0.015745 0.92136 
Cntnap5a 1.297273 -0.86058 5.694204 0.017021 0.92136 
Cntnap5b 1.56071 0.237802 6.289386 0.012146 0.92136 
Col8a1 -2.12645 -0.49369 4.060336 0.043902 0.92136 
Csf2rb2 -1.49059 -1.03465 6.029445 0.014069 0.92136 
Dbx1 1.199766 4.125421 24.32489 8.14E-07 0.00592 
Dct -1.28738 2.20927 12.00753 0.00053 0.318377 
Ebf1 1.154484 3.546801 22.50073 2.1E-06 0.009677 
Egr3 1.514941 0.059908 9.622646 0.001922 0.565128 
Erbb4 1.439934 2.252102 8.114557 0.004391 0.766187 
Fam135b 1.354867 -0.61144 6.179474 0.012924 0.92136 
Fam217b 1.130457 0.661525 7.569203 0.005937 0.811513 
Frmd7 -1.16082 0.164286 7.620011 0.005772 0.811513 
Gabbr2 1.135102 1.606292 10.43529 0.001236 0.471115 
Gjb2 -1.8318 0.387615 5.514841 0.018856 0.92136 
Gpr161 1.157476 4.680483 4.781493 0.028767 0.92136 
Gpr26 1.166205 2.198451 10.44708 0.001228 0.471115 
Gprin2 1.298518 0.482702 7.220252 0.007209 0.877049 
Hbb-bh1 -1.32465 7.118271 6.655916 0.009883 0.92136 
Hemgn -1.96168 1.543236 4.420255 0.035515 0.92136 
Hist1h1a 2.167643 -1.05249 13.50862 0.000237 0.234417 
Hist1h1b 2.602779 -0.72899 17.70724 2.58E-05 0.057077 
Hist1h1d 1.302365 -0.24869 8.096436 0.004435 0.766187 
Hist1h1e 1.818167 0.373351 12.43931 0.00042 0.284351 
Hist1h2af 1.508723 2.346636 6.530975 0.010601 0.92136 
Hist1h2bg 1.314979 -0.15295 9.178374 0.002449 0.573627 
Hist1h2bn 1.740887 -0.99176 7.136678 0.007552 0.884514 
Hist1h4a 1.377632 -1.1202 6.405658 0.011376 0.92136 
Hist1h4f 2.380765 -0.96538 15.96788 6.44E-05 0.089037 
Hist1h4h 1.186827 -0.6033 5.04129 0.02475 0.92136 
Hist1h4k 1.621516 0.05712 10.60877 0.001126 0.471115 
Hist2h2bb 2.553215 -0.79728 17.1239 0.000035 0.060495 
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Hist2h4 2.751735 -0.72786 13.37484 0.000255 0.234961 
Irx5 -1.1692 0.253105 4.10825 0.042674 0.92136 
Kcna3 1.54769 2.516219 4.503321 0.033829 0.92136 
Kcnq3 1.170605 1.674859 10.28775 0.001339 0.474545 
Lars2 2.533208 8.854135 21.01736 4.55E-06 0.015725 
Meig1 -1.1549 -0.89289 4.523722 0.033428 0.92136 
Msx2 -1.26761 1.357208 10.37367 0.001278 0.471115 
Nos1 1.67979 -0.30619 8.585586 0.003388 0.682594 
Pcdha12 1.10128 0.064415 4.043772 0.044335 0.92136 
Pcdha2 1.144361 -0.43926 7.910157 0.004916 0.799251 
Pcdhga1 1.206927 1.09205 6.360461 0.011669 0.92136 
Pcdhgb1 1.197129 1.569055 6.268258 0.012292 0.92136 
Perp -1.32018 0.034744 9.456184 0.002104 0.573339 
Pitx2 -4.7446 0.631186 9.687094 0.001856 0.563992 
Plcxd3 1.330921 1.543862 5.912378 0.015035 0.92136 
Ralgps1 1.107682 4.691633 7.261628 0.007044 0.877049 
Raver1-fdx1l 1.260868 3.162548 9.665846 0.001877 0.563992 
Rmrp 3.037495 2.033332 17.48817 2.89E-05 0.057077 
Rn45s 3.15516 12.21427 24.22584 8.57E-07 0.00592 
Rpph1 2.228112 0.701161 14.1144 0.000172 0.198112 
Rsg1 1.229102 1.144316 6.765745 0.009292 0.92136 
Sacs 1.593493 1.850426 8.454038 0.003642 0.708973 
Scarna9 2.471549 -0.70672 19.10659 1.24E-05 0.034168 
Serpinb1b -1.6577 -0.93456 7.459233 0.006311 0.828174 
Siah3 1.450913 3.368374 10.98219 0.00092 0.454044 
Six2 -1.67497 1.722135 4.922298 0.026512 0.92136 
Six6 1.881747 1.439062 7.610531 0.005803 0.811513 
Slc14a1 -1.15212 -0.43964 6.484926 0.010879 0.92136 
Snord17 1.808382 -0.72806 12.54137 0.000398 0.284351 
Sorl1 1.261155 5.063529 6.707069 0.009603 0.92136 
Sv2c 1.314702 0.337716 9.231957 0.002378 0.573339 
Sytl5 1.211748 0.711377 6.426157 0.011245 0.92136 
Tbx15 -1.80958 0.573199 10.14754 0.001445 0.48705 
Tekt4 -1.24037 -0.9023 6.492119 0.010835 0.92136 
Tnr 1.354219 1.265542 6.951823 0.008373 0.918414 
Twist1 -1.62539 1.893949 6.957485 0.008347 0.918414 
Xkr7 1.222064 2.869899 5.622179 0.017735 0.92136 
Zbtb20 1.237337 2.069767 12.14382 0.000493 0.309384 




Appendix Table 3: PolyA Pool deregulated genes 
Gene ID logFC logCPM LR PValue FDR 
2310002D06Rik 1.3561239 -0.2360265 6.8605015 0.0088122 0.1851118 
2410066E13Rik 1.2675779 4.16353375 14.121423 0.0001714 0.0815076 
2410137F16Rik 2.2442006 1.1253809 13.467701 0.0002427 0.0882681 
2610005L07Rik 1.1008607 5.94382492 10.249338 0.0013673 0.1242324 
3110021A11Rik 1.4262511 -0.3624843 12.492613 0.0004086 0.095701 
3110021N24Rik 1.2671154 1.30611769 5.8616267 0.0154745 0.1998302 
3300002I08Rik 1.133717 0.29492701 9.2071332 0.0024107 0.1429889 
4921525B02Rik 1.4563935 0.02386542 8.0024897 0.0046713 0.1634366 
4930444P10Rik -1.145201 0.31228925 6.480351 0.0109073 0.1881628 
4930455C13Rik 1.7289492 -0.7300606 10.471531 0.0012123 0.1219646 
4930506C21Rik 1.1027136 0.13830233 6.4100966 0.0113473 0.1881628 
4930565N06Rik 1.6518598 -0.4756614 4.3784136 0.0363969 0.2449998 
4932418E24Rik 1.4129412 0.72051371 8.6388123 0.0032908 0.1538584 
A630007B06Rik 1.2400253 4.01270748 6.0784247 0.0136843 0.1940084 
A730008H23Rik 1.3625055 0.69812514 6.7507036 0.0093711 0.1876902 
Abhd2 1.3297558 4.48023113 8.8128057 0.0029912 0.1517881 
Adamtsl3 1.1538691 -0.6429793 7.4733082 0.006262 0.1729126 
Adarb2 1.1262135 2.59455063 14.369209 0.0001502 0.0798578 
Adcy9 1.2851365 2.10894415 11.793681 0.0005943 0.1064152 
Aff2 1.5310844 4.24818856 8.0190285 0.0046288 0.1634366 
AI606473 -1.485263 2.38736639 24.897352 6.05E-07 0.0041782 
Alx1 -2.982993 0.44697804 18.194085 1.99E-05 0.0335573 
Ankfn1 1.4739203 0.63494283 5.0269185 0.0249563 0.223378 
Apom -1.167087 0.16248503 4.1627255 0.0413229 0.2526136 
Arid5b 1.190682 3.06400427 6.5194808 0.0106699 0.1881628 
Atf7 1.3124589 2.8917443 10.095082 0.0014867 0.1249683 
Atp2b3 1.2144098 1.23826606 10.190616 0.0014116 0.1242324 
BC005561 1.2989352 3.93039233 6.3217723 0.0119264 0.188537 
Bmpr2 1.324022 4.51440901 7.4429646 0.0063685 0.1729126 
Brwd3 1.2685316 4.33798559 10.635464 0.0011094 0.1176564 
Btbd7 1.1456785 5.44781968 6.4485061 0.0111046 0.1881628 
Btbd8 1.5300055 -0.2200918 11.348644 0.000755 0.1146651 
Cacna1e 1.1151647 3.72220386 6.3359227 0.0118317 0.1881628 
Cbl 1.6435622 5.22216452 7.5792149 0.0059045 0.1717113 
Ccnt1 1.2938552 4.03688978 7.1266275 0.0075947 0.180484 
Cdh3 -1.209288 0.35754329 7.012202 0.0080956 0.1810886 
Cdh6 1.4615827 3.5357246 7.9807352 0.0047278 0.1645789 
Cdk6 1.4627727 1.62898609 12.203993 0.0004769 0.1028121 
Cdkl5 1.6271567 2.76514046 13.273384 0.0002692 0.0930089 
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Cep85l 1.2929263 1.76597427 4.3427432 0.037167 0.2464186 
Cers6 1.2339961 4.32792844 8.3612326 0.0038331 0.156264 
Chrm3 1.3203625 -0.2451778 6.3985214 0.0114215 0.1881628 
Chrna7 1.3984376 1.54675243 9.6790738 0.0018638 0.1343934 
Clcn5 1.376978 4.27801912 7.1427949 0.0075266 0.1802726 
Cntnap5a 2.1374694 -0.8605756 13.113226 0.0002932 0.0940169 
Cntnap5b 2.3833674 0.2378017 13.168133 0.0002848 0.0940169 
Col8a1 -1.693433 -0.4936914 4.0161821 0.0450656 0.2581048 
Cpeb4 1.4630496 3.51367747 6.7824586 0.0092058 0.1854598 
Crabp1 -1.169186 2.16836668 11.796491 0.0005934 0.1064152 
Creb5 1.2320205 2.47485887 7.290717 0.0069312 0.1760452 
Csmd1 1.4411809 1.91787868 13.413759 0.0002498 0.0885137 
Csmd3 1.319581 1.81993404 9.4540025 0.0021069 0.1373453 
Cxcl14 -1.124257 1.86567352 12.047497 0.0005186 0.1054018 
Cyp4x1 1.1939767 -0.367116 5.16647 0.023027 0.2177747 
D10Bwg1379e 1.2792087 2.46890327 12.149545 0.000491 0.1028121 
D130040H23Rik 1.2194447 1.62674688 10.144556 0.0014473 0.1242324 
D830031N03Rik 1.6390382 4.47922221 9.508402 0.0020453 0.1359519 
Dgkh 1.487572 1.24433179 11.398733 0.0007349 0.1139708 
Dnajb14 1.2447785 1.90550765 8.7363789 0.0031192 0.1517881 
Dnm3os -1.371207 0.30909778 5.3611701 0.02059 0.2110929 
Dok6 1.496639 -0.170196 6.7838773 0.0091985 0.1854598 
Dpy19l4 1.3794931 3.72898839 7.4205904 0.0064482 0.1733728 
Dpysl3 1.3274025 7.90096013 11.988768 0.0005352 0.1064152 
E330009J07Rik 1.5137445 3.17154964 10.243104 0.001372 0.1242324 
Ebf1 1.1880799 3.54680125 27.542738 1.54E-07 0.0021236 
Egr3 1.4021273 0.05990763 9.8383048 0.0017091 0.1309183 
Eif2c2 1.3488753 6.11243439 7.710042 0.0054914 0.1703473 
Eif2c3 1.3022736 3.34211472 9.8845878 0.0016667 0.1309183 
Elfn2 1.1379369 1.94420735 10.368031 0.0012822 0.123052 
Elk4 1.2084196 2.42192488 8.1253693 0.004365 0.1611608 
Erbb4 2.2067006 2.25210207 16.452833 4.99E-05 0.0428617 
Ern1 1.3481517 3.47577446 7.5407683 0.0060318 0.1729126 
F730043M19Rik 1.168694 1.56264178 7.9534566 0.0047996 0.1658249 
Fam135b 2.0320269 -0.6114364 12.305926 0.0004515 0.1006458 
Fam171b 1.118847 5.86723463 5.1571344 0.0231511 0.2177747 
Fam217b 1.3756237 0.66152493 12.569766 0.000392 0.094991 
Fbxo48 1.2329618 2.35005849 5.675227 0.0172061 0.2038935 
Fktn 1.2554153 4.19806868 7.2065746 0.0072637 0.1778994 
Flrt1 1.1806204 3.24058121 11.721406 0.0006179 0.1064152 
Fos 1.1917105 -0.182691 5.7425044 0.0165592 0.203082 
240 
Foxo3 1.2406022 3.21450928 7.4246342 0.0064337 0.1733728 
Frmd7 -1.476607 0.16428633 15.67158 7.53E-05 0.0548057 
Gabbr2 1.1286179 1.6062922 12.584457 0.000389 0.094991 
Gabrq 1.2858098 0.72987385 4.8478426 0.0276807 0.2290527 
Gan 1.5889967 2.49579066 10.088439 0.001492 0.1249683 
Gatad2b 1.3144241 4.53513657 7.9443189 0.0048239 0.1662486 
Gdap10 1.4044553 0.62507397 3.8519919 0.049687 0.2646947 
Gfod1 1.1100188 3.13254029 15.840406 6.89E-05 0.0529114 
Gjb2 -1.609652 0.38761485 6.5607252 0.0104254 0.1881628 
Glg1 1.3600142 6.61513281 7.8161315 0.0051782 0.1703473 
Gm15421 -1.162578 1.43945242 4.5461502 0.0329928 0.2398151 
Gm16386 1.3854196 1.82012431 9.6638426 0.0018793 0.1343934 
Gm16982 1.1225415 -0.3742334 5.628065 0.0176751 0.2049241 
Gm19557 1.2576237 -0.5960542 8.3439726 0.0038697 0.1568302 
Gm3500 -1.51304 0.66258206 9.0039925 0.0026939 0.1491236 
Gpr161 1.5587569 4.68048305 9.6190551 0.0019257 0.1343934 
Gpr26 1.395007 2.19845097 16.678569 4.43E-05 0.0428617 
Gprin2 1.6724334 0.48270246 12.793622 0.0003478 0.0948142 
Gramd1b 1.1103153 2.85005035 9.8628126 0.0016865 0.1309183 
Grid2 1.1328186 -0.5129373 6.4273089 0.0112379 0.1881628 
Hbb-bh1 -1.126332 7.1182712 7.0553853 0.0079027 0.1810886 
Hdac4 1.11877 3.73058092 7.9069272 0.0049246 0.1672181 
Hdx 1.3316674 1.60423134 6.3479378 0.0117518 0.1881628 
Hhipl1 1.1790083 1.86648761 7.2147855 0.0072305 0.1778967 
Hipk2 1.5142718 5.4287414 12.624408 0.0003807 0.094991 
Hist1h1b 1.7573182 -0.7289896 5.0746768 0.0242778 0.2202976 
Hist1h4f 1.5683893 -0.9653768 4.5837253 0.032277 0.2380886 
Hist1h4k 1.1216218 0.05711985 4.8544875 0.0275743 0.228875 
Hivep3 1.2059305 1.23781664 9.1849325 0.0024402 0.1441152 
Hmbox1 1.3177839 4.70544322 8.0312028 0.0045978 0.1634366 
Hspb1 -1.285022 -0.466154 8.3906174 0.0037716 0.156264 
Igsf6 1.1587897 0.34377262 9.0287186 0.0026577 0.1491236 
Igsf9b 1.6695684 2.20356771 11.804103 0.000591 0.1064152 
Itgb8 1.4783435 3.68726197 5.5924601 0.0180379 0.2049241 
Kcna3 2.0734388 2.51621881 8.7993448 0.0030134 0.1517881 
Kcnb2 1.1017598 1.11638483 8.6326365 0.0033019 0.1538584 
Kcnh5 1.1499019 -0.0321468 7.0103018 0.0081042 0.1810886 
Kcnh7 1.1199508 2.70302243 8.0196187 0.0046273 0.1634366 
Kcnj3 1.338798 0.00666991 5.8191424 0.0158527 0.2001393 
Kcnn3 1.1627882 2.38943716 13.596267 0.0002266 0.0882681 
Kcnq3 1.6428116 1.67485854 18.699055 1.53E-05 0.0331369 
241 
Kif13b 1.240713 3.92009847 8.1601827 0.004282 0.1610859 
Klf12 1.330891 5.30633138 8.905197 0.0028436 0.1501806 
Klf7 1.4532961 3.1165427 11.427627 0.0007236 0.1136381 
Klhl11 1.5347816 2.93160066 7.3626893 0.0066591 0.1743286 
Ksr2 1.2580217 1.54865137 11.055269 0.0008844 0.116398 
Lars2 1.7019722 8.85413543 5.3527782 0.0206893 0.2111712 
Lcor 1.9382317 3.01317476 9.6634634 0.0018797 0.1343934 
Lmbrd2 1.5663355 3.4208898 6.7979695 0.0091262 0.1854598 
Lmln 1.1344013 3.58050769 7.4548396 0.0063266 0.1729126 
Lnpep 1.4653698 3.82301676 7.2106644 0.0072472 0.1778967 
Lrp1b 1.1682923 0.78181917 5.3360813 0.0208884 0.2119152 
Lrrc7 1.2017351 3.09987641 16.839048 4.07E-05 0.0428617 
Lrrc8b 1.2954932 3.81398802 6.4865244 0.0108695 0.1881628 
Lyst 1.3201609 4.56085623 8.6497288 0.0032711 0.1538584 
Med12l 1.1037723 4.48182261 8.2804209 0.0040075 0.1586918 
Megf9 1.2638878 4.94373456 6.1760378 0.0129492 0.1922092 
Meig1 -1.229587 -0.8928936 7.3292583 0.0067841 0.1758148 
Mgat5 1.6043859 3.69171551 10.947469 0.0009373 0.1176564 
Mib1 1.2861947 5.18663926 6.3421818 0.01179 0.1881628 
Mir124a-2 1.4697082 0.65358426 11.290546 0.000779 0.114946 
Mir16-1 1.2392291 -0.501519 5.1205097 0.0236447 0.2185748 
Mir703 -1.126489 3.9827852 5.7706762 0.0162958 0.2025247 
Mrs2 1.1636046 4.02913111 7.4523771 0.0063353 0.1729126 
N4bp2 1.4251061 5.92351548 6.420417 0.0112816 0.1881628 
Nav3 1.4140944 3.82229061 9.6799366 0.0018629 0.1343934 
Nbeal1 1.1911758 3.48803199 5.5702455 0.0182682 0.2049241 
Ncam2 1.1153518 2.34943125 10.590525 0.0011367 0.1181129 
Nos1 2.1748865 -0.3061876 14.520486 0.0001386 0.0766422 
Nr2c2 1.4062175 5.72104369 9.072255 0.0025952 0.1491236 
Nrip1 1.3620282 3.32762282 6.0670097 0.013773 0.1946245 
Nwd1 1.4332099 2.04412908 11.13296 0.0008481 0.11543 
Nyap2 1.494347 0.23455559 7.6209433 0.0057694 0.1704832 
Onecut1 1.41704 -0.1493713 4.1618754 0.0413436 0.2526136 
Pcdh11x 1.3646996 2.05128825 12.44176 0.0004198 0.0967031 
Pcdha12 1.3737504 0.06441496 7.2589242 0.007055 0.1772718 
Pcdha2 1.430592 -0.4392593 13.135868 0.0002897 0.0940169 
Pcdha6 1.3699191 -0.4979672 5.673356 0.0172245 0.2038935 
Pcdha7 1.2820794 -0.0001198 5.4843851 0.0191871 0.2082727 
Pcdha9 1.3901522 -0.0763711 8.8936739 0.0028616 0.1501806 
Pcdhac1 1.129472 0.50040776 5.7483547 0.0165041 0.2029242 
Pcdhac2 1.527899 2.59108694 7.8343024 0.0051264 0.1703473 
242 
Pcdhb2 1.3610621 -0.4181272 5.5448225 0.0185354 0.206414 
Pcdhga1 1.4632207 1.09204977 10.745195 0.0010455 0.1176564 
Pcdhga11 1.1454788 3.89702419 8.9341526 0.0027989 0.1501806 
Pcdhga2 1.1306602 2.01073866 7.0363875 0.007987 0.1810886 
Pcdhga4 1.1593769 3.1157316 11.099299 0.0008636 0.11543 
Pcdhga9 1.1331009 2.03225381 7.4443052 0.0063637 0.1729126 
Pcdhgb1 1.4604063 1.56905457 10.716565 0.0010618 0.1176564 
Pcdhgb4 1.1579528 1.67703648 8.446198 0.0036581 0.156264 
Pcdhgc3 1.122205 6.21386955 10.221658 0.001388 0.1242324 
Pdpr 1.559337 3.83323274 6.2949039 0.0121086 0.1895133 
Perp -1.456543 0.03474365 16.347552 5.27E-05 0.0428617 
Plcxd3 2.01632 1.54386228 12.879131 0.0003323 0.0940169 
Plxna4 1.1109436 6.11685725 16.92282 3.89E-05 0.0428617 
Pou3f4 1.1385536 3.92336887 8.3909334 0.003771 0.156264 
Ppm1l 1.2298516 4.83956573 10.731471 0.0010533 0.1176564 
Ppp1r12b 1.4323803 3.83299853 11.8488 0.000577 0.1064152 
Prdm10 1.2276944 4.29473514 7.3742104 0.0066166 0.1743286 
Ptar1 1.7259241 2.78368152 12.260936 0.0004625 0.101465 
Ptch1 1.1204745 5.45880645 6.4599501 0.0110333 0.1881628 
Ptpn4 1.376638 3.85004703 5.9142641 0.0150188 0.1992042 
Ptprt 1.4969137 1.62561562 10.159856 0.0014353 0.1242324 
Ralgps1 1.4823965 4.69163288 13.79346 0.000204 0.0854517 
Raver1-fdx1l 1.1319182 3.1625481 9.4947486 0.0020606 0.1359519 
Rims1 1.1333199 2.16819871 10.693796 0.001075 0.1176564 
Rmrp 2.1047888 2.03333224 4.7361075 0.0295358 0.2324191 
Rn45s 2.2566418 12.2142734 6.3499444 0.0117385 0.1881628 
Rps19-ps3 -1.176953 1.29062292 6.3497268 0.0117399 0.1881628 
Rsg1 1.3129682 1.14431611 9.4077231 0.0021607 0.1378491 
Sacs 2.4702528 1.85042552 17.040812 3.66E-05 0.0428617 
Scarna9 1.7430059 -0.7067179 6.8277507 0.0089752 0.1854598 
Sdk2 1.279603 3.11031449 9.3961089 0.0021745 0.1378491 
Sfn -1.209569 -0.0890799 7.2132257 0.0072368 0.1778967 
Shc3 1.1066244 2.64713288 7.6483741 0.0056824 0.1703473 
Siah3 1.5179208 3.36837413 14.610111 0.0001322 0.0761271 
Sik2 1.414189 3.84001919 9.6373162 0.0019066 0.1343934 
Six2 -1.903528 1.72213509 9.7273728 0.0018154 0.1343934 
Slc16a14 1.3635437 2.71896346 12.887139 0.0003308 0.0940169 
Slc30a3 -1.239792 -0.0305236 10.323052 0.0013138 0.1242324 
Slc36a4 1.3519272 3.9152104 8.085089 0.0044631 0.1617702 
Slc9a7 1.5006256 0.35680094 9.3093072 0.0022799 0.1399853 
Snord17 1.3837372 -0.7280553 7.3960909 0.0065366 0.1741388 
243 
Snord64 1.593969 0.6851508 5.3289398 0.0209741 0.2120429 
Sorl1 1.7159686 5.06352851 13.016992 0.0003087 0.0940169 
St6gal2 1.5807506 2.56149411 7.479596 0.0062402 0.1729126 
Sv2c 1.1058896 0.33771556 7.6155869 0.0057866 0.1704832 
Syt14 1.5351642 2.67032908 8.0159495 0.0046367 0.1634366 
Sytl5 1.5674831 0.71137704 11.687943 0.0006291 0.1064152 
Tbx15 -1.378061 0.57319855 8.3627592 0.0038299 0.156264 
Tekt4 -1.271828 -0.9022976 9.6777822 0.0018651 0.1343934 
Tenm1 1.9046239 1.81874756 8.8821453 0.0028797 0.1501806 
Tenm4 1.6114086 6.93802408 10.241648 0.001373 0.1242324 
Tmem178b 1.877436 3.25289359 7.1347205 0.0075605 0.180484 
Tmem245 1.1259243 3.99360364 7.2109243 0.0072461 0.1778967 
Tnfrsf18 1.147034 0.94868407 7.3656513 0.0066482 0.1743286 
Tnks 1.4134339 6.41418773 7.7911856 0.0052502 0.1703473 
Tnr 2.2114871 1.2655418 15.347712 8.94E-05 0.0617956 
Trip11 1.1957881 4.05696392 6.4962348 0.0108103 0.1881628 
Twist1 -1.684039 1.89394871 11.517571 0.0006894 0.1107873 
Ubald2 -1.294633 1.19059931 5.1020037 0.0238982 0.2190142 
Uhmk1 1.194381 3.15236305 4.925755 0.0264592 0.2261091 
Uprt 1.3940521 1.53375923 4.8705725 0.0273184 0.2281213 
Vps13c 1.3416624 4.65713801 8.4406591 0.0036692 0.156264 
Wdfy2 1.4321034 3.62963951 8.7548145 0.0030879 0.1517881 
Xkr4 1.7598324 1.70799631 10.092395 0.0014888 0.1249683 
Xkr7 1.5339784 2.86989879 10.090024 0.0014907 0.1249683 
Xpo4 1.3539973 4.19689655 8.6784169 0.00322 0.1538584 
Xrn1 1.5298196 4.7563551 8.2677347 0.0040356 0.1587374 
Xylt1 1.4323649 3.456239 8.0032885 0.0046692 0.1634366 
Zbed6 1.5445581 5.57454046 4.961358 0.0259198 0.225624 
Zbtb20 1.4480771 2.06976695 18.634564 1.58E-05 0.0331369 
Zbtb37 1.3482909 2.92165295 10.463019 0.0012179 0.1219646 
Zbtb38 1.338636 2.227117 11.682571 0.0006309 0.1064152 
Zc3h12b 1.3105452 1.16234478 8.1500622 0.004306 0.1610859 
Zfp369 1.7621415 3.0493847 10.696683 0.0010733 0.1176564 
Zfp536 1.6800347 4.28466461 18.020531 2.19E-05 0.0335573 
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ABSTRACT: The devastating clinical presentation of X-
linked lissencephaly with abnormal genitalia (XLAG) is
invariably caused by loss-of-function mutations in the
Aristaless-related homeobox (ARX) gene. Mutations in
this X-chromosome gene contribute to intellectual disabil-
ity (ID) with co-morbidities including seizures and move-
ment disorders such as dystonia in affected males. The
detection of affected females with mutations in ARX is in-
creasing. We present a family with multiple affected indi-
viduals, including two females. Two male siblings present-
ing with XLAG were deceased prior to full-term gestation
or within the first few weeks of life. Of the two female
siblings, one presented with behavioral disturbances, mild
ID, a seizure disorder, and complete agenesis of the cor-
pus callosum (ACC), similar to the mother’s phenotype.
A novel insertion mutation in Exon 2 of ARX was iden-
tified, c.982delCinsTTT predicted to cause a frameshift
at p.(Q328Ffs∗37). Our finding is consistent with loss-of-
function mutations in ARX causing XLAG in hemizygous
males and extends the findings of ID and seizures in het-
erozygous females. We review the reported phenotypes of
females with mutations in ARX and highlight the impor-
tance of screening ARX in male and female patients with
ID, seizures, and in particular with complete ACC.
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Introduction
The Aristaless-related homeobox gene (ARX; NM 139058.2;
MIM# 300382) [Shoubridge, et al., 2010] is critical for early devel-
opment and formation of a normal brain [Kitamura, et al., 2002],
[Ohira, et al., 2002], [Stromme, et al., 2002]. This paired-type
homeodomain transcription factor plays a vital role in telencephalic
development specifically in tangential migration and differentiation
of GABAergic and cholinergic neurons [Kitamura, et al., 2002],
[Colombo, et al., 2007], [Friocourt, et al., 2008], [Colasante, et al.,
2009], [Lee, et al., 2014]. Mutations in ARX result in a range of
phenotypes with intellectual disability (ID) as a consistent feature.
Mutations leading to loss-of-function of the ARX protein typi-
cally lead to brain malformation phenotypes, including X-linked
lissencephaly with abnormal genitalia (XLAG, also known as LISX2)
(MIM# 300215) [Kitamura, et al., 2002], [Shoubridge, et al., 2010].
XLAG is a developmental disorder characterized by structural brain
anomalies leading to agyria (absent cerebral grooves brain) or
pachygygria (reduced folds or grooves) and agenesis of the corpus
callosum (ACC). In addition, patients commonly have early-onset
intractable seizures, severe psychomotor retardation, and ambigu-
ous genitalia [Dobyns, et al., 1999; Kitamura, et al., 2002]. Males
are severely affected and often die within the first days or months
of life.
As the ARX gene is on the X-chromosome, mutations in this
gene typically result in families with affected males across multiple
generations transmitted via (usually) asymptomatic carrier females.
However, there is an increasing prevalence of reported mutations
in ARX that result in the severe phenotypic outcomes of XLAG in
male patients that, with variable penetrance, affect females within
the families resulting in a generally milder phenotype than affected
males [Eksioglu, et al., 2011; Kato, et al., 2004; Kitamura, et al., 2002;
Marsh, et al., 2009; Scheffer, et al., 2002; Stromme, et al., 2002]. Here,
we report a novel mutation in ARX in a family ascertained by a fe-
male proband displaying a phenotype of mild learning disabilities,
seizure disorder and ACC. As part of this work, we have reviewed
reported phenotype of females with mutations in ARX and recom-
mend screening of the ARX gene in female patients with suitable
ID, seizure phenotypes, and corpus callosum agenesis, particularly
if there is evidence of X-linkage and no surviving males. ARX adds
to a growing list of genes on the X chromosome including genes
such as USP9X, PHF6, and IQSEC2 that have phenotypic effects
C© 2017 WILEY PERIODICALS, INC.
in males and females that are distinct depending on the functional
severity of the mutation [Zweier, et al., 2013; Reijnders, et al., 2016;
Zarem et al., 2016].
Materials and Methods
Clinical Description of Patient and Family
The proband presented to a Genetics Clinic at 10 years of age with
learning difficulties, mild ID, and seizures. The proband was born
at term weighing 3.2 kg, with no admission into the neonatal inten-
sive care unit nor special-care nursery required. She was reported
as sitting with support at 9 months of age with single words spoken
at 9–10 months of age and walking at 22 months of age. Seizure
onset was around 5 years of age with the first seizure classified as
a prolonged generalized tonic-clonic which required intubation. At
this time, she was assessed and was able to draw a triangle with help,
able to hop, dress herself, and talk in simple sentences, knowing a
few colors and numbers. No unusual grasping is reported. She was
evaluated using the WISC-IV Australian at the age of 8 years and 10
months. She scored in the “Extremely Low” range for verbal com-
prehension, perceptual reasoning index, working memory index,
processing speed index with a resulting full scale IQ in the “Ex-
tremely Low” range. She was assessed as operating in the mild range
of ID. She subsequently had a number of complex partial seizures,
which were reasonably well controlled on Tegretol. Brain MRI re-
vealed complete ACC with mild dilated ventricles and colpocephaly.
No lissencephaly, dysmorphic features, or behavior problems were
reported.
The mother of the proband was aged 46 years old at the time of
this report and presented with mild ID, seizures, and mental health
challenges. After admission to the public health hospital she was
diagnosed with borderline personality disorder and major depres-
sive disorder, however no neuropsychiatric assessment is currently
available. She was non dysmorphic. History revealed that her first
seizure was around 7–8 years of age and classified as complex partial
seizures. Brain MRI scan done at the age of 38 showed complete ACC,
with no gray matter heterotopia. Small white matter lesions were
noted which comprised of tiny fluid-attenuated inversion recovery
hyperintensities involving the left centrum semiovale bilaterally and
in the frontal region. The treating neurologist at the time felt these
were specific white matter hyperintensities however the actual films
are no longer available for review. In addition, EEG showed inter-
mittent spike and wave discharge maximal over left hemispheres,
which were at frequency of 2.5–3.5 Hz.
Two male offspring of II-4 were affected and died in early infancy,
or were terminated during pregnancy. A maternal half-brother
(III-1) of the proband was born at 36 weeks of gestation with an
onset of seizures 20 min after birth. III-1 died at 26 days of age. In-
vestigation of brain morphology identified ACC, lissencephaly, gray
matter heterotopias, and bilateral optic nerve hypoplasia. Genitalia
were ambiguous with labioscrotal folds, bilateral gonads and mi-
crophallus. Pelvis ultrasonography revealed the presence of a bicor-
nuate uterus, while a male urethra was confirmed with a genitogram.
Karyotype analysis showed a normal male chromosomal constitu-
tion (46,XY). Facial dysmorphic features included a large head, large
anterior fontanels, low set ears, and abnormal nails. III-3 eventu-
ated with a medical termination of pregnancy due to identification
at 18 weeks gestation via ultrasonography of ventriculomegaly and
abnormal genitalia. Brain malformations were confirmed at post
mortem showing lissencephaly, absent corpus callosum, wide-open
sylvian fissure, and dilated ventricles. Facial dysmorphic features
included flattened facies, mild macrocephaly, and wide open su-
tures. Abnormal genitalia consisted of rudimentary genitalia with a
small phallus. Karyotype analysis established the presence of male
chromosomes.
Another pregnancy, III-5 was terminated when chorionic vil-
lus sampling revealed 45XO after ultrasound showed fetal hydrops.
The remaining sibling (III-2) is a healthy female with normal in-
telligence. A maternal uncle’s (II-1) death at 1 month of age was
attributed to sudden infant death syndrome. The maternal grand-
mother (I-2) is reported to be healthy with no seizures.
Molecular Analysis of ARX Gene
The screening protocols were approved by the appropriate in-
stitution review boards and informed consent was obtained from
the parents of patients. Genomic DNA from the proband was ex-
tracted from whole blood using standard techniques. Each of the
five exons of ARX was amplified by PCR using primers designed
to amplify coding and flanking non-coding sequence. The excep-
tion to this was exon 2, for which four overlapping amplicons were
used to achieve robust amplification of GC-rich regions coding for
three polyalanine tracts. The PCR conditions and primer sequences
are described in detail previously [Tan, et al., 2013]. Sequencing
reactions were performed using ABI Big Dye terminator chemistry
version 3.1 and purified products subjected to an automated capil-
lary sequencing on ABI 3100 sequencer (Applied Biosystems, Foster
City, CA) and sequence was compared to the ARX reference sequence
(NM 139058.2) using SeqMan module of the Lasergene DNA and
protein analysis software package (DNAStar, Inc., Madison, WI).
Results
Molecular Analysis of the ARX Variant
The diagnoses of ID and seizures in the female proband in con-
junction with XLAG in her male siblings, from two different fa-
thers, prompted evaluation of the ARX gene. Sequence analysis
demonstrated a novel indel mutation, c.982delCinsTTT in exon
2 of the ARX gene, that is predicted to result in the creation of
a premature stop codon, p.(Q328Ffs∗37) (LOVD ID 0000128956)
(http://www.lovd.nl/ARX). The child’s mother presented with a sim-
ilar phenotype and was confirmed to also be a symptomatic carrier
of this novel ARX mutation. The father (II-5) and unaffected sister
(III-2) do not carry the mutation (Fig. 1). The ARX mutation was
confirmed in III-4 in genomic DNA extracted from amniocytes. The
amino acid affected by the mutation p.328Q is located at the start of
the region containing the second nuclear localization signal (NLS2)
preceding the conserved paired-type homeodomain. The predicted
stop codon arising from this variant occurs within 29 nucleotides of
the exon 3–4 junction, and is likely to escape nonsense-mediated de-
cay (NMD). Due to restricted levels of ARX expression in the patient
derived materials we are unable to confirm if this truncated protein
is produced. Despite this, even if the predicted C-terminal trun-
cated protein was produced and subsisted at appreciable levels, the
severe XLAG phenotype in affected male patients is expected with
this variant resulting in a nonsense peptide being transcribed after
residue p.328 and complete loss of the paired-type homeodomain
residues (Fig. 1C).
A methylation-specific PCR at the human FraxA and Androgen
Receptor genes was performed on genomic DNA from blood as
previously described [Plenge, et al., 1997]. X-inactivation studies
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Figure 1. Identification of a c.982delCinsTTT mutation resulting in (p.(Q328Ffs∗37) in ARX. A: Pedigree of immediate family members tested.
Open symbols represent normal individuals, filled black circles represent females with moderate intellectual disability and seizures, filled squares
represent males with lissencephaly, hydrocephalus, profound developmental delay, and ambiguous genitalia. Individual generations are numbered
with Roman numerals on the left hand side of the pedigree. Individuals which were sequence confirmed to carry either the normal (N) or mutant
(M) are shown. B: DNA sequence electropherograms for the chrX: 25,031,130 (GRCh37/hg19 assembly) deletion of a C and insertion of TTT mutation
in exon 2 of 5 of ARX reported in this study. A normal sequence was confirmed in unaffected father (II-5) and sister (III-2) with normal sequence
shown. The mutation in the heterozygous state is shown in both the affected proband (III-4) and mother (II-4). The dotted line highlights the disrupted
heterozygous trace present in females caused by the insertion (solid black underline). Additional mutation sequence change seen in the hemizygous
state of an affected brother (III-3). C: Predicted functional consequence of a novel nonsense mutation in ARX. Schematic representation of the
human ARX protein (top panel). Human ARX domains and regions are indicated above the schematic. Known functional domains are highlighted,
octapeptide (OP) as horizontally hatched rectangle, nuclear localization sequences (NLS) as three black rectangles, polyalanine tracts (PA) as
four white rectangles, acidic domain as vertically hatched rectangle, homeodomain as crosshatched, and aristaless domain (OAR) as hatched. A
schematic representation of the homeodomain and the flaking NLS domains (middle panel) with the amino acid sequence below (homeodomain
sequence underlined). The amino acid change indicated by the first black arrow resulting in a nonsense peptide and a stop codon indicated by the
second black arrow.
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Table 1. Clinical Summary of Females with ARX mutations
Familial This report De novo Total
Females 25 2 4 31
Females with ID, with and without seizures 11 2 4 17
ID or DD 11 2 4 17
Seizures 5 2 4 11
Other clinical features Number (symptomatic:non-symptomatic)
MRI reported 10 (5:5) 2 (2:0) 3 15
Brain malformation 9 (4:5) 2 (2:0) 3 14 (9:5)
ACC 8 (4:4) 2 (2:0) 1 11 (7:4)
Other 1 (0:1) 0 2 3 (3:0)
Movement disorder 4 (3:1) 0 4 8 (7:1)
Psychiatric features 4 (3:1) 1 (1:0) 0 5 (4:1)
Behavior disturbance 2 (2:0) 0 0 2 (2:0)
for both the proband (III-3) and the healthy sister (III-2) detected
no significant deviation.
As part of initial investigations, both II-4 and III-3 were identified
to carry a duplication on chromosome 5 at 5p15.5 (Chr5:10,907,608-
11,363,857). This duplication contains only part of one gene,
Catenin Delta 2 (CTNND2). This duplication was classified as a
variant of unknown significance. This duplication was later also
identified in the female sibling III-2, who is healthy and has no
learning issues, indicating this copy number variant is unlikely to
contribute to the phenotype of the proband, her mother or affected
brothers.
Discussion
Here, we report a family with a novel truncating mutation
(c.982delCinsTTT/p.(Q328Ffs∗37)) in ARX. The mutation is pre-
dicted to yield a non-functional protein product after p.328 due to
the nonsense peptide prior to truncation of the protein at amino acid
364. This variant was not found in either the ExAC or 1000 genome
project databases. Although this mutation may escape NMD, the
resulting protein will have functional loss of the homeodomain and
Aristaless domains. The catastrophic phenotype of XLAG reported
in two males in this family is consistent with the predicted disrup-
tion of the ARX homeodomain function. The female proband and
mother have a milder phenotype consisting of ID, seizures, and ACC.
The investigation of ARX as a cause of the phenotype in the female
proband was due largely to the distinctive phenotypic presentation
and early deaths of the affected male siblings.
Our report underscores that a carrier female phenotype is likely
to be under ascertained for ARX. This is supported by a recent
examination of heterozygous females from families identified with
ARX mutations [Marsh, et al., 2009] and examples of gender bias
(92% male:8% female) in a recent cohort of patients referred for
molecular analysis of ARX [Marques, et al., 2015]. Under ascer-
tainment may be occurring due to several contributing factors.
Patients with phenotypes such as ID and infantile spasms have
been typically screened for mutations in known genes such as
STXBP1, CDKL5, KCNQ2, GRIN2A, MAGI2, and ARX. However,
in the case of ARX, screening is commonly only considered in af-
fected males. Moreover, as the majority of all mutations reported
to date in ARX lead to expansion of the first or second polyalanine
tracts, both located in exon 2, ARX mutation analysis is routinely
limited to screening exon 2 and often using size variant analysis
approaches [Marques, et al., 2015]. The expanding use of next gen-
eration sequencing approaches on cohorts of individuals with ID
and or seizure phenotypes are likely to provide a platform to poten-
tially overcome some of these biases. However, even these types of
approaches have constraints that need to be considered, particularly
for genes with high GC content or near regions of low gene density,
such as ARX. For example, sequence coverage across the ARX gene
in 50 representative whole exome sequencing (WES) experiments
undertaken at the Radboud University Medical Centre showed the
median coverage for ARX was 40-fold less than the coverage of all
ID genes; with the median percentages of ARX bases covered at 20×
only being 73% compared with 97% for all ID genes (Supp. Fig. S1).
However, experience at this, and other centers, indicates that the
coverage differences although lower for ARX generally, may also de-
pend upon the region of the gene being considered (Supp. Fig. S2).
Exome sequencing using benchtop ion proton machines also result
in poor coverage of the ARX gene, with mean coverage reported at
43% [Lacoste, et al., 2016]. It remains to be determined how the
increasing use of whole genome sequencing approaches as well as
improvements to WES technologies and analysis pipelines address
some of these coverage issues.
To date there have been both familial and de novo cases of affected
females due to ARX mutations [Bettella, et al., 2013; Eksioglu, et al.,
2011; Kato, et al., 2004; Kwong, et al., 2015; Marsh, et al., 2009;
Scheffer, et al., 2002; Wallerstein, et al., 2008] (Table 1). Penetrance
is variable both within and across families, with 55% of carrier
females in these families presenting with a phenotype of ID to some
degree with and without seizures (Table 1). ID and/or developmental
delay are prominent features in affected females across all families.
A seizure phenotype was reported in 64% of the females with ID
which equates to 35% of all females in these families (Table 1).
Similar to the novel case we report here, affected females have
been reported in families in which the male proband presents with
severe XLAG or seizure phenotypes [Eksioglu, et al., 2011; Kato,
et al., 2004; Marsh, et al., 2009; Scheffer, et al., 2002]. In these fa-
milial cases ascertained by the male proband, the mutations are
either missense mutations of residues in the homeodomain or non-
sense/deletion mutations resulting in a loss-of-function of the ARX
homeodomain and/or aristaless domain activity (Table 2). Similarly,
a smaller number of de novo cases also result in truncation and loss
of ARX function [Bettella, et al., 2013; Kwong, et al., 2015; Marsh,
et al., 2009; Wallerstein, et al., 2008]. Across these cases, there is a
consistent phenotype of ID and/or developmental delay, infantile
seizures, and hypotonia/dystonia/ ataxia (Table 3). The type and lo-
cation of mutations in affected females is restricted compared with
those contributing to affected males (Fig. 2).
Brain MRI imaging is reported in approximately 35% of all fe-
males in these cases/families, including the two females from this
current report. Interestingly, of those individuals screened, 73% had
features consistent with ACC but only 64% of these patients were
those classed as symptomatic based on ID and/or developmental
delay and seizure phenotypes. Hence, there are a number of asymp-
tomatic carrier females that do not display these key clinical features
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Figure 2. Identified ARX mutations in females and males leading to a range of phenotypes. A: ARX exon structure in relation to the ARX protein.
B: Overview of ARX including the homeodomain (crosshatched) and aristaless domain (hatched) and the location of reported mutations according
to their relative position at the protein level in both males and females. Differences in mutation type are indicated by a change in color, whereas
missense mutation shown in gray and all other nonsense, insertion, or deletion mutation in black. Phenotype severity is indicated on the y-axis with
unaffected carrier females (below clinical threshold) shown below the dotted line.
but still have the brain abnormality of ACC. There is also variable
penetrance of both psychiatric and behavioral phenotypes across
the symptomatic and asymptomatic females within these families.
Movement disorders including ataxia and hypotonia are noted, par-
ticularly prevalent in the cases of de novo mutations (Table 3).
Given that the ARX gene is located on the X chromosome and is
subject to X chromosome inactivation, the contribution of skewed
X-inactivation (80:20) to the phenotype in heterozygous females is
always a consideration. However, the female proband in this current
report detected no skewing of X-inactivation in samples collected
from blood. X-inactivation in previous studies has been inconclusive
with little correlation of the affected status in heterozygous females
to preferential inactivation of the normal ARX allele (measured in
blood) [Marsh, et al., 2009]. Indeed, skewing of X-inactivation that
is not consistent with disease severity has been reported for other
X-linked genes that were originally thought to affect males but have
had affected female cases described, including mutations in genes
such as USP9X, MTM1, SLC9A6, and MED12 [Prontera, et al., 2016;
Reijnders, et al., 2016; Savarese, et al., 2016; Sinajon, et al., 2016].
This highlights the complexity of X-linked inheritance. Recently,
the variability and complex X-inactivation status within the brain
has been demonstrated in an Arx knockout mouse model [Marsh,
et al., 2016]. Heterozygous female mice only have one functional
copy of Arx and consistent with human data, female mice showed
great variation of phenotype manifestations. These mice display stri-
ations of radially oriented streams of Arx positive neurons within
and emerging from the ganglionic eminence ventricular zone, which
were noted to vary dramatically between embryos. This is consis-
tent with the site of random X-inactivation suggested to occur in
the ventral forebrain, followed by clonal proliferation of Arx pos-
itive or negative cells migrate radially away during early stages of
development. Even this incomplete loss of Arx in female mice was
detrimental and resulted in a change in the profile of interneurons
in the adult female mice, consistent with a loss to a greater extent in
hemizygous male mice.
We have identified a novel truncating mutation (c.982delCins
TTT/p.(Q328Ffs∗37)) in ARX in a family ascertained by a female
proband displaying a phenotype of mild ID, seizure disorder and
ACC, in conjunction with a phenotype of XLAG in her deceased
male siblings. Review of the phenotypes of affected females with
published mutations in ARX indicates that screening of the ARX
gene in female patients with ID, seizure phenotypes, and ACC, par-
ticularly if there is evidence of X-linkage and no surviving males is
warranted. Moreover, recent de novo mutations reported in females
recommends scrutiny of ARX in all cases with suitable phenotypic
presentation with and without other indications of X-linked inher-
itance. The emerging appreciation of phenotypic consequences in
females with loss-of-function mutations in ARX will be important
in counseling of affected families.
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Abstract
The Aristaless-related homeobox (ARX) gene encodes a paired-type homeodomain transcription factor with critical roles in
embryonic development. Mutations in ARX give rise to intellectual disability (ID), epilepsy and brain malformation syn-
dromes. To capture the genetics and molecular disruptions that underpin the ARX-associated clinical phenotypes, we under-
took a transcriptome wide RNASeq approach to analyse developing (12.5 dpc) telencephalon of mice modelling two recurrent
polyalanine expansion mutations with different phenotypic severities in the ARX gene. Here we report 238 genes significantly
deregulated (Log2FC >þ/1.1, P-value<0.05) when both mutations are compared to wild-type (WT) animals. When each mu-
tation is considered separately, a greater number of genes were deregulated in the severe PA1 mice (825) than in the PA2 ani-
mals (78). Analysing genes deregulated in either or both mutant strains, we identified 12% as implicated in ID, epilepsy and
autism (99/858), with 5% of them as putative or known direct targets of ARX transcriptional regulation. We propose a core
pathway of transcription regulators, including Hdac4, involved in chromatin condensation and transcriptional repression,
and one of its targets, the transcription factor Twist1, as potential drivers of the ID and infantile spasms in patients with ARX
polyalanine expansion mutations. We predict that the subsequent disturbance to this pathway is a consequence of ARX pro-
tein reduction with a broader and more significant level of disruption in the PA1 in comparison to the PA2 mice. Identifying
early triggers of ARX-associated phenotypes contributes to our understanding of particular clusters/pathways underpinning
comorbid phenotypes that are shared by many neurodevelopmental disorders.
Introduction
Neurodevelopmental disorders (NDDs), which include intellec-
tual disability, seizure disorders and autism spectrum disorders
are prevalent in the population. Large-scale sequencing efforts
have highlighted the genetic heterogeneity contributing to each
of these disorders (1–5). Understanding how such divergent aeti-
ologies produce similar clinical features remains a major
challenge. Despite this, recent studies indicate that many of the
pathophysiological mechanisms might be shared, opening the
possibility that more than one condition may be amenable to a
treatment or disease modification that exploits a common mech-
anism (3–5). Here we investigate the molecular mechanisms and
functional impact of mutations in the disease-causing gene con-
tributing to intellectual disability and infantile spasms, the
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Aristaless-related homeobox gene (ARX) [NM_139058.2] (MIM
300382).
ARX is a member of the paired-type homeodomain tran-
scription factor family with critical roles in development, partic-
ularly in the developing brain (6–8). ARX is indispensable for
telencephalic morphogenesis particularly involved in radial and
tangential migration of GABAergic interneuron progenitors,
early commitment of cholinergic neurons and is emerging as a
selector gene important in preserving the identity of specific
brain regions (6,9–12). In accordance with the essential function
of ARX during early brain development, Arx expression is de-
tected in mice at embryonic day 8 in a restricted area of the neu-
roepithelium corresponding to the prospective forebrain (13).
During the peak neural proliferation and neurogenesis expres-
sion of Arx within the subpallium peaks between 12.5 to 14.5
days post coitum (dpc), persisting during embryogenesis and is
down regulated during postnatal life (6,14).
ARX is an X-chromosome gene. As such, patients are gener-
ally affected males with carrier females being asymptomatic.
Over 60% of all mutations in ARX expand the first or second pol-
yalanine tract, and affected males with these mutations invari-
ably present with intellectual disability with and without
infantile spasms and epilepsy (15,16). In particular, patients
with expansions to the first polyalanine tract (previously re-
ported as c.304ins(GCG)7, now following HGVS nomenclature re-
ported as c.306GGC[17]; referred to as a PA1 mutation in this
study) invariably display seizures, with infantile spasms in 85%
of these PA1 patients (16). The key phenotypic features seen in
these patients are recapitulated in well characterised mu-
tant mouse models, including infantile spasm-like movements,
electrodecremetal discharges, and multifocal EEG spikes, with
seizures in juvenile and older mice (17–19). The most frequent
mutation in ARX in patients results in an expansion to the sec-
ond polyalanine tract (previously reported as c.429_452dup,
now following HGVS nomenclature reported as c.441-464dup;
referred to as PA2 mutation in this study) with at least 10–15%
of these PA2 patients presenting with infantile spasms in
addition to intellectual disability (16). Although there is a
mouse model of the most common PA2 mutation (17), pheno-
typic data for this strain, including prevalence of seizures is
limited.
Our recent investigations in these mice modelling to two
most frequent polyalanine expansion mutations in human pa-
tients demonstrated aggregation of mutant Arx protein does
not occur in the embryonic brain. Instead, we identified a
marked reduction in mutant Arx protein expression in the de-
veloping forebrain (12,17). Interestingly, this data indicates that
both PA1 and PA2 mutations give rise to similar molecular out-
comes. Despite recent studies identifying genes regulated by
ARX (11,20,21) there is limited understanding of what impact
the expanded polyalanine tract mutations in Arx may have on
the transcriptional activity (12,22) and how this may contribute
to phenotypic outcomes. In this study, we use RNASeq on brain
tissue at 12.5 dpc during embryonic development to capture
early disruptions of Arx function. We show that the gene ex-
pression consequences of the polyalanine expansion mutations
of Arx do overlap but the PA1 mutation leads to a greater and
broader disturbance than the PA2 mutation. From our analysis
of the deregulated genes we propose a pathway involving
Histone Deacetylase 4 (Hdac4) and Twist Family BHLH
Transcription Factor 1 (Twist1) that when deregulated by either
Arx mutation contributes to the comorbid phenotypes of intel-
lectual disability and epilepsy.
Results
PA1 and PA2 mice deregulated transcriptomes overlap
Arx is indispensable for brain development with expression de-
tected as early as 8 dpc (13,14). To capture early changes to the
transcriptome due to mutations in Arx we collected and investi-
gated the 12.5 dpc telencephalon of mice modelling two muta-
tions in Arx, PA1 and PA2 (Supplementary Material, Fig. S1). We
compared four males from each strain with stage-matched WT
male littermates. Sequences were aligned using TopHat and
count data generated from HTSeq was used as the input for
EdgeR to identify genes with differential expression between
samples.
Analysis of the PA1 mice revealed 825 genes deregulated by
Log2 fold change greater thanþ/- 1.1 with a P-value of less than
0.05, with 54% found at higher levels of expression than WT
(Fig. 1A). In contrast, the PA2 mutation resulted in 78 genes
deregulated using the same fold cutoff, with 72% of these found
at higher levels of expression than the WT animals (Fig. 1A).
Despite the large difference in the number of genes significantly
deregulated between the two PolyA strains, we noted that ex-
pression of many of the genes deregulated in the PA1 mice
shared the same trend of deregulation in the PA2 mice although
the lower log2FC values did not reach the required significance
(Fig. 1B -within dotted lines). Given the similarities of the tran-
scriptome changes between PA1 and PA2 we speculate that the
disrupted pathway may be shared between PA1 and PA2. This is
supported by previous studies suggesting both PA mutations re-
sult in a reduction of the ARX protein together with the overlap
of clinical phenotypes in human patients with either PA1 or PA2
mutations. With this in mind, we analysed the genome wide ex-
pression data of both the PA1 and PA2 mice as a single mutation
group (referred to as PolyApool) compared to the WT samples to
capture genes deregulated in both mutant strains. Lists of
deregulated genes for each analysis are provided in
Supplementary Materials, Tables S1–S3. From this analysis a to-
tal of 238 genes were identified (Log2 fold change greater
thanþ/- 1.1 with a P-value< 0.05) (Fig. 1C). The majority of
genes deregulated in the PolyApool (89%) were at higher levels of
expression in mutant mice (Fig. 1A). Not surprisingly, all genes
identified as deregulated by this analysis had already been iden-
tified as deregulated in either PA1 or PA2 mice. When we con-
sider the 238 genes identified as deregulated in the PolyApool
analysis, the mean log2FC value of the more severe PA1 group
on its own is at 1.3, above the 1.1 cutoff value. In contrast,
the milder PA2 group when considered on its own is below the
1.1 cutoff at 0.7. This means that of the total 238 signifi-
cantly deregulated genes in the PolyApool data, 94% (224/238)
of genes in PA1 and 24% (56/238) of genes in PA2 met the
cut off values, respectively (Fig. 1D). Of the 238 genes that were
significantly deregulated in the PolyApool analysis, 42 genes
(18%) were significantly deregulated in both PA1 and PA2 ani-
mals when each mutant strain was considered independently
compared to WT (P> 3.753e-31). When considered indepen-
dently, 182 genes (76%) were significantly deregulated in
PA1 animals only and 14 genes (6%) were deregulated specifi-
cally in the PA2 animals. Of the 42 significantly deregulated
genes compared to WT in both PA1 and PA2, 79% (33/42) of
the genes had increased expression (Fig. 1E). The overall disrup-
tion to the transcriptome observed supports the notion that
PA1 and PA2 disrupt overlapping pathways, with PA2 mice be-
ing a ‘milder’ form of transcriptome deregulation of the PA1
mice.
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PA1 and PA2 mutations disturb overlapping biological
processes in the developing brain
Functional enrichment analysis is a common tool to understand
global changes in phenotypes in cells and tissues. EnrichR (23)
analysis was used to investigate the enrichment of groups of
genes with overlapping gene ontology (GO) terms representing
gene properties with the focus of biological process. To interro-
gate the types of genes disturbed due to polyalanine tract ex-
pansion mutations in Arx we focused on the deregulated genes
identified in our analysis with higher levels of expression com-
pared to WT (þ1.1 log2FC). This focus was due mainly to the
very small numbers of deregulated genes at lower levels of ex-
pression in PolyA mutant groups compared to WT in the core
and PolyApool subgroups. GO Terms were ranked using the
EnrichR method of combining the P-value computed using the
Fisher exact test with the z-score of the deviation from the ex-
pected rank by multiplying these two numbers as follows:
c¼ log(p) * z (23). Enrichment of GO biological process identified
PA1 PA2 PolyApool
# genes deregulated 825 78 238
Increased expression 446 (54%) 56 (72%) 212 (89%)





































































































































































































































































Figure 1. Transcriptome analysis of embryonic brains of PolyA Arx mutant mice. Differential expression of genes from 12.5 dpc mice was determined using EdgeR and
selected based on a Log2 fold change greater than þ/- 1.1 with a P-value < 0.05. (A) Total number of deregulated genes and the proportion of either increased or de-
creased expression from our analysis from both mutant mice strains independently, PA1 and PA2, and analysis of pooled PA1 and PA2 strains, PolyApool when com-
pared to WT animals. (B) Log2FC was plotted for all deregulated genes for both PA1 (orange) and PA2 (blue) (total ¼ 858). Genes within the darker red shaded area are
deregulated in different directions compared to WT with expression of genes significantly different between PA1 and PA2 (58/858, 6.75%). Genes within the lighter red
area are deregulated in the same direction in both PA mutation groups compared to WT, but are still significantly different between PA1 and PA2 (498/858, 58.05%). The
remaining genes are deregulated in the same direction compared to WT, but are not significantly different between PA1 and PA2 (35.2%). The dotted line indicates the
log2FC þ/- 1.1 cut off. (C) Gene lists from PA1 (orange), PA2 (blue) and PolyApool analysis (dotted outline) was used to determine the overlap of genes deregulated in each
group and visualised as a Venn diagram. Overlapping genes in PA1 and PA2 samples with log2FC>þ/1.1 in both lists and a P-value <0.05 are highlighted in grey (solid
outline) with logFC values for individual genes shown in (E). *significantly different between groups with a log2FC<1.1 and P-values <0.05, **significantly different be-
tween groups with a log2FC>þ1.1 and P-values <0.05.
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12 biological processes (adjusted P-value<0.05) enriched in the
differentially expressed genes (with higher levels of expression
compared to WT) relative to all expressed genes (Fig. 2). These
biological processes fall into three main categories; those impli-
cated in cell-cell adhesion (GO:0007156, GO:0098609,
GO:0098742); regulation of neuron differentiation/nervous sys-
tem development (GO:0045664, GO:0010975, GO:0007399); and
neuron membrane properties such as synaptic transmission
(GO:0007268), regulation of membrane potential (GO:0042391)
and potassium ion transmembrane transport (GO:0071805)
(Fig. 2). The levels to which each GO biological process is en-
riched in each group is displayed as a heat map on the right of
Figure 2. This analysis indicates that the same categories of GO
processes were enriched whether the deregulated genes consid-
ered were from the core overlap group, the PolyApool group or
the broadest PA1 group of deregulated genes, particularly for
the cell-cell adhesion process (Fig. 2). Overlap was also seen in
the terms identified by Panther pathway analysis when compar-
ing the top 10 enriched pathways in genes deregulated in PA1
mice and genes deregulated in PA2 mice (Supplementary
Materials, Tables S4 and S5).
Identifying early triggers of ARX associated phenotypes
To ascertain which of the deregulated genes were likely to be di-
rect transcriptional targets of Arx, the data from Arx knockout
expression analysis (11,21) and ChIP studies (24) were used to
identify that 46 genes deregulated in this study’s data set are ei-
ther known or putative direct targets of Arx. These targets ac-
counted for 5% of all 858 deregulated genes and were detected
across all groups considered, with a small level of enrichment
in the PolyApool group (Fig. 3). Consistent with the fact that ARX
is a transcriptional repressor, the majority of these targets were
detected at higher levels of expression in the PolyA mutant ani-
mals compared to WT. We have previously demonstrated a
marked reduction of mutant Arx protein abundance within the
developing forebrain of both PA1 and PA2 (12), indicating that
the expanded polyalanine tract mutations in our mouse models
represent a partial loss of Arx function. In Figure 3C, we cap-
tured the response of these target genes to PolyA mutation in
Arx in our study compared to the response in the previously re-
ported studies modelling knocked-out or ablated Arx expression
in mouse brain (11,21) or in response to exogenous Arx overex-
pression in N2a cells (24). This analysis indicates that less than
half (43%) of the direct gene targets of Arx identified as deregu-
lated in the brains of 12.5 dpc mice with Arx PolyA mutations
were also deregulated in Arx deficient mice. In general, the di-
rection of deregulation of the target genes was in agreement be-
tween the loss of function studies and the partial loss of
function in our PolyA mice. Not unexpectedly, there was more
variation in the direction of deregulation between our partial
loss of function in the PolyA mice when compared to the over-
expression of exogenous Arx in Na2 cells (Fig. 3C).
De-regulation of early triggers of ARX-associated
phenotypes persists across embryonic development
Considering the spatial expression of Arx in the subpallium is
restricted to the in both lateral and medial ganglionic eminence,
we were interested if there was any obvious relationship of spa-
tial localisation in regard to the genes de-regulated in our PA
mice. We compared expression of a number of deregulated
genes that had available expression data from the Allen
Developing Mouse Brain Atlas and EURExpress at suitable em-
bryonic stages. Genes with a similar spatial expression profiles
as determined by in situ hybridization images to that of Arx in-
clude Ebf1, Rapgef5, Myt1l, Erbb4, Al606473, Zfp536 and Gpr26. In
contrast, several genes had an opposite spatial expression pro-
files compared to Arx including Zbtb20, Ptch1 and Hdac4, which
are expressed within the proliferating cells in the ventricular
zone (Supplementary Material, Fig. S2). This analysis highlights
that the early triggers of Arx associated phenotypes identified in
GO 
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Figure 2. Gene ontology classification of deregulated genes. Functional enrichment analysis of gene ontology (GO) terms for biological processes shows the differen-
tially expressed genes within subgroups, PolyApool, PA1 only and all deregulated genes from both PA1 and PA2 (All deregulated (DE) genes) with a log2 fold change with-
þ>1.1 cutoff value used as the input into EnrichR. The GO terms were ranked based on the combined EnrichR score and all had a P-value <0.05.
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this study includes both directly regulated and indirectly regu-
lated gene targets contributing to disease outcomes.
To determine whether disruption to the transcriptome was
constrained to the very early development in the time point
tested by RNASeq or continued throughout embryonic life we
chose to test fifteen genes by quantitative PCR in the Wt com-
pared to PA1 mice across three developmental time points, 12.5,
14.5 and 18.5 dpc. The genes selected included a number a puta-
tive targets of Arx previously reported, Plcxd3, Gpr26, Ebf1, Myt1l,
Aspm, Hdac4 and Ptch1. Of interest also were deregulated genes
that were known neurodevelopment genes (Cdkl5, Erbb4, Sor1l,
Twist1, Myt1l, Aspm, Hdac4 and Ptch1) or displayed spatial ex-
pression patterns indicated above (Erbb4, Zfp536, Zbtb20, Gpr26,
Ebf1, Myt1l, Hdac4 and Ptch1), or were deregulated in both PA1
and PA2 (Kcna3 and Six2). Our analysis indicates that 11/15
genes validated with deregulated gene expression at 12.5 dpc by
quantitative PCR, but also had deregulated expression in PA1
mutant mice across more advanced stages of embryonic devel-
opment, with Myt1l, Plcxd3, and Six2 consistently significantly
deregulated across all time points examined (Supplementary
Material, Fig. S3). For several genes with validated deregulation
by quantitative PCR in PA1 mice we confirmed that the deregu-
lation was also validated in PA2 samples at 12.5 dpc by this
analysis, and moreover identified that deregulation in these
genes persisted in later embryonic developmental time points
(Supplementary Material, Fig. S3). Considering that the expres-
sion of Arx during development significantly diminishes at 18.5
dpc it was not surprising that we noted less consistent deregu-
lation of genes persisting in the 18.5 dpc time point compared
to earlier 14.5 dpc. This variability at 18.5 dpc could be due to a
number of factors, but is likely influenced by the increased com-
plexity and size of the brain (tissue sample collected) at this
time point and underscores the strategy for targeting the early
developmental stages where Arx expression is appreciable.
Deregulation of neurodevelopment disorder genes
contributes to the polyalanine expansion mutation
phenotype
Deregulated genes that overlap with lists of genes implicated in
epilepsy, ID and autism (4) showed in the total group of 858
deregulated genes, 99 genes (12%) are known disease-causing
genes for Epilepsy (55 genes), ID (29 genes) and Autism (51 genes)
(Fig. 4A). This overlap is significant when considering the total
group of deregulated genes (P< 0.014), the PolyApool group (29/
182¼ 16%, P< 0.003) and the core overlap group (9/42¼ 21%,
P< 0.014) but not in the PA1 only group (P< 0.292) (Fig. 4A and B).
Given the incidence of comorbidity of the phenotypic features of
these particular neurodevelopmental disorders (NDD), we were
not surprised to see that many of the ID genes (22/29¼ 76%) iden-
tified in our data also contribute to epilepsy and autism, with 8
genes contributing to all three comorbidities of epilepsy, ID and
autism (Fig. 4C). The distribution of these NDD genes that were
deregulated in our PolyA mice are shown in Fig. 4D. Of these 99
NDD genes, only 7 are currently identified as direct targets of ARX
(bold entries on Fig. 4D) (24). Movement disorders including dys-
tonia and dyskinesia are a frequent co-morbidity in patients with
expanded polyA mutations in ARX. Known genes for these disor-
ders are highlighted in the 99 NDD genes (underlined entries on
Fig. 4D) with a full list of these genes deregulated in the PolyA
mice in Supplementary Material, Table S6.
Early triggers of ARX associated phenotypes
de-regulates the arx-Hdac4-Twist1 pathway
The top 10 enriched terms by KEGG and Reactome pathway




































































































pool PA1 Only All DE Genes
Genes per
Group 42 182 598 858




































not deregulated with 





Figure 3. Disruption to putative and known ARX target genes. (A) The number of
putative and known direct targets of ARX and the direction of deregulation in
the PolyA mutant mice is shown for each subgroup of the RNASeq analysis. (B)
The putative and known direct gene targets of ARX are spread across all sub-
groups of the RNASeq analysis as illustrated on the Venn diagram. (C) For each
of these putative or direct gene targets of Arx identified in the PolyA mutant
mice the change in expression compared to WT from this study (PA1 and PA2)
with a comparison of the changes to expression in studies of Arx loss of function
(ARX KO) (11,21), Arx overexpression in N2a cells (ARX OE) (24) and ChIP studies
(24). Red indicates an increase in expression with Green a decrease in expression
compared to WT.
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the breadth of neurological processes impacted by the genes
deregulated in these mutant mice (Supplementary Materials,
Tables S7 and S8). Interestingly, from our analyses, we propose
one particular pathway of transcriptional regulators implicated
in NDD and deregulated in the PolyA mutant mice that may act
as potential drivers of the phenotypes, particularly ID and epi-
lepsy (Fig. 5). The pathway highlights direct interactions based
on Ingenuity Pathway analysis and includes manually curated
data from the literature based on ChIP studies to identify addi-
tional direct interactions across the pathway. We propose that
the reduced protein expression in the developing brains of the
PolyA mice (12) leads to inadequate regulation of Hdac4, in-
volved in chromatin condensation and transcriptional repres-
sion (25), which in turn has a flow on effects directly on targets
such as Mef2c and Twist1. Twist1 is a basic-helix-loop-helix tran-
scription factor involved in cell lineage determination & differ-
entiation (26). The expression of Twist1 was significantly
decreased in both the PA1 and PA2 mutant mice when analysed
independently and confirmed by qRT-PCR (Supplementary
Material, Fig. S3B).
A recent study using a ChIP approach to identify targets of
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Figure 4. Genes deregulated in expanded polyA mice include known ID, epilepsy and autism genes. (A) Total number of genes associated with overlapping phenotypes
of ID, epilepsy and autism and the proportion (%) per mutation subgroup. P-value indicates the significance of overlap between each PolyA mutant subgroup and the
known neurodevelopment disorder genes. (B) A combined graph showing the total number of genes per subgroup (grey bars) on the right-hand y-axis compared to the
proportion of overlap with known neurodevelopmental disorder genes across RNASeq analysis subgroups shown on the left-hand y-axis (legend for line graph shown
below the graph). (C) Venn diagram showing the overlap of genes associated with ID, Epilepsy and Autism comorbid phenotypes. (D) List of known neurodevelopmental
disorder genes within each PolyA mutant subgroup, grouped by the associated disease phenotypes. Known movement disorder genes are underlined. The putative
and known direct targets of ARX/Arx are highlighted in bold.
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study overlap with TWIST1 targets, 23/302 of which were
deregulated in both PA1 and PA2 mutant mice, 17/302 being
known ID genes and 32/302 being known epilepsy genes. We re-
cently demonstrated that there was a consistently greater level
of reduction of mutant Arx protein in the developing brains of
the PA1 mice with a more variable reduction of mutant protein
in the embryonic brains of PA2 mice (12). Hence, we propose
that adequate levels of Arx protein are required to regulate di-
rect targets such as Hdac4 for normal brain development. When
this regulation is not achieved the subsequent disturbance is
relative to the reduction in Arx mutant protein expression, with
a broader and more significant level of disruption observed in
the PA1 mice as compared to the PA2 mice.
Discussion
Expanded polyalanine tracts are the most frequent mutations
reported in the ARX gene (15) with the patients’ phenotypic fea-
tures invariably including ID with early onset seizures as a fre-
quent comorbidity. To gauge the early events of the
compromised ARX function, we assessed transcriptome-wide
outcomes of the two most frequent ARX polyalanine tract ex-
pansion mutations within the telencephalon of their respective
mouse models. RNASeq analysis of the forebrain of 12.5 dpc tel-
encephalon highlights early alterations that are common to
both PolyA mutants, with a greater impact in mice modelling
the more severe PA1 mutation. Our validation analysis indicates
that this deregulation identified at 12.5 dpc persists across em-
bryonic development. Many of the genes deregulated are known
ID, epilepsy or autism disease genes. The enrichment of genes
with synaptic function supports convergence of common path-
ways contributing to these disorders. Interrogating the profile of
deregulated genes from the developing brains of Arx PolyA mu-
tant mice we have identified a number of pathways impacted
by genes deregulated in the mutant mice including a ‘core’
pathway of transcriptional regulators that we suggest may rep-
resent early triggers of ARX-associated phenotypes.
The molecular pathogenesis of expanded polyalanine tracts
is not well understood. In the case of Arx/ARX, we have demon-
strated a marked reduction of the Arx protein expression in the
developing forebrain of mutant PA1 and PA2 mice, occurring as
early as embryonic stage 12.5 dpc (12). Reduced protein expres-
sion of mutant protein in vivo may be a common molecular
mechanism contributing to the disease associated with ex-
panded polyalanine tracts (3,12,28,29). At this early embryonic
stage Arx/ARX is highly expressed in the telencephalon during
peak cellular proliferation/neurogenesis and the first wave of
tangential migration of neurons from the ganglionic eminence
to the developing cortex. There is evidence that polyalanine ex-
pansion mutations in Arx retain transcription regulation capac-
ity for some gene targets, but fails to repress a subset of
predicted or known targets (12,22,24). Our RNASeq approach of-
fers an unbiased and comprehensive interrogation of deregula-
tion of gene expression due to these mutations. We show a
substantial number of deregulated genes as a consequence of
PolyA expansion mutations in Arx during early embryonic brain
development. Interestingly, most of the significantly deregu-
lated genes in the PA1 mutant mice were also perturbed in PA2
mice, but failed to reach significance by our analysis. We cannot
rule out the possibility that the structure and location of the
PA2 mutation within Arx contributes to the milder phenotypic
outcomes in both our mice and affected patients. However, a
combination of data from this study and our previous work
leads us to suggest an alternative hypothesis. We have shown
that the reduction in Arx mutant protein in the embryonic brain
appears more variable in the PA2 mice compared to the PA1
mice (12). Hence, the variability in Arx protein abundance in the
PA2 mouse brains may diminish the power with which to detect
significant deregulation of gene expression in some genes sig-
nificantly altered in the PA1 mice. Our previous report identified
expression of a direct transcriptional target of Arx, Lmo1 in the
PA1 mutant mice was deregulated significantly across all stages
of embryonic development tested. In contrast, the deregulated
expression of this gene did not reach significance in the PA2
mutant mice compared to wild-type until much later in embry-
onic development (12). Hence, in the subsequent analysis un-
dertaken in this study we included not only genes significantly
deregulated in both mutant animals but also those genes
deregulated in either PA1 and PA2 animals.
The deregulated expression of several genes tested was
maintained across increasing developmental time points. It is
attractive to speculate that perhaps the cells with altered gene
expression at E12.5 dpc maintain this altered state as they mi-
grate and develop, despite the reduction in Arx expression with
embryonic development. From our current data, we cannot
speculate on alterations to migration of particular neurons
Increased expression in PolyApool







Figure 5. Arx-Hdac4-Twist1 PolyA-deregulated pathway. Pathway analysis was used to assess connectivity of deregulated genes of PolyA-Arx loss-of-function embry-
onic brains. The geometric shapes reflect differing types of proteins as defined by ingenuity analysis (Ingenuity Systems) (see legend) with direct connections shown as
solid lines. Published ChIP data highlighting relationships between genes and proteins are shown as dotted lines. The direction of deregulation in PolyApool is indicated
with arrows (" ¼ increased expression, # ¼ decreased expression). Known NDD genes are shaded in grey.
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impacted by expanded polyA mutant Arx. However, we have
conducted our analysis on a very spatially discrete region of the
brain, namely the telencephalon at E12.5. We know from a re-
cent elegant study (30) that only a small subset of cells is af-
fected even when there is a complete loss of Arx function.
Hence, to address if there is a migration deficit in these mutant
animals extensive and painstaking cellular analysis of interneu-
ron migration will be required. In addition, other approaches
such as single cell expression analysis on the different interneu-
ron subtypes would be very powerful and with the increasing
technologies available, perhaps increasingly possible.
To date, there are only a handful of known or putative direct
targets of ARX. In our study, approximately 5% of the overall
deregulated genes in the PA1 and PA2 mice identified as direct
ARX targets (known or putative). Knock-out studies (11,21) in-
clude phosphatidylinositol-specific phospholipase C, X domain
containing 3 gene (PLCXD3) which is primarily expressed in
the brain and associated with lipid catabolism and signal trans-
duction, along with AF4/FMR2 Family, Member 2 (Aff2), Cellular
Retinoic Acid Binding Protein 1 (Crabp1) and 5’-3’
Exoribonuclease 1 (Xrn1). Other direct targets of Arx regulation
identified using ChIP based approaches (24) that were deregu-
lated in the PolyA Pool group included Histone Deacetylase 4
(Hdac4). However, we hypothesize that ARX drives key tran-
scriptional events not only through impact on specific gene tar-
gets but in combination with regulation of key transcription
factors and transcriptional regulators. Hence, we predict that
deregulation of other transcription factors and regulators are
likely to be contributing to the global changes observed in the
PolyA mutant mice.
A number of transcription factors are present in the list of
significantly deregulated genes in PA1 and PA2 mice, including
Twist1, ALX Homeobox 1 (Alx1), SIX Homeobox 2 (Six2), Early B-
Cell Factor 1 (Ebf1), Early Growth Response 3 (Egr3), Zinc Finger
And BTB Domain Containing 20 (Zbtb20) and Zinc Finger Protein
536 (Zfp536) which are likely contributing to the downstream de-
regulation of the transcriptome captured in this study. From our
analysis, we propose a ‘core’ Arx-Hdac4-Twist1 pathway likely
contributing to the downstream phenotypic outcomes. The
pathway indicates that Arx directly represses Hdac4, which in
turn is involved in chromatin condensation and transcriptional
repression (25). Overexpression of HDAC4 has been shown to
impair long-term memory in a drosophila model (31) and over-
expression has also been found in patients with autism (32).
Salt-inducible kinase 2 (SIK2) an AMP-activated protein kinase,
shown to regulate HDAC4 via phosphorylation, is significantly
up regulated in PA1 and PA2 (although the change in transcript
level is subtle). This modification of HDAC4 disrupts the MEF2C-
HDAC4 complexes and mediates the activation of MEF2-
dependent transcription. MEF2C is highly expressed during
embryo development and involved in neurogenesis and synap-
tic function. In mice, it has been indicated to have an essential
role in hippocampal-dependent learning and memory by sup-
pressing the number of excitatory synapses and thus regulating
basal and evoked synaptic transmission (33). The hyperexcit-
ability of hippocampal and neocortical networks found in Arx
PA1 mice is thought to be most likely due to an increase in excit-
atory drive rather than an inhibitory failure (19). Pathway analy-
sis indicates Arx has a direct interaction with Mef2c, although
we did not detect significant disturbances in transcript expres-
sion in our PolyA mutant mice at 12.5 dpc.
As we travel down the Arx-Hdac4-Twist1 pathway, likely out-
side of direct regulation by Arx, we encounter Twist1, a basic-
helix-loop-helix transcription factor involved in the cell linage
determination & differentiation (26). A wide range of mutations
have been reported in TWIST1 resulting in a variable phenotype
from mild to severe intellectual disability as a consequence of
large gene deletions, however the majority of missense and
nonsense mutations have been associated with the craniosyn-
ostosis disorder Saethre-Chotzen syndrome (34). A recent study
using a ChIP approach has identified targets of TWIST1, and
comparison with our deregulated gene lists indicates that over
one third of all deregulated genes in PolyA mutant mice identi-
fied in our current study are direct or likely targets of TWIST1
regulation, including genes known to cause ID and epilepsy (27).
The influence of TWIST1 is further demonstrated with the
down regulation of a known target Dnm30s (mir199a/214 clus-
ter) normally upregulated via TWIST1 during development (35).
Research has focused on determining the role of Twist1 in can-
cer development with little emphasis to date of the contribution
of Twist1 in brain development.
The Arx-Hdac4-Twist1 pathway we propose is one that may
reflect very early consequences of ARX loss (or partial loss) of
the function. For multiple genes deregulated at 12.5 dpc we
have confirmed that the deregulation persists across later
stages of embryonic development. Interestingly, genes that are
enriched in the proposed pathway contain oestrogen response
elements (EREs) in their promoter regions. More broadly, when
we examine our list of deregulated genes we find 30% contain
EREs (36–38). This is of significant interest given the recent find-
ings that early postnatal treatment with 17 b-estradiol (E2) pre-
vents spasms, restored depleted interneuron populations
without increasing GABAergic synaptic density and altered
mRNA levels of three downstream targets of ARX (Ebf3, Shox2,
Lgi1) in an independent PA1 mutant mouse model (39). It re-
mains to be established if administration of E2 during early
stages of postnatal life, leading to seizure ablation, is impacting
upon the transcriptome specifically at the ERE containing genes
we have identified as deregulated in the PolyA mice at early
stages of embryonic development.
In summary, we have interrogated the transcriptome of
mice modelling the most frequent expansion mutations of
PolyA tracts of ARX. Based on our analysis, we propose the Arx-
Hdac4-Twist1 as the ‘core’ pathway, which is contributing signif-
icantly to the ARX mutation-associated phenotypes, namely ID
and epilepsy. While other gene targets and factors are likely at




Animals and tissue collection
All animal procedures were approved by the relevant Animal
Ethics committees of the University of Adelaide, SA Pathology
and the Women’s and Children’s Hospital, Adelaide. ArxGCG7/
þ (PA1) and Arx432–455dup/þ (PA2) mice were obtained as described
in (12) and were maintained in the C57BL/6 background.
Pregnant dams were euthanized by cervical dislocation fol-
lowed by harvesting of the 12.5 dpc embryos from the uterus.
Skin and ectodermal layers were removed to isolate the telence-
phalic vesicles. Samples for RNA extraction were snap frozen
at80C until the time of assay.
Genotyping
Genomic DNA was extracted as per MaxwellVR 16 Tissue DNA
purification Kit manual (Promega). PCR was performed using
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FailSafeTM PCR 2X PreMix J (Epicentre) for 35 cycles of 30 s of
94C for denaturation, 30 s of 60C for annealing and 40 s of 72C
for elongation. Primers to amplify the Arx knock-in region were
described (17). We also included Sry sexing PCR as part of our
genotyping pipeline (12).
RNA-sequencing
RNA was extracted from the isolated telencephalon of hemizy-
gous male mice of each strain (PA1 and PA2) and stage matched
male wild-type littermates (WT) using Trizol (Invitrogen, Grand
Island, NY, USA) and RNeasy Mini Kit (QIAGEN, Hilden,
Germany), according to the manufacturer’s instructions. Library
preparation using the TruSeq RNA Sample Preparation Kit v2
was performed on 4.5 lg of RNA at the ACRF South Australia
Cancer Genomics Facility (Adelaide, Australia). Samples (n¼ 4
each from WT, PA1 and PA2) were sequenced on the Illumina
(San Diego, CA, USA) HISeq 2000 platform. RNA-SEQ reads were
mapped to the reference sequences, which includes the latest
build of the mouse genome (mm10). Reads were mapped at the
original 100 bp length. The number of reads mapped to each
gene was obtained using htseq-count (40). In order to correct for
variation between lanes/sample, the count data was normalized
to library size. Genes with low count data were excluded, the
minimum required at least two samples having>60–177 reads.
Differential gene expression was calculated using the R package
edgeR (41). Transcripts significantly altered compared to WT
were selected by applying a log2 fold change-cutoff of 1.1 and
P-value cutoff of0.05.
RT-qPCR – RNASeq validation
RNASeq results were validated using Taqman RT-qPCR on two
pools of RNA, a technical validation pool using RNA from the
same samples used for the RNASeq and a separate biological
validation pool of RNA from four different samples of each ge-
notype (Supplementary Material, Fig. S1). Collected tissues were
homogenized with a 21G needle and total RNA was extracted
using Trizol (Invitrogen) and RNeasy Mini Kit (Qiagen) and
treated with DNase I (Qiagen) according to the manufacturer’s
instruction. cDNA was prepared as described in SuperScript III
reverse transcriptase (Invitrogen) manual with 1 lg of RNA
primed by random hexanucleotides. Along with samples, tem-
plate negative and reverse transcriptase negative controls were
included to determine product specificity. Genes selected for
validation studies were assayed as described in TaqmanVR
PreAmp Master Mix Kit user guide (Applied Biosystem). For each
validation gene quantified with a Taqman probe labelled with
FAM, the expression values were normalized to the reference
gene Gapdh assayed in the same well using the Taqman probe
labelled with VIC. For further analysis, RNA was extracted from
12.5, 14.5 and 18.5 dpc telencephalon and pooled before cDNA
was prepared (as described previously). Expression of genes was
determined using TaqmanVR PreAmp Master Mix with gene spe-
cific Taqman probes labelled with FAM. The expression values
were normalized to the reference gene Tbp which was shown to
be stably expressed across the chosen time points. Taqman
probes used in this study are listed in Supplementary Material,
Table S9.
Functional annotations
Statistical analysis of the enrichment of Gene Ontology (GO) cat-
egories was performed using EnrichR, a bioinformatics tool that
retrieves molecular information from transcription factor data-
bases and defines transcription factors statistically enriched
from gene lists (23). To rank the enrichment results we used the
score calculated by EnrichR using the P-value and Z-score. The
top 10 results are shown with adjusted P-value of P< 0.05.
Pathway analysis
Ingenuity Pathway Analysis (Ingenuity Systems) was used to as-
sess connectivity of deregulated proteins. The requirements for
assessing protein-protein interconnectivity included direct in-
teractions observed experimentally. The permitted interaction
types were: protein-protein, protein-DNA, activation, inhibition,
phosphorylation, and ubiquitination. ARX (21,24) and TWIST1
(27) ChIP interaction data was manually superimposed onto this
pathway.
Statistics
The statistical significance of the overlap between two groups of
genes was calculated using exact hypergeometric probabil-
ity (http://nemates.org/MA/progs/overlap_stats.html; date last
accessed September 27, 2016). Total genes in this case equalled
13821 genes with detected reads.
Supplementary Material
Supplementary Material is available at HMG online.
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